paper,intervention_general,outcome_general,outcome_raters,outcome_followup,total_n,mean_age_q10,mean_age_q15,mean_age_q20,mean_age_q25,mean_age_q50,mean_age_q75,mean_age_q85,mean_age_q90,meta_review,intervention_augmentation,n_tot,perc_female,mean_age,mean_iq,duration_month,dose,available_age,available_IQ,available_control,available_rob,rob_num,low_RoB_num,RoB_Rand_num,RoB_Deviation_num,RoB_Missing_num,RoB_Report_num,RoB_Outcome_num,n_cct_intervention,n_outcome_intervention,n_meta_intervention,n_cor,n_es,n_studies,mean_age_n,author,year,first_author_meta,doi,intervention_precise,mono_aug,outcome_type,outcome_measure,trial_id_supp,design,diagnostic_criteria,control_group,dose_unit,amstar_rank,min_age_meta,max_age_meta,min_IQ_meta,max_IQ_meta,outcome_intervention,meta_intervention,min_age_intervention,max_age_intervention,min_IQ_intervention,max_IQ_intervention,year_meta,INTER_mean_IQ,INTER_IQ_q20,INTER_IQ_q80,Duration,IQ,IQ_precise,Intensity_global,Age,Age_precise,PICO_amstar,PICO_amstar_ID,PICO_amstar_precise,year_meta_num,unique_meta,row_id_meta,overall_scope,Factor,factor,available_control_agg
Ang (2023) Acupuncture,Combined ADHD symptoms (inattentive + hyperactive/impulsive) Parent-rated,At study endpoint (closest to 12 weeks), 171  9.000000, 9.000000, 9.000000, 9.000000, 9.500000, 9.500000  9.500000, 9.500000   93 100.000000  89.08187  15.789474  9.301170,NA  1.65277021,   3.000000,100.00000,  0.00000,100.00000,100,100.000000,100.000000,100.00000,100.00000,100.000000 100.00000 100.000000   2  4  1, 89.08187 1.000000, 2 1,Meng | Yu,2012 | 2021,Ang,10.3390/medicina59020392 Acupuncture Acupuncture plus conventional medicine vs. conventional medicine,Questionnaire,Conners parents symptom questionnaire (PSQ),NA,RCT (parallel, crossover, open-label),DSM-IV/5,Active (any credible active intervention),sessions/week,Critically low 9,9.5,NA,NA Generalized anxiety | Conduct Disorder symptoms | Learning disorder symptoms | Combined ADHD symptoms (inattentive + hyperactive/impulsive) Ang (2023),9 9.5 NA,NA NA NA,NA,NA,< 2 months NA,NA 3sessions/week,6-17 yo,Homogeneous,Acupuncture_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks)_6-17 yo Ang (2023) - Acupuncture_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks)_6-17 yo Acupuncture_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks)_6-17 yo - [Homogeneous],2023 Acupuncture_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks)   1 TRUE,Ang (2023)_Acupuncture_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks) Ang (2023)_Acupuncture_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks),100.00000
Ang (2023),Acupuncture,Conduct Disorder symptoms Parent-rated,At study endpoint (closest to 12 weeks), 171  9.000000  9.000000, 9.000000  9.000000, 9.500000, 9.500000  9.500000  9.500000,  93 100.000000  89.08187, 15.789474, 9.301170 NA, 1.65277021,   3.000000 100.00000,  0.00000,100.00000 100,100.000000 100.000000 100.00000,100.00000,100.000000,100.00000,100.000000   2  4  1, 89.08187 1.000000, 2,1,Meng | Yu 2012 | 2021 Ang 10.3390/medicina59020392,Acupuncture,Acupuncture plus conventional medicine vs. conventional medicine,Questionnaire Conners parents symptom questionnaire (PSQ),NA RCT (parallel, crossover, open-label) DSM-IV/5,Active (any credible active intervention) sessions/week,Critically low,9,9.5 NA,NA Generalized anxiety | Conduct Disorder symptoms | Learning disorder symptoms | Combined ADHD symptoms (inattentive + hyperactive/impulsive),Ang (2023) 9,9.5,NA NA,NA NA,NA,NA < 2 months NA NA,3sessions/week,6-17 yo Homogeneous Acupuncture_Conduct Disorder symptoms_Parent-rated_At study endpoint (closest to 12 weeks)_6-17 yo Ang (2023) - Acupuncture_Conduct Disorder symptoms_Parent-rated_At study endpoint (closest to 12 weeks)_6-17 yo,Acupuncture_Conduct Disorder symptoms_Parent-rated_At study endpoint (closest to 12 weeks)_6-17 yo - [Homogeneous] 2023,Acupuncture_Conduct Disorder symptoms_Parent-rated_At study endpoint (closest to 12 weeks)   2,TRUE,Ang (2023)_Acupuncture_Conduct Disorder symptoms_Parent-rated_At study endpoint (closest to 12 weeks),Ang (2023)_Acupuncture_Conduct Disorder symptoms_Parent-rated_At study endpoint (closest to 12 weeks),100.00000
Ang (2023),Acupuncture Generalized anxiety Parent-rated,At study endpoint (closest to 12 weeks)  171, 9.000000  9.000000, 9.000000, 9.000000  9.500000  9.500000, 9.500000  9.500000,  93,100.000000, 89.08187  15.789474, 9.301170 NA, 1.65277021    3.000000 100.00000   0.00000,100.00000 100,100.000000,100.000000 100.00000,100.00000,100.000000,100.00000,100.000000,  2, 4, 1, 89.08187,1.000000  2,1,Meng | Yu,2012 | 2021,Ang 10.3390/medicina59020392 Acupuncture,Acupuncture plus conventional medicine vs. conventional medicine,Questionnaire,Conners parents symptom questionnaire (PSQ) NA,RCT (parallel, crossover, open-label),DSM-IV/5,Active (any credible active intervention) sessions/week Critically low,9 9.5 NA NA,Generalized anxiety | Conduct Disorder symptoms | Learning disorder symptoms | Combined ADHD symptoms (inattentive + hyperactive/impulsive) Ang (2023) 9 9.5 NA,NA,NA,NA NA NA < 2 months NA,NA 3sessions/week,6-17 yo Homogeneous,Acupuncture_Generalized anxiety_Parent-rated_At study endpoint (closest to 12 weeks)_6-17 yo,Ang (2023) - Acupuncture_Generalized anxiety_Parent-rated_At study endpoint (closest to 12 weeks)_6-17 yo,Acupuncture_Generalized anxiety_Parent-rated_At study endpoint (closest to 12 weeks)_6-17 yo - [Homogeneous],2023,Acupuncture_Generalized anxiety_Parent-rated_At study endpoint (closest to 12 weeks)   3 TRUE,Ang (2023)_Acupuncture_Generalized anxiety_Parent-rated_At study endpoint (closest to 12 weeks) Ang (2023)_Acupuncture_Generalized anxiety_Parent-rated_At study endpoint (closest to 12 weeks),100.00000
Ang (2023),Acupuncture Learning disorder symptoms,Parent-rated At study endpoint (closest to 12 weeks), 171, 9.000000  9.000000  9.000000  9.000000, 9.500000  9.500000, 9.500000, 9.500000   93 100.000000, 89.08187, 15.789474, 9.301170,NA  1.65277021,   3.000000,100.00000,  0.00000,100.00000,100,100.000000 100.000000 100.00000 100.00000,100.000000 100.00000,100.000000,  2  4, 1  89.08187,1.000000, 2 1,Meng | Yu,2012 | 2021,Ang 10.3390/medicina59020392 Acupuncture Acupuncture plus conventional medicine vs. conventional medicine,Questionnaire,Conners parents symptom questionnaire (PSQ),NA,RCT (parallel, crossover, open-label) DSM-IV/5 Active (any credible active intervention) sessions/week Critically low 9,9.5 NA,NA,Generalized anxiety | Conduct Disorder symptoms | Learning disorder symptoms | Combined ADHD symptoms (inattentive + hyperactive/impulsive) Ang (2023),9,9.5 NA,NA NA NA,NA,NA,< 2 months NA NA 3sessions/week 6-17 yo,Homogeneous,Acupuncture_Learning disorder symptoms_Parent-rated_At study endpoint (closest to 12 weeks)_6-17 yo,Ang (2023) - Acupuncture_Learning disorder symptoms_Parent-rated_At study endpoint (closest to 12 weeks)_6-17 yo Acupuncture_Learning disorder symptoms_Parent-rated_At study endpoint (closest to 12 weeks)_6-17 yo - [Homogeneous] 2023,Acupuncture_Learning disorder symptoms_Parent-rated_At study endpoint (closest to 12 weeks),  4 TRUE,Ang (2023)_Acupuncture_Learning disorder symptoms_Parent-rated_At study endpoint (closest to 12 weeks),Ang (2023)_Acupuncture_Learning disorder symptoms_Parent-rated_At study endpoint (closest to 12 weeks) 100.00000
Bellato - adults (2024),Amphetamine,Quality of life (patients) Self-rated At study endpoint (closest to 12 weeks), 429 34.500000 34.500000 34.500000 34.500000 36.500000,36.500000 36.500000,36.500000 8888,  0.000000,227.84382  49.166900 35.749417 NA, 1.87016666 NA 100.00000   0.00000,100.00000,100 100.000000,100.000000,100.00000,100.00000  37.529138 100.00000 100.000000, 43 14  9 227.84382 6.000000  2,1,Adler | Spencer,2013 | 2008,Bellato - adults,10.1016/j.jaac.2024.05.023,LDX | Triple Bead MAS NA,Questionnaire,The ADHD Impact Module–Adult,NA,RCT (parallel, crossover, open-label),DSM-III, DSM-IV, DSM-V Placebo NA,High 34.5,36.5,NA,NA,Disruptive behaviors | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Academic/job performance | Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Depressive disorder symptoms | Generalized anxiety | Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Executive functioning (tests) Faraone (2002) | Punja (2016) | Castells (2018) | Elliott (2020) | Bellato - adults (2024) | Bellatto - children (2024) | Lenzi (2018) | Ostinelli (2025) | Cortese - Children (2018) 8 41.2,NA,NA NA,NA NA,NA,< 2 months NA,NA,NANA >= 18 yo,Homogeneous,Amphetamine_Quality of life (patients)_Self-rated_At study endpoint (closest to 12 weeks)_>= 18 yo Bellato - adults (2024) - Amphetamine_Quality of life (patients)_Self-rated_At study endpoint (closest to 12 weeks)_>= 18 yo,Amphetamine_Quality of life (patients)_Self-rated_At study endpoint (closest to 12 weeks)_>= 18 yo - [Homogeneous],2024 Amphetamine_Quality of life (patients)_Self-rated_At study endpoint (closest to 12 weeks)   5 FALSE,Bellato - adults (2024)_Amphetamine_Quality of life (patients)_Self-rated_At study endpoint (closest to 12 weeks),Bellato - adults (2024)_Amphetamine_Quality of life (patients)_Self-rated_At study endpoint (closest to 12 weeks) 100.00000
Bellatto - children (2024) Amphetamine Quality of life (patients),Self-rated At study endpoint (closest to 12 weeks), 521,10.900000 10.900000 10.900000,10.900000,15.000000 15.000000,15.000000 15.000000,8888,  0.000000,270.28983, 25.560269,13.347409,NA  1.19889829,NA,100.00000   0.00000,100.00000 100 100.000000 100.000000 100.00000,100.00000  59.692898 100.00000 100.000000  43,14, 9 270.28983,1.000000  2,1,Coghill | Findling 2013 | 2011 Bellatto - children,10.1016/j.jaac.2024.05.023,LDX NA Questionnaire,Child Health and Illness Profile–Child Edition | Youth Quality of Life–Research Version NA RCT (parallel, crossover, open-label),DSM-III, DSM-IV, DSM-V,Placebo NA High,10.9,15,NA NA Disruptive behaviors | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Academic/job performance | Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Depressive disorder symptoms | Generalized anxiety | Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Executive functioning (tests) Faraone (2002) | Punja (2016) | Castells (2018) | Elliott (2020) | Bellato - adults (2024) | Bellatto - children (2024) | Lenzi (2018) | Ostinelli (2025) | Cortese - Children (2018),8 41.2 NA NA NA,NA NA,NA,< 2 months,NA NA NANA,6-17 yo,Homogeneous,Amphetamine_Quality of life (patients)_Self-rated_At study endpoint (closest to 12 weeks)_6-17 yo Bellatto - children (2024) - Amphetamine_Quality of life (patients)_Self-rated_At study endpoint (closest to 12 weeks)_6-17 yo Amphetamine_Quality of life (patients)_Self-rated_At study endpoint (closest to 12 weeks)_6-17 yo - [Homogeneous] 2024,Amphetamine_Quality of life (patients)_Self-rated_At study endpoint (closest to 12 weeks),  6,FALSE Bellatto - children (2024)_Amphetamine_Quality of life (patients)_Self-rated_At study endpoint (closest to 12 weeks) Bellatto - children (2024)_Amphetamine_Quality of life (patients)_Self-rated_At study endpoint (closest to 12 weeks),100.00000
Bellatto - children (2024) Atomoxetine,Quality of life (patients),NA,At study endpoint (closest to 12 weeks),1179  9.000000  9.000000, 9.900000, 9.900000,11.000000 11.000000 11.950000 13.000000 8888,  0.000000,220.30789  20.642502,10.849279 NA  1.89136510 NA,100.00000   0.00000 100.00000 100  74.893978, 74.893978, 74.89398 100.00000, 59.881255 100.00000 100.000000  44, 9  7,220.30789 1.871925, 6,1,Bangs | Dittmann | Michelson | Newcorn | Svanborg | Weiss,2008 | 2011 | 2001 | 2009 | 2005,Bellatto - children 10.1016/j.jaac.2024.05.023,NA,NA Questionnaire NA,NA RCT (parallel, crossover, open-label),DSM-III, DSM-IV, DSM-V Placebo,NA High,9,13,NA NA,Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Generalized anxiety | Depressive disorder symptoms | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | CGI,Elliott (2020) | Bellatto - children (2024) | Lenzi (2018) | Bryant (2021) | Ostinelli (2025) | Cortese - Adults (2018) | Cortese - Children (2018) 8.65154639175258,42.10703125,NA NA,NA,NA NA,NA,< 2 months NA NA NANA,6-17 yo Homogeneous,Atomoxetine_Quality of life (patients)_NA_At study endpoint (closest to 12 weeks)_6-17 yo Bellatto - children (2024) - Atomoxetine_Quality of life (patients)_NA_At study endpoint (closest to 12 weeks)_6-17 yo Atomoxetine_Quality of life (patients)_NA_At study endpoint (closest to 12 weeks)_6-17 yo - [Homogeneous],2024 Atomoxetine_Quality of life (patients)_NA_At study endpoint (closest to 12 weeks)   7,NA Bellatto - children (2024)_Atomoxetine_Quality of life (patients)_NA_At study endpoint (closest to 12 weeks),Bellatto - children (2024)_Atomoxetine_Quality of life (patients)_NA_At study endpoint (closest to 12 weeks),100.00000
Bikic (2017),Organizational skills interventions,Academic/job performance Teacher-rated,At study endpoint (closest to 12 weeks)  929, 4.000000  4.000000  4.000000  5.500000,11.500000 12.500000,12.700000,12.700000  343 100.000000 134.41442, 30.212056  9.788698,NA, 3.84193752 NA 100.00000,  0.00000 100.00000,100,  2.475780,  2.475780,100.00000   2.47578 100.000000 100.00000   2.475780  11  1, 1,134.41442,1.091496,11,1,Abikoff | Evans | Langberg | Mautone | Power | Sibley 2013 | 2011 | 2014 | 2016 | 2008 | 2012 Bikic,10.1016/j.cpr.2016.12.004 Organizational skills training,0.36 on medication | 0.67 on medication | 0.5 on medication | 0.446 on medication | 0.43 on medication | 0.69 on medication | mono | 0.42 on medication | 0.389 on medication | 0.609 on medication | 0.344 on medication,Questionnaire | Questionnaire | Observational tool | Observational tool Academic Performance Rating Scale, Classroom Performance Survey, or Academic Competence Evaluation Scale | Academic Performance Rating Scale, Classroom Performance Survey, or Academic Competence Evaluation Scale | Grade Point Avarage | Grade Point Avarage,NA,RCT (parallel, crossover, open-label),DSM WLC (wait-list control) | Community control | Not a therapeutic intervention | TAU,NA,Critically low 4,15 NA NA Academic/job performance,Bikic (2017) 4 15 NA,NA NA,NA NA NA,2-6 months NA NA,NANA 6-17 yo,Mixed,Organizational skills interventions_Academic/job performance_Teacher-rated_At study endpoint (closest to 12 weeks)_6-17 yo Bikic (2017) - Organizational skills interventions_Academic/job performance_Teacher-rated_At study endpoint (closest to 12 weeks)_6-17 yo Organizational skills interventions_Academic/job performance_Teacher-rated_At study endpoint (closest to 12 weeks)_6-17 yo - [Mixed] 2017,Organizational skills interventions_Academic/job performance_Teacher-rated_At study endpoint (closest to 12 weeks)   8 FALSE Bikic (2017)_Organizational skills interventions_Academic/job performance_Teacher-rated_At study endpoint (closest to 12 weeks),Bikic (2017)_Organizational skills interventions_Academic/job performance_Teacher-rated_At study endpoint (closest to 12 weeks) 100.00000
Boesen (2022),Methylphenidate,Specific adverse events: decreased appetite NA,At study endpoint (closest to 12 weeks) 4491,34.000000,34.000000 35.000000 35.000000 35.000000 36.000000,38.000000,39.000000, 381   0.000000 370.96927  46.187575 35.772879 NA  2.99947805,  59.932866,100.00000   0.00000,100.00000 100, 25.005567, 25.005567,100.00000,100.00000, 10.598976  25.00557,100.000000,141,14 11,370.96927 1.000000 16,1,Adler | Biederman | Casas | Compas | Ginsberg | Goodman | Huss | Konstenius | Medori | Retz | Rösler | Spencer | Takahashi | Weisler | Weiss | Winhusen,2006 | 2003 | 2008 | 2007 | 2009 | 2010 | 2005 | 2004 | 2011 | 2014 Boesen,10.1002/14651858.CD012857.pub2 OROS methylphenidate | extended-release methylphenidate | Long-acting (LA) methylphenidate | Extended-release (ER) methylphenidate | dex-methylphenidate extended-release
Spencer 2003a 
Extended-release | Controlled-release (CR) methylphenidate,NA Interview,Interview,NA,RCT (parallel, crossover, open-label),DSM-IV | DSM-IV TR | DSM-5 Placebo mg/daily High 33 42 NA NA Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events),Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018) 4.42 50.1 60 109.9,NA  99.5875 97.45,105.60,2-6 months,NA NA,59.93mg/daily >= 18 yo Homogeneous,Methylphenidate_Specific adverse events: decreased appetite_NA_At study endpoint (closest to 12 weeks)_>= 18 yo Boesen (2022) - Methylphenidate_Specific adverse events: decreased appetite_NA_At study endpoint (closest to 12 weeks)_>= 18 yo Methylphenidate_Specific adverse events: decreased appetite_NA_At study endpoint (closest to 12 weeks)_>= 18 yo - [Homogeneous] 2022 Methylphenidate_Specific adverse events: decreased appetite_NA_At study endpoint (closest to 12 weeks),  9,FALSE,Boesen (2022)_Methylphenidate_Specific adverse events: decreased appetite_NA_At study endpoint (closest to 12 weeks) Boesen (2022)_Methylphenidate_Specific adverse events: decreased appetite_NA_At study endpoint (closest to 12 weeks),100.00000
Boesen (2022) Methylphenidate Specific adverse events: sleep problems NA,At study endpoint (closest to 12 weeks),4435 34.000000 34.000000 35.000000 35.000000 35.000000 36.000000 38.000000,39.000000  381,  0.000000 372.26945  45.241127,35.757384,NA, 3.04160726   57.235287,100.00000,  0.00000,100.00000 100  25.321308  25.321308 100.00000 100.00000,  7.080045, 25.32131 100.000000,141 14 11 372.26945,1.000000 16 1,Adler | Biederman | Casas | Compas | Ginsberg | Goodman | Huss | Konstenius | Levin | Medori | Rösler | Spencer | Takahashi | Weisler | Weiss | Winhusen 2006 | 2003 | 2008 | 2007 | 2009 | 2010 | 1998 | 2005 | 2004 | 2011 | 2014,Boesen,10.1002/14651858.CD012857.pub2,OROS methylphenidate | extended-release methylphenidate | Long-acting (LA) methylphenidate | methylphenidate sustained-release (SR) | Extended-release (ER) methylphenidate | dex-methylphenidate extended-release
Spencer 2003a 
Extended-release | Controlled-release (CR) methylphenidate,NA,Interview Interview NA,RCT (parallel, crossover, open-label),DSM-IV | DSM-IV TR | DSM-5 Placebo mg/daily,High 33,42,NA,NA Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events),Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018) 4.42,50.1 60,109.9 NA  99.5875,97.45 105.60 2-6 months,NA,NA,57.24mg/daily >= 18 yo Homogeneous Methylphenidate_Specific adverse events: sleep problems_NA_At study endpoint (closest to 12 weeks)_>= 18 yo,Boesen (2022) - Methylphenidate_Specific adverse events: sleep problems_NA_At study endpoint (closest to 12 weeks)_>= 18 yo,Methylphenidate_Specific adverse events: sleep problems_NA_At study endpoint (closest to 12 weeks)_>= 18 yo - [Homogeneous] 2022,Methylphenidate_Specific adverse events: sleep problems_NA_At study endpoint (closest to 12 weeks)  10 FALSE Boesen (2022)_Methylphenidate_Specific adverse events: sleep problems_NA_At study endpoint (closest to 12 weeks),Boesen (2022)_Methylphenidate_Specific adverse events: sleep problems_NA_At study endpoint (closest to 12 weeks),100.00000
Bryant (2021),Atomoxetine,Depressive disorder symptoms Mixed,At study endpoint (closest to 12 weeks), 774  9.800000  9.800000,11.000000,11.000000,11.000000 11.280000,14.400000,14.400000  474,  0.000000,218.42119  22.411370,11.396124 NA, 1.74307098    1.271253,100.00000   0.00000 100.00000 100,100.000000,100.000000,100.00000,100.00000,100.000000 100.00000,100.000000, 44  9, 7 218.42119 1.000000  4,1 Bangs | DellAgnello | Griffiths | Michelson 2007 | 2009 | 2018 | 2001 Bryant,10.1007/s00787-022-02004-8,NA NA NA CDRS-R | DASS NA RCT (parallel, crossover, open-label),DSM Placebo mg/kg Critically low,9.8 14.4,NA NA Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Generalized anxiety | Depressive disorder symptoms | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | CGI,Elliott (2020) | Bellatto - children (2024) | Lenzi (2018) | Bryant (2021) | Ostinelli (2025) | Cortese - Adults (2018) | Cortese - Children (2018) 8.65154639175258 42.10703125 NA,NA,NA,NA,NA,NA < 2 months,NA NA 1.27mg/kg,6-17 yo,Homogeneous Atomoxetine_Depressive disorder symptoms_Mixed_At study endpoint (closest to 12 weeks)_6-17 yo,Bryant (2021) - Atomoxetine_Depressive disorder symptoms_Mixed_At study endpoint (closest to 12 weeks)_6-17 yo,Atomoxetine_Depressive disorder symptoms_Mixed_At study endpoint (closest to 12 weeks)_6-17 yo - [Homogeneous],2021 Atomoxetine_Depressive disorder symptoms_Mixed_At study endpoint (closest to 12 weeks)  11 NA,Bryant (2021)_Atomoxetine_Depressive disorder symptoms_Mixed_At study endpoint (closest to 12 weeks),Bryant (2021)_Atomoxetine_Depressive disorder symptoms_Mixed_At study endpoint (closest to 12 weeks) 100.00000
Bryant (2021),Atomoxetine,Generalized anxiety Mixed,At study endpoint (closest to 12 weeks), 498  9.800000  9.800000  9.800000, 9.800000 11.280000 12.000000 12.000000 12.000000, 474   0.000000,172.63052  21.804618 11.097108,NA, 1.78481475    1.263855 100.00000   0.00000 100.00000 100 100.000000 100.000000,100.00000 100.00000 100.000000,100.00000 100.000000, 44  9  7,172.63052 1.000000  3 1 DellAgnello | Geller | Griffiths 2009 | 2007 | 2018,Bryant 10.1007/s00787-022-02004-8 NA,NA,NA,SCARED | MASC | STAI and STAI-C,NA,RCT (parallel, crossover, open-label),DSM,Placebo mg/kg,Critically low 9.8,12 NA,NA Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Generalized anxiety | Depressive disorder symptoms | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | CGI,Elliott (2020) | Bellatto - children (2024) | Lenzi (2018) | Bryant (2021) | Ostinelli (2025) | Cortese - Adults (2018) | Cortese - Children (2018) 8.65154639175258 42.10703125 NA,NA NA,NA NA,NA,< 2 months NA,NA 1.26mg/kg,6-17 yo Homogeneous,Atomoxetine_Generalized anxiety_Mixed_At study endpoint (closest to 12 weeks)_6-17 yo Bryant (2021) - Atomoxetine_Generalized anxiety_Mixed_At study endpoint (closest to 12 weeks)_6-17 yo,Atomoxetine_Generalized anxiety_Mixed_At study endpoint (closest to 12 weeks)_6-17 yo - [Homogeneous] 2021,Atomoxetine_Generalized anxiety_Mixed_At study endpoint (closest to 12 weeks), 12 NA,Bryant (2021)_Atomoxetine_Generalized anxiety_Mixed_At study endpoint (closest to 12 weeks) Bryant (2021)_Atomoxetine_Generalized anxiety_Mixed_At study endpoint (closest to 12 weeks),100.00000
Bryant (2021) Methylphenidate Generalized anxiety,Mixed,At study endpoint (closest to 12 weeks)  162, 8.800000, 8.800000  8.800000  8.800000,10.920000,10.920000,10.920000 13.600000  474,  0.000000, 65.90123  25.390123 10.551111,NA, 1.52296524   18.849074 100.00000,  0.00000,100.00000,100 100.000000 100.000000,100.00000, 86.41975, 51.851852 100.00000 100.000000,141,14 11  65.90123 1.000000  3,1,Aman | Brown | Lin 1993 | 1988 | 2014,Bryant 10.1007/s00787-022-02004-8 NA,NA NA RBPC -Anxiety/ Withdrawal scale | CPRS - Anxiety subscale | CBRS NA,RCT (parallel, crossover, open-label),DSM,Placebo,mg/kg | mg/d,Critically low 8.8 13.6 NA NA Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events),Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018) 4.42 50.1 60 109.9,NA, 99.5875 97.45,105.60 < 2 months NA NA 18.85mg/kg | mg/d 6-17 yo Homogeneous Methylphenidate_Generalized anxiety_Mixed_At study endpoint (closest to 12 weeks)_6-17 yo,Bryant (2021) - Methylphenidate_Generalized anxiety_Mixed_At study endpoint (closest to 12 weeks)_6-17 yo Methylphenidate_Generalized anxiety_Mixed_At study endpoint (closest to 12 weeks)_6-17 yo - [Homogeneous] 2021,Methylphenidate_Generalized anxiety_Mixed_At study endpoint (closest to 12 weeks)  13 NA,Bryant (2021)_Methylphenidate_Generalized anxiety_Mixed_At study endpoint (closest to 12 weeks),Bryant (2021)_Methylphenidate_Generalized anxiety_Mixed_At study endpoint (closest to 12 weeks) 100.00000
Candido (2021) Methylphenidate CGI Clinician-rated At study endpoint (closest to 12 weeks), 139,28.600000,28.600000 28.600000,28.600000,39.000000 39.000000,39.000000 39.000000  529 100.000000  75.54676, 30.217986 35.333813 NA, 2.42236590   20.575540,100.00000   0.00000 100.00000,100   0.000000   0.000000 100.00000,100.00000 100.000000   0.00000 100.000000 141 14,11  75.54676 1.352518  2 1 Kooij | Schrantee 2004 | 2016,Candido 10.1002/14651858.CD013011.pub2 methylphenidate immediate release,mono Observational tool Clinical impression: severity (change scores) | Clinical impression: severity (change scores) | Clinical Global Impression Scale (CGI) – Improvement (-I) ; End scores,NA,RCT (parallel, crossover, open-label) DSM-IV | DSM-IV, Diagnostic Interview
for ADHA in Adults (DIVA) Placebo mg/4-5timesad | mg/daily High 28.6 39,NA,NA,Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events),Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018),4.42 50.1,60 109.9,NA, 99.5875,97.45,105.60 2-6 months,NA NA,20.58mg/4-5timesad | mg/daily >= 18 yo Homogeneous Methylphenidate_CGI_Clinician-rated_At study endpoint (closest to 12 weeks)_>= 18 yo,Candido (2021) - Methylphenidate_CGI_Clinician-rated_At study endpoint (closest to 12 weeks)_>= 18 yo,Methylphenidate_CGI_Clinician-rated_At study endpoint (closest to 12 weeks)_>= 18 yo - [Homogeneous] 2021,Methylphenidate_CGI_Clinician-rated_At study endpoint (closest to 12 weeks)  14,FALSE Candido (2021)_Methylphenidate_CGI_Clinician-rated_At study endpoint (closest to 12 weeks) Candido (2021)_Methylphenidate_CGI_Clinician-rated_At study endpoint (closest to 12 weeks),100.00000
Castells (2018),Amphetamine CGI Mixed At study endpoint (closest to 12 weeks), 341 33.600000 33.600000,33.600000 33.600000,33.600000,33.600000 38.000000,38.000000, 563  22.873900,213.08211  44.947801,34.820411 NA  0.88415241,  58.307692 100.00000   0.00000 100.00000 100,100.000000 100.000000,100.00000,100.00000,100.000000,100.00000,100.000000, 43,14  9 213.08211,1.000000  3,1 Spencer | Waxmonsky | Weisler,2001 | 2014 | 2017,Castells,10.1002/14651858.CD007813.pub3,mixed amphetamine salts | lisdexamphetamine | triple bead mixed amphetamine salts,monotherapy Observational tool CGI NA RCT (parallel, crossover, open-label),DSM-IV Placebo,mg/d High 33.6 41.04 NA NA Disruptive behaviors | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Academic/job performance | Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Depressive disorder symptoms | Generalized anxiety | Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Executive functioning (tests),Faraone (2002) | Punja (2016) | Castells (2018) | Elliott (2020) | Bellato - adults (2024) | Bellatto - children (2024) | Lenzi (2018) | Ostinelli (2025) | Cortese - Children (2018) 8,41.2,NA,NA,NA,NA,NA,NA < 2 months NA,NA 58.31mg/d,>= 18 yo Homogeneous,Amphetamine_CGI_Mixed_At study endpoint (closest to 12 weeks)_>= 18 yo Castells (2018) - Amphetamine_CGI_Mixed_At study endpoint (closest to 12 weeks)_>= 18 yo Amphetamine_CGI_Mixed_At study endpoint (closest to 12 weeks)_>= 18 yo - [Homogeneous],2018 Amphetamine_CGI_Mixed_At study endpoint (closest to 12 weeks)  15,FALSE Castells (2018)_Amphetamine_CGI_Mixed_At study endpoint (closest to 12 weeks),Castells (2018)_Amphetamine_CGI_Mixed_At study endpoint (closest to 12 weeks) 100.00000
Castells (2018) Amphetamine,Depressive disorder symptoms Clinician-rated,At study endpoint (closest to 12 weeks)  110 21.600000,21.600000 21.600000,21.600000 21.600000 37.500000,37.500000 37.500000  563 100.000000, 55.65455  37.109091 28.682727 NA, 2.81619416,  47.727273 100.00000   0.00000 100.00000 100,100.000000,100.000000 100.00000,100.00000 100.000000 100.00000 100.000000  43 14, 9, 55.65455,1.000000  2 1,Biederman | Weiss 2012 | 2006,Castells,10.1002/14651858.CD007813.pub3,lisdexamphetamine | dexamphetamine,monotherapy | augmentation to psychotherapy Questionnaire,HAM-D NA RCT (parallel, crossover, open-label) DSM-IV,Placebo mg/d,High 21.6 37.5,NA NA,Disruptive behaviors | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Academic/job performance | Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Depressive disorder symptoms | Generalized anxiety | Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Executive functioning (tests) Faraone (2002) | Punja (2016) | Castells (2018) | Elliott (2020) | Bellato - adults (2024) | Bellatto - children (2024) | Lenzi (2018) | Ostinelli (2025) | Cortese - Children (2018) 8 41.2 NA,NA,NA,NA NA NA,2-6 months,NA,NA 47.73mg/d >= 18 yo,Homogeneous Amphetamine_Depressive disorder symptoms_Clinician-rated_At study endpoint (closest to 12 weeks)_>= 18 yo,Castells (2018) - Amphetamine_Depressive disorder symptoms_Clinician-rated_At study endpoint (closest to 12 weeks)_>= 18 yo Amphetamine_Depressive disorder symptoms_Clinician-rated_At study endpoint (closest to 12 weeks)_>= 18 yo - [Homogeneous],2018 Amphetamine_Depressive disorder symptoms_Clinician-rated_At study endpoint (closest to 12 weeks)  16 FALSE,Castells (2018)_Amphetamine_Depressive disorder symptoms_Clinician-rated_At study endpoint (closest to 12 weeks) Castells (2018)_Amphetamine_Depressive disorder symptoms_Clinician-rated_At study endpoint (closest to 12 weeks),100.00000
Castells (2018),Amphetamine,Generalized anxiety Clinician-rated,At study endpoint (closest to 12 weeks)  110 21.600000 21.600000,21.600000,21.600000 21.600000,37.500000 37.500000,37.500000  563,100.000000, 55.65455  37.109091 28.682727,NA, 2.81619416   47.727273,100.00000   0.00000,100.00000,100 100.000000,100.000000 100.00000,100.00000,100.000000 100.00000 100.000000  43 14  9  55.65455 1.000000, 2 1,Biederman | Weiss,2012 | 2006,Castells,10.1002/14651858.CD007813.pub3,lisdexamphetamine | dexamphetamine monotherapy | augmentation to psychotherapy,Questionnaire,HAM-A NA RCT (parallel, crossover, open-label) DSM-IV Placebo,mg/d,High 21.6 37.5 NA NA,Disruptive behaviors | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Academic/job performance | Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Depressive disorder symptoms | Generalized anxiety | Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Executive functioning (tests) Faraone (2002) | Punja (2016) | Castells (2018) | Elliott (2020) | Bellato - adults (2024) | Bellatto - children (2024) | Lenzi (2018) | Ostinelli (2025) | Cortese - Children (2018),8,41.2,NA NA NA,NA NA,NA,2-6 months NA,NA,47.73mg/d >= 18 yo Homogeneous,Amphetamine_Generalized anxiety_Clinician-rated_At study endpoint (closest to 12 weeks)_>= 18 yo,Castells (2018) - Amphetamine_Generalized anxiety_Clinician-rated_At study endpoint (closest to 12 weeks)_>= 18 yo Amphetamine_Generalized anxiety_Clinician-rated_At study endpoint (closest to 12 weeks)_>= 18 yo - [Homogeneous] 2018,Amphetamine_Generalized anxiety_Clinician-rated_At study endpoint (closest to 12 weeks), 17 FALSE,Castells (2018)_Amphetamine_Generalized anxiety_Clinician-rated_At study endpoint (closest to 12 weeks),Castells (2018)_Amphetamine_Generalized anxiety_Clinician-rated_At study endpoint (closest to 12 weeks),100.00000
Catala-Lopez (2017),Bupropion,Acceptability: all-cause discontinuation,NA At study endpoint (closest to 12 weeks)  139  8.500000  8.500000, 8.500000  8.500000  8.500000, 8.500000  8.700000  8.700000  575   0.000000, 91.94964, 12.158273, 8.543165,NA,NA NA,100.00000,  0.00000,100.00000 100,  0.000000   0.000000,100.00000,100.00000,  0.000000   0.00000 100.000000  10  7, 6, 91.94964 1.000000, 2,1,Casat | Conners 1987 | 1996,Catala-Lopez 10.1371/journal.pone.0180355,NA NA,NA,NA,NA RCT NA Placebo NA,Low,8.5,8.7 NA NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Depressive disorder symptoms | Generalized anxiety | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Executive functioning (tests) | Emotional dysregulation Stuhec (2015) | Verbeeck (2017) | Ostinelli (2025) | Cortese - Children (2018) | Cortese - Adults (2018) | Catala-Lopez (2017) 8.5,40.25 NA,NA,NA,NA,NA NA,NA,NA NA NANA,6-17 yo Homogeneous Bupropion_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_6-17 yo Catala-Lopez (2017) - Bupropion_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_6-17 yo,Bupropion_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_6-17 yo - [Homogeneous] 2017 Bupropion_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)  18 NA,Catala-Lopez (2017)_Bupropion_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks),Catala-Lopez (2017)_Bupropion_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks),100.00000
Catala-Lopez (2017),Bupropion,Tolerability (discontinuation due to adverse events),NA,At study endpoint (closest to 12 weeks)  139, 8.500000  8.500000, 8.500000, 8.500000, 8.500000  8.500000  8.700000  8.700000  575   0.000000  91.94964  12.158273  8.543165,NA NA NA,100.00000,  0.00000,100.00000,100,  0.000000   0.000000,100.00000,100.00000   0.000000   0.00000,100.000000  10, 7  6, 91.94964 1.000000, 2 1,Casat | Conners,1987 | 1996,Catala-Lopez,10.1371/journal.pone.0180355,NA NA,NA NA,NA RCT NA,Placebo,NA,Low 8.5,8.7,NA NA Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Depressive disorder symptoms | Generalized anxiety | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Executive functioning (tests) | Emotional dysregulation Stuhec (2015) | Verbeeck (2017) | Ostinelli (2025) | Cortese - Children (2018) | Cortese - Adults (2018) | Catala-Lopez (2017) 8.5 40.25,NA,NA,NA,NA,NA,NA NA NA,NA,NANA 6-17 yo,Homogeneous,Bupropion_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks)_6-17 yo,Catala-Lopez (2017) - Bupropion_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks)_6-17 yo Bupropion_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks)_6-17 yo - [Homogeneous] 2017 Bupropion_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks)  19,NA Catala-Lopez (2017)_Bupropion_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks) Catala-Lopez (2017)_Bupropion_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks),100.00000
Catala-Lopez (2017) Carnitine Acceptability: all-cause discontinuation NA At study endpoint (closest to 12 weeks)  247, 8.400000  8.400000, 8.400000  8.400000  8.600000  9.200000, 9.200000  9.500000, 575, 16.194332  81.65587, 17.279352, 8.752227 NA,NA,NA,100.00000   0.00000 100.00000,100, 74.493927  74.493927 100.00000 100.00000, 74.493927, 74.49393,100.000000   4, 1, 1  81.65587,1.000000, 4 1,Abbasi | Arnold | Torrioli | van Oudheusden 2011 | 2007 | 2008 | 2002 Catala-Lopez 10.1371/journal.pone.0180355,NA stimulant NA NA,NA RCT,NA Active (any credible active intervention) | Placebo NA,Low 8.4,9.5,NA,NA,Acceptability: all-cause discontinuation Catala-Lopez (2017),8.4,9.5 NA NA NA NA NA NA,NA NA NA,NANA 6-17 yo,Homogeneous,Carnitine_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_6-17 yo Catala-Lopez (2017) - Carnitine_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_6-17 yo Carnitine_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_6-17 yo - [Homogeneous],2017 Carnitine_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)  20 NA,Catala-Lopez (2017)_Carnitine_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks),Catala-Lopez (2017)_Carnitine_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks) 100.00000
Catala-Lopez (2017),Cognitive training,Acceptability: all-cause discontinuation,NA At study endpoint (closest to 12 weeks), 535  8.400000, 8.400000  8.400000, 8.400000  8.900000, 9.700000  9.800000,10.400000  575,  0.000000  73.72150  31.054579, 8.984860 NA NA,NA,100.00000   0.00000 100.00000 100, 47.663551  47.663551,100.00000, 66.35514, 94.392523, 94.39252, 53.271028  28  6  4  73.72150 1.000000  8,1 Bigorra | Chacko | Green | Hovik | Klingberg | Steiner | Tamm | van Dongen-Boomsma,2015 | 2014 | 2012 | 2013 | 2005 Catala-Lopez,10.1371/journal.pone.0180355,NA,NA,NA NA NA RCT,NA Placebo | Control | Waiting list,NA Low 6.6,10.4 NA NA,Academic/job performance | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (report) | Executive functioning (tests) | Acceptability: all-cause discontinuation | Quality of life (patients),Westwood - Children (2024) | Westwood - Adults (2024) | Ostinelli (2025) | Catala-Lopez (2017),6.55 41.5895454545455 NA,NA,NA,NA NA NA NA,NA NA NANA,6-17 yo Homogeneous Cognitive training_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_6-17 yo Catala-Lopez (2017) - Cognitive training_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_6-17 yo,Cognitive training_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_6-17 yo - [Homogeneous] 2017 Cognitive training_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks), 21,NA Catala-Lopez (2017)_Cognitive training_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks),Catala-Lopez (2017)_Cognitive training_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks),100.00000
Catala-Lopez (2017),Desipramine,Acceptability: all-cause discontinuation NA At study endpoint (closest to 12 weeks), 114,11.000000 11.000000,11.000000 11.000000,11.500000 11.500000 11.500000 11.500000  575   0.000000, 61.49123, 10.312281,11.320175 NA NA NA,100.00000,  0.00000 100.00000 100,100.000000 100.000000 100.00000,100.00000,100.000000 100.00000,100.000000,  4  3  2  61.49123 1.000000  2 1,Biederman | Spencer 2002c,1989 | 2002 Catala-Lopez 10.1371/journal.pone.0180355,NA NA,NA NA NA RCT NA Placebo NA Low 11,11.5 NA NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events),Otasowie (2014) | Catala-Lopez (2017) 11,11.5 NA NA NA,NA NA NA NA,NA NA,NANA 6-17 yo,Homogeneous Desipramine_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_6-17 yo Catala-Lopez (2017) - Desipramine_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_6-17 yo,Desipramine_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_6-17 yo - [Homogeneous],2017,Desipramine_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks), 22 NA Catala-Lopez (2017)_Desipramine_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks) Catala-Lopez (2017)_Desipramine_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks) 100.00000
Catala-Lopez (2017),Desipramine Tolerability (discontinuation due to adverse events),NA At study endpoint (closest to 12 weeks)  114 11.000000 11.000000,11.000000 11.000000 11.500000 11.500000 11.500000 11.500000, 575   0.000000, 61.49123  10.312281,11.320175,NA,NA NA,100.00000   0.00000 100.00000 100 100.000000 100.000000,100.00000,100.00000,100.000000 100.00000 100.000000,  4, 3  2, 61.49123,1.000000, 2,1,Biederman | Spencer 2002c,1989 | 2002,Catala-Lopez,10.1371/journal.pone.0180355,NA,NA NA NA NA,RCT NA,Placebo NA,Low,11,11.5,NA NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events),Otasowie (2014) | Catala-Lopez (2017),11,11.5 NA NA NA,NA NA,NA,NA NA,NA,NANA,6-17 yo Homogeneous Desipramine_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks)_6-17 yo Catala-Lopez (2017) - Desipramine_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks)_6-17 yo Desipramine_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks)_6-17 yo - [Homogeneous],2017 Desipramine_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks)  23 NA Catala-Lopez (2017)_Desipramine_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks),Catala-Lopez (2017)_Desipramine_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks),100.00000
Catala-Lopez (2017) Diet (restricted/elimination) Acceptability: all-cause discontinuation,NA At study endpoint (closest to 12 weeks)  273, 6.900000  6.900000  6.900000, 6.900000  8.400000, 8.400000  8.400000  9.300000, 575, 38.827839  86.31868  13.769461, 7.764835,NA NA,NA 100.00000   0.00000,100.00000,100, 75.457875  75.457875 100.00000  90.10989, 85.347985  85.34799  90.109890,  8  3, 2, 86.31868,1.000000, 4 1 Egger | Ghanizadeh | Pelsser,1992 | 2015 | 2009 | 2011 Catala-Lopez,10.1371/journal.pone.0180355,NA,stimulant NA NA NA RCT,NA,Placebo | Active (any credible active intervention) | Waiting list | Control,NA Low,6.2 9.3 NA,NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events),Sonuga-Barke (2014) | Catala-Lopez (2017) 4.5,9.5,NA,NA,NA NA NA,NA NA NA,NA NANA,6-17 yo,Homogeneous,Diet (restricted/elimination)_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_6-17 yo,Catala-Lopez (2017) - Diet (restricted/elimination)_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_6-17 yo,Diet (restricted/elimination)_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_6-17 yo - [Homogeneous] 2017 Diet (restricted/elimination)_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)  24,NA,Catala-Lopez (2017)_Diet (restricted/elimination)_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks) Catala-Lopez (2017)_Diet (restricted/elimination)_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks),100.00000
Catala-Lopez (2017),Diet (restricted/elimination),Tolerability (discontinuation due to adverse events) NA,At study endpoint (closest to 12 weeks)  127, 6.200000, 6.200000, 6.200000  6.900000  6.900000, 6.900000  6.900000  6.900000, 575,  0.000000  84.48031  14.956693, 6.751181,NA,NA NA 100.00000   0.00000 100.00000,100  78.740157, 78.740157,100.00000  78.74016,100.000000 100.00000  78.740157,  8, 3  2, 84.48031 1.000000  2 1,Pelsser 2009 | 2011 Catala-Lopez 10.1371/journal.pone.0180355 NA,NA,NA,NA NA RCT NA,Waiting list | Control,NA Low,6.2,6.9,NA,NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) Sonuga-Barke (2014) | Catala-Lopez (2017),4.5,9.5,NA,NA NA NA,NA NA NA,NA,NA,NANA,6-17 yo,Homogeneous,Diet (restricted/elimination)_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks)_6-17 yo Catala-Lopez (2017) - Diet (restricted/elimination)_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks)_6-17 yo,Diet (restricted/elimination)_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks)_6-17 yo - [Homogeneous] 2017 Diet (restricted/elimination)_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks), 25,NA Catala-Lopez (2017)_Diet (restricted/elimination)_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks) Catala-Lopez (2017)_Diet (restricted/elimination)_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks),100.00000
Catala-Lopez (2017) Homeopathy Acceptability: all-cause discontinuation,NA At study endpoint (closest to 12 weeks), 104  9.300000, 9.300000, 9.300000  9.300000, 9.300000, 9.300000  9.300000  9.300000  575,  0.000000, 53.55769, 21.599038  9.300000,NA,NA NA,100.00000   0.00000 100.00000,100, 41.346154  41.346154 100.00000, 41.34615 100.000000  41.34615 100.000000   3  3  2, 53.55769 1.000000  2 1,Jacobs | Oberai,2005 | 2013 Catala-Lopez 10.1371/journal.pone.0180355,NA,NA,NA NA NA RCT NA Placebo,NA Low,9.3 9.3,NA,NA Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Conduct Disorder symptoms/Oppositional Defiant Disorder symptoms | Acceptability: all-cause discontinuation Heirs (2007) | Catala-Lopez (2017) 8.5 9.3 NA NA,NA NA,NA,NA NA,NA NA,NANA,6-17 yo Homogeneous Homeopathy_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_6-17 yo Catala-Lopez (2017) - Homeopathy_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_6-17 yo,Homeopathy_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_6-17 yo - [Homogeneous],2017 Homeopathy_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks), 26 NA Catala-Lopez (2017)_Homeopathy_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks) Catala-Lopez (2017)_Homeopathy_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks),100.00000
Catala-Lopez (2017),Methylphenidate + Alpha-2 agonists (guanfacine / clonidine),Acceptability: all-cause discontinuation NA At study endpoint (closest to 12 weeks)  127  9.500000  9.500000, 9.500000, 9.500000,10.200000,10.200000 10.200000,10.200000, 575   0.000000, 63.53543  17.092126, 9.858268 NA,NA,NA,100.00000,  0.00000,100.00000,100 100.000000 100.000000 100.00000,100.00000,100.000000 100.00000 100.000000,  2  2, 1, 63.53543 1.000000, 2 1 Palumbo | TSSG,2008 | 2002 Catala-Lopez,10.1371/journal.pone.0180355,NA,NA,NA NA NA,RCT,NA,Placebo,NA,Low,9.5,10.2 NA,NA Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events),Catala-Lopez (2017),9.5 10.2,NA NA NA,NA NA,NA NA NA NA NANA,6-17 yo Homogeneous Methylphenidate + Alpha-2 agonists (guanfacine / clonidine)_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_6-17 yo,Catala-Lopez (2017) - Methylphenidate + Alpha-2 agonists (guanfacine / clonidine)_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_6-17 yo Methylphenidate + Alpha-2 agonists (guanfacine / clonidine)_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_6-17 yo - [Homogeneous] 2017 Methylphenidate + Alpha-2 agonists (guanfacine / clonidine)_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)  27,NA,Catala-Lopez (2017)_Methylphenidate + Alpha-2 agonists (guanfacine / clonidine)_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks),Catala-Lopez (2017)_Methylphenidate + Alpha-2 agonists (guanfacine / clonidine)_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks),100.00000
Catala-Lopez (2017) Methylphenidate + Alpha-2 agonists (guanfacine / clonidine),Tolerability (discontinuation due to adverse events) NA,At study endpoint (closest to 12 weeks), 127  9.500000  9.500000  9.500000  9.500000 10.200000,10.200000,10.200000 10.200000, 575   0.000000  63.53543  17.092126, 9.858268 NA,NA NA,100.00000   0.00000,100.00000 100 100.000000,100.000000,100.00000,100.00000,100.000000 100.00000 100.000000   2  2  1, 63.53543 1.000000, 2,1 Palumbo | TSSG 2008 | 2002 Catala-Lopez,10.1371/journal.pone.0180355,NA,NA NA NA NA RCT,NA Placebo NA,Low 9.5,10.2,NA NA,Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) Catala-Lopez (2017) 9.5 10.2,NA NA NA,NA,NA NA,NA NA,NA NANA,6-17 yo,Homogeneous Methylphenidate + Alpha-2 agonists (guanfacine / clonidine)_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks)_6-17 yo Catala-Lopez (2017) - Methylphenidate + Alpha-2 agonists (guanfacine / clonidine)_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks)_6-17 yo Methylphenidate + Alpha-2 agonists (guanfacine / clonidine)_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks)_6-17 yo - [Homogeneous],2017,Methylphenidate + Alpha-2 agonists (guanfacine / clonidine)_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks), 28 NA Catala-Lopez (2017)_Methylphenidate + Alpha-2 agonists (guanfacine / clonidine)_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks) Catala-Lopez (2017)_Methylphenidate + Alpha-2 agonists (guanfacine / clonidine)_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks) 100.00000
Catala-Lopez (2017) Multimodal behavioral interventions,Acceptability: all-cause discontinuation,NA At study endpoint (closest to 12 weeks), 584, 8.200000, 8.500000  8.500000  8.500000, 8.500000  8.600000, 8.600000, 8.600000  575, 18.150685,187.20890, 23.252740  8.618493,NA NA,NA 100.00000,  0.00000 100.00000,100   0.000000,  0.000000 100.00000   0.00000,100.000000  90.41096   0.000000   5  1, 1 187.20890,1.000000  5,1 Fabiano | MTA Cooperative | Pfiffner | Waxmonsky | van der Oord 2010 | 1999 | 2014 | 2007,Catala-Lopez 10.1371/journal.pone.0180355 NA non-stimulant | stimulant,NA,NA NA,RCT,NA Control | Standard care | Control (usual care) | Active (any credible active intervention),NA,Low,8.2,9.9,NA NA,Acceptability: all-cause discontinuation,Catala-Lopez (2017),8.2 9.9 NA,NA,NA NA,NA NA NA NA NA NANA 6-17 yo,Homogeneous Multimodal behavioral interventions_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_6-17 yo,Catala-Lopez (2017) - Multimodal behavioral interventions_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_6-17 yo Multimodal behavioral interventions_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_6-17 yo - [Homogeneous],2017,Multimodal behavioral interventions_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks), 29 NA,Catala-Lopez (2017)_Multimodal behavioral interventions_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks),Catala-Lopez (2017)_Multimodal behavioral interventions_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks) 100.00000
Catala-Lopez (2017) Neurofeedback Acceptability: all-cause discontinuation NA At study endpoint (closest to 12 weeks), 333  8.600000, 8.600000  8.600000  8.900000,10.600000 11.200000 11.200000 11.200000, 575, 45.783133  61.13253  24.747289,10.138855,NA,NA,NA 100.00000   0.00000 100.00000,100, 41.867470, 41.867470 100.00000  70.78313 100.000000 100.00000  41.867470, 36, 4  3  61.21386,1.081325  7 1,Arnold | Bakhshayesh | Duric | Li | Perreau-Linck | Steiner 2013 | 2011 | 2012 | 2010 | 2014 Catala-Lopez 10.1371/journal.pone.0180355 NA stimulant,NA NA NA,RCT NA Placebo | Control | Active (any credible active intervention) | Control | Waiting list,NA Low 8.6 12.4 NA,NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (tests) | Executive functioning (report) | Acceptability: all-cause discontinuation,Westwood - Children (2025) | Westwood - Adults (2025) | Catala-Lopez (2017),8.57,36.9,NA NA,NA NA,NA NA NA NA NA NANA 6-17 yo,Homogeneous,Neurofeedback_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_6-17 yo Catala-Lopez (2017) - Neurofeedback_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_6-17 yo,Neurofeedback_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_6-17 yo - [Homogeneous],2017 Neurofeedback_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks), 30,NA Catala-Lopez (2017)_Neurofeedback_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks) Catala-Lopez (2017)_Neurofeedback_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks) 100.00000
Catala-Lopez (2017),Parent-mediated behavioral interventions Acceptability: all-cause discontinuation,NA At study endpoint (closest to 12 weeks),1123, 4.000000, 4.000000, 4.000000, 4.100000, 8.600000 10.100000 10.600000,10.700000  575,  4.630454 127.80677, 27.891317, 7.750045,NA,NA NA,100.00000,  0.00000 100.00000,100  59.572573  59.572573  94.92431, 67.14159  90.293856  90.29386, 69.278718  33  4  5,127.80677,1.000000,12 1,Abikoff | Bor | Fabiano | Ferrin | Firestone | Hiscock | Pfiffner | Pisterman | Steeger | Thompson | van den Hoofdakker,2015 | 2002 | 2012 | 2014 | 2016 | 1986 | 1992 | 2009 | 2007 Catala-Lopez,10.1371/journal.pone.0180355 NA,stimulant NA,NA NA RCT NA Waiting list | Control (parent counseling with support) | Control (usual care) | Active (any credible active intervention) | Placebo | Control NA Low,3.6 12.5 NA,NA Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Conduct Disorder symptoms | Oppositional Defiant Disorder symptoms | Acceptability: all-cause discontinuation,Groenman - Preschool (2022) | Groenman (2022) | Doffer (2023) | Doffer - Preschool (2023) | Catala-Lopez (2017),3.5 13.99,94.15 108.21,NA 100.4569,94.15 103.76 NA NA NA NANA 6-17 yo Mixed Parent-mediated behavioral interventions_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_6-17 yo,Catala-Lopez (2017) - Parent-mediated behavioral interventions_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_6-17 yo,Parent-mediated behavioral interventions_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_6-17 yo - [Mixed],2017 Parent-mediated behavioral interventions_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks), 31 NA,Catala-Lopez (2017)_Parent-mediated behavioral interventions_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks),Catala-Lopez (2017)_Parent-mediated behavioral interventions_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks),100.00000
Catala-Lopez (2017),Polyunsaturated fatty acids,Tolerability (discontinuation due to adverse events),NA,At study endpoint (closest to 12 weeks)  584, 8.300000  9.200000, 9.200000  9.200000  9.300000 12.000000 12.000000,13.700000  575  10.273973 112.51712, 26.397432 10.311130,NA NA NA,100.00000,  0.00000 100.00000 100  29.109589, 29.109589 100.00000  89.72603  63.356164  29.10959, 89.726027, 28, 8, 3 112.51712 1.000000, 7 1,Barragán | Bos | Johnson | Manor | Matsudaira | Raz | Vaisman,2014 | 2015 | 2009 | 2012 | 2008 Catala-Lopez 10.1371/journal.pone.0180355,NA,stimulant+bt,NA,NA,NA,RCT NA Active (any credible active intervention) | Placebo,NA Low 8.3,13.7 NA,NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Conduct Disorder symptoms | Oppositional Defiant Disorder symptoms | Social-communication skills | Specific adverse events: sleep problems | Quality of life (patients) | Tolerability (discontinuation due to adverse events),Gillies (2023) | Handel (2021) | Catala-Lopez (2017) 6 13.7 NA,NA NA,NA NA,NA NA,NA,NA NANA 6-17 yo,Homogeneous,Polyunsaturated fatty acids_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks)_6-17 yo Catala-Lopez (2017) - Polyunsaturated fatty acids_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks)_6-17 yo,Polyunsaturated fatty acids_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks)_6-17 yo - [Homogeneous],2017,Polyunsaturated fatty acids_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks)  32,NA Catala-Lopez (2017)_Polyunsaturated fatty acids_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks) Catala-Lopez (2017)_Polyunsaturated fatty acids_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks) 100.00000
Catala-Lopez (2017),Risperidone,Acceptability: all-cause discontinuation,NA,At study endpoint (closest to 12 weeks)  193  8.100000  8.900000, 8.900000  8.900000  8.900000, 8.900000  8.900000, 8.900000  575 100.000000,149.47668  21.749223  8.796373 NA NA,NA,100.00000   0.00000,100.00000 100, 87.046632  87.046632 100.00000,100.00000 100.000000, 87.04663 100.000000   2  1  1,149.47668 1.000000, 2,1 Aman | Armenteros,2014 | 2007,Catala-Lopez 10.1371/journal.pone.0180355,NA stimulant+bt | stimulant,NA NA,NA,RCT NA Active (any credible active intervention) NA,Low,8.1 8.9 NA NA,Acceptability: all-cause discontinuation Catala-Lopez (2017) 8.1,8.9 NA,NA NA NA NA,NA,NA NA,NA NANA,6-17 yo,Homogeneous Risperidone_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_6-17 yo,Catala-Lopez (2017) - Risperidone_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_6-17 yo,Risperidone_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_6-17 yo - [Homogeneous] 2017 Risperidone_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks), 33 NA,Catala-Lopez (2017)_Risperidone_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks),Catala-Lopez (2017)_Risperidone_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks) 100.00000
Catala-Lopez (2017) Zinc Acceptability: all-cause discontinuation NA,At study endpoint (closest to 12 weeks)  536  9.600000, 9.600000  9.600000  9.600000  9.600000  9.600000  9.600000, 9.600000  575, 15.671642,310.14925  20.520896, 9.460448 NA,NA NA 100.00000,  0.00000 100.00000 100  92.537313  92.537313  92.53731 100.00000, 92.537313  92.53731 100.000000   6  3  2 310.14925 1.000000, 4 1 Akhondzadeh | Arnold | Bilici | Zamora 2004 | 2011 Catala-Lopez 10.1371/journal.pone.0180355 NA stimulant,NA NA NA,RCT NA Active (any credible active intervention) | Placebo NA Low 7.9,9.6 NA,NA Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events),Talebi (2021) | Catala-Lopez (2017) 7.14 9.92,NA NA NA,NA,NA,NA NA NA,NA NANA 6-17 yo,Homogeneous Zinc_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_6-17 yo,Catala-Lopez (2017) - Zinc_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_6-17 yo,Zinc_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_6-17 yo - [Homogeneous],2017,Zinc_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)  34 NA Catala-Lopez (2017)_Zinc_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks) Catala-Lopez (2017)_Zinc_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks) 100.00000
Catala-Lopez (2017) Zinc Tolerability (discontinuation due to adverse events) NA At study endpoint (closest to 12 weeks), 456  9.600000  9.600000  9.600000  9.600000, 9.600000, 9.600000  9.600000, 9.600000  575,  0.000000,363.85965, 17.920175  9.600000,NA NA,NA 100.00000   0.00000 100.00000,100,100.000000,100.000000,100.00000 100.00000 100.000000,100.00000,100.000000   6, 3  2,363.85965,1.000000  2 1,Arnold | Bilici 2011 | 2004,Catala-Lopez,10.1371/journal.pone.0180355,NA NA NA,NA,NA RCT NA Placebo,NA,Low,9.6 9.6 NA NA Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events),Talebi (2021) | Catala-Lopez (2017),7.14,9.92,NA,NA,NA,NA,NA NA NA NA,NA NANA,6-17 yo Homogeneous,Zinc_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks)_6-17 yo,Catala-Lopez (2017) - Zinc_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks)_6-17 yo Zinc_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks)_6-17 yo - [Homogeneous] 2017,Zinc_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks)  35 NA,Catala-Lopez (2017)_Zinc_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks) Catala-Lopez (2017)_Zinc_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks),100.00000
Chiu (2022),Methylphenidate Combined ADHD symptoms (inattentive + hyperactive/impulsive),Parent-rated At study endpoint (closest to 12 weeks)  623, 4.420000, 4.740000, 4.740000, 4.740000  4.740000, 4.890000, 4.900000  4.900000  662,  0.000000 210.58909  24.585593, 4.779454  97.82250  0.42040167   13.630042,100.00000, 66.77368 100.00000 100 100.000000,100.000000 100.00000,100.00000, 76.243981,100.00000,100.000000 141 14 11,210.58909,1.000000  5 1 Abikoff | Childress | Greenhill | Musten | Short,2007 | 2020 | 2006 | 1997 | 2004 Chiu,10.1192/j.eurpsy.2023.11 MPH IR | MPH-MLR | MPH IR or MAS,NA,Questionnaire SWAN total, inattention, hyperactivity/impulsivity | ADHD-RS-IV total score | CLAM/SKAMP composite, SKAMP Attention and SKAMP Deportment | CPRS Learning, conduct and hyperactivity index NA,RCT (parallel, crossover, open-label),DSM-IV | DSM-5 | DSM-III-R Placebo,mg/d | mg/kg High,4.42 5.25,97.41,97.93,Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events) Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018),4.42 50.1,60,109.9,NA  99.5875,97.45 105.60 < 2 months Average (80-119) NA 13.63mg/d | mg/kg < 6 yo Homogeneous,Methylphenidate_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks)_< 6 yo,Chiu (2022) - Methylphenidate_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks)_< 6 yo Methylphenidate_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks)_< 6 yo - [Homogeneous],2022,Methylphenidate_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks), 36 FALSE Chiu (2022)_Methylphenidate_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks),Chiu (2022)_Methylphenidate_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks) 100.00000
Chiu (2022) Methylphenidate Combined ADHD symptoms (inattentive + hyperactive/impulsive) Teacher-rated At study endpoint (closest to 12 weeks), 526, 4.420000  4.740000, 4.740000, 4.740000, 4.740000  4.867500  5.250000, 6.130000  662,  0.000000,228.34221, 22.748669  4.935285, 96.75234  0.54080780,   9.731250,100.00000  92.77567 100.00000 100,100.000000,100.000000,100.00000 100.00000, 87.832700,100.00000 100.000000 141,14,11,228.34221 1.000000, 5 1,Abikoff | Chaco | Greenhill | Handen | Short,2007 | 2004 | 2006 | 1999 Chiu 10.1192/j.eurpsy.2023.11,MPH IR | MPH IR or MAS,NA Questionnaire | Observational tool,SWAN total, inattention, hyperactivity/impulsivity | point system - Percentage following activity rules | CLAM/SKAMP composite, SKAMP Attention and SKAMP Deportment NA,RCT (parallel, crossover, open-label) DSM-IV | DSM-llI-R or DSM-IV | DSM-III-R,Placebo mg/kg | mg/d High 4.42 6.13 60 102,Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events) Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018),4.42,50.1 60,109.9,NA  99.5875,97.45,105.60 < 2 months,Average (80-119),NA 9.73mg/kg | mg/d,< 6 yo,Homogeneous Methylphenidate_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Teacher-rated_At study endpoint (closest to 12 weeks)_< 6 yo Chiu (2022) - Methylphenidate_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Teacher-rated_At study endpoint (closest to 12 weeks)_< 6 yo Methylphenidate_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Teacher-rated_At study endpoint (closest to 12 weeks)_< 6 yo - [Homogeneous] 2022,Methylphenidate_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Teacher-rated_At study endpoint (closest to 12 weeks)  37 FALSE,Chiu (2022)_Methylphenidate_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Teacher-rated_At study endpoint (closest to 12 weeks) Chiu (2022)_Methylphenidate_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Teacher-rated_At study endpoint (closest to 12 weeks) 100.00000
Cortese - Adults (2018) Atomoxetine,CGI Clinician-rated,At follow-up (closest to 26 weeks)  410 36.727073,36.727073 36.727073 36.727073 36.727073,36.727073 36.727073 36.727073  757,  0.000000 410.00000, 41.459024,36.727073 NA, 5.52359033   85.200000 100.00000,  0.00000 100.00000 100,100.000000,100.000000 100.00000,100.00000 100.000000,100.00000 100.000000  44, 9  7 410.00000,1.000000, 1 1,Adler 2008a,Cortese - Adults,10.1016/S2215-0366(18)30269-4,Atomoxetine,NA NA,CGI-I NA,RCT NA,Placebo,mg/d High 36.7270731707317,36.7270731707317,NA NA Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Generalized anxiety | Depressive disorder symptoms | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | CGI Elliott (2020) | Bellatto - children (2024) | Lenzi (2018) | Bryant (2021) | Ostinelli (2025) | Cortese - Adults (2018) | Cortese - Children (2018) 8.65154639175258,42.10703125 NA NA NA NA,NA,NA 2-6 months NA NA 85.2mg/d,>= 18 yo Homogeneous,Atomoxetine_CGI_Clinician-rated_At follow-up (closest to 26 weeks)_>= 18 yo,Cortese - Adults (2018) - Atomoxetine_CGI_Clinician-rated_At follow-up (closest to 26 weeks)_>= 18 yo Atomoxetine_CGI_Clinician-rated_At follow-up (closest to 26 weeks)_>= 18 yo - [Homogeneous] 2018 Atomoxetine_CGI_Clinician-rated_At follow-up (closest to 26 weeks), 38 TRUE Cortese - Adults (2018)_Atomoxetine_CGI_Clinician-rated_At follow-up (closest to 26 weeks),Cortese - Adults (2018)_Atomoxetine_CGI_Clinician-rated_At follow-up (closest to 26 weeks),100.00000
Cortese - Adults (2018) Bupropion,Combined ADHD symptoms (inattentive + hyperactive/impulsive) Clinician-rated,At study endpoint (closest to 12 weeks), 202 38.235000 38.235000 40.250000,40.250000,40.250000,40.250000,40.250000 40.250000, 757,  0.000000 137.84158  41.371287 39.850990,NA  1.75004842, 462.554455 100.00000   0.00000 100.00000,100,100.000000 100.000000,100.00000 100.00000 100.000000 100.00000,100.000000  10  7, 6 137.84158 1.000000, 2,1,Wilens,2001 | 2005a,Cortese - Adults,10.1016/S2215-0366(18)30269-4,Bupropion,NA NA,1:ADHD-RS Total | 4:ADHD-SRS Total,NA,RCT NA Placebo mg/d High,38.235 40.25 NA,NA Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Depressive disorder symptoms | Generalized anxiety | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Executive functioning (tests) | Emotional dysregulation Stuhec (2015) | Verbeeck (2017) | Ostinelli (2025) | Cortese - Children (2018) | Cortese - Adults (2018) | Catala-Lopez (2017),8.5 40.25 NA,NA NA NA NA,NA < 2 months,NA NA,462.55mg/d,>= 18 yo Homogeneous Bupropion_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks)_>= 18 yo Cortese - Adults (2018) - Bupropion_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks)_>= 18 yo,Bupropion_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks)_>= 18 yo - [Homogeneous],2018 Bupropion_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks)  39 TRUE Cortese - Adults (2018)_Bupropion_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks),Cortese - Adults (2018)_Bupropion_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks) 100.00000
Cortese - Adults (2018) Modafinil,Acceptability: all-cause discontinuation,NA At study endpoint (closest to 12 weeks), 148,39.004445 39.004445 39.004445,39.004445 39.004445 39.004445 39.004445,39.004445  757   0.000000,140.00000  42.806843,39.004445 NA, 2.07134638, 382.500000 100.00000   0.00000,100.00000,100 100.000000,100.000000,100.00000,100.00000,100.000000 100.00000,100.000000,  8  4, 3 148.00000 4.000000, 1 1,Arnold,2014 Cortese - Adults 10.1016/S2215-0366(18)30269-4,Modafinil NA,NA,Acceptability,NA RCT,NA,Placebo mg/d High,38.1034013605442,39.8414965986395 NA NA Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) Ostinelli (2025) | Cortese - Adults (2018) | Cortese - Children (2018) 7.875 40.8,NA NA NA NA,NA,NA,2-6 months NA NA 382.5mg/d,>= 18 yo Homogeneous Modafinil_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_>= 18 yo Cortese - Adults (2018) - Modafinil_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_>= 18 yo,Modafinil_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_>= 18 yo - [Homogeneous] 2018,Modafinil_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)  40 TRUE,Cortese - Adults (2018)_Modafinil_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks),Cortese - Adults (2018)_Modafinil_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks),100.00000
Cortese - Adults (2018),Modafinil,Combined ADHD symptoms (inattentive + hyperactive/impulsive) Clinician-rated,At study endpoint (closest to 12 weeks), 144 39.002783 39.002783 39.002783 39.002783 39.002783 39.002783,39.002783,39.002783, 757,  0.000000,135.50000, 42.844459,39.002783 NA  2.07134638, 382.500000 100.00000,  0.00000,100.00000 100 100.000000,100.000000 100.00000 100.00000,100.000000 100.00000 100.000000   8  4, 3,144.00000 4.000000, 1 1 Arnold 2014,Cortese - Adults,10.1016/S2215-0366(18)30269-4,Modafinil NA NA,17:Other,NA RCT NA,Placebo,mg/d,High,38.1070422535211 39.8412587412587,NA,NA Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events),Ostinelli (2025) | Cortese - Adults (2018) | Cortese - Children (2018),7.875 40.8 NA,NA,NA NA,NA NA 2-6 months NA,NA,382.5mg/d,>= 18 yo,Homogeneous Modafinil_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks)_>= 18 yo,Cortese - Adults (2018) - Modafinil_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks)_>= 18 yo Modafinil_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks)_>= 18 yo - [Homogeneous] 2018,Modafinil_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks)  41,TRUE,Cortese - Adults (2018)_Modafinil_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks) Cortese - Adults (2018)_Modafinil_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks),100.00000
Cortese - Adults (2018) Modafinil Tolerability (discontinuation due to adverse events) NA At study endpoint (closest to 12 weeks), 148,39.004445 39.004445,39.004445,39.004445,39.004445 39.004445,39.004445 39.004445  757,  0.000000 140.00000, 42.806843,39.004445 NA, 2.07134638, 382.500000 100.00000,  0.00000,100.00000,100 100.000000,100.000000 100.00000,100.00000 100.000000,100.00000,100.000000,  8  4, 3,148.00000 4.000000  1,1 Arnold,2014,Cortese - Adults,10.1016/S2215-0366(18)30269-4,Modafinil,NA,NA Tolerability NA,RCT,NA Placebo,mg/d,High 38.1034013605442 39.8414965986395 NA,NA Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) Ostinelli (2025) | Cortese - Adults (2018) | Cortese - Children (2018),7.875,40.8 NA,NA NA,NA NA NA,2-6 months NA,NA 382.5mg/d >= 18 yo Homogeneous Modafinil_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks)_>= 18 yo Cortese - Adults (2018) - Modafinil_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks)_>= 18 yo,Modafinil_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks)_>= 18 yo - [Homogeneous],2018 Modafinil_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks)  42 TRUE Cortese - Adults (2018)_Modafinil_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks) Cortese - Adults (2018)_Modafinil_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks),100.00000
Cortese - Children (2018) Alpha-2 agonists (guanfacine / clonidine),Acceptability: all-cause discontinuation,NA At study endpoint (closest to 12 weeks) 1456, 9.050441, 9.050441  9.203279  9.363594, 9.450000,10.550000,10.593264 12.664045, 757,  0.000000 162.31004, 28.280244 10.068502,NA, 1.86964194,   2.070000, 94.90475,  0.00000 100.00000 100  84.404407, 84.404407,100.00000  84.40441  80.204269 100.00000, 84.404407  20, 7, 5,162.71001 1.868028,11,1,Biederman | Connor | Jain | Kollins | Kurlan | McCracken | NCT01069523 | Newcorn | Palumbo | Sallee | Singer,2008 | 2010 | 2011 | 2002 | 2016 | 2013 | 2009 | 1995 Cortese - Children,10.1016/S2215-0366(18)30269-4 Alpha-2 agonists (guanfacine / clonidine) NA NA,Acceptability NA,RCT NA Placebo,mg/d | mgTDS,High 8.23931034482759,12.6640449438202,NA,NA Specific adverse events: sleep problems | Tics/Tourette disorder symptoms | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Emotional dysregulation | Quality of life (patients) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) Ruggiero (2014) | Fahrat (2024) | Radonjic (2023) | Ostinelli (2025) | Cortese - Children (2018),8.23931034482759,41.2 NA NA NA NA NA NA,< 2 months,NA NA 2.07mg/d | mgTDS,6-17 yo Homogeneous Alpha-2 agonists (guanfacine / clonidine)_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_6-17 yo Cortese - Children (2018) - Alpha-2 agonists (guanfacine / clonidine)_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_6-17 yo Alpha-2 agonists (guanfacine / clonidine)_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_6-17 yo - [Homogeneous],2018 Alpha-2 agonists (guanfacine / clonidine)_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)  43,TRUE Cortese - Children (2018)_Alpha-2 agonists (guanfacine / clonidine)_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks),Cortese - Children (2018)_Alpha-2 agonists (guanfacine / clonidine)_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks),100.00000
Cortese - Children (2018) Alpha-2 agonists (guanfacine / clonidine) Combined ADHD symptoms (inattentive + hyperactive/impulsive),Clinician-rated,At study endpoint (closest to 12 weeks),1497, 9.049051  9.363415, 9.363415, 9.363415,10.549261 12.664045 14.549679,14.549679, 757,  0.000000 202.83295  30.535469,11.104097 NA, 1.55830591    2.697679,100.00000   0.00000 100.00000,100, 85.369135  85.369135 100.00000, 85.36914  85.369135,100.00000  85.369135, 20  7  5 204.00942 1.806828, 8 1,Biederman | Connor | Jain | Kollins | McCracken | Newcorn | Sallee | Wilens 2008 | 2010 | 2011 | 2016 | 2013 | 2009 | 2015 Cortese - Children 10.1016/S2215-0366(18)30269-4 Alpha-2 agonists (guanfacine / clonidine),NA NA,1:ADHD-RS Total | 4:ADHD-SRS Total NA,RCT NA Placebo,mg/d,High,8.99719626168224,14.5496794871795,NA NA,Specific adverse events: sleep problems | Tics/Tourette disorder symptoms | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Emotional dysregulation | Quality of life (patients) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events),Ruggiero (2014) | Fahrat (2024) | Radonjic (2023) | Ostinelli (2025) | Cortese - Children (2018),8.23931034482759 41.2 NA,NA NA NA,NA NA,< 2 months,NA NA 2.7mg/d,6-17 yo,Homogeneous,Alpha-2 agonists (guanfacine / clonidine)_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks)_6-17 yo,Cortese - Children (2018) - Alpha-2 agonists (guanfacine / clonidine)_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks)_6-17 yo,Alpha-2 agonists (guanfacine / clonidine)_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks)_6-17 yo - [Homogeneous],2018,Alpha-2 agonists (guanfacine / clonidine)_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks), 44 TRUE Cortese - Children (2018)_Alpha-2 agonists (guanfacine / clonidine)_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks) Cortese - Children (2018)_Alpha-2 agonists (guanfacine / clonidine)_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks),100.00000
Cortese - Children (2018) Alpha-2 agonists (guanfacine / clonidine) Combined ADHD symptoms (inattentive + hyperactive/impulsive),Parent-rated At study endpoint (closest to 12 weeks)   34,10.600000,10.600000 10.600000,10.600000 10.600000,10.600000,10.600000 10.600000  757   0.000000  34.00000 NA,10.600000 NA  1.84119678,   1.000000,100.00000   0.00000,100.00000 100,100.000000 100.000000,100.00000,100.00000 100.000000,100.00000 100.000000  20  7, 5  34.00000 1.000000, 1,1,Schahill 2001 Cortese - Children,10.1016/S2215-0366(18)30269-4 Alpha-2 agonists (guanfacine / clonidine),NA,NA 24:Other,NA RCT,NA Placebo,mg/d,High,10.6,10.6,NA NA Specific adverse events: sleep problems | Tics/Tourette disorder symptoms | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Emotional dysregulation | Quality of life (patients) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) Ruggiero (2014) | Fahrat (2024) | Radonjic (2023) | Ostinelli (2025) | Cortese - Children (2018),8.23931034482759 41.2 NA NA,NA,NA NA NA,< 2 months,NA,NA,1mg/d 6-17 yo,Homogeneous Alpha-2 agonists (guanfacine / clonidine)_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks)_6-17 yo,Cortese - Children (2018) - Alpha-2 agonists (guanfacine / clonidine)_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks)_6-17 yo Alpha-2 agonists (guanfacine / clonidine)_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks)_6-17 yo - [Homogeneous] 2018,Alpha-2 agonists (guanfacine / clonidine)_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks), 45,TRUE,Cortese - Children (2018)_Alpha-2 agonists (guanfacine / clonidine)_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks),Cortese - Children (2018)_Alpha-2 agonists (guanfacine / clonidine)_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks),100.00000
Cortese - Children (2018) Alpha-2 agonists (guanfacine / clonidine),Combined ADHD symptoms (inattentive + hyperactive/impulsive),Teacher-rated,At study endpoint (closest to 12 weeks)   34,10.600000,10.600000,10.600000,10.600000,10.600000,10.600000 10.600000 10.600000  757,  0.000000  34.00000,NA,10.600000 NA  1.84119678,   1.000000 100.00000   0.00000,100.00000 100,100.000000,100.000000 100.00000,100.00000,100.000000 100.00000,100.000000  20, 7  5, 34.00000,1.000000  1 1 Schahill 2001,Cortese - Children 10.1016/S2215-0366(18)30269-4,Alpha-2 agonists (guanfacine / clonidine),NA NA,5:ADHD-RS Total,NA RCT,NA,Placebo mg/d,High 10.6 10.6,NA NA,Specific adverse events: sleep problems | Tics/Tourette disorder symptoms | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Emotional dysregulation | Quality of life (patients) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events),Ruggiero (2014) | Fahrat (2024) | Radonjic (2023) | Ostinelli (2025) | Cortese - Children (2018),8.23931034482759,41.2 NA NA NA NA,NA NA < 2 months NA NA 1mg/d,6-17 yo Homogeneous Alpha-2 agonists (guanfacine / clonidine)_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Teacher-rated_At study endpoint (closest to 12 weeks)_6-17 yo Cortese - Children (2018) - Alpha-2 agonists (guanfacine / clonidine)_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Teacher-rated_At study endpoint (closest to 12 weeks)_6-17 yo,Alpha-2 agonists (guanfacine / clonidine)_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Teacher-rated_At study endpoint (closest to 12 weeks)_6-17 yo - [Homogeneous] 2018 Alpha-2 agonists (guanfacine / clonidine)_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Teacher-rated_At study endpoint (closest to 12 weeks)  46 TRUE Cortese - Children (2018)_Alpha-2 agonists (guanfacine / clonidine)_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Teacher-rated_At study endpoint (closest to 12 weeks) Cortese - Children (2018)_Alpha-2 agonists (guanfacine / clonidine)_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Teacher-rated_At study endpoint (closest to 12 weeks),100.00000
Cortese - Children (2018) Alpha-2 agonists (guanfacine / clonidine) Tolerability (discontinuation due to adverse events),NA,At study endpoint (closest to 12 weeks),1287, 9.050441, 9.050441, 9.203279  9.363594  9.450000,10.550000 10.593264 12.664045  757,  0.000000,175.36775, 28.737353 10.128789,NA  1.82604277    2.350327 100.00000   0.00000,100.00000,100  82.350649, 82.350649,100.00000, 82.35065, 77.597403 100.00000, 82.350649  20  7, 5,175.82039,1.982338  8 1 Biederman | Connor | Jain | Kollins | McCracken | Newcorn | Palumbo | Sallee 2008 | 2010 | 2011 | 2016 | 2013 | 2009,Cortese - Children 10.1016/S2215-0366(18)30269-4 Alpha-2 agonists (guanfacine / clonidine) NA NA,Tolerability NA,RCT NA Placebo,mg/d | mgTDS,High,9 12.6640449438202 NA,NA Specific adverse events: sleep problems | Tics/Tourette disorder symptoms | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Emotional dysregulation | Quality of life (patients) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) Ruggiero (2014) | Fahrat (2024) | Radonjic (2023) | Ostinelli (2025) | Cortese - Children (2018),8.23931034482759 41.2 NA NA NA,NA,NA NA,< 2 months NA,NA,2.35mg/d | mgTDS 6-17 yo,Homogeneous Alpha-2 agonists (guanfacine / clonidine)_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks)_6-17 yo Cortese - Children (2018) - Alpha-2 agonists (guanfacine / clonidine)_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks)_6-17 yo,Alpha-2 agonists (guanfacine / clonidine)_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks)_6-17 yo - [Homogeneous],2018 Alpha-2 agonists (guanfacine / clonidine)_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks), 47 TRUE Cortese - Children (2018)_Alpha-2 agonists (guanfacine / clonidine)_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks) Cortese - Children (2018)_Alpha-2 agonists (guanfacine / clonidine)_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks) 100.00000
Cortese - Children (2018) Amphetamine Acceptability: all-cause discontinuation,NA At study endpoint (closest to 12 weeks),1343  8.587696, 8.587696, 8.587696  8.587696 10.949554 14.533333 14.633537,14.633537, 757,  0.000000,246.12569, 28.340273,11.693542,NA, 1.08508935   48.982624,100.00000,  0.00000 100.00000,100,100.000000 100.000000,100.00000 100.00000  83.241895 100.00000,100.000000, 43 14, 9,247.43342,2.034913, 7,1 Biederman | Coghill | Findling | NCT01552902 | Plizka | Spencer,2002 | 2007b | 2013 | 2011 | 2000 | 2006b,Cortese - Children,10.1016/S2215-0366(18)30269-4,Amphetamine,NA NA Acceptability NA,RCT,NA Placebo,mg/d,High 8.22105263157895 14.6335365853659,NA,NA Disruptive behaviors | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Academic/job performance | Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Depressive disorder symptoms | Generalized anxiety | Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Executive functioning (tests),Faraone (2002) | Punja (2016) | Castells (2018) | Elliott (2020) | Bellato - adults (2024) | Bellatto - children (2024) | Lenzi (2018) | Ostinelli (2025) | Cortese - Children (2018),8 41.2,NA NA,NA,NA NA,NA,< 2 months,NA NA,48.98mg/d 6-17 yo,Homogeneous Amphetamine_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_6-17 yo Cortese - Children (2018) - Amphetamine_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_6-17 yo,Amphetamine_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_6-17 yo - [Homogeneous] 2018 Amphetamine_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks), 48 TRUE,Cortese - Children (2018)_Amphetamine_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks),Cortese - Children (2018)_Amphetamine_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks),100.00000
Cortese - Children (2018),Amphetamine,Combined ADHD symptoms (inattentive + hyperactive/impulsive) Clinician-rated At study endpoint (closest to 12 weeks)  876, 9.134530  9.134530 10.951485,10.951485 14.398814 14.634701,14.634701 14.634701  757   0.000000,192.50643  29.954596 12.834703,NA, 1.22172213,  51.537250,100.00000   0.00000,100.00000,100,100.000000 100.000000,100.00000,100.00000  76.856979,100.00000,100.000000  43,14, 9,193.01241 1.802177, 5 1 Biederman | Coghill | Findling | NCT01552902 | Spencer 2007b | 2013 | 2011 | 2006b,Cortese - Children 10.1016/S2215-0366(18)30269-4,Amphetamine NA,NA,1:ADHD-RS Total | 4:ADHD-SRS Total NA,RCT NA,Placebo mg/d High,9.04758620689655 14.6347014925373,NA,NA Disruptive behaviors | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Academic/job performance | Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Depressive disorder symptoms | Generalized anxiety | Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Executive functioning (tests),Faraone (2002) | Punja (2016) | Castells (2018) | Elliott (2020) | Bellato - adults (2024) | Bellatto - children (2024) | Lenzi (2018) | Ostinelli (2025) | Cortese - Children (2018) 8,41.2,NA NA,NA,NA,NA,NA < 2 months NA NA 51.54mg/d,6-17 yo Homogeneous Amphetamine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks)_6-17 yo Cortese - Children (2018) - Amphetamine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks)_6-17 yo Amphetamine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks)_6-17 yo - [Homogeneous],2018,Amphetamine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks)  49,TRUE,Cortese - Children (2018)_Amphetamine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks),Cortese - Children (2018)_Amphetamine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks),100.00000
Cortese - Children (2018) Amphetamine,Combined ADHD symptoms (inattentive + hyperactive/impulsive) Parent-rated At study endpoint (closest to 12 weeks)  144, 9.137133, 9.137133, 9.137133, 9.137133, 9.137133  9.137133  9.137133, 9.137133  757,  0.000000 141.66667, 30.984397  9.137133,NA  0.92059839   50.000000 100.00000   0.00000 100.00000 100 100.000000 100.000000,100.00000 100.00000 100.000000 100.00000 100.000000, 43,14, 9,144.00000,3.000000  1,1,Biederman,2007b,Cortese - Children,10.1016/S2215-0366(18)30269-4 Amphetamine,NA NA,13:CPRS-R:S,NA RCT NA,Placebo,mg/d High,9.05,9.20425531914894,NA NA,Disruptive behaviors | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Academic/job performance | Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Depressive disorder symptoms | Generalized anxiety | Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Executive functioning (tests) Faraone (2002) | Punja (2016) | Castells (2018) | Elliott (2020) | Bellato - adults (2024) | Bellatto - children (2024) | Lenzi (2018) | Ostinelli (2025) | Cortese - Children (2018),8,41.2,NA,NA,NA,NA,NA NA < 2 months,NA,NA,50mg/d,6-17 yo Homogeneous Amphetamine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks)_6-17 yo,Cortese - Children (2018) - Amphetamine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks)_6-17 yo Amphetamine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks)_6-17 yo - [Homogeneous],2018,Amphetamine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks), 50,TRUE,Cortese - Children (2018)_Amphetamine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks),Cortese - Children (2018)_Amphetamine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks),100.00000
Cortese - Children (2018) Amphetamine,Tolerability (discontinuation due to adverse events) NA,At study endpoint (closest to 12 weeks) 1343, 8.587696  8.587696  8.587696  8.587696 10.949554,14.533333 14.633537 14.633537, 757,  0.000000 246.12569  28.340273 11.693542,NA  1.08508935   48.982624,100.00000   0.00000,100.00000,100,100.000000 100.000000,100.00000,100.00000  83.241895,100.00000,100.000000  43 14, 9 247.43342,2.034913, 7,1 Biederman | Coghill | Findling | NCT01552902 | Plizka | Spencer,2002 | 2007b | 2013 | 2011 | 2000 | 2006b,Cortese - Children 10.1016/S2215-0366(18)30269-4 Amphetamine,NA NA Tolerability,NA RCT NA,Placebo,mg/d,High 8.22105263157895,14.6335365853659,NA,NA,Disruptive behaviors | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Academic/job performance | Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Depressive disorder symptoms | Generalized anxiety | Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Executive functioning (tests) Faraone (2002) | Punja (2016) | Castells (2018) | Elliott (2020) | Bellato - adults (2024) | Bellatto - children (2024) | Lenzi (2018) | Ostinelli (2025) | Cortese - Children (2018),8,41.2,NA,NA,NA,NA,NA,NA,< 2 months NA,NA 48.98mg/d 6-17 yo,Homogeneous,Amphetamine_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks)_6-17 yo,Cortese - Children (2018) - Amphetamine_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks)_6-17 yo,Amphetamine_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks)_6-17 yo - [Homogeneous] 2018,Amphetamine_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks)  51,TRUE Cortese - Children (2018)_Amphetamine_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks),Cortese - Children (2018)_Amphetamine_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks),100.00000
Cortese - Children (2018) Atomoxetine Acceptability: all-cause discontinuation,NA At study endpoint (closest to 12 weeks),1831  9.000000, 9.561947  9.561947  9.561947 10.250000,11.023750 11.118750,11.448485  757,  0.000000 165.90575  22.532738,10.257662,NA, 2.01727585,   2.689097,100.00000   0.00000 100.00000 100,100.000000,100.000000,100.00000 100.00000,100.000000 100.00000,100.000000, 44  9  7,167.67800,1.285793,13,1,Arnold | Bangs | Dell'Agnello | Dittman | Michelson | Montoya | Newcorn | Spencer | Svanborg | Takahashi | Wehmeier | Wietecha | Wilens 2006 | 2008 | 2009 | 2011 | 2001 | 2002 | 2012 | 2013,Cortese - Children 10.1016/S2215-0366(18)30269-4 Atomoxetine,NA NA Acceptability NA RCT,NA,Placebo,mg/kg/d,High,8.65154639175258,12.2493548387097 NA,NA,Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Generalized anxiety | Depressive disorder symptoms | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | CGI Elliott (2020) | Bellatto - children (2024) | Lenzi (2018) | Bryant (2021) | Ostinelli (2025) | Cortese - Adults (2018) | Cortese - Children (2018) 8.65154639175258 42.10703125,NA,NA,NA,NA,NA,NA 2-6 months,NA,NA 2.69mg/kg/d 6-17 yo,Homogeneous Atomoxetine_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_6-17 yo,Cortese - Children (2018) - Atomoxetine_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_6-17 yo Atomoxetine_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_6-17 yo - [Homogeneous],2018,Atomoxetine_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks), 52,TRUE Cortese - Children (2018)_Atomoxetine_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks),Cortese - Children (2018)_Atomoxetine_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks) 100.00000
Cortese - Children (2018),Atomoxetine,Combined ADHD symptoms (inattentive + hyperactive/impulsive) Clinician-rated,At study endpoint (closest to 12 weeks) 2467  9.228302, 9.467742  9.467742, 9.561538 10.250000 11.023750 11.119152 11.448485, 757,  0.000000 161.02343  23.930159 10.238072 NA, 1.66864345    1.241782,100.00000,  0.00000 100.00000,100,100.000000 100.000000 100.00000 100.00000,100.000000,100.00000 100.000000, 44  9  7,162.40127,1.208922 17,1 Bangs | Dittman | Gau | Geller | Kelsey | Martenyi | Michelson | Montoya | Newcorn | Spencer | Svanborg | Takahashi | Wehmeier | Weiss | Wietecha | Wilens,2008 | 2011 | 2007 | 2004 | 2010 | 2001 | 2002 | 2009 | 2012 | 2005 | 2013,Cortese - Children,10.1016/S2215-0366(18)30269-4 Atomoxetine,NA NA 16:SNAP-IV-Short-Hyper-Impuls | 1:ADHD-RS Total | 4:ADHD-SRS Total | 6:ADHD-SRS-Hyp-Imp NA,RCT,NA Placebo,mg/kg/d High 8.65157894736842 12.2493333333333 NA NA,Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Generalized anxiety | Depressive disorder symptoms | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | CGI Elliott (2020) | Bellatto - children (2024) | Lenzi (2018) | Bryant (2021) | Ostinelli (2025) | Cortese - Adults (2018) | Cortese - Children (2018) 8.65154639175258 42.10703125,NA NA,NA NA NA NA,< 2 months NA NA,1.24mg/kg/d,6-17 yo Homogeneous Atomoxetine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks)_6-17 yo,Cortese - Children (2018) - Atomoxetine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks)_6-17 yo,Atomoxetine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks)_6-17 yo - [Homogeneous],2018 Atomoxetine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks)  53 TRUE,Cortese - Children (2018)_Atomoxetine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks) Cortese - Children (2018)_Atomoxetine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks) 100.00000
Cortese - Children (2018),Atomoxetine Combined ADHD symptoms (inattentive + hyperactive/impulsive),Parent-rated At study endpoint (closest to 12 weeks),1218, 9.561751  9.561751, 9.561751  9.771111 10.251825 10.300000,11.023750,11.119152, 757   0.000000,179.07917  17.920363 10.187359 NA, 1.88392089    3.052427,100.00000   0.00000,100.00000 100 100.000000,100.000000 100.00000 100.00000,100.000000,100.00000,100.000000  44  9  7,182.28517 1.322134  8 1 Arnold | Bangs | Dell'Agnello | Dittman | Michelson | Montoya | Newcorn | Spencer 2006 | 2008 | 2009 | 2011 | 2001 | 2002 Cortese - Children,10.1016/S2215-0366(18)30269-4,Atomoxetine,NA,NA,24:Other | 13:CPRS-R:S,NA RCT,NA Placebo,mg/kg/d High 9.26,11.2017964071856,NA NA Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Generalized anxiety | Depressive disorder symptoms | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | CGI Elliott (2020) | Bellatto - children (2024) | Lenzi (2018) | Bryant (2021) | Ostinelli (2025) | Cortese - Adults (2018) | Cortese - Children (2018),8.65154639175258 42.10703125,NA,NA NA,NA,NA NA < 2 months NA NA,3.05mg/kg/d,6-17 yo Homogeneous Atomoxetine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks)_6-17 yo,Cortese - Children (2018) - Atomoxetine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks)_6-17 yo Atomoxetine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks)_6-17 yo - [Homogeneous] 2018 Atomoxetine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks), 54,TRUE Cortese - Children (2018)_Atomoxetine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks) Cortese - Children (2018)_Atomoxetine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks),100.00000
Cortese - Children (2018),Atomoxetine,Combined ADHD symptoms (inattentive + hyperactive/impulsive) Teacher-rated,At study endpoint (closest to 12 weeks), 119  9.771053, 9.771053, 9.771053  9.771053, 9.771053,12.250465,12.250465,12.250465, 757,  0.000000  64.07563  17.743697,10.666975,NA  2.50650318    1.100000,100.00000,  0.00000 100.00000,100,100.000000 100.000000,100.00000 100.00000,100.000000 100.00000,100.000000  44, 9  7  64.07563 1.000000, 2 1 Dell'Agnello | Wietecha 2009 | 2013 Cortese - Children 10.1016/S2215-0366(18)30269-4 Atomoxetine,NA,NA 13:CTRS-R:S | 5:ADHD-RS Total,NA,RCT,NA Placebo,mg/kg/d High 9.77105263157895,12.2504651162791 NA,NA Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Generalized anxiety | Depressive disorder symptoms | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | CGI Elliott (2020) | Bellatto - children (2024) | Lenzi (2018) | Bryant (2021) | Ostinelli (2025) | Cortese - Adults (2018) | Cortese - Children (2018) 8.65154639175258 42.10703125,NA,NA,NA,NA NA NA,2-6 months NA NA,1.1mg/kg/d,6-17 yo Homogeneous Atomoxetine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Teacher-rated_At study endpoint (closest to 12 weeks)_6-17 yo,Cortese - Children (2018) - Atomoxetine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Teacher-rated_At study endpoint (closest to 12 weeks)_6-17 yo,Atomoxetine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Teacher-rated_At study endpoint (closest to 12 weeks)_6-17 yo - [Homogeneous],2018,Atomoxetine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Teacher-rated_At study endpoint (closest to 12 weeks), 55 TRUE Cortese - Children (2018)_Atomoxetine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Teacher-rated_At study endpoint (closest to 12 weeks) Cortese - Children (2018)_Atomoxetine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Teacher-rated_At study endpoint (closest to 12 weeks),100.00000
Cortese - Children (2018) Atomoxetine Tolerability (discontinuation due to adverse events),NA At study endpoint (closest to 12 weeks),1799, 9.000000  9.561947  9.561947  9.561947 10.250000,11.023750 11.118750,11.448485  757,  0.000000,168.31711  22.488308,10.275628 NA  2.02873567,   1.218871 100.00000,  0.00000 100.00000,100 100.000000,100.000000,100.00000 100.00000,100.000000 100.00000,100.000000, 44  9  7 170.12127,1.290940 12 1 Bangs | Dell'Agnello | Dittman | Michelson | Montoya | Newcorn | Spencer | Svanborg | Takahashi | Wehmeier | Wietecha | Wilens,2008 | 2009 | 2011 | 2001 | 2002 | 2012 | 2013 Cortese - Children 10.1016/S2215-0366(18)30269-4 Atomoxetine NA NA,Tolerability,NA,RCT NA,Placebo,mg/kg/d,High,8.65154639175258,12.2493548387097,NA,NA Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Generalized anxiety | Depressive disorder symptoms | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | CGI Elliott (2020) | Bellatto - children (2024) | Lenzi (2018) | Bryant (2021) | Ostinelli (2025) | Cortese - Adults (2018) | Cortese - Children (2018),8.65154639175258 42.10703125 NA NA,NA,NA NA NA,2-6 months NA,NA,1.22mg/kg/d 6-17 yo Homogeneous,Atomoxetine_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks)_6-17 yo Cortese - Children (2018) - Atomoxetine_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks)_6-17 yo Atomoxetine_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks)_6-17 yo - [Homogeneous],2018 Atomoxetine_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks), 56 TRUE,Cortese - Children (2018)_Atomoxetine_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks),Cortese - Children (2018)_Atomoxetine_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks),100.00000
Cortese - Children (2018) Bupropion,Acceptability: all-cause discontinuation NA,At study endpoint (closest to 12 weeks),  30 11.500000 11.500000,11.500000 11.500000,11.500000,11.500000 11.500000 11.500000, 757,  0.000000  30.00000,NA 11.500000,NA  0.92059839 NA 100.00000,  0.00000,100.00000 100,100.000000,100.000000 100.00000,100.00000,100.000000,100.00000 100.000000, 10  7, 6, 30.00000,1.000000  1,1 Casat 1989,Cortese - Children,10.1016/S2215-0366(18)30269-4 Bupropion,NA,NA Acceptability NA RCT NA Placebo NA High 11.5 11.5 NA,NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Depressive disorder symptoms | Generalized anxiety | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Executive functioning (tests) | Emotional dysregulation Stuhec (2015) | Verbeeck (2017) | Ostinelli (2025) | Cortese - Children (2018) | Cortese - Adults (2018) | Catala-Lopez (2017),8.5,40.25,NA NA NA,NA NA NA,< 2 months NA,NA,NANA 6-17 yo Homogeneous Bupropion_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_6-17 yo,Cortese - Children (2018) - Bupropion_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_6-17 yo,Bupropion_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_6-17 yo - [Homogeneous] 2018,Bupropion_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks), 57 TRUE,Cortese - Children (2018)_Bupropion_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks),Cortese - Children (2018)_Bupropion_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks) 100.00000
Cortese - Children (2018) Bupropion Tolerability (discontinuation due to adverse events) NA At study endpoint (closest to 12 weeks)   30 11.500000 11.500000,11.500000 11.500000,11.500000,11.500000 11.500000,11.500000  757   0.000000  30.00000,NA 11.500000,NA  0.92059839 NA 100.00000   0.00000 100.00000,100 100.000000 100.000000 100.00000 100.00000 100.000000,100.00000 100.000000  10  7  6, 30.00000,1.000000  1 1 Casat,1989 Cortese - Children 10.1016/S2215-0366(18)30269-4,Bupropion NA,NA,Tolerability,NA RCT,NA,Placebo NA High 11.5,11.5,NA NA Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Depressive disorder symptoms | Generalized anxiety | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Executive functioning (tests) | Emotional dysregulation Stuhec (2015) | Verbeeck (2017) | Ostinelli (2025) | Cortese - Children (2018) | Cortese - Adults (2018) | Catala-Lopez (2017) 8.5,40.25,NA NA NA NA NA NA,< 2 months NA,NA,NANA,6-17 yo,Homogeneous Bupropion_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks)_6-17 yo,Cortese - Children (2018) - Bupropion_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks)_6-17 yo,Bupropion_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks)_6-17 yo - [Homogeneous] 2018,Bupropion_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks)  58 TRUE,Cortese - Children (2018)_Bupropion_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks),Cortese - Children (2018)_Bupropion_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks),100.00000
Cortese - Children (2018),Methylphenidate Acceptability: all-cause discontinuation NA At study endpoint (closest to 12 weeks) 2947  8.654945  8.700036  9.000000  9.000000 10.050000,10.926316 11.350000 14.700000, 757,  0.000000 244.29886, 23.134384,10.420004,NA  1.24812364   38.139881  81.73314,  0.00000 100.00000 100,100.000000,100.000000,100.00000,100.00000, 90.407348 100.00000,100.000000,141 14 11 244.54630,1.195680,21,1,Abikoff | Buitelaar | Childress | Coghill | Cook | Dopfner | Findling | Greenhill | Grizenko | Kurlan | Lin | NCT01552902 | Newcorn | Palumbo | Plizka | Schrantee | Spencer | Taylor | Wigal 2009 | 1996 | 2013 | 1993 | 2003 | 2008 | 2002 | 2006b | 2012 | 2014 | 2000 | 2016 | 1987 | 2004 | 2015 Cortese - Children,10.1016/S2215-0366(18)30269-4 Methylphenidate,NA NA Acceptability NA RCT,NA,Placebo mg/d | mg/kg/d | mgTDS High,7.9578947368421,14.7 NA,NA Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events),Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018) 4.42,50.1,60 109.9,NA, 99.5875,97.45,105.60 < 2 months,NA,NA,38.14mg/d | mg/kg/d | mgTDS 6-17 yo,Homogeneous,Methylphenidate_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_6-17 yo,Cortese - Children (2018) - Methylphenidate_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_6-17 yo Methylphenidate_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_6-17 yo - [Homogeneous] 2018,Methylphenidate_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)  59 TRUE,Cortese - Children (2018)_Methylphenidate_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks),Cortese - Children (2018)_Methylphenidate_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks),100.00000
Cortese - Children (2018) Methylphenidate Combined ADHD symptoms (inattentive + hyperactive/impulsive) Clinician-rated,At study endpoint (closest to 12 weeks) 1038 10.174830,10.174830 10.174830,10.174830 10.950242,14.700000,14.700000,14.700000, 757   0.000000 219.42292  26.912828 11.629407,NA, 1.41919082,  42.172455,100.00000,  0.00000 100.00000 100,100.000000 100.000000 100.00000,100.00000  79.946718 100.00000,100.000000 141 14 11,219.90651,1.336885, 6,1,Coghill | Lin | NCT01552902 | Newcorn | Spencer | Wigal 2013 | 2014 | 2008 | 2002 | 2015,Cortese - Children,10.1016/S2215-0366(18)30269-4,Methylphenidate,NA,NA,4:ADHD-SRS Total | 1:ADHD-RS Total,NA RCT NA Placebo mg/d | mg/kg/d High 9.745,14.7 NA,NA,Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events),Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018),4.42 50.1 60,109.9 NA  99.5875,97.45,105.60,< 2 months NA,NA,42.17mg/d | mg/kg/d 6-17 yo Homogeneous,Methylphenidate_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks)_6-17 yo Cortese - Children (2018) - Methylphenidate_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks)_6-17 yo,Methylphenidate_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks)_6-17 yo - [Homogeneous],2018 Methylphenidate_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks)  60,TRUE,Cortese - Children (2018)_Methylphenidate_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks),Cortese - Children (2018)_Methylphenidate_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks) 100.00000
Cortese - Children (2018),Methylphenidate Combined ADHD symptoms (inattentive + hyperactive/impulsive) Parent-rated At study endpoint (closest to 12 weeks), 852, 8.705725  9.755255, 9.755255, 9.800000  9.971134 10.174713 10.174713 10.174713  757   0.000000,142.88199  25.935617, 9.909220 NA, 1.37542493,  39.222523 100.00000   0.00000 100.00000 100 100.000000,100.000000 100.00000,100.00000,100.000000,100.00000 100.000000 141 14,11 143.17657,1.244261, 8 1,Abikoff | Childress | Dopfner | Greenhill | Lin | Newcorn | Spencer | Wigal,2009 | 2003 | 2006b | 2014 | 2008 | 2002 | 2004 Cortese - Children 10.1016/S2215-0366(18)30269-4 Methylphenidate NA,NA,21:SNAP-IV-short-Total | 24:Other | 13:CPRS-R:S | 18:SNAP-IV-Long Total,NA RCT,NA,Placebo mg/d | mg/kg/d,High 8.60731707317073,10.9714285714286,NA,NA,Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events),Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018) 4.42,50.1 60 109.9 NA  99.5875 97.45 105.60 < 2 months NA,NA,39.22mg/d | mg/kg/d,6-17 yo,Homogeneous,Methylphenidate_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks)_6-17 yo,Cortese - Children (2018) - Methylphenidate_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks)_6-17 yo,Methylphenidate_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks)_6-17 yo - [Homogeneous],2018,Methylphenidate_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks), 61 TRUE Cortese - Children (2018)_Methylphenidate_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks),Cortese - Children (2018)_Methylphenidate_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks) 100.00000
Cortese - Children (2018) Methylphenidate Combined ADHD symptoms (inattentive + hyperactive/impulsive) Teacher-rated At study endpoint (closest to 12 weeks), 437  8.704059, 8.704059  8.704059  8.704059, 9.751205  9.800000  9.971134, 9.971134, 757   0.000000, 93.85362  25.769252  9.409124,NA, 1.21548582   36.129109,100.00000   0.00000 100.00000 100,100.000000 100.000000 100.00000,100.00000,100.000000,100.00000,100.000000 141,14,11  94.23077 1.471871  5 1,Childress | Dopfner | Greenhill | Wigal | van der Meere,2009 | 2003 | 2006b | 2004 | 1999 Cortese - Children 10.1016/S2215-0366(18)30269-4,Methylphenidate,NA NA,24:Other | 21:SNAP-IV-short Total | 13:CTRS-R:S NA RCT NA Placebo,mg/d High,8.60483870967742 9.97113402061856 NA NA Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events) Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018) 4.42,50.1 60 109.9,NA  99.5875,97.45 105.60 < 2 months,NA,NA 36.13mg/d 6-17 yo Homogeneous,Methylphenidate_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Teacher-rated_At study endpoint (closest to 12 weeks)_6-17 yo Cortese - Children (2018) - Methylphenidate_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Teacher-rated_At study endpoint (closest to 12 weeks)_6-17 yo,Methylphenidate_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Teacher-rated_At study endpoint (closest to 12 weeks)_6-17 yo - [Homogeneous],2018 Methylphenidate_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Teacher-rated_At study endpoint (closest to 12 weeks), 62,TRUE Cortese - Children (2018)_Methylphenidate_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Teacher-rated_At study endpoint (closest to 12 weeks) Cortese - Children (2018)_Methylphenidate_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Teacher-rated_At study endpoint (closest to 12 weeks) 100.00000
Cortese - Children (2018),Methylphenidate Tolerability (discontinuation due to adverse events) NA At study endpoint (closest to 12 weeks),2878, 8.654945  8.700036  9.000000  9.000000, 9.988350,10.949776 11.350000 14.700000, 757,  0.000000 248.51226  23.568138 10.425437,NA, 1.18961467,  38.859371, 81.29409   0.00000 100.00000,100 100.000000,100.000000,100.00000,100.00000, 90.176783,100.00000,100.000000,141 14 11 248.76565 1.200383 20 1 Abikoff | Buitelaar | Childress | Coghill | Cook | Dopfner | Findling | Greenhill | Grizenko | Lin | NCT01552902 | Newcorn | Palumbo | Plizka | Schrantee | Spencer | Taylor | Wigal,2009 | 1996 | 2013 | 1993 | 2003 | 2008 | 2002 | 2006b | 2012 | 2014 | 2000 | 2016 | 1987 | 2004 | 2015 Cortese - Children,10.1016/S2215-0366(18)30269-4 Methylphenidate NA NA Tolerability NA,RCT,NA Placebo,mg/d | mg/kg/d | mgTDS High,7.9578947368421 14.7,NA NA Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events),Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018),4.42,50.1 60,109.9,NA, 99.5875,97.45,105.60 < 2 months,NA,NA,38.86mg/d | mg/kg/d | mgTDS 6-17 yo Homogeneous Methylphenidate_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks)_6-17 yo,Cortese - Children (2018) - Methylphenidate_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks)_6-17 yo,Methylphenidate_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks)_6-17 yo - [Homogeneous] 2018 Methylphenidate_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks)  63 TRUE Cortese - Children (2018)_Methylphenidate_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks),Cortese - Children (2018)_Methylphenidate_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks),100.00000
Cortese - Children (2018) Modafinil,Acceptability: all-cause discontinuation,NA,At study endpoint (closest to 12 weeks)  809, 9.109757, 9.109757, 9.109757  9.900000  9.965263,10.298387,10.298387,10.298387  757   0.000000 186.01431  27.107952  9.831912 NA  1.76061238  354.015291,100.00000   0.00000,100.00000,100 100.000000 100.000000 100.00000,100.00000  21.064027 100.00000,100.000000   8, 4, 3 186.10733 1.372100  6,1,Biederman | Greenhill | Kahbazi | Rugino | Swanson 2005 | 2006b | 2006a | 2009 | 2003 | 2006,Cortese - Children 10.1016/S2215-0366(18)30269-4,Modafinil,NA,NA,Acceptability,NA,RCT NA,Placebo,mg/d High 7.875,10.2983870967742,NA NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events),Ostinelli (2025) | Cortese - Adults (2018) | Cortese - Children (2018) 7.875 40.8 NA,NA NA NA NA NA < 2 months,NA,NA 354.02mg/d,6-17 yo,Homogeneous,Modafinil_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_6-17 yo,Cortese - Children (2018) - Modafinil_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_6-17 yo,Modafinil_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_6-17 yo - [Homogeneous],2018 Modafinil_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks), 64,TRUE Cortese - Children (2018)_Modafinil_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks) Cortese - Children (2018)_Modafinil_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks),100.00000
Cortese - Children (2018),Modafinil,Combined ADHD symptoms (inattentive + hyperactive/impulsive) Clinician-rated At study endpoint (closest to 12 weeks), 768  9.109363  9.109363  9.900000, 9.900000  9.962295 10.300410 10.300410 10.300410  757,  0.000000 186.14993  26.832651  9.889083 NA  1.77008145  357.854275,100.00000   0.00000,100.00000,100 100.000000 100.000000,100.00000 100.00000  19.035202,100.00000,100.000000   8  4  3,186.28031,1.391134, 5 1 Biederman | Greenhill | Kahbazi | Swanson 2005 | 2006b | 2006a | 2009 | 2006 Cortese - Children,10.1016/S2215-0366(18)30269-4 Modafinil,NA NA 1:ADHD-RS Total | 6:ADHD-SRS-Hyp-Imp NA RCT,NA Placebo,mg/d High 8.85049504950495 10.3004098360656,NA,NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events),Ostinelli (2025) | Cortese - Adults (2018) | Cortese - Children (2018),7.875,40.8,NA,NA NA NA NA NA < 2 months,NA NA,357.85mg/d,6-17 yo Homogeneous,Modafinil_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks)_6-17 yo,Cortese - Children (2018) - Modafinil_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks)_6-17 yo,Modafinil_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks)_6-17 yo - [Homogeneous],2018 Modafinil_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks), 65 TRUE Cortese - Children (2018)_Modafinil_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks) Cortese - Children (2018)_Modafinil_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks) 100.00000
Cortese - Children (2018),Modafinil,Combined ADHD symptoms (inattentive + hyperactive/impulsive) Parent-rated,At study endpoint (closest to 12 weeks), 722, 9.109363  9.900000  9.900000, 9.900000, 9.962295,10.300410 10.300410,10.300410, 757   0.000000,195.09154, 27.018798, 9.941659,NA, 1.79491149  357.854275 100.00000,  0.00000,100.00000,100,100.000000,100.000000,100.00000,100.00000, 13.869626,100.00000,100.000000,  8, 4  3,195.23024 1.416089  4 1,Biederman | Greenhill | Swanson,2005 | 2006b | 2006a | 2006,Cortese - Children,10.1016/S2215-0366(18)30269-4,Modafinil NA,NA,13:CPRS-R:S | 24:Other,NA RCT,NA,Placebo mg/d High 8.85049504950495 10.3004098360656,NA,NA Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events),Ostinelli (2025) | Cortese - Adults (2018) | Cortese - Children (2018) 7.875 40.8,NA,NA,NA NA NA,NA < 2 months NA NA,357.85mg/d,6-17 yo Homogeneous Modafinil_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks)_6-17 yo Cortese - Children (2018) - Modafinil_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks)_6-17 yo,Modafinil_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks)_6-17 yo - [Homogeneous] 2018 Modafinil_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks), 66 TRUE,Cortese - Children (2018)_Modafinil_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks),Cortese - Children (2018)_Modafinil_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks) 100.00000
Cortese - Children (2018),Modafinil Combined ADHD symptoms (inattentive + hyperactive/impulsive),Teacher-rated At study endpoint (closest to 12 weeks), 524, 9.109363, 9.109363  9.109363  9.109363  9.900000, 9.962295  9.962295, 9.962295, 757   0.000000 159.16061  25.662798  9.697182 NA, 1.62952956, 349.019048,100.00000,  0.00000 100.00000 100 100.000000,100.000000,100.00000 100.00000  27.915870 100.00000,100.000000   8, 4, 3,159.35182 1.573614, 4 1 Biederman | Greenhill | Kahbazi | Swanson 2006b | 2006a | 2009 | 2006 Cortese - Children 10.1016/S2215-0366(18)30269-4 Modafinil,NA NA 5:ADHD-RS Total | 1:ACTeRS-2,NA,RCT NA Placebo mg/d,High,8.85049504950495 9.96229508196721 NA NA Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events),Ostinelli (2025) | Cortese - Adults (2018) | Cortese - Children (2018),7.875 40.8,NA,NA,NA,NA NA,NA,< 2 months,NA,NA,349.02mg/d 6-17 yo Homogeneous Modafinil_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Teacher-rated_At study endpoint (closest to 12 weeks)_6-17 yo Cortese - Children (2018) - Modafinil_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Teacher-rated_At study endpoint (closest to 12 weeks)_6-17 yo,Modafinil_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Teacher-rated_At study endpoint (closest to 12 weeks)_6-17 yo - [Homogeneous] 2018 Modafinil_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Teacher-rated_At study endpoint (closest to 12 weeks)  67,TRUE,Cortese - Children (2018)_Modafinil_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Teacher-rated_At study endpoint (closest to 12 weeks) Cortese - Children (2018)_Modafinil_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Teacher-rated_At study endpoint (closest to 12 weeks),100.00000
Cortese - Children (2018),Modafinil,Tolerability (discontinuation due to adverse events) NA,At study endpoint (closest to 12 weeks), 809, 9.109757, 9.109757  9.109757  9.900000, 9.965263 10.298387,10.298387,10.298387  757,  0.000000 186.01431, 27.107952  9.831912 NA  1.76061238, 354.015291,100.00000,  0.00000,100.00000 100 100.000000 100.000000,100.00000 100.00000, 21.064027 100.00000,100.000000   8  4, 3 186.10733,1.372100, 6 1,Biederman | Greenhill | Kahbazi | Rugino | Swanson,2005 | 2006b | 2006a | 2009 | 2003 | 2006 Cortese - Children,10.1016/S2215-0366(18)30269-4,Modafinil,NA,NA,Tolerability,NA,RCT,NA,Placebo,mg/d,High 7.875 10.2983870967742 NA,NA Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events),Ostinelli (2025) | Cortese - Adults (2018) | Cortese - Children (2018),7.875 40.8 NA,NA,NA NA NA NA < 2 months NA NA,354.02mg/d,6-17 yo,Homogeneous Modafinil_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks)_6-17 yo,Cortese - Children (2018) - Modafinil_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks)_6-17 yo,Modafinil_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks)_6-17 yo - [Homogeneous],2018 Modafinil_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks)  68,TRUE,Cortese - Children (2018)_Modafinil_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks) Cortese - Children (2018)_Modafinil_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks) 100.00000
Ding (2018) Cognitive Behavioral Therapy (CBT) Combined ADHD symptoms (inattentive + hyperactive/impulsive) Mixed,At study endpoint (closest to 12 weeks)  167,10.300000,10.300000,10.300000,10.300000,10.300000 16.000000,16.000000 16.000000, 962 100.000000  56.50898 NA,12.750467,NA, 2.76215348,   0.915978, 64.07186,  0.00000,100.00000,100 100.000000,100.000000,100.00000   0.00000 100.000000,100.00000 100.000000, 20, 9  4, 56.50898,1.000000, 3,1 Sprich | Xu | Yang 2016 | 2015 | 2012 Ding,10.1142/S2575900018400013 Cognitive Behavioral Therapy (CBT),medication | atomoxetine | methylphenidate,Questionnaire ADHD Severity Ratings + Symptom Inventory Scale of ADHD + Conners parents symptom questionnaire NA,RCT (parallel, crossover, open-label) DSM-5/ICD-10 Active (any credible active intervention),h/wk,Critically low,10.3,16 NA,NA Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Depressive disorder symptoms | Generalized anxiety | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Executive functioning (tests) | Quality of life (patients) | Emotional dysregulation Ding (2018) | Liu (2022) | Lopez (2018) | Ostinelli (2025) 10.3,43.15,NA,NA,NA NA NA NA,2-6 months NA NA,0.92h/wk 6-17 yo Homogeneous Cognitive Behavioral Therapy (CBT)_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Mixed_At study endpoint (closest to 12 weeks)_6-17 yo Ding (2018) - Cognitive Behavioral Therapy (CBT)_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Mixed_At study endpoint (closest to 12 weeks)_6-17 yo,Cognitive Behavioral Therapy (CBT)_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Mixed_At study endpoint (closest to 12 weeks)_6-17 yo - [Homogeneous],2018 Cognitive Behavioral Therapy (CBT)_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Mixed_At study endpoint (closest to 12 weeks), 69,TRUE,Ding (2018)_Cognitive Behavioral Therapy (CBT)_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Mixed_At study endpoint (closest to 12 weeks),Ding (2018)_Cognitive Behavioral Therapy (CBT)_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Mixed_At study endpoint (closest to 12 weeks),100.00000
Doffer (2023) Parent-mediated behavioral interventions,Combined ADHD symptoms (inattentive + hyperactive/impulsive) Parent-rated Closest to 52 weeks, 571, 8.636800, 8.636800, 8.636800,10.712174,12.745313,13.970000 13.970000 13.970000  973,  0.000000 187.38466, 31.906834,12.277123  97.49454 NA    1.081655 100.00000 100.00000 100.00000,100,  0.000000   0.000000, 50.90508,  0.00000,100.000000,100.00000, 49.094923, 33  4, 5 188.33466,4.485651, 4 1,Ferrin | Pfiffner | Sibley 2016 | 2014 | 2021 Doffer 10.1002/jcv2.12196,NA,NA Questionnaire,CPRS-H/I | CPRS-I | CTRS-Total | P-CSI | T-CSI | DBD-Total | C3RS-H/I | DSM-checklist-H/I-p | DSM-checklist-H/I-t | C3RS-I | DSM-checklist-I-p | DSM-checklist-I-t,NA,RCT (parallel, crossover, open-label),DSM-IV | DSM-V,TAU h/wk Critically low 8.6368,13.97,94.15 104.416 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Conduct Disorder symptoms | Oppositional Defiant Disorder symptoms | Acceptability: all-cause discontinuation Groenman - Preschool (2022) | Groenman (2022) | Doffer (2023) | Doffer - Preschool (2023) | Catala-Lopez (2017) 3.5 13.99 94.15 108.21 NA,100.4569 94.15 103.76 NA,Average (80-119),NA,1.08h/wk,6-17 yo Homogeneous,Parent-mediated behavioral interventions_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_Closest to 52 weeks_6-17 yo,Doffer (2023) - Parent-mediated behavioral interventions_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_Closest to 52 weeks_6-17 yo,Parent-mediated behavioral interventions_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_Closest to 52 weeks_6-17 yo - [Homogeneous] 2023 Parent-mediated behavioral interventions_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_Closest to 52 weeks, 70 NA Doffer (2023)_Parent-mediated behavioral interventions_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_Closest to 52 weeks,Doffer (2023)_Parent-mediated behavioral interventions_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_Closest to 52 weeks 100.00000
Doffer (2023) Parent-mediated behavioral interventions Oppositional Defiant Disorder symptoms Parent-rated,At follow-up (closest to 26 weeks)  149, 7.850000, 7.850000, 7.850000, 7.850000, 7.850000,10.712174 10.712174 10.712174, 973,  0.000000, 74.90604, 21.774094  9.175436  94.58725,NA,   2.268456,100.00000  46.30872,100.00000,100, 53.691275, 53.691275,100.00000   0.00000,100.000000,100.00000  53.691275  33, 4  5, 74.90604 1.536913, 2 1,Chacko | Ferrin,2009 | 2016,Doffer 10.1002/jcv2.12196 NA NA,Questionnaire DBD-ODD | CPRS-Opposition NA RCT (parallel, crossover, open-label),DSM-IV WLC (wait-list control) | TAU h/wk Critically low,7.85 10.71217391 94.58724638 94.58724638,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Conduct Disorder symptoms | Oppositional Defiant Disorder symptoms | Acceptability: all-cause discontinuation,Groenman - Preschool (2022) | Groenman (2022) | Doffer (2023) | Doffer - Preschool (2023) | Catala-Lopez (2017),3.5,13.99 94.15 108.21 NA,100.4569,94.15,103.76 NA Average (80-119),NA,2.27h/wk,6-17 yo,Homogeneous Parent-mediated behavioral interventions_Oppositional Defiant Disorder symptoms_Parent-rated_At follow-up (closest to 26 weeks)_6-17 yo,Doffer (2023) - Parent-mediated behavioral interventions_Oppositional Defiant Disorder symptoms_Parent-rated_At follow-up (closest to 26 weeks)_6-17 yo Parent-mediated behavioral interventions_Oppositional Defiant Disorder symptoms_Parent-rated_At follow-up (closest to 26 weeks)_6-17 yo - [Homogeneous] 2023 Parent-mediated behavioral interventions_Oppositional Defiant Disorder symptoms_Parent-rated_At follow-up (closest to 26 weeks)  71,NA,Doffer (2023)_Parent-mediated behavioral interventions_Oppositional Defiant Disorder symptoms_Parent-rated_At follow-up (closest to 26 weeks),Doffer (2023)_Parent-mediated behavioral interventions_Oppositional Defiant Disorder symptoms_Parent-rated_At follow-up (closest to 26 weeks) 100.00000
Doffer - Preschool (2023) Parent-mediated behavioral interventions Combined ADHD symptoms (inattentive + hyperactive/impulsive),Parent-rated,At follow-up (closest to 26 weeks), 164  3.500000  3.500000  3.500000, 3.500000  3.500000  4.146000, 4.460000  4.460000, 973   0.000000  66.13415  19.240000  3.852866,103.44333 NA,   1.045732 100.00000, 27.43902 100.00000 100,100.000000,100.000000 100.00000   0.00000  54.268293 100.00000 100.000000  33  4  5, 66.13415 3.000000  3,1,Pisterman | Sonuga-Barke | Thompson 1992 | 2004 | 2009,Doffer - Preschool 10.1002/jcv2.12196 NA NA,Questionnaire Attention on-task parent supervised | Attention on-task independent | Attention free play | PACS-ADHD | WWP | BCL-Hyperactivity | PACS-ADHD | WWP | Observation FarmYard,NA,RCT (parallel, crossover, open-label) DSM-III | DSM-IV WLC (wait-list control) | TAU h/wk,Critically low,3.5 4.46,103.4433333,103.4433333 Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Conduct Disorder symptoms | Oppositional Defiant Disorder symptoms | Acceptability: all-cause discontinuation,Groenman - Preschool (2022) | Groenman (2022) | Doffer (2023) | Doffer - Preschool (2023) | Catala-Lopez (2017),3.5 13.99 94.15 108.21 NA 100.4569 94.15,103.76,NA Average (80-119) NA,1.05h/wk,< 6 yo,Homogeneous Parent-mediated behavioral interventions_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At follow-up (closest to 26 weeks)_< 6 yo Doffer - Preschool (2023) - Parent-mediated behavioral interventions_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At follow-up (closest to 26 weeks)_< 6 yo Parent-mediated behavioral interventions_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At follow-up (closest to 26 weeks)_< 6 yo - [Homogeneous],2023 Parent-mediated behavioral interventions_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At follow-up (closest to 26 weeks), 72 NA Doffer - Preschool (2023)_Parent-mediated behavioral interventions_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At follow-up (closest to 26 weeks) Doffer - Preschool (2023)_Parent-mediated behavioral interventions_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At follow-up (closest to 26 weeks),100.00000
Elliott (2020) Amphetamine Executive functioning (report),Mixed,At study endpoint (closest to 12 weeks), 722 29.100000 29.100000,29.100000,33.100000,34.552174 36.550000,36.550000,36.550000,1056,100.000000 197.50970  46.318560,33.857756,NA, 1.34870214   42.157202 100.00000,  0.00000 100.00000 100   0.000000   0.000000,100.00000   0.00000  39.750693,  0.00000 100.000000, 43 14, 9 197.50970 1.178670, 4,1,Adler | Spencer | Wigal 2013 | 2008 | 2018a | 2018b Elliott 10.1371/journal.pone.0240584 lisdexamphetamine | mixed amphetamine salts xr | mixed amphetamine salts | triple bead mixed amphetamine salts,monotherapy,Questionnaire,BRIEF-A p481 | p111,RCT (parallel, crossover, open-label),DSM-IV-TR Placebo mg/d,Critically low 29.1,36.55,NA,NA Disruptive behaviors | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Academic/job performance | Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Depressive disorder symptoms | Generalized anxiety | Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Executive functioning (tests),Faraone (2002) | Punja (2016) | Castells (2018) | Elliott (2020) | Bellato - adults (2024) | Bellatto - children (2024) | Lenzi (2018) | Ostinelli (2025) | Cortese - Children (2018),8,41.2 NA,NA NA,NA,NA,NA < 2 months NA NA,42.16mg/d,>= 18 yo Homogeneous Amphetamine_Executive functioning (report)_Mixed_At study endpoint (closest to 12 weeks)_>= 18 yo,Elliott (2020) - Amphetamine_Executive functioning (report)_Mixed_At study endpoint (closest to 12 weeks)_>= 18 yo,Amphetamine_Executive functioning (report)_Mixed_At study endpoint (closest to 12 weeks)_>= 18 yo - [Homogeneous],2020,Amphetamine_Executive functioning (report)_Mixed_At study endpoint (closest to 12 weeks), 73 FALSE Elliott (2020)_Amphetamine_Executive functioning (report)_Mixed_At study endpoint (closest to 12 weeks),Elliott (2020)_Amphetamine_Executive functioning (report)_Mixed_At study endpoint (closest to 12 weeks) 100.00000
Elliott (2020),Atomoxetine,Executive functioning (report),Mixed At study endpoint (closest to 12 weeks), 535 32.248593,32.248593,32.248593,32.248593 32.248593,37.000000 37.000000,37.000000 1056,  0.000000,324.51776  49.293084,33.527477,NA  2.17760236 NA 100.00000,  0.00000,100.00000 100,  0.000000,  0.000000,100.00000,  0.00000, 73.084112,  0.00000,100.000000  44, 9, 7,324.51776 1.000000, 2 1,Goto | Sutherland 2017 | 2012,Elliott,10.1371/journal.pone.0240584 Atomoxetine NA,Questionnaire,BRIEF-A NA,RCT (parallel, crossover, open-label),DSM-IV-TR Placebo,mg/d,Critically low,32.2485933503836 37 NA NA Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Generalized anxiety | Depressive disorder symptoms | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | CGI,Elliott (2020) | Bellatto - children (2024) | Lenzi (2018) | Bryant (2021) | Ostinelli (2025) | Cortese - Adults (2018) | Cortese - Children (2018) 8.65154639175258,42.10703125,NA NA,NA,NA,NA,NA 2-6 months,NA NA NAmg/d,>= 18 yo,Homogeneous Atomoxetine_Executive functioning (report)_Mixed_At study endpoint (closest to 12 weeks)_>= 18 yo,Elliott (2020) - Atomoxetine_Executive functioning (report)_Mixed_At study endpoint (closest to 12 weeks)_>= 18 yo,Atomoxetine_Executive functioning (report)_Mixed_At study endpoint (closest to 12 weeks)_>= 18 yo - [Homogeneous],2020,Atomoxetine_Executive functioning (report)_Mixed_At study endpoint (closest to 12 weeks), 74 TRUE Elliott (2020)_Atomoxetine_Executive functioning (report)_Mixed_At study endpoint (closest to 12 weeks),Elliott (2020)_Atomoxetine_Executive functioning (report)_Mixed_At study endpoint (closest to 12 weeks),100.00000
Elliott (2020) Methylphenidate Executive functioning (report),Self-rated,At study endpoint (closest to 12 weeks) 1579,33.967581 33.967581 33.967581 33.967581,35.299310,35.747059,35.747059 35.747059,1056,  0.000000,518.76567  45.499557,35.325332 NA  1.66395681,  55.145662,100.00000,  0.00000 100.00000 100   0.000000,  0.000000 100.00000   0.00000, 95.820139   0.00000 100.000000,141,14,11 518.76567 1.000000  5,1 Ginsberg | Goodman | Huss | Medori | Tenenbaum 2012 | 2017 | 2014 | 2008 | 2002 Elliott 10.1371/journal.pone.0240584 Methylphenidate Osmotic-Controlled Release Oral System | Methylphenidate Hydrochloride – Long-Acting Capsule | Methylphenidate Immediate-Release NA,Questionnaire,Brief Rating Inventory of Executive Function for Adults [BRIEF-A],NA,RCT (parallel, crossover, open-label) DSM-IV | DSM-IV, ADHD-RS | DSM-IV by CAADID | DSM-IV, ADSA,Placebo mg/d,Critically low 33.9675810473815 42 NA NA Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events) Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018),4.42 50.1 60,109.9,NA  99.5875,97.45 105.60,< 2 months NA NA 55.15mg/d,>= 18 yo Homogeneous,Methylphenidate_Executive functioning (report)_Self-rated_At study endpoint (closest to 12 weeks)_>= 18 yo Elliott (2020) - Methylphenidate_Executive functioning (report)_Self-rated_At study endpoint (closest to 12 weeks)_>= 18 yo,Methylphenidate_Executive functioning (report)_Self-rated_At study endpoint (closest to 12 weeks)_>= 18 yo - [Homogeneous],2020,Methylphenidate_Executive functioning (report)_Self-rated_At study endpoint (closest to 12 weeks), 75 FALSE Elliott (2020)_Methylphenidate_Executive functioning (report)_Self-rated_At study endpoint (closest to 12 weeks),Elliott (2020)_Methylphenidate_Executive functioning (report)_Self-rated_At study endpoint (closest to 12 weeks) 100.00000
Fahrat (2024),Alpha-2 agonists (guanfacine / clonidine),Tics/Tourette disorder symptoms,Mixed At study endpoint (closest to 12 weeks) NA, 9.070000, 9.070000  9.070000  9.070000  9.070000 10.600000,10.600000,10.600000,8992   0.000000, 95.67249   9.132751  9.721790,NA, 1.70451405    1.111004 100.00000,  0.00000 100.00000 100 100.000000 100.000000 100.00000,100.00000,100.000000 100.00000,100.000000, 20, 7  5  95.67249 1.000000  4 1,Chen | Scahill | Singer | TSSG 2024 | 2001 | 1995 | 2002,Fahrat,10.1089/cap.2024.0049 NA NA Questionnaire,VAS (ADHD symptoms and TICS) | The Yale Global Tic Severity Scale,NA RCT (parallel, crossover, open-label),DSM-IV | DSM-III-R Placebo,mg/d High 9.07,10.6,NA NA,Specific adverse events: sleep problems | Tics/Tourette disorder symptoms | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Emotional dysregulation | Quality of life (patients) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events),Ruggiero (2014) | Fahrat (2024) | Radonjic (2023) | Ostinelli (2025) | Cortese - Children (2018),8.23931034482759,41.2,NA,NA NA,NA NA NA < 2 months NA,NA 1.11mg/d,6-17 yo Homogeneous Alpha-2 agonists (guanfacine / clonidine)_Tics/Tourette disorder symptoms_Mixed_At study endpoint (closest to 12 weeks)_6-17 yo Fahrat (2024) - Alpha-2 agonists (guanfacine / clonidine)_Tics/Tourette disorder symptoms_Mixed_At study endpoint (closest to 12 weeks)_6-17 yo,Alpha-2 agonists (guanfacine / clonidine)_Tics/Tourette disorder symptoms_Mixed_At study endpoint (closest to 12 weeks)_6-17 yo - [Homogeneous],2024,Alpha-2 agonists (guanfacine / clonidine)_Tics/Tourette disorder symptoms_Mixed_At study endpoint (closest to 12 weeks), 76,NA,Fahrat (2024)_Alpha-2 agonists (guanfacine / clonidine)_Tics/Tourette disorder symptoms_Mixed_At study endpoint (closest to 12 weeks) Fahrat (2024)_Alpha-2 agonists (guanfacine / clonidine)_Tics/Tourette disorder symptoms_Mixed_At study endpoint (closest to 12 weeks),100.00000
Faraone (2002) Amphetamine,Disruptive behaviors Mixed,At study endpoint (closest to 12 weeks), 130, 8.000000  8.000000  8.000000, 8.000000, 9.500000, 9.500000  9.500000, 9.500000 1110,  0.000000, 43.90769 NA, 9.061538,NA  0.69044879,   0.600000,100.00000   0.00000 100.00000,100,  0.000000,  0.000000   0.00000,  0.00000,  0.000000   0.00000   0.000000, 43,14, 9, 43.90769,2.415385, 3 1,Pelham, Aronoff | Pelham, Gnagy | Pliszka 1999 | 2000,Faraone 10.1177/108705470200600203,Adderall,NA Questionnaire Iowa Conners Rating Scale,NA RCT (crossover) | RCT (parallel),NA,Placebo,mg | mg/kg/d Critically low 8,9.5,NA,NA Disruptive behaviors | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Academic/job performance | Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Depressive disorder symptoms | Generalized anxiety | Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Executive functioning (tests) Faraone (2002) | Punja (2016) | Castells (2018) | Elliott (2020) | Bellato - adults (2024) | Bellatto - children (2024) | Lenzi (2018) | Ostinelli (2025) | Cortese - Children (2018) 8 41.2,NA NA NA,NA,NA,NA,< 2 months,NA,NA 0.6mg | mg/kg/d,6-17 yo Homogeneous Amphetamine_Disruptive behaviors_Mixed_At study endpoint (closest to 12 weeks)_6-17 yo Faraone (2002) - Amphetamine_Disruptive behaviors_Mixed_At study endpoint (closest to 12 weeks)_6-17 yo,Amphetamine_Disruptive behaviors_Mixed_At study endpoint (closest to 12 weeks)_6-17 yo - [Homogeneous] 2002 Amphetamine_Disruptive behaviors_Mixed_At study endpoint (closest to 12 weeks)  77,FALSE Faraone (2002)_Amphetamine_Disruptive behaviors_Mixed_At study endpoint (closest to 12 weeks) Faraone (2002)_Amphetamine_Disruptive behaviors_Mixed_At study endpoint (closest to 12 weeks) 100.00000
Farhat (2024),Methylphenidate Tics/Tourette disorder symptoms,Mixed At study endpoint (closest to 12 weeks)  217, 8.900000, 8.900000  8.900000  8.900000 10.200000 10.200000,10.200000 10.200000,8992   0.000000,108.92627, 15.595853  9.742396,NA, 2.49028228,  18.952995,100.00000,  0.00000 100.00000,100,100.000000 100.000000,100.00000,100.00000 100.000000,100.00000 100.000000,141 14,11 108.92627,1.000000  3,1,Castellanos | Gadow | TSSG,1997 | 2007 | 2002,Farhat 10.1089/cap.2024.0049,NA NA,Observational tool YGTSS, Yale Global Tic Severity Scale NA,RCT (crossover) | RCT (parallel) DSM-III-R | DSM-IV,Placebo mg/d | mg/kg/d,High 8.9 10.2 NA NA Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events),Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018) 4.42,50.1,60 109.9,NA, 99.5875 97.45 105.60,2-6 months,NA NA,18.95mg/d | mg/kg/d,6-17 yo Homogeneous Methylphenidate_Tics/Tourette disorder symptoms_Mixed_At study endpoint (closest to 12 weeks)_6-17 yo Farhat (2024) - Methylphenidate_Tics/Tourette disorder symptoms_Mixed_At study endpoint (closest to 12 weeks)_6-17 yo,Methylphenidate_Tics/Tourette disorder symptoms_Mixed_At study endpoint (closest to 12 weeks)_6-17 yo - [Homogeneous],2024,Methylphenidate_Tics/Tourette disorder symptoms_Mixed_At study endpoint (closest to 12 weeks), 78 NA Farhat (2024)_Methylphenidate_Tics/Tourette disorder symptoms_Mixed_At study endpoint (closest to 12 weeks) Farhat (2024)_Methylphenidate_Tics/Tourette disorder symptoms_Mixed_At study endpoint (closest to 12 weeks),100.00000
Gan (2019) Vitamin D,Combined ADHD symptoms (inattentive + hyperactive/impulsive),Mixed At study endpoint (closest to 12 weeks), 125, 8.500000, 8.500000, 8.500000, 8.500000  9.500000, 9.500000, 9.500000, 9.500000,1255,100.000000, 63.65600, 22.141935  9.068000,NA  2.49939701,1432.000000,100.00000,  0.00000,100.00000 100 100.000000 100.000000,100.00000,100.00000,100.000000,100.00000 100.000000   3, 2, 1  63.65600 1.000000  2 1,Mohammadpour | Naeini 2018 | 2019,Gan 10.1089/cap.2019.0059,Vitamin D,methylphenidate,Questionnaire Conners Parent Questionnaire + Attention-deficit/hyperactivity disorder | Conners Parent Questionnaire,NA RCT,DSM-IV Active (any credible active intervention),IU/d Low,8.5,9.5,NA,NA Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Oppositional Defiant Disorder symptoms Gan (2019) 8.5 10.5 NA,NA,NA NA,NA,NA,2-6 months,NA NA 1432IU/d 6-17 yo,Homogeneous,Vitamin D_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Mixed_At study endpoint (closest to 12 weeks)_6-17 yo,Gan (2019) - Vitamin D_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Mixed_At study endpoint (closest to 12 weeks)_6-17 yo,Vitamin D_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Mixed_At study endpoint (closest to 12 weeks)_6-17 yo - [Homogeneous] 2019 Vitamin D_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Mixed_At study endpoint (closest to 12 weeks), 79 TRUE Gan (2019)_Vitamin D_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Mixed_At study endpoint (closest to 12 weeks) Gan (2019)_Vitamin D_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Mixed_At study endpoint (closest to 12 weeks),100.00000
Gan (2019) Vitamin D Oppositional Defiant Disorder symptoms Mixed At study endpoint (closest to 12 weeks)   89, 8.500000, 8.500000, 8.500000, 8.500000  8.500000,10.500000,10.500000 10.500000,1255 100.000000  46.52809  22.212154  9.286517 NA  2.20322985 2393.258427 100.00000   0.00000 100.00000,100,100.000000 100.000000,100.00000,100.00000 100.000000 100.00000,100.000000   3, 2, 1, 46.52809 1.000000  2 1 Elshorbagy | Mohammadpour,2018,Gan,10.1089/cap.2019.0059,Vitamin D methylphenidate,Questionnaire Conners Parent Questionnaire, ODD subscale,NA,RCT DSM-IV,Active (any credible active intervention),IU/d Low 8.5 10.5 NA,NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Oppositional Defiant Disorder symptoms,Gan (2019) 8.5,10.5,NA NA,NA NA NA NA 2-6 months,NA NA 2393.26IU/d,6-17 yo Homogeneous,Vitamin D_Oppositional Defiant Disorder symptoms_Mixed_At study endpoint (closest to 12 weeks)_6-17 yo Gan (2019) - Vitamin D_Oppositional Defiant Disorder symptoms_Mixed_At study endpoint (closest to 12 weeks)_6-17 yo Vitamin D_Oppositional Defiant Disorder symptoms_Mixed_At study endpoint (closest to 12 weeks)_6-17 yo - [Homogeneous],2019,Vitamin D_Oppositional Defiant Disorder symptoms_Mixed_At study endpoint (closest to 12 weeks), 80,TRUE,Gan (2019)_Vitamin D_Oppositional Defiant Disorder symptoms_Mixed_At study endpoint (closest to 12 weeks) Gan (2019)_Vitamin D_Oppositional Defiant Disorder symptoms_Mixed_At study endpoint (closest to 12 weeks) 100.00000
Gillies (2023),Polyunsaturated fatty acids,Acceptability: all-cause discontinuation,NA,At study endpoint (closest to 12 weeks)  603, 7.950000, 8.700000  8.700000, 9.000000  9.200000, 9.300000  9.300000  9.300000 1318, 29.353234,108.34992, 24.848192  9.126984 NA  2.72090449, 439.438522  94.02985   0.00000,100.00000,100  39.469320  39.469320 100.00000 100.00000, 35.986733  39.46932,100.000000, 28  8, 3 108.34992 1.000000  8,1 Arnold | Behdani | Dubnov-Raz | Hirayama | Manor | Mohammadzadeh | Vaisman | Voigt 1989 | 2013 | 2014 | 2004 | 2012 | 2019 | 2008 | 2001 Gillies 10.1002/14651858.CD007986.pub2 NA,Dexamfetamine | Metilphenidate | MPH,NA NA NA,RCT (parallel, crossover, open-label) DSM-III | DSM-IV TR | DSM (clinical diag) | DSM-IV Active (any credible active intervention) | Placebo mg/d,High 7.95,11,NA,NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Conduct Disorder symptoms | Oppositional Defiant Disorder symptoms | Social-communication skills | Specific adverse events: sleep problems | Quality of life (patients) | Tolerability (discontinuation due to adverse events) Gillies (2023) | Handel (2021) | Catala-Lopez (2017),6,13.7 NA,NA,NA NA,NA NA 2-6 months,NA,NA,439.44mg/d 6-17 yo,Homogeneous Polyunsaturated fatty acids_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_6-17 yo Gillies (2023) - Polyunsaturated fatty acids_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_6-17 yo,Polyunsaturated fatty acids_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_6-17 yo - [Homogeneous],2023 Polyunsaturated fatty acids_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)  81 NA Gillies (2023)_Polyunsaturated fatty acids_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks) Gillies (2023)_Polyunsaturated fatty acids_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks) 100.00000
Gillies (2023) Polyunsaturated fatty acids Combined ADHD symptoms (inattentive + hyperactive/impulsive) Parent-rated,At follow-up (closest to 26 weeks)  963, 8.270000, 8.900000, 8.900000, 9.300000, 9.490000  9.900000 10.985000,11.700000 1318, 11.422638  80.36656  19.410824, 9.666698,NA, 4.45056257  679.884614,100.00000,  0.00000 100.00000 100, 80.477674, 80.477674, 89.82347  93.76947  79.543094  90.65421, 93.769470  28, 8, 3  80.36656,1.000000 15 1,Anand | Barragan | Bos | Chang | Cornu | Crippa | Gustafsson | Manor | Matsudaira | NCT01807299 | Perera | Rodriguez | Stevens | Vaisman | Widenhorn-Muller,2016 | 2017 | 2015 | 2019 | 2018 | 2010 | 2012 | 2013 | 2003 | 2008 | 2014 Gillies 10.1002/14651858.CD007986.pub2,NA,Atomoxetine | Metilphenidate,Questionnaire,Validated scales such as the Child Behavior Checklist, Achenbach 1983, or Conners Rating Scales, Conners 1998. NA,RCT (parallel, crossover, open-label),DSM-IV | DSM-IV TR | DSM-5 | DSM (clinical diag),Active (any credible active intervention) | Placebo mg/d,High 6,13.7,NA,NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Conduct Disorder symptoms | Oppositional Defiant Disorder symptoms | Social-communication skills | Specific adverse events: sleep problems | Quality of life (patients) | Tolerability (discontinuation due to adverse events) Gillies (2023) | Handel (2021) | Catala-Lopez (2017),6 13.7,NA NA,NA,NA NA NA,2-6 months,NA NA 679.88mg/d 6-17 yo Homogeneous,Polyunsaturated fatty acids_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At follow-up (closest to 26 weeks)_6-17 yo,Gillies (2023) - Polyunsaturated fatty acids_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At follow-up (closest to 26 weeks)_6-17 yo,Polyunsaturated fatty acids_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At follow-up (closest to 26 weeks)_6-17 yo - [Homogeneous],2023,Polyunsaturated fatty acids_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At follow-up (closest to 26 weeks), 82,NA Gillies (2023)_Polyunsaturated fatty acids_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At follow-up (closest to 26 weeks),Gillies (2023)_Polyunsaturated fatty acids_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At follow-up (closest to 26 weeks),100.00000
Gillies (2023),Polyunsaturated fatty acids Combined ADHD symptoms (inattentive + hyperactive/impulsive) Parent-rated,At study endpoint (closest to 12 weeks), 329  7.941667, 7.941667  8.270000, 8.270000  8.700000, 8.850000  8.850000  9.100000,1318,100.000000  71.61398  25.529694, 8.577508,NA, 3.52597577  498.723404,100.00000   0.00000,100.00000 100, 63.525836, 63.525836  81.76292  81.76292,100.000000, 81.76292  81.762918, 28  8, 3  71.61398 1.000000  5,1,Assareh | Barragan | Behdani | Mohammadzadeh | Salehi 2017 | 2013 | 2019 | 2016,Gillies 10.1002/14651858.CD007986.pub2,NA,Metilphenidate | MPH,Questionnaire,Validated scales such as the Child Behavior Checklist, Achenbach 1983, or Conners Rating Scales, Conners 1998.,NA,RCT (parallel, crossover, open-label),DSM-IV | DSM-IV TR Active (any credible active intervention),mg/d High 7.94166666666667 9.1,NA,NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Conduct Disorder symptoms | Oppositional Defiant Disorder symptoms | Social-communication skills | Specific adverse events: sleep problems | Quality of life (patients) | Tolerability (discontinuation due to adverse events),Gillies (2023) | Handel (2021) | Catala-Lopez (2017) 6,13.7 NA NA NA NA,NA,NA 2-6 months NA NA 498.72mg/d,6-17 yo Homogeneous,Polyunsaturated fatty acids_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks)_6-17 yo Gillies (2023) - Polyunsaturated fatty acids_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks)_6-17 yo,Polyunsaturated fatty acids_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks)_6-17 yo - [Homogeneous] 2023 Polyunsaturated fatty acids_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks), 83,NA,Gillies (2023)_Polyunsaturated fatty acids_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks),Gillies (2023)_Polyunsaturated fatty acids_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks),100.00000
Gillies (2023) Polyunsaturated fatty acids,Combined ADHD symptoms (inattentive + hyperactive/impulsive),Teacher-rated At follow-up (closest to 26 weeks)  498, 8.900000, 8.900000, 9.200000  9.200000, 9.490000  9.500000  9.800000 13.700000,1318   0.000000, 94.22490, 18.483473  9.915803,NA  3.31708422, 580.396145,100.00000   0.00000 100.00000,100  72.690763, 72.690763,100.00000,100.00000, 66.064257  72.69076 100.000000, 28  8, 3  94.22490 1.000000, 6 1,Chang | Gustafsson | Manor | Matsudaira | Stevens | Widenhorn-Muller 2019 | 2010 | 2012 | 2015 | 2003 | 2014,Gillies 10.1002/14651858.CD007986.pub2 NA,NA,Questionnaire Validated scales such as the Child Behavior Checklist, Achenbach 1983, or Conners Rating Scales, Conners 1998. NA RCT (parallel, crossover, open-label) DSM-5 | DSM-IV | DSM (clinical diag),Placebo mg/d,High,8.9 13.7,NA NA Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Conduct Disorder symptoms | Oppositional Defiant Disorder symptoms | Social-communication skills | Specific adverse events: sleep problems | Quality of life (patients) | Tolerability (discontinuation due to adverse events) Gillies (2023) | Handel (2021) | Catala-Lopez (2017),6 13.7,NA,NA NA NA,NA,NA 2-6 months NA NA 580.4mg/d 6-17 yo,Homogeneous Polyunsaturated fatty acids_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Teacher-rated_At follow-up (closest to 26 weeks)_6-17 yo,Gillies (2023) - Polyunsaturated fatty acids_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Teacher-rated_At follow-up (closest to 26 weeks)_6-17 yo,Polyunsaturated fatty acids_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Teacher-rated_At follow-up (closest to 26 weeks)_6-17 yo - [Homogeneous] 2023 Polyunsaturated fatty acids_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Teacher-rated_At follow-up (closest to 26 weeks)  84 NA Gillies (2023)_Polyunsaturated fatty acids_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Teacher-rated_At follow-up (closest to 26 weeks) Gillies (2023)_Polyunsaturated fatty acids_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Teacher-rated_At follow-up (closest to 26 weeks),100.00000
Gillies (2023) Polyunsaturated fatty acids Combined ADHD symptoms (inattentive + hyperactive/impulsive),Teacher-rated At study endpoint (closest to 12 weeks)  185  8.700000, 8.700000  8.700000  8.700000 10.500000 10.500000 10.500000 11.000000 1318  56.756757, 55.75676, 24.874919  9.723490,NA  1.59912916  559.135135, 80.54054,  0.00000,100.00000,100  46.486486, 46.486486 100.00000 100.00000, 56.756757, 46.48649 100.000000  28, 8, 3  55.75676,1.000000  4,1,Arnold | Behdani | Dubnov-Raz | Raz,1989 | 2013 | 2014 | 2009,Gillies,10.1002/14651858.CD007986.pub2,NA,Dexamfetamine | Metilphenidate Questionnaire,Validated scales such as the Child Behavior Checklist, Achenbach 1983, or Conners Rating Scales, Conners 1998. NA RCT (parallel, crossover, open-label) DSM-III | DSM-IV TR | DSM (clinical diag) Active (any credible active intervention) | Placebo,mg/d,High 8.7 11,NA NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Conduct Disorder symptoms | Oppositional Defiant Disorder symptoms | Social-communication skills | Specific adverse events: sleep problems | Quality of life (patients) | Tolerability (discontinuation due to adverse events),Gillies (2023) | Handel (2021) | Catala-Lopez (2017),6,13.7,NA NA NA,NA,NA,NA < 2 months NA NA,559.14mg/d 6-17 yo Homogeneous Polyunsaturated fatty acids_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Teacher-rated_At study endpoint (closest to 12 weeks)_6-17 yo Gillies (2023) - Polyunsaturated fatty acids_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Teacher-rated_At study endpoint (closest to 12 weeks)_6-17 yo Polyunsaturated fatty acids_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Teacher-rated_At study endpoint (closest to 12 weeks)_6-17 yo - [Homogeneous],2023 Polyunsaturated fatty acids_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Teacher-rated_At study endpoint (closest to 12 weeks)  85,NA,Gillies (2023)_Polyunsaturated fatty acids_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Teacher-rated_At study endpoint (closest to 12 weeks),Gillies (2023)_Polyunsaturated fatty acids_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Teacher-rated_At study endpoint (closest to 12 weeks) 100.00000
Gillies (2023) Polyunsaturated fatty acids,Conduct Disorder symptoms,Mixed,At follow-up (closest to 26 weeks), 332, 8.820000  8.820000  8.900000  8.900000, 9.490000  9.567500 10.214750 10.985000,1318,  0.000000  73.39498, 15.484353, 9.457169,NA, 3.71815257, 481.926004 100.00000,  0.00000 100.00000 100  64.992390, 64.992390 100.00000,100.00000  70.167428, 64.99239 100.000000  28, 8  3  74.33790,1.369863, 5,1 Chang | Crippa | Kean | Stevens | Widenhorn-Muller 2019 | 2017 | 2003 | 2014,Gillies,10.1002/14651858.CD007986.pub2 NA,NA,Questionnaire Measured by scales such as the Child Behavior Checklist NA RCT (parallel, crossover, open-label),DSM-5 | DSM-IV TR | DSM-IV | DSM (clinical diag),Placebo mg/d High 8.82 10.985,NA,NA Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Conduct Disorder symptoms | Oppositional Defiant Disorder symptoms | Social-communication skills | Specific adverse events: sleep problems | Quality of life (patients) | Tolerability (discontinuation due to adverse events),Gillies (2023) | Handel (2021) | Catala-Lopez (2017) 6,13.7,NA,NA,NA,NA,NA NA 2-6 months NA,NA 481.93mg/d,6-17 yo Homogeneous,Polyunsaturated fatty acids_Conduct Disorder symptoms_Mixed_At follow-up (closest to 26 weeks)_6-17 yo,Gillies (2023) - Polyunsaturated fatty acids_Conduct Disorder symptoms_Mixed_At follow-up (closest to 26 weeks)_6-17 yo,Polyunsaturated fatty acids_Conduct Disorder symptoms_Mixed_At follow-up (closest to 26 weeks)_6-17 yo - [Homogeneous],2023 Polyunsaturated fatty acids_Conduct Disorder symptoms_Mixed_At follow-up (closest to 26 weeks), 86,NA,Gillies (2023)_Polyunsaturated fatty acids_Conduct Disorder symptoms_Mixed_At follow-up (closest to 26 weeks),Gillies (2023)_Polyunsaturated fatty acids_Conduct Disorder symptoms_Mixed_At follow-up (closest to 26 weeks),100.00000
Gillies (2023),Polyunsaturated fatty acids,Oppositional Defiant Disorder symptoms,Mixed At follow-up (closest to 26 weeks), 423  8.820000, 8.820000, 9.200000  9.200000, 9.490000  9.500000  9.500000  9.500000 1318,  0.000000, 97.66846, 20.571394  9.317993 NA  3.30790689, 394.590812 100.00000   0.00000 100.00000 100, 51.851852, 51.851852,100.00000,100.00000  43.966547, 51.85185 100.000000, 28, 8  3, 99.13620 1.545998  5 1 Chang | Gustafsson | Kean | Manor | Stevens,2019 | 2010 | 2017 | 2012 | 2003 Gillies,10.1002/14651858.CD007986.pub2,NA,NA Questionnaire,Measured by scales such as the Child Behavior Checklist NA,RCT (parallel, crossover, open-label) DSM-5 | DSM-IV | DSM (clinical diag) Placebo mg/d,High 8.82,9.8,NA,NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Conduct Disorder symptoms | Oppositional Defiant Disorder symptoms | Social-communication skills | Specific adverse events: sleep problems | Quality of life (patients) | Tolerability (discontinuation due to adverse events) Gillies (2023) | Handel (2021) | Catala-Lopez (2017),6 13.7,NA NA,NA,NA NA NA 2-6 months NA NA 394.59mg/d,6-17 yo,Homogeneous Polyunsaturated fatty acids_Oppositional Defiant Disorder symptoms_Mixed_At follow-up (closest to 26 weeks)_6-17 yo Gillies (2023) - Polyunsaturated fatty acids_Oppositional Defiant Disorder symptoms_Mixed_At follow-up (closest to 26 weeks)_6-17 yo Polyunsaturated fatty acids_Oppositional Defiant Disorder symptoms_Mixed_At follow-up (closest to 26 weeks)_6-17 yo - [Homogeneous],2023,Polyunsaturated fatty acids_Oppositional Defiant Disorder symptoms_Mixed_At follow-up (closest to 26 weeks)  87,NA Gillies (2023)_Polyunsaturated fatty acids_Oppositional Defiant Disorder symptoms_Mixed_At follow-up (closest to 26 weeks) Gillies (2023)_Polyunsaturated fatty acids_Oppositional Defiant Disorder symptoms_Mixed_At follow-up (closest to 26 weeks) 100.00000
Gillies (2023) Polyunsaturated fatty acids Social-communication skills,Mixed At follow-up (closest to 26 weeks)  145  8.900000  8.900000, 8.900000, 8.900000  8.900000, 9.300000  9.300000  9.300000 1318,  0.000000, 75.20318, 22.137456, 9.049823 NA  3.80135569  579.540636 100.00000,  0.00000 100.00000,100  62.544170  62.544170,100.00000 100.00000  62.544170, 62.54417 100.000000  28, 8, 3, 77.39223,1.625442  2,1 Voigt | Widenhorn-Muller,2001 | 2014 Gillies 10.1002/14651858.CD007986.pub2 NA NA Unclear (not able to identify the tools used to measure the outcome),NA NA,RCT (parallel, crossover, open-label),DSM (clinical diag) | DSM-IV Placebo mg/d High,8.9,9.3,NA NA Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Conduct Disorder symptoms | Oppositional Defiant Disorder symptoms | Social-communication skills | Specific adverse events: sleep problems | Quality of life (patients) | Tolerability (discontinuation due to adverse events) Gillies (2023) | Handel (2021) | Catala-Lopez (2017),6 13.7 NA,NA,NA NA NA,NA 2-6 months NA NA,579.54mg/d,6-17 yo,Homogeneous Polyunsaturated fatty acids_Social-communication skills_Mixed_At follow-up (closest to 26 weeks)_6-17 yo Gillies (2023) - Polyunsaturated fatty acids_Social-communication skills_Mixed_At follow-up (closest to 26 weeks)_6-17 yo Polyunsaturated fatty acids_Social-communication skills_Mixed_At follow-up (closest to 26 weeks)_6-17 yo - [Homogeneous],2023 Polyunsaturated fatty acids_Social-communication skills_Mixed_At follow-up (closest to 26 weeks), 88,NA,Gillies (2023)_Polyunsaturated fatty acids_Social-communication skills_Mixed_At follow-up (closest to 26 weeks) Gillies (2023)_Polyunsaturated fatty acids_Social-communication skills_Mixed_At follow-up (closest to 26 weeks),100.00000
Gillies (2023),Polyunsaturated fatty acids Specific adverse events: sleep problems NA,At study endpoint (closest to 12 weeks)  122  7.933871  7.933871  7.933871, 7.933871  7.933871  8.270000  8.270000  8.270000 1318 100.000000, 61.01639  25.760000, 8.099180,NA  6.83732951  694.426230 100.00000,  0.00000 100.00000 100   0.000000,  0.000000, 50.81967  50.81967 100.000000  49.18033, 50.819672, 28, 8  3  61.01639,1.000000, 2 1 Barragan | Mohammadzadeh,2017 | 2019,Gillies 10.1002/14651858.CD007986.pub2,NA Metilphenidate | MPH,Unclear (not able to identify the tools used to measure the outcome) NA NA,RCT (parallel, crossover, open-label) DSM-IV TR Active (any credible active intervention),mg/d High,7.93387096774194,8.27,NA NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Conduct Disorder symptoms | Oppositional Defiant Disorder symptoms | Social-communication skills | Specific adverse events: sleep problems | Quality of life (patients) | Tolerability (discontinuation due to adverse events),Gillies (2023) | Handel (2021) | Catala-Lopez (2017) 6 13.7,NA,NA NA,NA,NA NA 7-12 months NA NA,694.43mg/d,6-17 yo Homogeneous Polyunsaturated fatty acids_Specific adverse events: sleep problems_NA_At study endpoint (closest to 12 weeks)_6-17 yo,Gillies (2023) - Polyunsaturated fatty acids_Specific adverse events: sleep problems_NA_At study endpoint (closest to 12 weeks)_6-17 yo Polyunsaturated fatty acids_Specific adverse events: sleep problems_NA_At study endpoint (closest to 12 weeks)_6-17 yo - [Homogeneous] 2023,Polyunsaturated fatty acids_Specific adverse events: sleep problems_NA_At study endpoint (closest to 12 weeks)  89,NA Gillies (2023)_Polyunsaturated fatty acids_Specific adverse events: sleep problems_NA_At study endpoint (closest to 12 weeks),Gillies (2023)_Polyunsaturated fatty acids_Specific adverse events: sleep problems_NA_At study endpoint (closest to 12 weeks),100.00000
Groenman (2022) Parent-mediated behavioral interventions Combined ADHD symptoms (inattentive + hyperactive/impulsive) Parent-rated At study endpoint (closest to 12 weeks) 1625  7.760000, 7.760000  7.760000  7.760000, 8.580000  8.670000, 9.790000,10.710000 9002   0.000000,161.83631, 21.448223, 8.888891 101.90111,13.13464303,NA 100.00000  44.22544 100.00000,100   8.808131,  8.808131, 80.32030, 17.49307  80.320296  80.32030,  8.808131, 33, 4, 5,161.88451,1.260856,16 1,Daley | Dose | Dupaul | Fabiano | Ferrin | Hornstra | Lauth | Lauthprecondis | MTA | Pfiffner | Schramm | Shimabukuro | Shum | Vdhoofdakker,2013 | 2017 | 2018 | 2012 | 2016 | 2021 | 2005 | 1999 | 2007 | 2014 | 2020 | 2025 Groenman,10.1016/j.jaac.2021.02.024,New Forest Parenting Programme Self Help | Telephone-assisted self-help (TASH) intervention | online BPT+Face to face BPT | COACHES | psychoeducation | Behavioral parent training with consequence-based techniques only | Standard Behavioral Parent Training (BPT)+Combination of Standard BPT & Child training+Attention and social skills child training | Cognitive-behavioral Training (BPT) | parent training, child docused treatment and a school-based intervention | Child life and attentions kills program | Parent Focused treatment+Child life and attentions kills program (IPT) | collaborative life skills | Learning skills training for adolescents with ADHD (LeJa) | Tuning into Kids+Mindful Parenting | Behavioral parent training Groningen,NA Questionnaire Dupaul ADHD rating scale | German questionnaire FBB-ADHS | Conners early beahvior inattention hyperactivity t scores | DBD rating symptoms | CPRS ADHD index scores | SWAN total | Conners total | CBCL Attention Scale | SNAP total ADHD parent | average score Child symptom Inverntory | average score Child symptom Inventory | Child symptom Inventory ADHD severity | Fremdbeurteilungsbogen fur hyperkinetische storungen (ADHD symptom checklist) | SNAP mother SUM | SNAP ADHD symptoms | CPRS ADHD index t scores,NA,RCT (parallel, crossover, open-label),DSM WLC (wait-list control) | TAU,NA Critically low 7.28,13.99 95.59 108.21,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Conduct Disorder symptoms | Oppositional Defiant Disorder symptoms | Acceptability: all-cause discontinuation Groenman - Preschool (2022) | Groenman (2022) | Doffer (2023) | Doffer - Preschool (2023) | Catala-Lopez (2017) 3.5 13.99,94.15 108.21 NA,100.4569,94.15,103.76,> 12 months Average (80-119),NA,NANA,6-17 yo Homogeneous Parent-mediated behavioral interventions_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks)_6-17 yo Groenman (2022) - Parent-mediated behavioral interventions_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks)_6-17 yo,Parent-mediated behavioral interventions_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks)_6-17 yo - [Homogeneous] 2022,Parent-mediated behavioral interventions_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks), 90 FALSE,Groenman (2022)_Parent-mediated behavioral interventions_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks),Groenman (2022)_Parent-mediated behavioral interventions_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks) 100.00000
Groenman (2022) Parent-mediated behavioral interventions Conduct Disorder symptoms,Parent-rated,At study endpoint (closest to 12 weeks),1428, 7.760000  7.760000, 7.760000, 8.350000, 8.580000, 8.670000  9.790000,10.710000,9002   0.000000,175.43375  21.832380, 9.029902 102.28687 12.68399291 NA 100.00000  41.64038 100.00000,100   7.921486,  7.921486, 77.60252, 17.80582  77.602524, 77.60252   7.921486, 33, 4  5 175.48861 1.154574 12,1,Dose | Fabiano | Ferrin | Hornstra | Lauthprecondis | MTA | Pfiffner | Schramm | Shimabukuro | Shum,2017 | 2012 | 2016 | 2021 | 2013 | 1999 | 2007 | 2014 | 2020 | 2025 Groenman,10.1016/j.jaac.2021.02.024 Telephone-assisted self-help (TASH) intervention | COACHES | psychoeducation | Behavioral parent training with consequence-based techniques only | Cognitive-behavioral Training (BPT) | parent training, child docused treatment and a school-based intervention | Child life and attentions kills program | Parent Focused treatment+Child life and attentions kills program (IPT) | collaborative life skills | Learning skills training for adolescents with ADHD (LeJa) | Tuning into Kids+Mindful Parenting,NA,Questionnaire German questionnaire FBB-SSV Conduct Problems | DBD rating conduct symptoms | SDQ conduct problems | CBCL Rule-breaking behavior | Aggression-Conduct Problems Scale - DSM-IV | CSI average CD | CBCL DSM conduct problems subscale | SDQ CD symptoms,NA,RCT (parallel, crossover, open-label),DSM,TAU | WLC (wait-list control) NA Critically low 7.76 13.99 95.59 108.06,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Conduct Disorder symptoms | Oppositional Defiant Disorder symptoms | Acceptability: all-cause discontinuation Groenman - Preschool (2022) | Groenman (2022) | Doffer (2023) | Doffer - Preschool (2023) | Catala-Lopez (2017),3.5,13.99 94.15,108.21 NA,100.4569,94.15,103.76,> 12 months,Average (80-119) NA NANA 6-17 yo,Homogeneous,Parent-mediated behavioral interventions_Conduct Disorder symptoms_Parent-rated_At study endpoint (closest to 12 weeks)_6-17 yo,Groenman (2022) - Parent-mediated behavioral interventions_Conduct Disorder symptoms_Parent-rated_At study endpoint (closest to 12 weeks)_6-17 yo,Parent-mediated behavioral interventions_Conduct Disorder symptoms_Parent-rated_At study endpoint (closest to 12 weeks)_6-17 yo - [Homogeneous] 2022 Parent-mediated behavioral interventions_Conduct Disorder symptoms_Parent-rated_At study endpoint (closest to 12 weeks), 91,FALSE Groenman (2022)_Parent-mediated behavioral interventions_Conduct Disorder symptoms_Parent-rated_At study endpoint (closest to 12 weeks) Groenman (2022)_Parent-mediated behavioral interventions_Conduct Disorder symptoms_Parent-rated_At study endpoint (closest to 12 weeks) 100.00000
Groenman (2022) Parent-mediated behavioral interventions,Oppositional Defiant Disorder symptoms Parent-rated At study endpoint (closest to 12 weeks),1439, 7.760000  7.760000  7.760000  7.760000, 8.510000  8.640000, 8.670000, 9.790000 9002   0.000000 171.98139, 22.307263, 8.525986,101.62602 13.50334879 NA,100.00000, 47.86087,100.00000,100,  7.860870   7.860870, 77.77391  17.66957  77.773913, 77.77391   7.860870, 33, 4  5 172.03583 1.174261,13,1 Dose | Dupaul | Fabiano | Ferrin | Hornstra | Lauthprecondis | MTA | Pfiffner | Shimabukuro | Shum | Vdhoofdakker,2017 | 2018 | 2012 | 2016 | 2021 | 2013 | 1999 | 2007 | 2014 | 2020 | 2025 Groenman,10.1016/j.jaac.2021.02.024,Telephone-assisted self-help (TASH) intervention | online BPT+Face to face BPT | COACHES | psychoeducation | Behavioral parent training with consequence-based techniques only | Cognitive-behavioral Training (BPT) | parent training, child docused treatment and a school-based intervention | Child life and attentions kills program | Parent Focused treatment+Child life and attentions kills program (IPT) | collaborative life skills | Tuning into Kids+Mindful Parenting | Behavioral parent training Groningen,NA Questionnaire German questionnaire FBB-SSV Oppositional | CERS defiant temp t score | DBD rating oppositional symptoms | CPRS oppositional | Dutch version of Disruptive Behavior Disorder Rating Scale | CBCL Aggression Scale | SNAP ODD | CSI ODD average score | SNAP ODD sum Mother | SNAP ODD symptoms NA RCT (parallel, crossover, open-label),DSM,TAU | WLC (wait-list control),NA,Critically low 7.43 10.71 95.59 108.06,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Conduct Disorder symptoms | Oppositional Defiant Disorder symptoms | Acceptability: all-cause discontinuation,Groenman - Preschool (2022) | Groenman (2022) | Doffer (2023) | Doffer - Preschool (2023) | Catala-Lopez (2017) 3.5,13.99 94.15 108.21,NA 100.4569 94.15 103.76 > 12 months,Average (80-119) NA NANA,6-17 yo,Homogeneous Parent-mediated behavioral interventions_Oppositional Defiant Disorder symptoms_Parent-rated_At study endpoint (closest to 12 weeks)_6-17 yo Groenman (2022) - Parent-mediated behavioral interventions_Oppositional Defiant Disorder symptoms_Parent-rated_At study endpoint (closest to 12 weeks)_6-17 yo Parent-mediated behavioral interventions_Oppositional Defiant Disorder symptoms_Parent-rated_At study endpoint (closest to 12 weeks)_6-17 yo - [Homogeneous],2022,Parent-mediated behavioral interventions_Oppositional Defiant Disorder symptoms_Parent-rated_At study endpoint (closest to 12 weeks), 92 FALSE,Groenman (2022)_Parent-mediated behavioral interventions_Oppositional Defiant Disorder symptoms_Parent-rated_At study endpoint (closest to 12 weeks),Groenman (2022)_Parent-mediated behavioral interventions_Oppositional Defiant Disorder symptoms_Parent-rated_At study endpoint (closest to 12 weeks),100.00000
Groenman - Preschool (2022),Parent-mediated behavioral interventions Combined ADHD symptoms (inattentive + hyperactive/impulsive) Parent-rated,At study endpoint (closest to 12 weeks), 399  3.510000  3.510000, 3.510000, 3.510000  3.970000  4.580000  5.360000  5.360000 9002   0.000000,114.39196  39.595226, 4.183794,NA,14.00000000,NA 100.00000,  0.00000 100.00000 100  54.020101  54.020101 100.00000   0.00000, 89.698492 100.00000, 54.020101  33, 4, 5 114.82915,1.437186, 5,1,Franke | Herbert | SonugaBarkeCoppi | Thompson | Websterstratton 2016 | 2013 | 2018 | 2009 | 2011 Groenman - Preschool 10.1016/j.jaac.2021.02.024 Triple P Online | Parenting Your Hyperactive Preschooler (parent training and emotion socialization) | Incredible years+a-New forest parenting program | New forest parenting plan | Incredible years NA Questionnaire Conners Early Childhood Behaviour scale (mother-rated) Inattention/ hyperactivity scales (T-score) | DBRS mother total symptoms | SNAP ADHD sum score | Werry Weis peters total score | Conners parent ADHD Dsm total NA RCT (parallel, crossover, open-label) DSM WLC (wait-list control) | TAU,NA,Critically low,3.51,5.36,NA,NA Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Conduct Disorder symptoms | Oppositional Defiant Disorder symptoms | Acceptability: all-cause discontinuation,Groenman - Preschool (2022) | Groenman (2022) | Doffer (2023) | Doffer - Preschool (2023) | Catala-Lopez (2017) 3.5 13.99 94.15,108.21 NA 100.4569 94.15,103.76 > 12 months,NA NA,NANA < 6 yo Homogeneous,Parent-mediated behavioral interventions_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks)_< 6 yo Groenman - Preschool (2022) - Parent-mediated behavioral interventions_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks)_< 6 yo Parent-mediated behavioral interventions_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks)_< 6 yo - [Homogeneous] 2022,Parent-mediated behavioral interventions_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks), 93 FALSE Groenman - Preschool (2022)_Parent-mediated behavioral interventions_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks),Groenman - Preschool (2022)_Parent-mediated behavioral interventions_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks) 100.00000
Groenman - Preschool (2022),Parent-mediated behavioral interventions Conduct Disorder symptoms Parent-rated At study endpoint (closest to 12 weeks)  315  3.510000  3.510000, 3.510000  3.510000, 3.510000  5.360000  5.360000  5.360000 9002,  0.000000,132.98726  35.538217  4.180764,NA,14.00000000 NA,100.00000,  0.00000 100.00000,100, 68.471338, 68.471338 100.00000   0.00000  86.942675 100.00000, 68.471338  33, 4, 5 133.54140 1.554140  3 1,SonugaBarkeCoppi | Thompson | Websterstratton,2018 | 2009 | 2011 Groenman - Preschool,10.1016/j.jaac.2021.02.024 Incredible years+a-New forest parenting program | New forest parenting plan | Incredible years NA Questionnaire,ECBI CD symptoms | PACS conduct problems in last 6 months | Child symptom inventory CD symptoms,NA,RCT (parallel, crossover, open-label),DSM,TAU | WLC (wait-list control) NA Critically low 3.51,5.36 NA NA Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Conduct Disorder symptoms | Oppositional Defiant Disorder symptoms | Acceptability: all-cause discontinuation,Groenman - Preschool (2022) | Groenman (2022) | Doffer (2023) | Doffer - Preschool (2023) | Catala-Lopez (2017) 3.5,13.99 94.15 108.21,NA,100.4569 94.15 103.76 > 12 months,NA NA NANA < 6 yo,Homogeneous,Parent-mediated behavioral interventions_Conduct Disorder symptoms_Parent-rated_At study endpoint (closest to 12 weeks)_< 6 yo Groenman - Preschool (2022) - Parent-mediated behavioral interventions_Conduct Disorder symptoms_Parent-rated_At study endpoint (closest to 12 weeks)_< 6 yo Parent-mediated behavioral interventions_Conduct Disorder symptoms_Parent-rated_At study endpoint (closest to 12 weeks)_< 6 yo - [Homogeneous],2022,Parent-mediated behavioral interventions_Conduct Disorder symptoms_Parent-rated_At study endpoint (closest to 12 weeks), 94,FALSE,Groenman - Preschool (2022)_Parent-mediated behavioral interventions_Conduct Disorder symptoms_Parent-rated_At study endpoint (closest to 12 weeks) Groenman - Preschool (2022)_Parent-mediated behavioral interventions_Conduct Disorder symptoms_Parent-rated_At study endpoint (closest to 12 weeks) 100.00000
Groenman - Preschool (2022) Parent-mediated behavioral interventions,Oppositional Defiant Disorder symptoms Parent-rated,At study endpoint (closest to 12 weeks)  305, 3.510000  3.510000  3.510000, 3.510000, 3.510000  5.360000, 5.360000  5.360000 9002,  0.000000,134.99342, 25.851316  4.221579 NA,14.80921053,NA,100.00000,  0.00000 100.00000,100, 57.236842  57.236842,100.00000   0.00000,100.000000 100.00000, 57.236842, 33, 4  5 135.56579 1.572368  3 1 Herbert | SonugaBarkeCoppi | Websterstratton 2013 | 2018 | 2011,Groenman - Preschool,10.1016/j.jaac.2021.02.024,Parenting Your Hyperactive Preschooler (parent training and emotion socialization) | Incredible years+a-New forest parenting program | Incredible years NA,Questionnaire,DBRS ODD average score mother | SNAP ODD average score | Conners parent oppositional NA RCT (parallel, crossover, open-label) DSM,WLC (wait-list control) | TAU NA Critically low,3.51 5.36,NA,NA Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Conduct Disorder symptoms | Oppositional Defiant Disorder symptoms | Acceptability: all-cause discontinuation,Groenman - Preschool (2022) | Groenman (2022) | Doffer (2023) | Doffer - Preschool (2023) | Catala-Lopez (2017) 3.5 13.99,94.15,108.21,NA,100.4569,94.15,103.76 > 12 months,NA,NA NANA < 6 yo Homogeneous Parent-mediated behavioral interventions_Oppositional Defiant Disorder symptoms_Parent-rated_At study endpoint (closest to 12 weeks)_< 6 yo,Groenman - Preschool (2022) - Parent-mediated behavioral interventions_Oppositional Defiant Disorder symptoms_Parent-rated_At study endpoint (closest to 12 weeks)_< 6 yo,Parent-mediated behavioral interventions_Oppositional Defiant Disorder symptoms_Parent-rated_At study endpoint (closest to 12 weeks)_< 6 yo - [Homogeneous],2022 Parent-mediated behavioral interventions_Oppositional Defiant Disorder symptoms_Parent-rated_At study endpoint (closest to 12 weeks)  95,FALSE Groenman - Preschool (2022)_Parent-mediated behavioral interventions_Oppositional Defiant Disorder symptoms_Parent-rated_At study endpoint (closest to 12 weeks),Groenman - Preschool (2022)_Parent-mediated behavioral interventions_Oppositional Defiant Disorder symptoms_Parent-rated_At study endpoint (closest to 12 weeks),100.00000
Handel (2021),Polyunsaturated fatty acids,Quality of life (patients) Mixed,At follow-up (closest to 26 weeks)  188, 9.200000, 9.200000  9.200000  9.200000, 9.200000,10.985000 10.985000,10.985000 1459   0.000000 114.59574  23.882979, 9.674734,NA, 4.12983865, 574.255319,100.00000   0.00000 100.00000 100,  0.000000   0.000000,100.00000 100.00000  26.595745, 26.59574  73.404255  28, 8, 3,114.59574 1.000000, 2 1,Crippa | Manor,2019 | 2011 Handel 10.3390/nu13041226,Supplementation of PUFAs:  omega 3 and 6 fatty acids NA NA NA,NA,RCT (parallel, crossover, open-label),DSM,Placebo,mg/d Moderate 9.2,10.985 NA NA Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Conduct Disorder symptoms | Oppositional Defiant Disorder symptoms | Social-communication skills | Specific adverse events: sleep problems | Quality of life (patients) | Tolerability (discontinuation due to adverse events) Gillies (2023) | Handel (2021) | Catala-Lopez (2017) 6 13.7,NA NA NA NA NA NA,2-6 months,NA NA,574.26mg/d 6-17 yo Homogeneous Polyunsaturated fatty acids_Quality of life (patients)_Mixed_At follow-up (closest to 26 weeks)_6-17 yo Handel (2021) - Polyunsaturated fatty acids_Quality of life (patients)_Mixed_At follow-up (closest to 26 weeks)_6-17 yo Polyunsaturated fatty acids_Quality of life (patients)_Mixed_At follow-up (closest to 26 weeks)_6-17 yo - [Homogeneous] 2021 Polyunsaturated fatty acids_Quality of life (patients)_Mixed_At follow-up (closest to 26 weeks), 96 FALSE Handel (2021)_Polyunsaturated fatty acids_Quality of life (patients)_Mixed_At follow-up (closest to 26 weeks) Handel (2021)_Polyunsaturated fatty acids_Quality of life (patients)_Mixed_At follow-up (closest to 26 weeks) 100.00000
Heirs (2007) Homeopathy Combined ADHD symptoms (inattentive + hyperactive/impulsive),Parent-rated,At study endpoint (closest to 12 weeks),  63, 8.500000, 8.500000, 8.500000  8.500000, 9.000000  9.000000, 9.000000, 9.000000, 798,  0.000000  35.69841, 10.000000, 8.841270,NA  3.46247283 NA,100.00000   0.00000 100.00000 100,  0.000000,  0.000000 100.00000,  0.00000, 68.253968   0.00000,100.000000   3, 3  2  35.69841,1.000000, 2,1 Jacobs | Strauss 2005 | 2000,Heirs,10.1002/14651858.CD005648.pub2 Homeopathy NA,Questionnaire,Conners' Parent Rating Scale–Revised, ADHD Index subscale NA RCT,Diagnostic Interview Schedule for Children,Placebo NA High,8.5,9 NA NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Conduct Disorder symptoms/Oppositional Defiant Disorder symptoms | Acceptability: all-cause discontinuation,Heirs (2007) | Catala-Lopez (2017) 8.5,9.3,NA,NA,NA,NA NA NA,2-6 months,NA NA NANA,6-17 yo Homogeneous,Homeopathy_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks)_6-17 yo,Heirs (2007) - Homeopathy_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks)_6-17 yo Homeopathy_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks)_6-17 yo - [Homogeneous] 2007 Homeopathy_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks)  97 TRUE,Heirs (2007)_Homeopathy_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks),Heirs (2007)_Homeopathy_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks) 100.00000
Heirs (2007),Homeopathy,Conduct Disorder symptoms/Oppositional Defiant Disorder symptoms,Parent-rated At study endpoint (closest to 12 weeks)   63, 8.500000  8.500000  8.500000  8.500000, 9.000000  9.000000, 9.000000  9.000000  798   0.000000  35.69841  10.000000, 8.841270,NA, 3.46247283 NA,100.00000,  0.00000 100.00000,100   0.000000,  0.000000 100.00000   0.00000  68.253968   0.00000 100.000000,  3, 3  2, 35.69841,1.000000, 2 1 Jacobs | Strauss,2005 | 2000 Heirs,10.1002/14651858.CD005648.pub2 Homeopathy NA,Questionnaire,Conners' Parent Rating Scale–Revised, Oppositional subscale,NA RCT Diagnostic Interview Schedule for Children,Placebo NA High,8.5,9 NA NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Conduct Disorder symptoms/Oppositional Defiant Disorder symptoms | Acceptability: all-cause discontinuation,Heirs (2007) | Catala-Lopez (2017),8.5,9.3 NA NA NA NA NA,NA 2-6 months NA NA,NANA,6-17 yo Homogeneous,Homeopathy_Conduct Disorder symptoms/Oppositional Defiant Disorder symptoms_Parent-rated_At study endpoint (closest to 12 weeks)_6-17 yo Heirs (2007) - Homeopathy_Conduct Disorder symptoms/Oppositional Defiant Disorder symptoms_Parent-rated_At study endpoint (closest to 12 weeks)_6-17 yo,Homeopathy_Conduct Disorder symptoms/Oppositional Defiant Disorder symptoms_Parent-rated_At study endpoint (closest to 12 weeks)_6-17 yo - [Homogeneous] 2007 Homeopathy_Conduct Disorder symptoms/Oppositional Defiant Disorder symptoms_Parent-rated_At study endpoint (closest to 12 weeks), 98,TRUE,Heirs (2007)_Homeopathy_Conduct Disorder symptoms/Oppositional Defiant Disorder symptoms_Parent-rated_At study endpoint (closest to 12 weeks),Heirs (2007)_Homeopathy_Conduct Disorder symptoms/Oppositional Defiant Disorder symptoms_Parent-rated_At study endpoint (closest to 12 weeks) 100.00000
Huang (2022),Physical training Executive functioning (tests),Clinician-rated At study endpoint (closest to 12 weeks), 445, 8.300000, 8.400000, 8.400000, 8.400000  9.400000 12.000000,14.500000 14.500000,1598, 28.386112, 37.66559, 19.709556 10.600536,NA, 3.66623654 NA  85.34910,  0.00000 100.00000,100,  0.000000   0.000000   0.00000   0.00000  67.874857  47.72987  73.826784, 22  4  3  37.99695,1.618466,16 1 Benzing | Bustamante | Chang | Chen | Choi | Da Silva | Hattabi | Kadri | Kang | Lee | Liang | Liu | Memarmoghaddam | Pan | Song | Ziereis,2019 | 2017 | 2022 | 2015 | 2011 | 2018 | 2016 | 2014 Huang 10.1542/peds.2022-057745 Physical training,augumentation Test Simon Task | Flanker Task | Color span backward | STOPIT | AWMA Verbal | AWMA Visuospatial | Stroop color-word test | WCST | Stroop color-word test | Cognitive Flexibility Test | N-Back | WCST | Cognitive Flexibility Test | Stroop test | ROCF Test | Stroop color-word test | Digit Symbol Scores | TMT-B | Flanker Task | Tower of London | TMT-B | Coris Test | Stroop test | Stroop color-word test | TMT-B | ROCF test | Digit span task,NA,RCT,DSM-IV, DSM-V,Not a therapeutic intervention | No intervention NA Low 7.7,15.8 NA,NA Executive functioning (tests) | Acceptability: all-cause discontinuation | Social-communication skills | Combined ADHD symptoms (inattentive + hyperactive/impulsive),Huang (2022) | Seiffer (2022) | Ostinelli (2025) 7.7,35.3230769230769 NA,NA NA,NA,NA NA,2-6 months NA NA NANA,6-17 yo,Homogeneous,Physical training_Executive functioning (tests)_Clinician-rated_At study endpoint (closest to 12 weeks)_6-17 yo,Huang (2022) - Physical training_Executive functioning (tests)_Clinician-rated_At study endpoint (closest to 12 weeks)_6-17 yo,Physical training_Executive functioning (tests)_Clinician-rated_At study endpoint (closest to 12 weeks)_6-17 yo - [Homogeneous] 2022 Physical training_Executive functioning (tests)_Clinician-rated_At study endpoint (closest to 12 weeks), 99 TRUE Huang (2022)_Physical training_Executive functioning (tests)_Clinician-rated_At study endpoint (closest to 12 weeks) Huang (2022)_Physical training_Executive functioning (tests)_Clinician-rated_At study endpoint (closest to 12 weeks) 100.00000
Lenzi (2018) Amphetamine,Emotional dysregulation,Mixed At study endpoint (closest to 12 weeks), 235,20.085000 20.085000 20.085000 34.552201 34.552201 34.552201 34.552201,40.700000,2027,  0.000000 120.71915, 46.998298 32.329702,NA  2.41901917,  70.000000 100.00000   0.00000,100.00000,100 100.000000,100.000000 100.00000 100.00000,100.000000 100.00000 100.000000, 43 14  9 120.71915,1.000000  3,1 Adler | DuPaul | Waxmonsky 2013 | 2012 | 2014 Lenzi 10.1016/j.neubiorev.2017.08.010,NA,NA NA BRIEF-A | CAARS, BRIEF-A | BADDS,NA NA NA,Placebo mg/d Critically low,20.085,40.7 NA NA,Disruptive behaviors | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Academic/job performance | Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Depressive disorder symptoms | Generalized anxiety | Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Executive functioning (tests),Faraone (2002) | Punja (2016) | Castells (2018) | Elliott (2020) | Bellato - adults (2024) | Bellatto - children (2024) | Lenzi (2018) | Ostinelli (2025) | Cortese - Children (2018) 8 41.2,NA NA NA,NA NA,NA,2-6 months NA NA 70mg/d,>= 18 yo,Homogeneous,Amphetamine_Emotional dysregulation_Mixed_At study endpoint (closest to 12 weeks)_>= 18 yo,Lenzi (2018) - Amphetamine_Emotional dysregulation_Mixed_At study endpoint (closest to 12 weeks)_>= 18 yo,Amphetamine_Emotional dysregulation_Mixed_At study endpoint (closest to 12 weeks)_>= 18 yo - [Homogeneous],2018,Amphetamine_Emotional dysregulation_Mixed_At study endpoint (closest to 12 weeks),100 NA Lenzi (2018)_Amphetamine_Emotional dysregulation_Mixed_At study endpoint (closest to 12 weeks) Lenzi (2018)_Amphetamine_Emotional dysregulation_Mixed_At study endpoint (closest to 12 weeks),100.00000
Lenzi (2018) Atomoxetine Emotional dysregulation Mixed,At study endpoint (closest to 12 weeks) 2373,24.000000 24.000000 32.247165 32.247165,33.059924 37.549701,41.175825,41.175825 2027   0.000000 480.13949  43.512895 33.937316,NA  2.45344934   85.183312,100.00000,  0.00000 100.00000 100 100.000000 100.000000 100.00000 100.00000,100.000000,100.00000,100.000000  44, 9, 7,480.13949,1.000000  5,1 Adler | Brown | Goto | Robison 2014a | 2014b | 2011 | 2017 | 2008 Lenzi,10.1016/j.neubiorev.2017.08.010 NA NA NA,BRIEF-A | BADDS | BRIEF-A (self-reported and informant) | WRAADDS,NA,NA,NA Placebo,mg/dbid | mg/d,Critically low,24 41.1758252427185 NA,NA Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Generalized anxiety | Depressive disorder symptoms | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | CGI,Elliott (2020) | Bellatto - children (2024) | Lenzi (2018) | Bryant (2021) | Ostinelli (2025) | Cortese - Adults (2018) | Cortese - Children (2018),8.65154639175258,42.10703125,NA,NA NA NA NA NA 2-6 months NA NA 85.18mg/dbid | mg/d >= 18 yo Homogeneous,Atomoxetine_Emotional dysregulation_Mixed_At study endpoint (closest to 12 weeks)_>= 18 yo Lenzi (2018) - Atomoxetine_Emotional dysregulation_Mixed_At study endpoint (closest to 12 weeks)_>= 18 yo Atomoxetine_Emotional dysregulation_Mixed_At study endpoint (closest to 12 weeks)_>= 18 yo - [Homogeneous],2018,Atomoxetine_Emotional dysregulation_Mixed_At study endpoint (closest to 12 weeks),101 NA Lenzi (2018)_Atomoxetine_Emotional dysregulation_Mixed_At study endpoint (closest to 12 weeks),Lenzi (2018)_Atomoxetine_Emotional dysregulation_Mixed_At study endpoint (closest to 12 weeks),100.00000
Liang (2024) Probiotics Acceptability: all-cause discontinuation NA At study endpoint (closest to 12 weeks)  224, 8.800000, 8.800000, 8.800000, 9.100000,11.880000 12.000000,12.000000 12.000000 9001, 40.178571  67.52679, 26.839509 10.749107 NA, 2.08675818,NA,100.00000   0.00000 100.00000,100,100.000000 100.000000 100.00000 100.00000, 33.482143,100.00000,100.000000   5  2, 1, 67.52679 1.000000  4 1 Ghanaatgar | Kumperscak | Sepehrmanesh | Skott,2022 | 2020 | 2021 Liang 10.1192/bjo.2023.645,Probiotics,aug,NA,NA NA RCT (parallel, crossover, open-label) NA Active (any credible active intervention) | Placebo NA Moderate 8.8 12 NA,NA Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation Liang (2024) 8.8,12,NA,NA,NA,NA,NA,NA,2-6 months NA,NA,NANA 6-17 yo Homogeneous,Probiotics_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_6-17 yo Liang (2024) - Probiotics_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_6-17 yo Probiotics_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_6-17 yo - [Homogeneous] 2024 Probiotics_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks),102,TRUE Liang (2024)_Probiotics_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks) Liang (2024)_Probiotics_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks),100.00000
Liang (2024),Probiotics Combined ADHD symptoms (inattentive + hyperactive/impulsive),Mixed At study endpoint (closest to 12 weeks), 220, 8.800000  8.800000  9.100000  9.100000  9.750000 12.000000,12.000000,12.000000 9001  32.727273  47.96364  26.837091 10.490727,NA  1.84538132 NA,100.00000   0.00000,100.00000 100,100.000000 100.000000 100.00000 100.00000  51.818182,100.00000,100.000000   5  2, 1, 47.96364 1.000000  5 1,Bazinet | Ghanaatgar | Kumperscak | Sepehrmanesh | Skott 2017 | 2022 | 2020 | 2021,Liang,10.1192/bjo.2023.645 Probiotics aug,NA DBD | CPRS-r: total | ADHD rating scale | SNAP NA,RCT (parallel, crossover, open-label),NA Placebo | Active (any credible active intervention) NA Moderate 8.8,12 NA,NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation Liang (2024) 8.8 12,NA,NA,NA,NA,NA,NA < 2 months NA NA,NANA 6-17 yo,Homogeneous Probiotics_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Mixed_At study endpoint (closest to 12 weeks)_6-17 yo Liang (2024) - Probiotics_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Mixed_At study endpoint (closest to 12 weeks)_6-17 yo Probiotics_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Mixed_At study endpoint (closest to 12 weeks)_6-17 yo - [Homogeneous],2024,Probiotics_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Mixed_At study endpoint (closest to 12 weeks) 103 TRUE Liang (2024)_Probiotics_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Mixed_At study endpoint (closest to 12 weeks) Liang (2024)_Probiotics_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Mixed_At study endpoint (closest to 12 weeks) 100.00000
Liu (2022) Cognitive Behavioral Therapy (CBT),CGI,Clinician-rated At study endpoint (closest to 12 weeks), 260 35.169579 35.169579 35.169579,35.169579,35.169579 39.105000 39.460938 39.460938,2118,  0.000000  62.42308, 59.323077,37.033714 NA  2.14658759,NA, 67.30769,  0.00000,100.00000,100  69.230769, 69.230769, 81.53846, 24.23077 100.000000,100.00000, 87.692308, 20, 9, 4  62.42308,1.000000  5,1 Emilsson | Nakashima | Safren | Vidal | Young,2011 | 2021 | 2005 | 2013 | 2015,Liu,10.1111/papt.12455 CBT NA Questionnaire Clinical global impression (CGI),NA,RCT (parallel, crossover, open-label) DSM-IV, DSM-V,TAU,NA,Low,35.1695789473684,39.4609375 NA,NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Depressive disorder symptoms | Generalized anxiety | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Executive functioning (tests) | Quality of life (patients) | Emotional dysregulation Ding (2018) | Liu (2022) | Lopez (2018) | Ostinelli (2025) 10.3 43.15 NA NA,NA,NA,NA,NA 2-6 months NA NA,NANA,>= 18 yo Homogeneous,Cognitive Behavioral Therapy (CBT)_CGI_Clinician-rated_At study endpoint (closest to 12 weeks)_>= 18 yo,Liu (2022) - Cognitive Behavioral Therapy (CBT)_CGI_Clinician-rated_At study endpoint (closest to 12 weeks)_>= 18 yo Cognitive Behavioral Therapy (CBT)_CGI_Clinician-rated_At study endpoint (closest to 12 weeks)_>= 18 yo - [Homogeneous],2022 Cognitive Behavioral Therapy (CBT)_CGI_Clinician-rated_At study endpoint (closest to 12 weeks),104 FALSE Liu (2022)_Cognitive Behavioral Therapy (CBT)_CGI_Clinician-rated_At study endpoint (closest to 12 weeks),Liu (2022)_Cognitive Behavioral Therapy (CBT)_CGI_Clinician-rated_At study endpoint (closest to 12 weeks) 100.00000
Liu (2023) Mindfulness,Depressive disorder symptoms,Mixed At study endpoint (closest to 12 weeks)  157 20.291852,20.291852 20.291852,20.291852,35.894175 35.894175,35.894175 35.894175,2118 100.000000, 86.14650  51.070064,30.527771 NA, 2.28683676,   1.000000,100.00000,  0.00000 100.00000,100  65.605096, 65.605096,100.00000   0.00000,100.000000 100.00000, 65.605096  13  8  4, 86.14650 1.000000, 2 1,Gu | Hepark,2018 | 2019,Liu 10.1111/papt.12455,Mindfulness-based CBT TAU Unclear (not able to identify the tools used to measure the outcome),NA NA,RCT (parallel, crossover, open-label) DSM-V | DSM-IV WLC (wait-list control) session/week,Low,20.2918518518519 35.8941747572816,NA,NA Generalized anxiety | Depressive disorder symptoms | Quality of life (patients) | Executive functioning (mixed) | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (tests) | Acceptability: all-cause discontinuation | Emotional dysregulation,Lopez-Pinar (2019) | Liu (2023) | Zhang (2023) | Ostinelli (2025),6.08 39.35 NA,NA NA,NA,NA,NA 2-6 months,NA,NA,1session/week,>= 18 yo,Homogeneous,Mindfulness_Depressive disorder symptoms_Mixed_At study endpoint (closest to 12 weeks)_>= 18 yo,Liu (2023) - Mindfulness_Depressive disorder symptoms_Mixed_At study endpoint (closest to 12 weeks)_>= 18 yo Mindfulness_Depressive disorder symptoms_Mixed_At study endpoint (closest to 12 weeks)_>= 18 yo - [Homogeneous],2023 Mindfulness_Depressive disorder symptoms_Mixed_At study endpoint (closest to 12 weeks),105,FALSE,Liu (2023)_Mindfulness_Depressive disorder symptoms_Mixed_At study endpoint (closest to 12 weeks),Liu (2023)_Mindfulness_Depressive disorder symptoms_Mixed_At study endpoint (closest to 12 weeks),100.00000
Liu (2023),Mindfulness Quality of life (patients) Mixed At study endpoint (closest to 12 weeks), 223 35.894175 35.894175,35.894175 35.894175 39.350000 39.350000,39.350000,39.350000 2118,100.000000,112.14798, 53.713004,37.753812 NA, 2.26640590    1.000000 100.00000,  0.00000 100.00000,100, 46.188341  46.188341  46.18834   0.00000,100.000000,100.00000,100.000000, 13, 8, 4 112.14798 1.000000  2,1,Hepark | Janssen,2019,Liu,10.1111/papt.12455 Mindfulness-based CBT TAU Unclear (not able to identify the tools used to measure the outcome) NA NA RCT (parallel, crossover, open-label) DSM-IV,WLC (wait-list control) | TAU session/week,Low 35.8941747572816,39.35,NA,NA,Generalized anxiety | Depressive disorder symptoms | Quality of life (patients) | Executive functioning (mixed) | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (tests) | Acceptability: all-cause discontinuation | Emotional dysregulation,Lopez-Pinar (2019) | Liu (2023) | Zhang (2023) | Ostinelli (2025),6.08 39.35,NA NA,NA,NA,NA NA 2-6 months NA,NA,1session/week >= 18 yo,Homogeneous,Mindfulness_Quality of life (patients)_Mixed_At study endpoint (closest to 12 weeks)_>= 18 yo Liu (2023) - Mindfulness_Quality of life (patients)_Mixed_At study endpoint (closest to 12 weeks)_>= 18 yo,Mindfulness_Quality of life (patients)_Mixed_At study endpoint (closest to 12 weeks)_>= 18 yo - [Homogeneous] 2023 Mindfulness_Quality of life (patients)_Mixed_At study endpoint (closest to 12 weeks),106,FALSE,Liu (2023)_Mindfulness_Quality of life (patients)_Mixed_At study endpoint (closest to 12 weeks),Liu (2023)_Mindfulness_Quality of life (patients)_Mixed_At study endpoint (closest to 12 weeks),100.00000
Lopez (2018) Cognitive Behavioral Therapy (CBT),Depressive disorder symptoms Self-rated,At study endpoint (closest to 12 weeks), 187,33.680000,33.800000,33.800000,33.800000 36.791228 37.400000 41.500000,41.500000 2154  35.294118  41.82353, 60.728501 36.824064 NA  2.01103980   90.000000,100.00000   0.00000 100.00000,100 100.000000,100.000000 100.00000   0.00000, 57.219251 100.00000 100.000000  20  9  4, 41.82353 1.000000, 5 1 Emilsson | Moell | Pettersson | Safren | Virta,2011 | 2015 | 2017 | 2005 | 2010 Lopez,10.1002/14651858.CD010840.pub2 CBT Medication Questionnaire Beck Depression Inventory (BDI) | Anxiety and Depression - Hospital anxiety and depression scale | Beck Depression Inventory, second edition | Depression - Hamilton Depression Scale (HAM-D),NA,RCT (parallel, crossover, open-label) DSM-IV | DSM-IV-TR,Active (any credible active intervention) | WLC (wait-list control),mn/session,High,33.5,41.5,NA,NA Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Depressive disorder symptoms | Generalized anxiety | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Executive functioning (tests) | Quality of life (patients) | Emotional dysregulation Ding (2018) | Liu (2022) | Lopez (2018) | Ostinelli (2025) 10.3,43.15,NA,NA,NA,NA NA NA,2-6 months,NA NA,90mn/session,>= 18 yo,Homogeneous Cognitive Behavioral Therapy (CBT)_Depressive disorder symptoms_Self-rated_At study endpoint (closest to 12 weeks)_>= 18 yo,Lopez (2018) - Cognitive Behavioral Therapy (CBT)_Depressive disorder symptoms_Self-rated_At study endpoint (closest to 12 weeks)_>= 18 yo,Cognitive Behavioral Therapy (CBT)_Depressive disorder symptoms_Self-rated_At study endpoint (closest to 12 weeks)_>= 18 yo - [Homogeneous],2018 Cognitive Behavioral Therapy (CBT)_Depressive disorder symptoms_Self-rated_At study endpoint (closest to 12 weeks),107 FALSE,Lopez (2018)_Cognitive Behavioral Therapy (CBT)_Depressive disorder symptoms_Self-rated_At study endpoint (closest to 12 weeks),Lopez (2018)_Cognitive Behavioral Therapy (CBT)_Depressive disorder symptoms_Self-rated_At study endpoint (closest to 12 weeks),100.00000
Lopez (2018),Cognitive Behavioral Therapy (CBT),Generalized anxiety,Self-rated At study endpoint (closest to 12 weeks), 168,33.800000,33.800000 33.800000,36.791228,36.791228 37.400000,41.500000 41.500000 2154  39.285714  44.40476, 61.746852,37.200000 NA, 1.97819059   90.000000,100.00000,  0.00000,100.00000,100,100.000000 100.000000,100.00000,  0.00000, 52.380952 100.00000,100.000000  20, 9  4, 44.40476,1.000000  4 1,Emilsson | Moell | Pettersson | Safren 2011 | 2015 | 2017 | 2005,Lopez 10.1002/14651858.CD010840.pub2 CBT Medication,Questionnaire,Beck Anxiety Inventory | Anxiety and Depression - Hospital anxiety and depression scale | Anxiety - Beck Anxiety Inventory | Anxiety - Hamilton Anxiety Scale (HAM-A) NA,RCT (parallel, crossover, open-label) DSM-IV | DSM-IV-TR Active (any credible active intervention) | WLC (wait-list control) mn/session,High 33.8 41.5,NA NA Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Depressive disorder symptoms | Generalized anxiety | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Executive functioning (tests) | Quality of life (patients) | Emotional dysregulation Ding (2018) | Liu (2022) | Lopez (2018) | Ostinelli (2025) 10.3 43.15 NA NA,NA NA NA,NA,< 2 months NA,NA,90mn/session >= 18 yo Homogeneous Cognitive Behavioral Therapy (CBT)_Generalized anxiety_Self-rated_At study endpoint (closest to 12 weeks)_>= 18 yo Lopez (2018) - Cognitive Behavioral Therapy (CBT)_Generalized anxiety_Self-rated_At study endpoint (closest to 12 weeks)_>= 18 yo Cognitive Behavioral Therapy (CBT)_Generalized anxiety_Self-rated_At study endpoint (closest to 12 weeks)_>= 18 yo - [Homogeneous] 2018 Cognitive Behavioral Therapy (CBT)_Generalized anxiety_Self-rated_At study endpoint (closest to 12 weeks) 108,FALSE Lopez (2018)_Cognitive Behavioral Therapy (CBT)_Generalized anxiety_Self-rated_At study endpoint (closest to 12 weeks),Lopez (2018)_Cognitive Behavioral Therapy (CBT)_Generalized anxiety_Self-rated_At study endpoint (closest to 12 weeks),100.00000
Lopez-Pinar (2019),Mindfulness Generalized anxiety Self-rated,At study endpoint (closest to 12 weeks)  137,21.500000 21.500000,21.500000,21.500000,35.842169,35.842169,35.842169 35.842169,2157   0.000000, 71.56934, 45.052624 30.189051,NA, 2.21749977    1.000000 100.00000   0.00000 100.00000 100   0.000000,  0.000000,100.00000   0.00000 100.000000,100.00000,  0.000000  13  8  4  71.56934 1.000000, 2,1 Gu | Hepark 2017 | 2015,Lopez-Pinar,10.1177/1087054719855685 NA NA,Unclear (not able to identify the tools used to measure the outcome),NA,NA RCT,DSM-IV,WLC (wait-list control) h/wk Critically low,21.5,35.8421686746988,NA NA,Generalized anxiety | Depressive disorder symptoms | Quality of life (patients) | Executive functioning (mixed) | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (tests) | Acceptability: all-cause discontinuation | Emotional dysregulation,Lopez-Pinar (2019) | Liu (2023) | Zhang (2023) | Ostinelli (2025) 6.08 39.35,NA,NA NA,NA NA NA,2-6 months NA NA,1h/wk,>= 18 yo Homogeneous Mindfulness_Generalized anxiety_Self-rated_At study endpoint (closest to 12 weeks)_>= 18 yo,Lopez-Pinar (2019) - Mindfulness_Generalized anxiety_Self-rated_At study endpoint (closest to 12 weeks)_>= 18 yo Mindfulness_Generalized anxiety_Self-rated_At study endpoint (closest to 12 weeks)_>= 18 yo - [Homogeneous],2019 Mindfulness_Generalized anxiety_Self-rated_At study endpoint (closest to 12 weeks),109,NA,Lopez-Pinar (2019)_Mindfulness_Generalized anxiety_Self-rated_At study endpoint (closest to 12 weeks) Lopez-Pinar (2019)_Mindfulness_Generalized anxiety_Self-rated_At study endpoint (closest to 12 weeks),100.00000
Maiti - Adults (2024),Dasotraline,CGI Mixed,At study endpoint (closest to 12 weeks)  482 36.500000,36.500000 36.500000 36.500000,36.500000 36.500000 36.500000,36.500000,8991,  0.000000 261.22356 NA 36.500000,NA, 1.52212027,   5.346597,100.00000   0.00000,100.00000 100 100.000000 100.000000,100.00000,100.00000 100.000000,100.00000 100.000000   5, 4  2,263.09005 2.000000  2 1 Adler | Koblan 2021 | 2015,Maiti - Adults 10.4103/indianjpsychiatry.indianjpsychiatry_3_24 Dasotraline NA,Observational tool,Clinical Global Impression-Severity scale Subgroup 5: Dasotreline 4mg vs Placebo | Subgroup 6: Dasotreline 6mg vs Placebo | Subgroup 3: Dasotreline 4mg vs Placebo | Subgroup 4: Dasotreline 8mg vs Placebo RCT (parallel, crossover, open-label),DSM 5 Placebo mg/d Critically low,36.5,36.5,NA,NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Specific adverse events: sleep problems | Specific adverse events: decreased appetite,Maiti - Children (2024) | Maiti - Adults (2024) 9,36.5 NA,NA,NA NA NA,NA < 2 months NA,NA 5.35mg/d,>= 18 yo Homogeneous Dasotraline_CGI_Mixed_At study endpoint (closest to 12 weeks)_>= 18 yo Maiti - Adults (2024) - Dasotraline_CGI_Mixed_At study endpoint (closest to 12 weeks)_>= 18 yo,Dasotraline_CGI_Mixed_At study endpoint (closest to 12 weeks)_>= 18 yo - [Homogeneous] 2024 Dasotraline_CGI_Mixed_At study endpoint (closest to 12 weeks) 110,TRUE Maiti - Adults (2024)_Dasotraline_CGI_Mixed_At study endpoint (closest to 12 weeks) Maiti - Adults (2024)_Dasotraline_CGI_Mixed_At study endpoint (closest to 12 weeks) 100.00000
Maiti - Adults (2024) Dasotraline,Combined ADHD symptoms (inattentive + hyperactive/impulsive),Mixed,At study endpoint (closest to 12 weeks)  482 36.500000,36.500000,36.500000 36.500000,36.500000 36.500000 36.500000 36.500000,8991,  0.000000 261.22356,NA,36.500000,NA, 1.52212027,   5.346597,100.00000,  0.00000 100.00000 100,100.000000,100.000000,100.00000,100.00000 100.000000 100.00000 100.000000   5  4  2,263.09005 2.000000, 2,1 Adler | Koblan,2021 | 2015 Maiti - Adults,10.4103/indianjpsychiatry.indianjpsychiatry_3_24,Dasotraline,NA Questionnaire,ADHD Rating Scale IV Subgroup 5: Dasotreline 4mg vs Placebo | Subgroup 6: Dasotreline 6mg vs Placebo | Subgroup 3: Dasotreline 4mg vs Placebo | Subgroup 4: Dasotreline 8mg vs Placebo,RCT (parallel, crossover, open-label) DSM 5 Placebo mg/d,Critically low 36.5 36.5,NA NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Specific adverse events: sleep problems | Specific adverse events: decreased appetite,Maiti - Children (2024) | Maiti - Adults (2024) 9,36.5,NA NA NA,NA NA,NA,< 2 months NA,NA 5.35mg/d,>= 18 yo,Homogeneous Dasotraline_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Mixed_At study endpoint (closest to 12 weeks)_>= 18 yo Maiti - Adults (2024) - Dasotraline_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Mixed_At study endpoint (closest to 12 weeks)_>= 18 yo Dasotraline_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Mixed_At study endpoint (closest to 12 weeks)_>= 18 yo - [Homogeneous],2024 Dasotraline_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Mixed_At study endpoint (closest to 12 weeks),111 TRUE Maiti - Adults (2024)_Dasotraline_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Mixed_At study endpoint (closest to 12 weeks) Maiti - Adults (2024)_Dasotraline_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Mixed_At study endpoint (closest to 12 weeks),100.00000
Maiti - Adults (2024) Dasotraline Specific adverse events: decreased appetite NA At study endpoint (closest to 12 weeks), 491 36.500000 36.500000 36.500000 36.500000 36.500000 36.500000 36.500000,36.500000 8991,  0.000000,266.29363,NA 36.500000,NA  1.52172834    5.347023 100.00000,  0.00000,100.00000,100,100.000000,100.000000,100.00000,100.00000 100.000000 100.00000,100.000000   5, 4  2 267.98768,2.000000, 2,1,Adler | Koblan 2021 | 2015 Maiti - Adults 10.4103/indianjpsychiatry.indianjpsychiatry_3_24,Dasotraline,NA Unclear (not able to identify the tools used to measure the outcome) NA,Subgroup 5: Dasotreline 4mg vs Placebo | Subgroup 6: Dasotreline 6mg vs Placebo | Subgroup 3: Dasotreline 4mg vs Placebo | Subgroup 4: Dasotreline 8mg vs Placebo RCT (parallel, crossover, open-label),DSM 5,Placebo mg/d Critically low,36.5 36.5,NA NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Specific adverse events: sleep problems | Specific adverse events: decreased appetite,Maiti - Children (2024) | Maiti - Adults (2024) 9,36.5,NA,NA NA NA,NA,NA < 2 months,NA,NA 5.35mg/d >= 18 yo,Homogeneous,Dasotraline_Specific adverse events: decreased appetite_NA_At study endpoint (closest to 12 weeks)_>= 18 yo,Maiti - Adults (2024) - Dasotraline_Specific adverse events: decreased appetite_NA_At study endpoint (closest to 12 weeks)_>= 18 yo Dasotraline_Specific adverse events: decreased appetite_NA_At study endpoint (closest to 12 weeks)_>= 18 yo - [Homogeneous],2024,Dasotraline_Specific adverse events: decreased appetite_NA_At study endpoint (closest to 12 weeks),112 TRUE Maiti - Adults (2024)_Dasotraline_Specific adverse events: decreased appetite_NA_At study endpoint (closest to 12 weeks),Maiti - Adults (2024)_Dasotraline_Specific adverse events: decreased appetite_NA_At study endpoint (closest to 12 weeks) 100.00000
Maiti - Adults (2024) Dasotraline,Specific adverse events: sleep problems NA,At study endpoint (closest to 12 weeks)  492 36.500000,36.500000 36.500000 36.500000,36.500000 36.500000,36.500000,36.500000,8991   0.000000,266.29363 NA,36.500000,NA  1.52172834    5.347023,100.00000,  0.00000 100.00000 100,100.000000 100.000000,100.00000,100.00000 100.000000,100.00000,100.000000,  5  4, 2 268.64066,2.000000  2,1 Adler | Koblan 2021 | 2015,Maiti - Adults,10.4103/indianjpsychiatry.indianjpsychiatry_3_24 Dasotraline NA Unclear (not able to identify the tools used to measure the outcome) NA Subgroup 5: Dasotreline 4mg vs Placebo | Subgroup 6: Dasotreline 6mg vs Placebo | Subgroup 3: Dasotreline 4mg vs Placebo | Subgroup 4: Dasotreline 8mg vs Placebo,RCT (parallel, crossover, open-label) DSM 5 Placebo mg/d,Critically low 36.5,36.5 NA NA Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Specific adverse events: sleep problems | Specific adverse events: decreased appetite,Maiti - Children (2024) | Maiti - Adults (2024),9,36.5 NA NA NA NA NA,NA,< 2 months NA NA,5.35mg/d,>= 18 yo Homogeneous,Dasotraline_Specific adverse events: sleep problems_NA_At study endpoint (closest to 12 weeks)_>= 18 yo,Maiti - Adults (2024) - Dasotraline_Specific adverse events: sleep problems_NA_At study endpoint (closest to 12 weeks)_>= 18 yo,Dasotraline_Specific adverse events: sleep problems_NA_At study endpoint (closest to 12 weeks)_>= 18 yo - [Homogeneous] 2024,Dasotraline_Specific adverse events: sleep problems_NA_At study endpoint (closest to 12 weeks) 113 TRUE Maiti - Adults (2024)_Dasotraline_Specific adverse events: sleep problems_NA_At study endpoint (closest to 12 weeks) Maiti - Adults (2024)_Dasotraline_Specific adverse events: sleep problems_NA_At study endpoint (closest to 12 weeks),100.00000
Maiti - Children (2024),Dasotraline,Combined ADHD symptoms (inattentive + hyperactive/impulsive) Mixed At study endpoint (closest to 12 weeks), 378, 9.000000, 9.000000, 9.000000, 9.000000  9.000000  9.000000, 9.000000  9.000000 8991,  0.000000 132.78133,NA  9.000000 NA, 0.87272727    3.045333,100.00000   0.00000 100.00000,100 100.000000 100.000000 100.00000,100.00000,100.000000,100.00000 100.000000,  5, 4, 2 134.12533,1.448000, 3 1 Findling | Wigal 2019 | 2020 | 2022 Maiti - Children,10.4103/indianjpsychiatry.indianjpsychiatry_3_24,Dasotraline NA,Questionnaire | Observational tool ADHD Rating Scale IV | Swanson, Kotkin, Agler, M-Flynn, and Pelham rating scale (SCAMP-CS),Subgroup 1: Dasotreline 2mg vs Placebo | Subgroup 2: Dasotreline 4mg vs Placebo RCT (parallel, crossover, open-label) DSM 5,Placebo,mg/d,Critically low 9 9,NA NA Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Specific adverse events: sleep problems | Specific adverse events: decreased appetite,Maiti - Children (2024) | Maiti - Adults (2024) 9 36.5,NA NA,NA,NA,NA,NA,< 2 months NA NA 3.05mg/d,6-17 yo,Homogeneous Dasotraline_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Mixed_At study endpoint (closest to 12 weeks)_6-17 yo,Maiti - Children (2024) - Dasotraline_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Mixed_At study endpoint (closest to 12 weeks)_6-17 yo,Dasotraline_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Mixed_At study endpoint (closest to 12 weeks)_6-17 yo - [Homogeneous],2024,Dasotraline_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Mixed_At study endpoint (closest to 12 weeks),114 TRUE Maiti - Children (2024)_Dasotraline_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Mixed_At study endpoint (closest to 12 weeks),Maiti - Children (2024)_Dasotraline_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Mixed_At study endpoint (closest to 12 weeks),100.00000
Maiti - Children (2024) Dasotraline Specific adverse events: decreased appetite,NA,At study endpoint (closest to 12 weeks)  380  9.000000, 9.000000, 9.000000  9.000000, 9.000000, 9.000000, 9.000000  9.000000 8991   0.000000 134.41799 NA  9.000000,NA, 0.87676037    3.044974,100.00000   0.00000,100.00000,100,100.000000 100.000000 100.00000,100.00000,100.000000 100.00000 100.000000   5, 4  2 135.32275 1.452381, 3 1 Findling | Wigal 2019 | 2020 | 2022 Maiti - Children 10.4103/indianjpsychiatry.indianjpsychiatry_3_24,Dasotraline,NA,Unclear (not able to identify the tools used to measure the outcome) NA,Subgroup 1: Dasotreline 2mg vs Placebo | Subgroup 2: Dasotreline 4mg vs Placebo RCT (parallel, crossover, open-label),DSM 5,Placebo mg/d,Critically low 9,9 NA NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Specific adverse events: sleep problems | Specific adverse events: decreased appetite,Maiti - Children (2024) | Maiti - Adults (2024),9,36.5,NA NA NA NA,NA,NA < 2 months,NA NA 3.04mg/d,6-17 yo,Homogeneous Dasotraline_Specific adverse events: decreased appetite_NA_At study endpoint (closest to 12 weeks)_6-17 yo Maiti - Children (2024) - Dasotraline_Specific adverse events: decreased appetite_NA_At study endpoint (closest to 12 weeks)_6-17 yo Dasotraline_Specific adverse events: decreased appetite_NA_At study endpoint (closest to 12 weeks)_6-17 yo - [Homogeneous],2024,Dasotraline_Specific adverse events: decreased appetite_NA_At study endpoint (closest to 12 weeks),115,TRUE,Maiti - Children (2024)_Dasotraline_Specific adverse events: decreased appetite_NA_At study endpoint (closest to 12 weeks) Maiti - Children (2024)_Dasotraline_Specific adverse events: decreased appetite_NA_At study endpoint (closest to 12 weeks),100.00000
Maiti - Children (2024) Dasotraline Specific adverse events: sleep problems NA At study endpoint (closest to 12 weeks), 380, 9.000000, 9.000000  9.000000, 9.000000  9.000000, 9.000000, 9.000000  9.000000,8991,  0.000000,134.41799 NA  9.000000,NA, 0.87676037,   3.044974 100.00000   0.00000,100.00000 100,100.000000 100.000000,100.00000,100.00000,100.000000,100.00000,100.000000   5  4, 2 135.32275,1.452381, 3 1,Findling | Wigal 2019 | 2020 | 2022,Maiti - Children,10.4103/indianjpsychiatry.indianjpsychiatry_3_24 Dasotraline,NA,Unclear (not able to identify the tools used to measure the outcome) NA Subgroup 1: Dasotreline 2mg vs Placebo | Subgroup 2: Dasotreline 4mg vs Placebo RCT (parallel, crossover, open-label) DSM 5,Placebo mg/d Critically low 9 9,NA NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Specific adverse events: sleep problems | Specific adverse events: decreased appetite Maiti - Children (2024) | Maiti - Adults (2024),9,36.5,NA NA,NA NA,NA,NA,< 2 months,NA,NA 3.04mg/d,6-17 yo Homogeneous Dasotraline_Specific adverse events: sleep problems_NA_At study endpoint (closest to 12 weeks)_6-17 yo,Maiti - Children (2024) - Dasotraline_Specific adverse events: sleep problems_NA_At study endpoint (closest to 12 weeks)_6-17 yo,Dasotraline_Specific adverse events: sleep problems_NA_At study endpoint (closest to 12 weeks)_6-17 yo - [Homogeneous] 2024 Dasotraline_Specific adverse events: sleep problems_NA_At study endpoint (closest to 12 weeks) 116 TRUE,Maiti - Children (2024)_Dasotraline_Specific adverse events: sleep problems_NA_At study endpoint (closest to 12 weeks),Maiti - Children (2024)_Dasotraline_Specific adverse events: sleep problems_NA_At study endpoint (closest to 12 weeks),100.00000
Maji (2024.0) Centafanadine,Combined ADHD symptoms (inattentive + hyperactive/impulsive),Mixed At study endpoint (closest to 12 weeks)  444 35.478857,35.478857 35.478857,35.478857,35.478857,38.000000,38.000000,38.000000,8993   0.000000 239.64692, 47.079769,36.357524 NA  1.14026281  300.000000,100.00000,  0.00000,100.00000,100 100.000000,100.000000,100.00000 100.00000 100.000000 100.00000 100.000000   2  1, 1 242.90433 1.651481, 2 1,Adler | Wigal,2022.0 | 2020.0 Maji 10.1016/j.jpsychires.2024.06.048,NA NA,Questionnaire,AISRS (modified ADHD-RS) | ADHD-RS-IV,200mg | 400mg RCT (parallel, crossover, open-label) DSM-V | DSM-IV,Placebo mg/d,Critically low 35.1494661921708 38,NA NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive) Maji (2024.0) 35.1494661921708,38 NA NA NA,NA,NA,NA < 2 months NA NA,300mg/d >= 18 yo,Homogeneous,Centafanadine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Mixed_At study endpoint (closest to 12 weeks)_>= 18 yo,Maji (2024.0) - Centafanadine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Mixed_At study endpoint (closest to 12 weeks)_>= 18 yo,Centafanadine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Mixed_At study endpoint (closest to 12 weeks)_>= 18 yo - [Homogeneous],2024,Centafanadine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Mixed_At study endpoint (closest to 12 weeks) 117,NA Maji (2024.0)_Centafanadine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Mixed_At study endpoint (closest to 12 weeks),Maji (2024.0)_Centafanadine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Mixed_At study endpoint (closest to 12 weeks) 100.00000
Ostinelli (2025),Alpha-2 agonists (guanfacine / clonidine) Acceptability: all-cause discontinuation NA At study endpoint (closest to 12 weeks), 201,32.443284,32.443284 32.443284,32.443284 32.443284,32.443284 32.443284 32.443284, 999   0.000000,201.00000  35.492537 32.443284,NA, 2.76179517,   5.070000,100.00000,  0.00000 100.00000 100,100.000000,100.000000,100.00000,100.00000 100.000000 100.00000,100.000000, 20  7, 5,201.00000 1.000000, 1 1 Iwanami,2020 Ostinelli,10.1016/S2215-0366(24)00360-2 Alpha-2 agonists (guanfacine / clonidine),NA,NA,Acceptability,NA RCT,NA Placebo,mg/d,High,32.4432835820896 32.4432835820896,NA NA,Specific adverse events: sleep problems | Tics/Tourette disorder symptoms | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Emotional dysregulation | Quality of life (patients) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) Ruggiero (2014) | Fahrat (2024) | Radonjic (2023) | Ostinelli (2025) | Cortese - Children (2018),8.23931034482759,41.2,NA,NA NA NA,NA,NA 2-6 months,NA,NA 5.07mg/d,>= 18 yo,Homogeneous Alpha-2 agonists (guanfacine / clonidine)_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_>= 18 yo Ostinelli (2025) - Alpha-2 agonists (guanfacine / clonidine)_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_>= 18 yo,Alpha-2 agonists (guanfacine / clonidine)_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_>= 18 yo - [Homogeneous],2025 Alpha-2 agonists (guanfacine / clonidine)_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks),118 TRUE Ostinelli (2025)_Alpha-2 agonists (guanfacine / clonidine)_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks) Ostinelli (2025)_Alpha-2 agonists (guanfacine / clonidine)_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks) 100.00000
Ostinelli (2025),Alpha-2 agonists (guanfacine / clonidine) Combined ADHD symptoms (inattentive + hyperactive/impulsive) Clinician-rated At study endpoint (closest to 12 weeks), 200 32.450000,32.450000,32.450000,32.450000 32.450000,32.450000 32.450000,32.450000  999   0.000000,200.00000  35.500000 32.450000 NA  2.76179517,   5.070000 100.00000   0.00000,100.00000 100 100.000000 100.000000,100.00000 100.00000,  0.000000,100.00000,100.000000  20  7  5,200.00000,1.000000  1 1,Iwanami,2020,Ostinelli 10.1016/S2215-0366(24)00360-2,Alpha-2 agonists (guanfacine / clonidine),NA,NA,ADHD-RS total NA RCT,NA,Placebo,mg/d High,32.45 32.45 NA NA Specific adverse events: sleep problems | Tics/Tourette disorder symptoms | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Emotional dysregulation | Quality of life (patients) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) Ruggiero (2014) | Fahrat (2024) | Radonjic (2023) | Ostinelli (2025) | Cortese - Children (2018) 8.23931034482759,41.2,NA,NA NA NA NA NA,2-6 months,NA NA 5.07mg/d >= 18 yo Homogeneous Alpha-2 agonists (guanfacine / clonidine)_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks)_>= 18 yo Ostinelli (2025) - Alpha-2 agonists (guanfacine / clonidine)_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks)_>= 18 yo,Alpha-2 agonists (guanfacine / clonidine)_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks)_>= 18 yo - [Homogeneous],2025,Alpha-2 agonists (guanfacine / clonidine)_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks) 119 TRUE,Ostinelli (2025)_Alpha-2 agonists (guanfacine / clonidine)_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks),Ostinelli (2025)_Alpha-2 agonists (guanfacine / clonidine)_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks),100.00000
Ostinelli (2025) Alpha-2 agonists (guanfacine / clonidine),Combined ADHD symptoms (inattentive + hyperactive/impulsive) Self-rated At study endpoint (closest to 12 weeks),  34 41.200000 41.200000 41.200000 41.200000,41.200000 41.200000 41.200000 41.200000  999   0.000000, 34.00000, 59.000000 41.200000 NA  0.46029919,   1.100000,100.00000   0.00000 100.00000,100 100.000000,100.000000 100.00000,100.00000,100.000000 100.00000 100.000000, 20, 7, 5, 34.00000,1.000000  1 1,Taylor,2001,Ostinelli,10.1016/S2215-0366(24)00360-2 Alpha-2 agonists (guanfacine / clonidine) NA,NA,Other NA RCT,NA,Placebo,mg/d,High 41.2,41.2 NA,NA,Specific adverse events: sleep problems | Tics/Tourette disorder symptoms | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Emotional dysregulation | Quality of life (patients) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events),Ruggiero (2014) | Fahrat (2024) | Radonjic (2023) | Ostinelli (2025) | Cortese - Children (2018),8.23931034482759,41.2 NA,NA,NA NA,NA,NA < 2 months,NA,NA 1.1mg/d,>= 18 yo,Homogeneous Alpha-2 agonists (guanfacine / clonidine)_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Self-rated_At study endpoint (closest to 12 weeks)_>= 18 yo,Ostinelli (2025) - Alpha-2 agonists (guanfacine / clonidine)_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Self-rated_At study endpoint (closest to 12 weeks)_>= 18 yo Alpha-2 agonists (guanfacine / clonidine)_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Self-rated_At study endpoint (closest to 12 weeks)_>= 18 yo - [Homogeneous],2025 Alpha-2 agonists (guanfacine / clonidine)_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Self-rated_At study endpoint (closest to 12 weeks),120,TRUE Ostinelli (2025)_Alpha-2 agonists (guanfacine / clonidine)_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Self-rated_At study endpoint (closest to 12 weeks) Ostinelli (2025)_Alpha-2 agonists (guanfacine / clonidine)_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Self-rated_At study endpoint (closest to 12 weeks),100.00000
Ostinelli (2025) Alpha-2 agonists (guanfacine / clonidine) Emotional dysregulation,Mixed At study endpoint (closest to 12 weeks), 200 32.450000 32.450000,32.450000,32.450000,32.450000 32.450000 32.450000 32.450000  999,  0.000000,200.00000  35.500000,32.450000,NA, 2.76179517,   5.070000 100.00000   0.00000 100.00000,100,100.000000,100.000000,100.00000,100.00000   0.000000 100.00000 100.000000  20, 7, 5,200.00000 1.000000  1,1 Iwanami 2020,Ostinelli,10.1016/S2215-0366(24)00360-2 Alpha-2 agonists (guanfacine / clonidine),NA NA,BRIEF-ASR Emotional control,NA,RCT,NA Placebo,mg/d High 32.45,32.45,NA,NA,Specific adverse events: sleep problems | Tics/Tourette disorder symptoms | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Emotional dysregulation | Quality of life (patients) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events),Ruggiero (2014) | Fahrat (2024) | Radonjic (2023) | Ostinelli (2025) | Cortese - Children (2018) 8.23931034482759,41.2,NA,NA,NA,NA,NA NA,2-6 months NA,NA 5.07mg/d >= 18 yo,Homogeneous Alpha-2 agonists (guanfacine / clonidine)_Emotional dysregulation_Mixed_At study endpoint (closest to 12 weeks)_>= 18 yo,Ostinelli (2025) - Alpha-2 agonists (guanfacine / clonidine)_Emotional dysregulation_Mixed_At study endpoint (closest to 12 weeks)_>= 18 yo,Alpha-2 agonists (guanfacine / clonidine)_Emotional dysregulation_Mixed_At study endpoint (closest to 12 weeks)_>= 18 yo - [Homogeneous],2025,Alpha-2 agonists (guanfacine / clonidine)_Emotional dysregulation_Mixed_At study endpoint (closest to 12 weeks),121 TRUE,Ostinelli (2025)_Alpha-2 agonists (guanfacine / clonidine)_Emotional dysregulation_Mixed_At study endpoint (closest to 12 weeks),Ostinelli (2025)_Alpha-2 agonists (guanfacine / clonidine)_Emotional dysregulation_Mixed_At study endpoint (closest to 12 weeks) 100.00000
Ostinelli (2025),Alpha-2 agonists (guanfacine / clonidine),Quality of life (patients) Mixed,At study endpoint (closest to 12 weeks)  200 32.450000 32.450000 32.450000,32.450000,32.450000 32.450000,32.450000,32.450000  999   0.000000,200.00000, 35.500000,32.450000 NA  2.76179517    5.070000,100.00000,  0.00000 100.00000 100 100.000000,100.000000 100.00000,100.00000   0.000000,100.00000 100.000000  20  7  5,200.00000,1.000000  1,1,Iwanami 2020,Ostinelli 10.1016/S2215-0366(24)00360-2,Alpha-2 agonists (guanfacine / clonidine) NA NA,AAQoL NA RCT,NA,Placebo,mg/d High,32.45,32.45,NA NA,Specific adverse events: sleep problems | Tics/Tourette disorder symptoms | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Emotional dysregulation | Quality of life (patients) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) Ruggiero (2014) | Fahrat (2024) | Radonjic (2023) | Ostinelli (2025) | Cortese - Children (2018),8.23931034482759 41.2 NA,NA NA NA,NA NA 2-6 months NA NA 5.07mg/d >= 18 yo,Homogeneous,Alpha-2 agonists (guanfacine / clonidine)_Quality of life (patients)_Mixed_At study endpoint (closest to 12 weeks)_>= 18 yo,Ostinelli (2025) - Alpha-2 agonists (guanfacine / clonidine)_Quality of life (patients)_Mixed_At study endpoint (closest to 12 weeks)_>= 18 yo,Alpha-2 agonists (guanfacine / clonidine)_Quality of life (patients)_Mixed_At study endpoint (closest to 12 weeks)_>= 18 yo - [Homogeneous],2025 Alpha-2 agonists (guanfacine / clonidine)_Quality of life (patients)_Mixed_At study endpoint (closest to 12 weeks),122 TRUE Ostinelli (2025)_Alpha-2 agonists (guanfacine / clonidine)_Quality of life (patients)_Mixed_At study endpoint (closest to 12 weeks),Ostinelli (2025)_Alpha-2 agonists (guanfacine / clonidine)_Quality of life (patients)_Mixed_At study endpoint (closest to 12 weeks),100.00000
Ostinelli (2025) Alpha-2 agonists (guanfacine / clonidine),Tolerability (discontinuation due to adverse events),NA,At study endpoint (closest to 12 weeks)  201,32.443284 32.443284,32.443284 32.443284 32.443284,32.443284,32.443284,32.443284, 999,  0.000000,201.00000  35.492537,32.443284,NA, 2.76179517    5.070000 100.00000,  0.00000 100.00000 100 100.000000,100.000000 100.00000,100.00000,100.000000,100.00000,100.000000, 20  7  5 201.00000,1.000000  1 1 Iwanami,2020 Ostinelli,10.1016/S2215-0366(24)00360-2,Alpha-2 agonists (guanfacine / clonidine),NA NA Tolerability NA,RCT,NA,Placebo,mg/d,High,32.4432835820896 32.4432835820896,NA NA Specific adverse events: sleep problems | Tics/Tourette disorder symptoms | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Emotional dysregulation | Quality of life (patients) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events),Ruggiero (2014) | Fahrat (2024) | Radonjic (2023) | Ostinelli (2025) | Cortese - Children (2018),8.23931034482759 41.2 NA NA NA,NA,NA NA 2-6 months,NA NA 5.07mg/d,>= 18 yo,Homogeneous,Alpha-2 agonists (guanfacine / clonidine)_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks)_>= 18 yo,Ostinelli (2025) - Alpha-2 agonists (guanfacine / clonidine)_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks)_>= 18 yo Alpha-2 agonists (guanfacine / clonidine)_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks)_>= 18 yo - [Homogeneous],2025 Alpha-2 agonists (guanfacine / clonidine)_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks) 123,TRUE Ostinelli (2025)_Alpha-2 agonists (guanfacine / clonidine)_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks),Ostinelli (2025)_Alpha-2 agonists (guanfacine / clonidine)_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks),100.00000
Ostinelli (2025) Amphetamine Acceptability: all-cause discontinuation NA,At study endpoint (closest to 12 weeks),1957,32.450000 33.295636 33.295636,34.467500,35.114762,36.926861,36.926861,38.869588  999   0.000000 275.46500  52.787837,34.859804,NA  1.16674203,  36.703933  99.02913   0.00000 100.00000 100,100.000000 100.000000,100.00000,100.00000 100.000000 100.00000,100.000000  43 14  9 275.46500,1.000000 10,1 Adler | Biederman | Cutler | Faraone | Frick | Kay | Spencer | Weisler 2008 | 2013 | 2012 | 2022 | 2021 | 2017 | 2009 | 2001 | 2006 Ostinelli 10.1016/S2215-0366(24)00360-2,Amphetamine,NA NA,Acceptability NA,RCT,NA Placebo mg/d | mg/kg/d,High 22.2057971014493 39.0319587628866 NA,NA Disruptive behaviors | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Academic/job performance | Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Depressive disorder symptoms | Generalized anxiety | Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Executive functioning (tests) Faraone (2002) | Punja (2016) | Castells (2018) | Elliott (2020) | Bellato - adults (2024) | Bellatto - children (2024) | Lenzi (2018) | Ostinelli (2025) | Cortese - Children (2018) 8,41.2,NA,NA,NA,NA NA,NA,< 2 months NA NA,36.7mg/d | mg/kg/d,>= 18 yo,Homogeneous Amphetamine_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_>= 18 yo,Ostinelli (2025) - Amphetamine_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_>= 18 yo,Amphetamine_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_>= 18 yo - [Homogeneous] 2025,Amphetamine_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks),124 TRUE Ostinelli (2025)_Amphetamine_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks) Ostinelli (2025)_Amphetamine_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks) 100.00000
Ostinelli (2025) Amphetamine,Combined ADHD symptoms (inattentive + hyperactive/impulsive) Clinician-rated At study endpoint (closest to 12 weeks),1857 33.288593,33.288593 33.288593 34.467500 35.114976 36.928990,36.928990 39.027660  999   0.000000,277.89284, 52.780896 34.842736,NA, 1.17813790,  36.744771,100.00000   0.00000 100.00000,100  82.767905  82.767905, 82.76791  82.76791  72.644050, 82.76791  82.767905  43 14, 9 277.89284 1.000000, 9 1,Adler | Biederman | Cutler | Faraone | Frick | Spencer | Weisler 2008 | 2013 | 2012 | 2022 | 2021 | 2017 | 2001 | 2006,Ostinelli 10.1016/S2215-0366(24)00360-2,Amphetamine,NA NA ADHD-RS total | ADHD-SRS total | AISRS | Other,NA,RCT NA Placebo,mg/d,High 22.2059016393443,39.0276595744681,NA NA,Disruptive behaviors | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Academic/job performance | Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Depressive disorder symptoms | Generalized anxiety | Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Executive functioning (tests) Faraone (2002) | Punja (2016) | Castells (2018) | Elliott (2020) | Bellato - adults (2024) | Bellatto - children (2024) | Lenzi (2018) | Ostinelli (2025) | Cortese - Children (2018) 8,41.2,NA,NA NA NA NA NA < 2 months NA,NA 36.74mg/d,>= 18 yo Homogeneous Amphetamine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks)_>= 18 yo,Ostinelli (2025) - Amphetamine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks)_>= 18 yo,Amphetamine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks)_>= 18 yo - [Homogeneous] 2025,Amphetamine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks) 125,TRUE Ostinelli (2025)_Amphetamine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks),Ostinelli (2025)_Amphetamine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks) 100.00000
Ostinelli (2025) Amphetamine Combined ADHD symptoms (inattentive + hyperactive/impulsive) Self-rated,At study endpoint (closest to 12 weeks), 300,39.031073,39.031073,39.031073,39.031073,39.031073,40.800000,40.800000 41.200000, 999   0.000000 121.48667, 40.186275 39.625490 NA  0.86996548   25.945098, 85.00000,  0.00000,100.00000,100 100.000000,100.000000,100.00000 100.00000, 41.000000 100.00000,100.000000, 43 14, 9,121.48667,1.000000, 4,1,Paterson | Taylor | Weisler 1999 | 2000 | 2001 | 2006,Ostinelli 10.1016/S2215-0366(24)00360-2,Amphetamine NA NA,Other | CAARS-S:S NA RCT NA,Placebo,mg/d,High 39.0310734463277,41.2 NA NA,Disruptive behaviors | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Academic/job performance | Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Depressive disorder symptoms | Generalized anxiety | Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Executive functioning (tests) Faraone (2002) | Punja (2016) | Castells (2018) | Elliott (2020) | Bellato - adults (2024) | Bellatto - children (2024) | Lenzi (2018) | Ostinelli (2025) | Cortese - Children (2018) 8 41.2,NA,NA,NA,NA NA NA < 2 months NA,NA,25.95mg/d,>= 18 yo,Homogeneous,Amphetamine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Self-rated_At study endpoint (closest to 12 weeks)_>= 18 yo Ostinelli (2025) - Amphetamine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Self-rated_At study endpoint (closest to 12 weeks)_>= 18 yo Amphetamine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Self-rated_At study endpoint (closest to 12 weeks)_>= 18 yo - [Homogeneous] 2025 Amphetamine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Self-rated_At study endpoint (closest to 12 weeks),126,TRUE,Ostinelli (2025)_Amphetamine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Self-rated_At study endpoint (closest to 12 weeks) Ostinelli (2025)_Amphetamine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Self-rated_At study endpoint (closest to 12 weeks),100.00000
Ostinelli (2025) Amphetamine Executive functioning (tests),Mixed At study endpoint (closest to 12 weeks)  124,32.450000,32.450000 32.450000,32.450000 32.450000,32.450000,32.450000 32.450000, 999   0.000000 124.00000  59.950000,32.450000,NA, 1.15074799   20.000000,100.00000,  0.00000,100.00000,100 100.000000,100.000000 100.00000 100.00000,100.000000,100.00000 100.000000, 43,14  9 124.00000 1.000000  1,1 Cutler,2022,Ostinelli 10.1016/S2215-0366(24)00360-2,Amphetamine NA,NA DSST NA RCT,NA Placebo,mg/d High,32.45,32.45 NA NA Disruptive behaviors | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Academic/job performance | Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Depressive disorder symptoms | Generalized anxiety | Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Executive functioning (tests),Faraone (2002) | Punja (2016) | Castells (2018) | Elliott (2020) | Bellato - adults (2024) | Bellatto - children (2024) | Lenzi (2018) | Ostinelli (2025) | Cortese - Children (2018),8 41.2 NA,NA NA NA NA,NA < 2 months,NA NA,20mg/d,>= 18 yo Homogeneous Amphetamine_Executive functioning (tests)_Mixed_At study endpoint (closest to 12 weeks)_>= 18 yo Ostinelli (2025) - Amphetamine_Executive functioning (tests)_Mixed_At study endpoint (closest to 12 weeks)_>= 18 yo,Amphetamine_Executive functioning (tests)_Mixed_At study endpoint (closest to 12 weeks)_>= 18 yo - [Homogeneous],2025 Amphetamine_Executive functioning (tests)_Mixed_At study endpoint (closest to 12 weeks),127,TRUE,Ostinelli (2025)_Amphetamine_Executive functioning (tests)_Mixed_At study endpoint (closest to 12 weeks) Ostinelli (2025)_Amphetamine_Executive functioning (tests)_Mixed_At study endpoint (closest to 12 weeks) 100.00000
Ostinelli (2025),Amphetamine Tolerability (discontinuation due to adverse events),NA,At study endpoint (closest to 12 weeks),1995 32.450000 33.295636 33.295636,34.000000,34.552174 36.926861 36.926861,38.800000  999   0.000000 270.94185  53.035687,34.843269,NA  1.16205358,  37.257282  99.04762,  0.00000,100.00000 100, 98.095238  98.095238, 98.09524, 98.09524, 98.095238  98.09524  98.095238, 43,14  9,270.94185 1.000000 11 1 Adler | Biederman | Cutler | Faraone | Frick | Kay | Spencer | Weisler 2008 | 2013 | 2021 | 2012 | 2022 | 2017 | 2009 | 2001 | 2006,Ostinelli 10.1016/S2215-0366(24)00360-2 Amphetamine,NA,NA,Tolerability,NA RCT,NA,Placebo,mg/d,High,22.2057971014493 39.0319587628866,NA NA,Disruptive behaviors | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Academic/job performance | Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Depressive disorder symptoms | Generalized anxiety | Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Executive functioning (tests) Faraone (2002) | Punja (2016) | Castells (2018) | Elliott (2020) | Bellato - adults (2024) | Bellatto - children (2024) | Lenzi (2018) | Ostinelli (2025) | Cortese - Children (2018) 8,41.2 NA,NA,NA,NA NA NA,< 2 months NA NA,37.26mg/d >= 18 yo Homogeneous Amphetamine_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks)_>= 18 yo Ostinelli (2025) - Amphetamine_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks)_>= 18 yo,Amphetamine_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks)_>= 18 yo - [Homogeneous] 2025,Amphetamine_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks),128 TRUE,Ostinelli (2025)_Amphetamine_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks),Ostinelli (2025)_Amphetamine_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks) 100.00000
Ostinelli (2025) Atomoxetine Acceptability: all-cause discontinuation,NA,At study endpoint (closest to 12 weeks) 3292 24.700000 29.900000,32.248593,32.248593,36.727073,37.779114,41.293227 41.293227  999,  0.000000 358.24988, 44.544644 35.122034,NA  3.55098065   86.858447  95.07768   0.00000,100.00000 100,100.000000,100.000000 100.00000 100.00000,100.000000,100.00000 100.000000, 44, 9, 7 363.51838,1.227503,14 1,Adler | Durell | Goto | Kay | Lin | McRae-Clark | Michelson | NCT03324581 | Spencer | Sutherland | Weisler | Wilens | Young,2008 | 2009 | 2013 | 2016 | 2010 | 2003 | 2018 | 1998 | 2012 | 2011,Ostinelli 10.1016/S2215-0366(24)00360-2 Atomoxetine,NA NA Acceptability,NA RCT NA,Placebo,mg/d,High,24.7 42.10703125,NA,NA Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Generalized anxiety | Depressive disorder symptoms | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | CGI Elliott (2020) | Bellatto - children (2024) | Lenzi (2018) | Bryant (2021) | Ostinelli (2025) | Cortese - Adults (2018) | Cortese - Children (2018),8.65154639175258,42.10703125,NA NA,NA,NA,NA,NA,2-6 months NA,NA 86.86mg/d,>= 18 yo,Homogeneous,Atomoxetine_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_>= 18 yo,Ostinelli (2025) - Atomoxetine_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_>= 18 yo,Atomoxetine_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_>= 18 yo - [Homogeneous],2025,Atomoxetine_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks) 129,TRUE,Ostinelli (2025)_Atomoxetine_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks) Ostinelli (2025)_Atomoxetine_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks),100.00000
Ostinelli (2025) Atomoxetine Combined ADHD symptoms (inattentive + hyperactive/impulsive),Clinician-rated,At follow-up (closest to 26 weeks),1006 36.692177,36.692177 36.692177 36.692177,37.560926 41.293548 41.293548 41.293548, 999,  0.000000 376.84692  48.459990,39.147376 NA  5.75694281   87.564215 100.00000   0.00000,100.00000,100,100.000000 100.000000,100.00000 100.00000  50.695825 100.00000,100.000000, 44  9, 7,376.84692 1.000000  3 1 Adler | Young,2008 | 2009 | 2011,Ostinelli 10.1016/S2215-0366(24)00360-2 Atomoxetine,NA NA CAARS-INV:SV | Other | CAARS-O:L,NA RCT,NA Placebo mg/d High,36.6921768707483,41.2935483870968 NA NA Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Generalized anxiety | Depressive disorder symptoms | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | CGI,Elliott (2020) | Bellatto - children (2024) | Lenzi (2018) | Bryant (2021) | Ostinelli (2025) | Cortese - Adults (2018) | Cortese - Children (2018) 8.65154639175258 42.10703125 NA NA,NA,NA,NA NA,2-6 months NA NA 87.56mg/d >= 18 yo,Homogeneous,Atomoxetine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At follow-up (closest to 26 weeks)_>= 18 yo Ostinelli (2025) - Atomoxetine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At follow-up (closest to 26 weeks)_>= 18 yo,Atomoxetine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At follow-up (closest to 26 weeks)_>= 18 yo - [Homogeneous],2025 Atomoxetine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At follow-up (closest to 26 weeks),130 TRUE,Ostinelli (2025)_Atomoxetine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At follow-up (closest to 26 weeks) Ostinelli (2025)_Atomoxetine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At follow-up (closest to 26 weeks),100.00000
Ostinelli (2025),Atomoxetine Combined ADHD symptoms (inattentive + hyperactive/impulsive) Clinician-rated At study endpoint (closest to 12 weeks),2537,24.700000 32.244301 32.244301 32.244301,36.200000 41.175094,41.293548 41.293548  999   0.000000 310.76163  45.653866,35.882149,NA, 3.15208862,  87.450759  94.27435,  0.00000,100.00000,100,100.000000 100.000000,100.00000 100.00000, 52.077535,100.00000,100.000000, 44  9  7,313.72485 1.261630,11 1,Adler | Bain | Durell | Goto | Michelson | NCT03324581 | Spencer | Sutherland | Weisler | Wilens | Young 2009 | 2013 | 2003 | 2018 | 1998 | 2012 | 2008 | 2011 Ostinelli,10.1016/S2215-0366(24)00360-2 Atomoxetine NA NA,CAARS-INV:SV | Other | CAARS-INV:SV | ADHD-RS total | CAARS-O | Other | ADHD-SRS total NA RCT NA,Placebo mg/d | mg/kg/d,High 24.7,42.1,NA,NA,Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Generalized anxiety | Depressive disorder symptoms | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | CGI,Elliott (2020) | Bellatto - children (2024) | Lenzi (2018) | Bryant (2021) | Ostinelli (2025) | Cortese - Adults (2018) | Cortese - Children (2018),8.65154639175258 42.10703125,NA,NA,NA,NA NA,NA,2-6 months NA,NA,87.45mg/d | mg/kg/d,>= 18 yo,Homogeneous,Atomoxetine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks)_>= 18 yo,Ostinelli (2025) - Atomoxetine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks)_>= 18 yo,Atomoxetine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks)_>= 18 yo - [Homogeneous] 2025,Atomoxetine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks) 131 TRUE Ostinelli (2025)_Atomoxetine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks) Ostinelli (2025)_Atomoxetine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks),100.00000
Ostinelli (2025) Atomoxetine Combined ADHD symptoms (inattentive + hyperactive/impulsive),Self-rated At follow-up (closest to 26 weeks)  872 36.717143,36.717143 36.717143 36.717143,37.569138,37.569138,37.569138,37.569138, 999   0.000000 441.96560  45.808429,37.192970 NA, 5.98388953,  84.809060 100.00000,  0.00000,100.00000,100 100.000000,100.000000 100.00000,100.00000 100.000000 100.00000 100.000000, 44  9, 7 441.96560 1.000000  2 1 Adler,2008 | 2009 Ostinelli,10.1016/S2215-0366(24)00360-2 Atomoxetine,NA NA,CAARS-S:S | ASRS,NA,RCT,NA,Placebo mg/d,High 36.7171428571429 37.5691375770021,NA NA,Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Generalized anxiety | Depressive disorder symptoms | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | CGI Elliott (2020) | Bellatto - children (2024) | Lenzi (2018) | Bryant (2021) | Ostinelli (2025) | Cortese - Adults (2018) | Cortese - Children (2018) 8.65154639175258 42.10703125,NA,NA NA NA,NA,NA 2-6 months,NA NA,84.81mg/d >= 18 yo Homogeneous,Atomoxetine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Self-rated_At follow-up (closest to 26 weeks)_>= 18 yo Ostinelli (2025) - Atomoxetine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Self-rated_At follow-up (closest to 26 weeks)_>= 18 yo,Atomoxetine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Self-rated_At follow-up (closest to 26 weeks)_>= 18 yo - [Homogeneous],2025 Atomoxetine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Self-rated_At follow-up (closest to 26 weeks),132 TRUE,Ostinelli (2025)_Atomoxetine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Self-rated_At follow-up (closest to 26 weeks),Ostinelli (2025)_Atomoxetine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Self-rated_At follow-up (closest to 26 weeks) 100.00000
Ostinelli (2025),Atomoxetine Combined ADHD symptoms (inattentive + hyperactive/impulsive),Self-rated At study endpoint (closest to 12 weeks),1734,24.700000,24.700000 24.700000,30.125000 36.717143 37.569138 41.175094,41.175094, 999   0.000000 362.03262, 40.509038,34.507310,NA, 4.30951618   85.943630,100.00000,  0.00000 100.00000,100 100.000000,100.000000,100.00000,100.00000  69.092491,100.00000 100.000000  44  9, 7 363.45115,1.149319, 7,1,Adler | Durell | Lin | McRae-Clark | Michelson | Wilens,2008 | 2009 | 2013 | 2016 | 2010 | 2003,Ostinelli 10.1016/S2215-0366(24)00360-2,Atomoxetine,NA,NA CAARS-S:S | ASRS | CAARS-S:L,NA RCT,NA Placebo mg/d High 24.7 42.1 NA NA Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Generalized anxiety | Depressive disorder symptoms | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | CGI,Elliott (2020) | Bellatto - children (2024) | Lenzi (2018) | Bryant (2021) | Ostinelli (2025) | Cortese - Adults (2018) | Cortese - Children (2018) 8.65154639175258 42.10703125,NA NA NA,NA NA NA 2-6 months,NA NA 85.94mg/d >= 18 yo Homogeneous Atomoxetine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Self-rated_At study endpoint (closest to 12 weeks)_>= 18 yo,Ostinelli (2025) - Atomoxetine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Self-rated_At study endpoint (closest to 12 weeks)_>= 18 yo Atomoxetine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Self-rated_At study endpoint (closest to 12 weeks)_>= 18 yo - [Homogeneous] 2025,Atomoxetine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Self-rated_At study endpoint (closest to 12 weeks) 133,TRUE Ostinelli (2025)_Atomoxetine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Self-rated_At study endpoint (closest to 12 weeks),Ostinelli (2025)_Atomoxetine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Self-rated_At study endpoint (closest to 12 weeks) 100.00000
Ostinelli (2025) Atomoxetine Emotional dysregulation,Mixed At study endpoint (closest to 12 weeks), 267 41.175094,41.175094 41.175094 41.175094,41.175094,41.175094,41.175094 41.175094, 999,  0.000000 257.50000  35.026779,41.175094 NA  2.30149597 NA 100.00000,  0.00000,100.00000 100 100.000000,100.000000 100.00000 100.00000 100.000000 100.00000,100.000000  44  9  7,267.00000,2.000000  1 1 Michelson,2003 Ostinelli 10.1016/S2215-0366(24)00360-2,Atomoxetine NA NA,WRAADDS,NA,RCT,NA Placebo,NA,High,40.2501872659176 42.1 NA,NA Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Generalized anxiety | Depressive disorder symptoms | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | CGI Elliott (2020) | Bellatto - children (2024) | Lenzi (2018) | Bryant (2021) | Ostinelli (2025) | Cortese - Adults (2018) | Cortese - Children (2018),8.65154639175258 42.10703125 NA NA NA,NA NA NA,2-6 months,NA NA NANA,>= 18 yo,Homogeneous Atomoxetine_Emotional dysregulation_Mixed_At study endpoint (closest to 12 weeks)_>= 18 yo Ostinelli (2025) - Atomoxetine_Emotional dysregulation_Mixed_At study endpoint (closest to 12 weeks)_>= 18 yo,Atomoxetine_Emotional dysregulation_Mixed_At study endpoint (closest to 12 weeks)_>= 18 yo - [Homogeneous],2025,Atomoxetine_Emotional dysregulation_Mixed_At study endpoint (closest to 12 weeks) 134,TRUE,Ostinelli (2025)_Atomoxetine_Emotional dysregulation_Mixed_At study endpoint (closest to 12 weeks) Ostinelli (2025)_Atomoxetine_Emotional dysregulation_Mixed_At study endpoint (closest to 12 weeks),100.00000
Ostinelli (2025) Atomoxetine,Quality of life (patients) Mixed,At study endpoint (closest to 12 weeks), 651,24.700000 24.700000,24.700000,24.700000 24.700000 37.994167 37.994167,37.994167, 999,  0.000000,337.11982  44.224009,30.091183,NA, 2.94846028,  85.337327,100.00000,  0.00000,100.00000,100,100.000000 100.000000,100.00000,100.00000,  0.000000,100.00000 100.000000  44  9, 7,337.11982 1.000000, 2,1,Adler | Durell 2009 | 2013 Ostinelli,10.1016/S2215-0366(24)00360-2 Atomoxetine NA NA AAQoL,NA,RCT NA,Placebo mg/d,High 24.7,37.9941666666667,NA NA,Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Generalized anxiety | Depressive disorder symptoms | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | CGI,Elliott (2020) | Bellatto - children (2024) | Lenzi (2018) | Bryant (2021) | Ostinelli (2025) | Cortese - Adults (2018) | Cortese - Children (2018) 8.65154639175258 42.10703125,NA,NA NA,NA NA NA,2-6 months,NA,NA,85.34mg/d,>= 18 yo Homogeneous Atomoxetine_Quality of life (patients)_Mixed_At study endpoint (closest to 12 weeks)_>= 18 yo,Ostinelli (2025) - Atomoxetine_Quality of life (patients)_Mixed_At study endpoint (closest to 12 weeks)_>= 18 yo Atomoxetine_Quality of life (patients)_Mixed_At study endpoint (closest to 12 weeks)_>= 18 yo - [Homogeneous],2025 Atomoxetine_Quality of life (patients)_Mixed_At study endpoint (closest to 12 weeks),135 TRUE Ostinelli (2025)_Atomoxetine_Quality of life (patients)_Mixed_At study endpoint (closest to 12 weeks) Ostinelli (2025)_Atomoxetine_Quality of life (patients)_Mixed_At study endpoint (closest to 12 weeks),100.00000
Ostinelli (2025) Atomoxetine Tolerability (discontinuation due to adverse events),NA,At study endpoint (closest to 12 weeks) 3292,24.700000 29.900000,32.248593,32.248593,36.727073 37.779114,41.293227,41.293227, 999,  0.000000,358.24988, 44.544644 35.122034 NA  3.55098065   86.858447  95.07768,  0.00000,100.00000,100 100.000000 100.000000,100.00000,100.00000,100.000000,100.00000,100.000000, 44  9  7,363.51838,1.227503 14 1,Adler | Durell | Goto | Kay | Lin | McRae-Clark | Michelson | NCT03324581 | Spencer | Sutherland | Weisler | Wilens | Young 2008 | 2009 | 2013 | 2016 | 2010 | 2003 | 2018 | 1998 | 2012 | 2011 Ostinelli 10.1016/S2215-0366(24)00360-2,Atomoxetine NA NA Tolerability NA RCT NA,Placebo,mg/d High,24.7 42.10703125,NA,NA Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Generalized anxiety | Depressive disorder symptoms | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | CGI,Elliott (2020) | Bellatto - children (2024) | Lenzi (2018) | Bryant (2021) | Ostinelli (2025) | Cortese - Adults (2018) | Cortese - Children (2018) 8.65154639175258 42.10703125 NA NA NA NA NA,NA,2-6 months NA NA,86.86mg/d,>= 18 yo Homogeneous,Atomoxetine_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks)_>= 18 yo,Ostinelli (2025) - Atomoxetine_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks)_>= 18 yo Atomoxetine_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks)_>= 18 yo - [Homogeneous] 2025,Atomoxetine_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks),136 TRUE Ostinelli (2025)_Atomoxetine_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks),Ostinelli (2025)_Atomoxetine_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks),100.00000
Ostinelli (2025) Bupropion,Acceptability: all-cause discontinuation NA At study endpoint (closest to 12 weeks)   99,34.422034,34.422034 34.422034 34.422034,34.422034,38.235000 38.235000,38.235000, 999,  0.000000, 51.32323  34.313131 35.962626 NA, 1.38089758, 323.858586 100.00000,  0.00000 100.00000 100,100.000000 100.000000,100.00000,100.00000,100.000000,100.00000,100.000000, 10  7, 6, 51.32323 1.000000, 2,1 Reimherr | Wilens,2005 | 2001,Ostinelli 10.1016/S2215-0366(24)00360-2 Bupropion NA,NA Acceptability,NA,RCT NA,Placebo,mg/d High 34.4220338983051,38.235 NA,NA Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Depressive disorder symptoms | Generalized anxiety | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Executive functioning (tests) | Emotional dysregulation,Stuhec (2015) | Verbeeck (2017) | Ostinelli (2025) | Cortese - Children (2018) | Cortese - Adults (2018) | Catala-Lopez (2017),8.5,40.25 NA NA,NA,NA NA NA < 2 months NA,NA 323.86mg/d,>= 18 yo,Homogeneous Bupropion_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_>= 18 yo Ostinelli (2025) - Bupropion_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_>= 18 yo Bupropion_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_>= 18 yo - [Homogeneous] 2025,Bupropion_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks),137 TRUE Ostinelli (2025)_Bupropion_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks) Ostinelli (2025)_Bupropion_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks),100.00000
Ostinelli (2025) Bupropion,Combined ADHD symptoms (inattentive + hyperactive/impulsive) Self-rated,At study endpoint (closest to 12 weeks)   64 32.700000 32.700000 32.700000,32.700000 33.545000,33.545000 33.545000 33.545000, 999   0.000000  35.12500  29.826563,33.254531,NA  1.46001151  150.000000,100.00000,  0.00000 100.00000,100 100.000000,100.000000,100.00000,100.00000,100.000000 100.00000,100.000000, 10, 7, 6  35.12500,1.000000, 2,1,Hamedi | Kuperman,2014 | 2001,Ostinelli,10.1016/S2215-0366(24)00360-2,Bupropion,NA,NA,CAARS-S:L | Other NA,RCT,NA,Placebo,mg/d,High 32.7 33.545,NA,NA Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Depressive disorder symptoms | Generalized anxiety | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Executive functioning (tests) | Emotional dysregulation Stuhec (2015) | Verbeeck (2017) | Ostinelli (2025) | Cortese - Children (2018) | Cortese - Adults (2018) | Catala-Lopez (2017),8.5,40.25 NA NA,NA NA,NA,NA < 2 months,NA NA 150mg/d >= 18 yo,Homogeneous Bupropion_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Self-rated_At study endpoint (closest to 12 weeks)_>= 18 yo,Ostinelli (2025) - Bupropion_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Self-rated_At study endpoint (closest to 12 weeks)_>= 18 yo Bupropion_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Self-rated_At study endpoint (closest to 12 weeks)_>= 18 yo - [Homogeneous],2025 Bupropion_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Self-rated_At study endpoint (closest to 12 weeks) 138 TRUE,Ostinelli (2025)_Bupropion_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Self-rated_At study endpoint (closest to 12 weeks) Ostinelli (2025)_Bupropion_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Self-rated_At study endpoint (closest to 12 weeks),100.00000
Ostinelli (2025),Bupropion Emotional dysregulation,Mixed,At study endpoint (closest to 12 weeks)   47 34.414894,34.414894,34.414894 34.414894,34.414894 34.414894 34.414894,34.414894, 999   0.000000, 47.00000, 27.221277 34.414894 NA, 1.38089758  298.000000,100.00000   0.00000 100.00000 100,  0.000000   0.000000   0.00000,  0.00000,  0.000000,  0.00000,  0.000000, 10, 7, 6, 47.00000,1.000000, 1 1,Reimherr 2005,Ostinelli,10.1016/S2215-0366(24)00360-2,Bupropion,NA,NA,WRAADDS,NA,RCT,NA,Placebo,mg/d High,34.4148936170213,34.4148936170213 NA,NA Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Depressive disorder symptoms | Generalized anxiety | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Executive functioning (tests) | Emotional dysregulation Stuhec (2015) | Verbeeck (2017) | Ostinelli (2025) | Cortese - Children (2018) | Cortese - Adults (2018) | Catala-Lopez (2017),8.5 40.25 NA NA,NA NA,NA,NA,< 2 months,NA,NA 298mg/d,>= 18 yo Homogeneous,Bupropion_Emotional dysregulation_Mixed_At study endpoint (closest to 12 weeks)_>= 18 yo Ostinelli (2025) - Bupropion_Emotional dysregulation_Mixed_At study endpoint (closest to 12 weeks)_>= 18 yo Bupropion_Emotional dysregulation_Mixed_At study endpoint (closest to 12 weeks)_>= 18 yo - [Homogeneous] 2025 Bupropion_Emotional dysregulation_Mixed_At study endpoint (closest to 12 weeks),139 TRUE,Ostinelli (2025)_Bupropion_Emotional dysregulation_Mixed_At study endpoint (closest to 12 weeks) Ostinelli (2025)_Bupropion_Emotional dysregulation_Mixed_At study endpoint (closest to 12 weeks) 100.00000
Ostinelli (2025) Bupropion Executive functioning (tests),Mixed,At study endpoint (closest to 12 weeks),  18 32.644444,32.644444 32.644444,32.644444,32.644444,32.644444 32.644444,32.644444, 999,  0.000000, 18.00000  31.000000 32.644444,NA  1.61104718,NA 100.00000,  0.00000 100.00000 100,100.000000,100.000000,100.00000,100.00000,100.000000,100.00000,100.000000  10  7  6, 18.00000,1.000000  1,1,Kuperman 2001,Ostinelli,10.1016/S2215-0366(24)00360-2,Bupropion NA,NA,CPT d',NA,RCT NA,Placebo,NA,High 32.6444444444444 32.6444444444444 NA NA Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Depressive disorder symptoms | Generalized anxiety | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Executive functioning (tests) | Emotional dysregulation Stuhec (2015) | Verbeeck (2017) | Ostinelli (2025) | Cortese - Children (2018) | Cortese - Adults (2018) | Catala-Lopez (2017),8.5,40.25 NA NA NA NA NA NA < 2 months,NA,NA NANA,>= 18 yo,Homogeneous,Bupropion_Executive functioning (tests)_Mixed_At study endpoint (closest to 12 weeks)_>= 18 yo,Ostinelli (2025) - Bupropion_Executive functioning (tests)_Mixed_At study endpoint (closest to 12 weeks)_>= 18 yo,Bupropion_Executive functioning (tests)_Mixed_At study endpoint (closest to 12 weeks)_>= 18 yo - [Homogeneous] 2025,Bupropion_Executive functioning (tests)_Mixed_At study endpoint (closest to 12 weeks) 140 TRUE Ostinelli (2025)_Bupropion_Executive functioning (tests)_Mixed_At study endpoint (closest to 12 weeks),Ostinelli (2025)_Bupropion_Executive functioning (tests)_Mixed_At study endpoint (closest to 12 weeks) 100.00000
Ostinelli (2025),Bupropion Tolerability (discontinuation due to adverse events),NA At study endpoint (closest to 12 weeks),  99 34.422034 34.422034 34.422034 34.422034 34.422034 38.235000,38.235000 38.235000  999   0.000000, 51.32323  34.313131,35.962626 NA, 1.38089758  323.858586 100.00000,  0.00000,100.00000,100,100.000000,100.000000 100.00000 100.00000 100.000000,100.00000,100.000000  10, 7  6, 51.32323,1.000000, 2 1,Reimherr | Wilens 2005 | 2001 Ostinelli 10.1016/S2215-0366(24)00360-2,Bupropion NA NA,Tolerability NA RCT,NA,Placebo mg/d High,34.4220338983051 38.235,NA NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Depressive disorder symptoms | Generalized anxiety | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Executive functioning (tests) | Emotional dysregulation Stuhec (2015) | Verbeeck (2017) | Ostinelli (2025) | Cortese - Children (2018) | Cortese - Adults (2018) | Catala-Lopez (2017) 8.5 40.25 NA,NA,NA NA NA NA < 2 months NA NA,323.86mg/d >= 18 yo,Homogeneous Bupropion_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks)_>= 18 yo,Ostinelli (2025) - Bupropion_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks)_>= 18 yo,Bupropion_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks)_>= 18 yo - [Homogeneous] 2025,Bupropion_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks) 141,TRUE Ostinelli (2025)_Bupropion_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks) Ostinelli (2025)_Bupropion_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks),100.00000
Ostinelli (2025) Cognitive Behavioral Therapy (CBT) Acceptability: all-cause discontinuation,NA,At study endpoint (closest to 12 weeks)  867 19.653214 19.653214,19.653214,19.653214,35.900000,39.105000,41.689886 43.150000  999, 18.685121,140.13725  57.679348 30.604335,NA, 2.09245055 NA  90.19608,  0.00000,100.00000,100,100.000000 100.000000,100.00000, 93.07958,100.000000 100.00000,100.000000, 20  9  4 140.13725,1.000000,10 1 Anastopoulos | Dittner | Emilsson | Huang | Nakashima | Nasri | Pettersson | Safren | Solanto,2021 | 2018 | 2011 | 2015 | 2022 | 2014 | 2004 | 2010,Ostinelli 10.1016/S2215-0366(24)00360-2 Cognitive Behavioral Therapy (CBT),tau NA,Acceptability,NA,RCT,NA,WLC | TAU | Relaxation therapy | Psychological placebo,NA High,19.6532142857143,43.15 NA,NA Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Depressive disorder symptoms | Generalized anxiety | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Executive functioning (tests) | Quality of life (patients) | Emotional dysregulation Ding (2018) | Liu (2022) | Lopez (2018) | Ostinelli (2025) 10.3,43.15 NA,NA NA NA NA,NA 2-6 months NA NA,NANA >= 18 yo,Homogeneous,Cognitive Behavioral Therapy (CBT)_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_>= 18 yo Ostinelli (2025) - Cognitive Behavioral Therapy (CBT)_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_>= 18 yo,Cognitive Behavioral Therapy (CBT)_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_>= 18 yo - [Homogeneous] 2025,Cognitive Behavioral Therapy (CBT)_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks),142,TRUE Ostinelli (2025)_Cognitive Behavioral Therapy (CBT)_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks),Ostinelli (2025)_Cognitive Behavioral Therapy (CBT)_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks) 100.00000
Ostinelli (2025) Cognitive Behavioral Therapy (CBT) Combined ADHD symptoms (inattentive + hyperactive/impulsive),Clinician-rated,At follow-up (closest to 26 weeks), 109 39.158810 39.158810 39.158810,39.158810,43.061194 43.061194,43.061194,43.061194  999  38.532110  57.36697  60.884404 41.557523 NA  2.83147349,NA 100.00000   0.00000,100.00000 100 100.000000 100.000000 100.00000,100.00000,100.000000,100.00000,100.000000, 20, 9, 4  57.36697,1.000000  2,1 Nakashima | Safren,2021 | 2010,Ostinelli 10.1016/S2215-0366(24)00360-2 Cognitive Behavioral Therapy (CBT) tau,NA CAARS-Ob-IN | ADHD-RS total,NA RCT NA TAU | Relaxation therapy NA High 39.1588095238095 43.0611940298507 NA NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Depressive disorder symptoms | Generalized anxiety | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Executive functioning (tests) | Quality of life (patients) | Emotional dysregulation,Ding (2018) | Liu (2022) | Lopez (2018) | Ostinelli (2025) 10.3,43.15 NA NA NA,NA NA NA 2-6 months NA,NA,NANA >= 18 yo,Homogeneous Cognitive Behavioral Therapy (CBT)_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At follow-up (closest to 26 weeks)_>= 18 yo Ostinelli (2025) - Cognitive Behavioral Therapy (CBT)_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At follow-up (closest to 26 weeks)_>= 18 yo Cognitive Behavioral Therapy (CBT)_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At follow-up (closest to 26 weeks)_>= 18 yo - [Homogeneous] 2025,Cognitive Behavioral Therapy (CBT)_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At follow-up (closest to 26 weeks) 143 TRUE Ostinelli (2025)_Cognitive Behavioral Therapy (CBT)_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At follow-up (closest to 26 weeks) Ostinelli (2025)_Cognitive Behavioral Therapy (CBT)_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At follow-up (closest to 26 weeks),100.00000
Ostinelli (2025) Cognitive Behavioral Therapy (CBT) Combined ADHD symptoms (inattentive + hyperactive/impulsive),Clinician-rated At follow-up (closest to 52 weeks)   70 43.077143,43.077143 43.077143,43.077143,43.077143,43.077143 43.077143,43.077143, 999,  0.000000, 70.00000, 44.200000 43.077143,NA  3.45224396,NA 100.00000,  0.00000 100.00000 100,100.000000 100.000000 100.00000,100.00000,100.000000,100.00000 100.000000  20  9, 4  70.00000 1.000000  1 1 Safren 2010 Ostinelli,10.1016/S2215-0366(24)00360-2,Cognitive Behavioral Therapy (CBT),NA NA,ADHD-RS total,NA RCT,NA,Relaxation therapy,NA High,43.0771428571429 43.0771428571429,NA NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Depressive disorder symptoms | Generalized anxiety | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Executive functioning (tests) | Quality of life (patients) | Emotional dysregulation Ding (2018) | Liu (2022) | Lopez (2018) | Ostinelli (2025),10.3,43.15,NA NA NA NA NA NA,2-6 months,NA NA,NANA,>= 18 yo,Homogeneous,Cognitive Behavioral Therapy (CBT)_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At follow-up (closest to 52 weeks)_>= 18 yo,Ostinelli (2025) - Cognitive Behavioral Therapy (CBT)_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At follow-up (closest to 52 weeks)_>= 18 yo,Cognitive Behavioral Therapy (CBT)_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At follow-up (closest to 52 weeks)_>= 18 yo - [Homogeneous],2025 Cognitive Behavioral Therapy (CBT)_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At follow-up (closest to 52 weeks) 144,TRUE,Ostinelli (2025)_Cognitive Behavioral Therapy (CBT)_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At follow-up (closest to 52 weeks) Ostinelli (2025)_Cognitive Behavioral Therapy (CBT)_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At follow-up (closest to 52 weeks),100.00000
Ostinelli (2025),Cognitive Behavioral Therapy (CBT),Combined ADHD symptoms (inattentive + hyperactive/impulsive),Clinician-rated,At study endpoint (closest to 12 weeks)  265 39.173902,39.173902 39.173902 41.696790,41.696790 43.106410 43.106410 43.106410  999  28.301887  62.04906, 61.930500 41.729350 NA  2.78524437 NA, 75.47170,  0.00000 100.00000 100 100.000000,100.000000,100.00000,100.00000 100.000000 100.00000 100.000000, 20  9  4, 62.04906 1.000000, 5,1,Emilsson | Nakashima | Safren | Solanto 2011 | 2021 | 2004 | 2010,Ostinelli,10.1016/S2215-0366(24)00360-2 Cognitive Behavioral Therapy (CBT),tau NA Kiddie SADS | CAARS-Ob-IN | ADHD-RS total | ADHD-SRS total,NA RCT NA TAU | Relaxation therapy | Psychological placebo NA High,39.1739024390244 43.1064102564103,NA,NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Depressive disorder symptoms | Generalized anxiety | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Executive functioning (tests) | Quality of life (patients) | Emotional dysregulation,Ding (2018) | Liu (2022) | Lopez (2018) | Ostinelli (2025) 10.3,43.15,NA NA NA NA NA,NA,2-6 months NA,NA NANA,>= 18 yo,Homogeneous Cognitive Behavioral Therapy (CBT)_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks)_>= 18 yo,Ostinelli (2025) - Cognitive Behavioral Therapy (CBT)_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks)_>= 18 yo,Cognitive Behavioral Therapy (CBT)_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks)_>= 18 yo - [Homogeneous],2025 Cognitive Behavioral Therapy (CBT)_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks) 145 TRUE,Ostinelli (2025)_Cognitive Behavioral Therapy (CBT)_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks),Ostinelli (2025)_Cognitive Behavioral Therapy (CBT)_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks),100.00000
Ostinelli (2025),Cognitive Behavioral Therapy (CBT) Combined ADHD symptoms (inattentive + hyperactive/impulsive) Self-rated,At follow-up (closest to 26 weeks), 413 19.648223,19.648223,19.648223,19.648223,35.865217,36.942090 39.158810 43.052459  999  21.307506,123.24213, 59.920097,29.700944,NA  2.27703866,NA,100.00000   0.00000 100.00000,100, 88.861985, 88.861985  88.86199, 88.86199, 88.861985  88.86199, 88.861985  20, 9, 4 123.24213 1.000000  5 1,Anastopoulos | Dittner | Nakashima | Nasri | Safren 2021 | 2018 | 2022 | 2010 Ostinelli,10.1016/S2215-0366(24)00360-2 Cognitive Behavioral Therapy (CBT) tau NA CAARS-S:L | Adult Barkley CSS | CAARS-S | ASRS | Current Symptoms Scale- self report NA RCT,NA,WLC | TAU | Relaxation therapy,NA,High 19.6482233502538,43.0524590163934 NA NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Depressive disorder symptoms | Generalized anxiety | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Executive functioning (tests) | Quality of life (patients) | Emotional dysregulation,Ding (2018) | Liu (2022) | Lopez (2018) | Ostinelli (2025) 10.3,43.15 NA NA,NA NA,NA NA 2-6 months NA NA,NANA >= 18 yo Homogeneous Cognitive Behavioral Therapy (CBT)_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Self-rated_At follow-up (closest to 26 weeks)_>= 18 yo,Ostinelli (2025) - Cognitive Behavioral Therapy (CBT)_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Self-rated_At follow-up (closest to 26 weeks)_>= 18 yo Cognitive Behavioral Therapy (CBT)_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Self-rated_At follow-up (closest to 26 weeks)_>= 18 yo - [Homogeneous],2025,Cognitive Behavioral Therapy (CBT)_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Self-rated_At follow-up (closest to 26 weeks) 146,TRUE Ostinelli (2025)_Cognitive Behavioral Therapy (CBT)_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Self-rated_At follow-up (closest to 26 weeks),Ostinelli (2025)_Cognitive Behavioral Therapy (CBT)_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Self-rated_At follow-up (closest to 26 weeks),100.00000
Ostinelli (2025) Cognitive Behavioral Therapy (CBT),Combined ADHD symptoms (inattentive + hyperactive/impulsive),Self-rated,At follow-up (closest to 52 weeks)  109 35.854545 35.854545 35.854545 35.854545,43.058462 43.058462,43.058462 43.058462  999, 40.366972, 56.52294, 37.723853 40.150459,NA  3.45224396 NA 100.00000   0.00000,100.00000 100, 59.633028, 59.633028  59.63303  59.63303  59.633028, 59.63303, 59.633028, 20, 9, 4  56.52294 1.000000  2 1 Dittner | Safren 2018 | 2010 Ostinelli 10.1016/S2215-0366(24)00360-2,Cognitive Behavioral Therapy (CBT) tau,NA Adult Barkley CSS | Current Symptoms Scale- self report,NA,RCT,NA,TAU | Relaxation therapy NA,High,35.8545454545455,43.0584615384615 NA,NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Depressive disorder symptoms | Generalized anxiety | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Executive functioning (tests) | Quality of life (patients) | Emotional dysregulation Ding (2018) | Liu (2022) | Lopez (2018) | Ostinelli (2025) 10.3,43.15 NA NA NA NA NA,NA,2-6 months NA NA,NANA >= 18 yo,Homogeneous Cognitive Behavioral Therapy (CBT)_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Self-rated_At follow-up (closest to 52 weeks)_>= 18 yo,Ostinelli (2025) - Cognitive Behavioral Therapy (CBT)_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Self-rated_At follow-up (closest to 52 weeks)_>= 18 yo Cognitive Behavioral Therapy (CBT)_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Self-rated_At follow-up (closest to 52 weeks)_>= 18 yo - [Homogeneous],2025,Cognitive Behavioral Therapy (CBT)_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Self-rated_At follow-up (closest to 52 weeks),147 TRUE Ostinelli (2025)_Cognitive Behavioral Therapy (CBT)_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Self-rated_At follow-up (closest to 52 weeks) Ostinelli (2025)_Cognitive Behavioral Therapy (CBT)_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Self-rated_At follow-up (closest to 52 weeks) 100.00000
Ostinelli (2025) Cognitive Behavioral Therapy (CBT) Combined ADHD symptoms (inattentive + hyperactive/impulsive),Self-rated,At study endpoint (closest to 12 weeks)  607 19.650455,19.650455,19.650455 19.650455,36.942090,37.080000 39.173902 43.102778, 999, 12.520593 115.55354  60.260536 30.880166 NA, 2.48235488,NA  89.12685   0.00000,100.00000 100  87.479407, 87.479407  87.47941, 87.47941  87.479407  87.47941, 87.479407  20  9, 4 115.55354 1.000000  9,1 Anastopoulos | Emilsson | Nakashima | Nasri | Pettersson | Safren | Schoenenberg | Virta,2021 | 2011 | 2022 | 2014 | 2004 | 2010 | 2017 Ostinelli,10.1016/S2215-0366(24)00360-2,Cognitive Behavioral Therapy (CBT) tau NA,CAARS-S:L | Other | CAARS-S | ASRS | Current Symptoms Scale- self report | BADDS-adults NA,RCT,NA,WLC | TAU | Relaxation therapy | Sham | No treatment,NA High,19.6504545454545 43.1027777777778,NA NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Depressive disorder symptoms | Generalized anxiety | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Executive functioning (tests) | Quality of life (patients) | Emotional dysregulation Ding (2018) | Liu (2022) | Lopez (2018) | Ostinelli (2025),10.3,43.15,NA,NA,NA NA,NA,NA 2-6 months,NA,NA,NANA,>= 18 yo Homogeneous,Cognitive Behavioral Therapy (CBT)_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Self-rated_At study endpoint (closest to 12 weeks)_>= 18 yo Ostinelli (2025) - Cognitive Behavioral Therapy (CBT)_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Self-rated_At study endpoint (closest to 12 weeks)_>= 18 yo,Cognitive Behavioral Therapy (CBT)_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Self-rated_At study endpoint (closest to 12 weeks)_>= 18 yo - [Homogeneous],2025,Cognitive Behavioral Therapy (CBT)_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Self-rated_At study endpoint (closest to 12 weeks),148 TRUE Ostinelli (2025)_Cognitive Behavioral Therapy (CBT)_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Self-rated_At study endpoint (closest to 12 weeks),Ostinelli (2025)_Cognitive Behavioral Therapy (CBT)_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Self-rated_At study endpoint (closest to 12 weeks),100.00000
Ostinelli (2025) Cognitive Behavioral Therapy (CBT),Emotional dysregulation,Mixed,At follow-up (closest to 26 weeks),  54 36.968889,36.968889,36.968889 36.968889,36.968889,36.968889,36.968889 36.968889  999,  0.000000  54.00000  61.222222,36.968889 NA  2.76179517,NA,100.00000,  0.00000 100.00000,100 100.000000,100.000000,100.00000 100.00000 100.000000 100.00000,100.000000, 20  9  4  54.00000,1.000000, 1 1 Nasri,2022,Ostinelli 10.1016/S2215-0366(24)00360-2 Cognitive Behavioral Therapy (CBT),NA NA DERS NA RCT,NA,WLC NA High,36.9688888888889,36.9688888888889,NA,NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Depressive disorder symptoms | Generalized anxiety | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Executive functioning (tests) | Quality of life (patients) | Emotional dysregulation,Ding (2018) | Liu (2022) | Lopez (2018) | Ostinelli (2025),10.3,43.15 NA NA,NA NA,NA NA 2-6 months,NA,NA NANA >= 18 yo,Homogeneous Cognitive Behavioral Therapy (CBT)_Emotional dysregulation_Mixed_At follow-up (closest to 26 weeks)_>= 18 yo Ostinelli (2025) - Cognitive Behavioral Therapy (CBT)_Emotional dysregulation_Mixed_At follow-up (closest to 26 weeks)_>= 18 yo,Cognitive Behavioral Therapy (CBT)_Emotional dysregulation_Mixed_At follow-up (closest to 26 weeks)_>= 18 yo - [Homogeneous],2025,Cognitive Behavioral Therapy (CBT)_Emotional dysregulation_Mixed_At follow-up (closest to 26 weeks),149,TRUE Ostinelli (2025)_Cognitive Behavioral Therapy (CBT)_Emotional dysregulation_Mixed_At follow-up (closest to 26 weeks),Ostinelli (2025)_Cognitive Behavioral Therapy (CBT)_Emotional dysregulation_Mixed_At follow-up (closest to 26 weeks),100.00000
Ostinelli (2025),Cognitive Behavioral Therapy (CBT) Emotional dysregulation Mixed,At study endpoint (closest to 12 weeks),  57 36.964211,36.964211,36.964211,36.964211,36.964211,36.964211 36.964211,36.964211, 999,  0.000000  57.00000  61.368421 36.964211 NA, 2.76179517,NA,100.00000   0.00000 100.00000 100 100.000000,100.000000,100.00000 100.00000,100.000000,100.00000 100.000000  20, 9  4, 57.00000,1.000000, 1,1 Nasri 2022 Ostinelli,10.1016/S2215-0366(24)00360-2,Cognitive Behavioral Therapy (CBT),NA NA DERS NA RCT,NA,WLC NA High,36.9642105263158,36.9642105263158,NA,NA Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Depressive disorder symptoms | Generalized anxiety | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Executive functioning (tests) | Quality of life (patients) | Emotional dysregulation,Ding (2018) | Liu (2022) | Lopez (2018) | Ostinelli (2025) 10.3,43.15,NA,NA,NA,NA,NA,NA,2-6 months NA NA,NANA,>= 18 yo Homogeneous Cognitive Behavioral Therapy (CBT)_Emotional dysregulation_Mixed_At study endpoint (closest to 12 weeks)_>= 18 yo,Ostinelli (2025) - Cognitive Behavioral Therapy (CBT)_Emotional dysregulation_Mixed_At study endpoint (closest to 12 weeks)_>= 18 yo,Cognitive Behavioral Therapy (CBT)_Emotional dysregulation_Mixed_At study endpoint (closest to 12 weeks)_>= 18 yo - [Homogeneous] 2025,Cognitive Behavioral Therapy (CBT)_Emotional dysregulation_Mixed_At study endpoint (closest to 12 weeks),150 TRUE,Ostinelli (2025)_Cognitive Behavioral Therapy (CBT)_Emotional dysregulation_Mixed_At study endpoint (closest to 12 weeks) Ostinelli (2025)_Cognitive Behavioral Therapy (CBT)_Emotional dysregulation_Mixed_At study endpoint (closest to 12 weeks),100.00000
Ostinelli (2025),Cognitive Behavioral Therapy (CBT) Executive functioning (tests),Mixed At study endpoint (closest to 12 weeks),  76,36.945000,36.945000 36.945000,36.945000,36.945000 36.945000,36.945000 36.945000  999,  0.000000  76.00000, 40.500000 36.945000 NA  3.45224396,NA,100.00000   0.00000,100.00000 100   0.000000   0.000000,  0.00000   0.00000   0.000000   0.00000,  0.000000, 20, 9, 4, 76.00000,1.000000  1,1,Schoenenberg,2017 Ostinelli,10.1016/S2215-0366(24)00360-2,Cognitive Behavioral Therapy (CBT) NA,NA CPT reaction time NA,RCT NA,Sham NA High,36.945 36.945 NA,NA Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Depressive disorder symptoms | Generalized anxiety | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Executive functioning (tests) | Quality of life (patients) | Emotional dysregulation Ding (2018) | Liu (2022) | Lopez (2018) | Ostinelli (2025) 10.3,43.15 NA,NA,NA NA NA NA 2-6 months,NA NA,NANA,>= 18 yo,Homogeneous,Cognitive Behavioral Therapy (CBT)_Executive functioning (tests)_Mixed_At study endpoint (closest to 12 weeks)_>= 18 yo,Ostinelli (2025) - Cognitive Behavioral Therapy (CBT)_Executive functioning (tests)_Mixed_At study endpoint (closest to 12 weeks)_>= 18 yo Cognitive Behavioral Therapy (CBT)_Executive functioning (tests)_Mixed_At study endpoint (closest to 12 weeks)_>= 18 yo - [Homogeneous],2025,Cognitive Behavioral Therapy (CBT)_Executive functioning (tests)_Mixed_At study endpoint (closest to 12 weeks) 151,TRUE Ostinelli (2025)_Cognitive Behavioral Therapy (CBT)_Executive functioning (tests)_Mixed_At study endpoint (closest to 12 weeks),Ostinelli (2025)_Cognitive Behavioral Therapy (CBT)_Executive functioning (tests)_Mixed_At study endpoint (closest to 12 weeks) 100.00000
Ostinelli (2025) Cognitive Behavioral Therapy (CBT) Quality of life (patients) Mixed At follow-up (closest to 26 weeks)   54 36.968889 36.968889 36.968889 36.968889,36.968889 36.968889 36.968889,36.968889  999   0.000000, 54.00000  61.222222 36.968889 NA  2.76179517 NA 100.00000   0.00000,100.00000,100 100.000000 100.000000,100.00000 100.00000,100.000000 100.00000,100.000000  20  9, 4  54.00000 1.000000  1,1 Nasri 2022,Ostinelli,10.1016/S2215-0366(24)00360-2,Cognitive Behavioral Therapy (CBT) NA,NA AAQoL NA,RCT NA,WLC,NA,High 36.9688888888889,36.9688888888889,NA NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Depressive disorder symptoms | Generalized anxiety | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Executive functioning (tests) | Quality of life (patients) | Emotional dysregulation,Ding (2018) | Liu (2022) | Lopez (2018) | Ostinelli (2025),10.3,43.15,NA NA,NA NA NA NA 2-6 months,NA,NA,NANA,>= 18 yo Homogeneous Cognitive Behavioral Therapy (CBT)_Quality of life (patients)_Mixed_At follow-up (closest to 26 weeks)_>= 18 yo Ostinelli (2025) - Cognitive Behavioral Therapy (CBT)_Quality of life (patients)_Mixed_At follow-up (closest to 26 weeks)_>= 18 yo Cognitive Behavioral Therapy (CBT)_Quality of life (patients)_Mixed_At follow-up (closest to 26 weeks)_>= 18 yo - [Homogeneous],2025,Cognitive Behavioral Therapy (CBT)_Quality of life (patients)_Mixed_At follow-up (closest to 26 weeks),152 TRUE,Ostinelli (2025)_Cognitive Behavioral Therapy (CBT)_Quality of life (patients)_Mixed_At follow-up (closest to 26 weeks),Ostinelli (2025)_Cognitive Behavioral Therapy (CBT)_Quality of life (patients)_Mixed_At follow-up (closest to 26 weeks) 100.00000
Ostinelli (2025) Cognitive Behavioral Therapy (CBT),Quality of life (patients),Mixed,At study endpoint (closest to 12 weeks)   77,36.100000 36.100000,36.100000 36.100000 36.964211,36.964211,36.964211 36.964211  999,  0.000000  47.38961  62.311688,36.739740,NA  2.76179517 NA,100.00000   0.00000 100.00000 100,100.000000,100.000000 100.00000,100.00000 100.000000,100.00000,100.000000  20, 9, 4  47.38961,1.000000  2,1 Nasri | Virta 2022 | 2010,Ostinelli 10.1016/S2215-0366(24)00360-2 Cognitive Behavioral Therapy (CBT) NA NA AAQoL | Q-LES-Q NA RCT NA,WLC | No treatment,NA High,36.1,36.9642105263158,NA,NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Depressive disorder symptoms | Generalized anxiety | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Executive functioning (tests) | Quality of life (patients) | Emotional dysregulation Ding (2018) | Liu (2022) | Lopez (2018) | Ostinelli (2025) 10.3 43.15,NA NA NA NA,NA NA,2-6 months,NA,NA NANA,>= 18 yo Homogeneous Cognitive Behavioral Therapy (CBT)_Quality of life (patients)_Mixed_At study endpoint (closest to 12 weeks)_>= 18 yo,Ostinelli (2025) - Cognitive Behavioral Therapy (CBT)_Quality of life (patients)_Mixed_At study endpoint (closest to 12 weeks)_>= 18 yo Cognitive Behavioral Therapy (CBT)_Quality of life (patients)_Mixed_At study endpoint (closest to 12 weeks)_>= 18 yo - [Homogeneous] 2025,Cognitive Behavioral Therapy (CBT)_Quality of life (patients)_Mixed_At study endpoint (closest to 12 weeks) 153 TRUE Ostinelli (2025)_Cognitive Behavioral Therapy (CBT)_Quality of life (patients)_Mixed_At study endpoint (closest to 12 weeks),Ostinelli (2025)_Cognitive Behavioral Therapy (CBT)_Quality of life (patients)_Mixed_At study endpoint (closest to 12 weeks) 100.00000
Ostinelli (2025),Cognitive Behavioral Therapy (CBT) Tolerability (discontinuation due to adverse events),NA,At study endpoint (closest to 12 weeks)  184 36.942090,36.942090,36.942090 36.942090,43.150000,43.150000 43.150000 43.150000, 999   0.000000, 69.81522  52.020915 40.431503 NA  3.20083054 NA, 83.15217,  0.00000 100.00000,100 100.000000 100.000000,100.00000 100.00000 100.000000 100.00000,100.000000  20  9  4, 69.81522 1.000000, 3,1 Nasri | Safren 2022 | 2004 | 2010 Ostinelli,10.1016/S2215-0366(24)00360-2 Cognitive Behavioral Therapy (CBT),NA,NA,Tolerability,NA RCT,NA WLC | TAU | Relaxation therapy NA,High,36.9420895522388,43.15 NA,NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Depressive disorder symptoms | Generalized anxiety | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Executive functioning (tests) | Quality of life (patients) | Emotional dysregulation,Ding (2018) | Liu (2022) | Lopez (2018) | Ostinelli (2025) 10.3,43.15 NA,NA NA,NA NA,NA 2-6 months NA,NA NANA,>= 18 yo,Homogeneous Cognitive Behavioral Therapy (CBT)_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks)_>= 18 yo,Ostinelli (2025) - Cognitive Behavioral Therapy (CBT)_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks)_>= 18 yo Cognitive Behavioral Therapy (CBT)_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks)_>= 18 yo - [Homogeneous] 2025,Cognitive Behavioral Therapy (CBT)_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks),154,TRUE Ostinelli (2025)_Cognitive Behavioral Therapy (CBT)_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks) Ostinelli (2025)_Cognitive Behavioral Therapy (CBT)_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks) 100.00000
Ostinelli (2025),Cognitive training Acceptability: all-cause discontinuation,NA,At study endpoint (closest to 12 weeks), 189,25.705882 25.705882 25.705882 25.705882,35.875000 37.305333 37.305333 37.305333  999,  0.000000  67.51852  53.067725,31.755661,NA  2.34046310 NA,100.00000   0.00000 100.00000 100  55.026455, 55.026455, 55.02646  55.02646, 55.026455  55.02646, 55.026455  28, 6, 4, 67.51852 1.000000  3,1 NCT02489279 | Stern | Stevenson,2019 | 2014 | 2002 Ostinelli,10.1016/S2215-0366(24)00360-2 Cognitive training NA NA,Acceptability NA RCT,NA,Cognitive placebo | WLC,NA High 25.7058823529412,37.3053333333333 NA NA Academic/job performance | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (report) | Executive functioning (tests) | Acceptability: all-cause discontinuation | Quality of life (patients),Westwood - Children (2024) | Westwood - Adults (2024) | Ostinelli (2025) | Catala-Lopez (2017),6.55,41.5895454545455,NA,NA,NA NA NA,NA,2-6 months NA NA,NANA >= 18 yo,Homogeneous,Cognitive training_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_>= 18 yo,Ostinelli (2025) - Cognitive training_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_>= 18 yo Cognitive training_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_>= 18 yo - [Homogeneous],2025 Cognitive training_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks),155,TRUE,Ostinelli (2025)_Cognitive training_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks) Ostinelli (2025)_Cognitive training_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks),100.00000
Ostinelli (2025) Cognitive training Combined ADHD symptoms (inattentive + hyperactive/impulsive) Clinician-rated At study endpoint (closest to 12 weeks)   43 35.862791,35.862791,35.862791 35.862791 35.862791 35.862791 35.862791 35.862791  999,  0.000000, 43.00000, 36.441860,35.862791 NA, 1.84119678 NA,100.00000   0.00000,100.00000 100 100.000000,100.000000,100.00000 100.00000,100.000000 100.00000 100.000000, 28  6  4, 43.00000 1.000000, 1,1 Stevenson,2002,Ostinelli 10.1016/S2215-0366(24)00360-2 Cognitive training,NA,NA,DSM-IIIR symptom checklist NA RCT,NA WLC NA,High,35.8627906976744,35.8627906976744,NA,NA,Academic/job performance | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (report) | Executive functioning (tests) | Acceptability: all-cause discontinuation | Quality of life (patients) Westwood - Children (2024) | Westwood - Adults (2024) | Ostinelli (2025) | Catala-Lopez (2017),6.55 41.5895454545455,NA,NA,NA,NA,NA,NA,< 2 months,NA,NA NANA >= 18 yo Homogeneous,Cognitive training_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks)_>= 18 yo Ostinelli (2025) - Cognitive training_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks)_>= 18 yo,Cognitive training_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks)_>= 18 yo - [Homogeneous],2025,Cognitive training_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks),156,TRUE,Ostinelli (2025)_Cognitive training_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks),Ostinelli (2025)_Cognitive training_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks) 100.00000
Ostinelli (2025),Cognitive training Combined ADHD symptoms (inattentive + hyperactive/impulsive) Self-rated,At study endpoint (closest to 12 weeks), 160 25.793103,25.793103 25.793103 25.793103 37.463333 41.589545 41.589545,41.589545, 999,  0.000000, 44.88750, 56.796250,33.843813,NA  2.15189873 NA 100.00000   0.00000 100.00000,100 100.000000 100.000000 100.00000 100.00000,100.000000 100.00000,100.000000  28  6  4  44.88750,1.000000, 4 1,Dentz | NCT02489279 | Stern | Virta,2017 | 2019 | 2014 | 2010,Ostinelli 10.1016/S2215-0366(24)00360-2,Cognitive training,NA NA CAARS hyperactivity | ASRS | BADDS-adults NA,RCT NA,Cognitive placebo | No treatment NA High,25.7931034482759,41.5895454545455,NA,NA,Academic/job performance | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (report) | Executive functioning (tests) | Acceptability: all-cause discontinuation | Quality of life (patients),Westwood - Children (2024) | Westwood - Adults (2024) | Ostinelli (2025) | Catala-Lopez (2017),6.55,41.5895454545455,NA,NA,NA NA NA,NA,2-6 months,NA NA,NANA,>= 18 yo Homogeneous,Cognitive training_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Self-rated_At study endpoint (closest to 12 weeks)_>= 18 yo,Ostinelli (2025) - Cognitive training_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Self-rated_At study endpoint (closest to 12 weeks)_>= 18 yo,Cognitive training_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Self-rated_At study endpoint (closest to 12 weeks)_>= 18 yo - [Homogeneous],2025 Cognitive training_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Self-rated_At study endpoint (closest to 12 weeks),157,TRUE,Ostinelli (2025)_Cognitive training_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Self-rated_At study endpoint (closest to 12 weeks),Ostinelli (2025)_Cognitive training_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Self-rated_At study endpoint (closest to 12 weeks) 100.00000
Ostinelli (2025),Cognitive training Executive functioning (tests) Mixed At study endpoint (closest to 12 weeks)   59,25.771186 25.771186 25.771186 25.771186,25.771186,25.771186,25.771186 25.771186  999,  0.000000  59.00000  58.323729,25.771186,NA  2.30149597,NA,100.00000   0.00000,100.00000,100 100.000000,100.000000,100.00000,100.00000 100.000000 100.00000 100.000000  28  6  4  59.00000,1.000000, 1 1,NCT02489279,2019 Ostinelli,10.1016/S2215-0366(24)00360-2,Cognitive training,NA,NA,CPT reaction time variability,NA RCT,NA,Cognitive placebo NA,High 25.771186440678 25.771186440678,NA,NA Academic/job performance | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (report) | Executive functioning (tests) | Acceptability: all-cause discontinuation | Quality of life (patients) Westwood - Children (2024) | Westwood - Adults (2024) | Ostinelli (2025) | Catala-Lopez (2017),6.55,41.5895454545455,NA,NA NA NA NA,NA 2-6 months,NA NA,NANA,>= 18 yo Homogeneous,Cognitive training_Executive functioning (tests)_Mixed_At study endpoint (closest to 12 weeks)_>= 18 yo,Ostinelli (2025) - Cognitive training_Executive functioning (tests)_Mixed_At study endpoint (closest to 12 weeks)_>= 18 yo,Cognitive training_Executive functioning (tests)_Mixed_At study endpoint (closest to 12 weeks)_>= 18 yo - [Homogeneous] 2025,Cognitive training_Executive functioning (tests)_Mixed_At study endpoint (closest to 12 weeks),158 TRUE,Ostinelli (2025)_Cognitive training_Executive functioning (tests)_Mixed_At study endpoint (closest to 12 weeks) Ostinelli (2025)_Cognitive training_Executive functioning (tests)_Mixed_At study endpoint (closest to 12 weeks) 100.00000
Ostinelli (2025) Cognitive training Quality of life (patients),Mixed,At study endpoint (closest to 12 weeks)   58 33.052632 33.052632 33.052632 33.052632,37.463333,37.463333 37.463333,37.463333  999,  0.000000  32.44828, 52.017241,36.018448 NA, 2.76179517 NA,100.00000   0.00000,100.00000 100,100.000000,100.000000,100.00000,100.00000,100.000000 100.00000,100.000000, 28, 6  4, 32.44828,1.000000  2 1 Stern | Virta,2014 | 2010 Ostinelli 10.1016/S2215-0366(24)00360-2,Cognitive training NA NA AAQoL | Q-LES-Q,NA RCT NA Cognitive placebo | No treatment,NA High,33.0526315789474 37.4633333333333 NA,NA,Academic/job performance | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (report) | Executive functioning (tests) | Acceptability: all-cause discontinuation | Quality of life (patients) Westwood - Children (2024) | Westwood - Adults (2024) | Ostinelli (2025) | Catala-Lopez (2017) 6.55,41.5895454545455,NA,NA,NA NA NA NA 2-6 months NA NA,NANA >= 18 yo,Homogeneous,Cognitive training_Quality of life (patients)_Mixed_At study endpoint (closest to 12 weeks)_>= 18 yo Ostinelli (2025) - Cognitive training_Quality of life (patients)_Mixed_At study endpoint (closest to 12 weeks)_>= 18 yo Cognitive training_Quality of life (patients)_Mixed_At study endpoint (closest to 12 weeks)_>= 18 yo - [Homogeneous] 2025,Cognitive training_Quality of life (patients)_Mixed_At study endpoint (closest to 12 weeks),159 TRUE,Ostinelli (2025)_Cognitive training_Quality of life (patients)_Mixed_At study endpoint (closest to 12 weeks),Ostinelli (2025)_Cognitive training_Quality of life (patients)_Mixed_At study endpoint (closest to 12 weeks) 100.00000
Ostinelli (2025),Dialectical Behavioral Therapy (DBT),Acceptability: all-cause discontinuation,NA At study endpoint (closest to 12 weeks)  368,35.253241 35.253241,35.253241 35.253241 35.253241,37.004132,37.004132 37.004132  999  67.119565 169.17935, 52.224036,35.881899 NA  8.31665583,NA, 91.57609   0.00000 100.00000 100 100.000000 100.000000,100.00000,100.00000,100.000000 100.00000,100.000000   3, 5, 1,169.17935 1.000000  3 1 Halmoy | Moritz | Philipsen 2022 | 2020 | 2015,Ostinelli 10.1016/S2215-0366(24)00360-2,Dialectical Behavioral Therapy (DBT),tau | placebo NA,Acceptability,NA,RCT NA,WLC | TAU | Placebo,NA,High 35.2532407407407,37.004132231405 NA,NA Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Quality of life (patients) | Emotional dysregulation | Tolerability (discontinuation due to adverse events),Ostinelli (2025),35.2532407407407,37.004132231405,NA,NA NA NA,NA,NA,7-12 months,NA NA,NANA >= 18 yo,Homogeneous Dialectical Behavioral Therapy (DBT)_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_>= 18 yo Ostinelli (2025) - Dialectical Behavioral Therapy (DBT)_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_>= 18 yo Dialectical Behavioral Therapy (DBT)_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_>= 18 yo - [Homogeneous],2025,Dialectical Behavioral Therapy (DBT)_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks) 160 TRUE Ostinelli (2025)_Dialectical Behavioral Therapy (DBT)_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks),Ostinelli (2025)_Dialectical Behavioral Therapy (DBT)_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks) 100.00000
Ostinelli (2025) Dialectical Behavioral Therapy (DBT),Combined ADHD symptoms (inattentive + hyperactive/impulsive) Clinician-rated At follow-up (closest to 26 weeks)  137,35.283212,35.283212 35.283212 35.283212,35.283212 35.283212 35.283212 35.283212, 999,100.000000,137.00000  49.656204,35.283212,NA,11.96777906 NA,100.00000   0.00000,100.00000,100 100.000000 100.000000 100.00000 100.00000,100.000000 100.00000,100.000000   3, 5  1 137.00000 1.000000, 1 1 Philipsen,2015 Ostinelli 10.1016/S2215-0366(24)00360-2,Dialectical Behavioral Therapy (DBT),placebo,NA CAARS-O:L NA,RCT NA Placebo,NA,High,35.2832116788321 35.2832116788321,NA,NA Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Quality of life (patients) | Emotional dysregulation | Tolerability (discontinuation due to adverse events),Ostinelli (2025) 35.2532407407407,37.004132231405 NA NA,NA NA,NA NA,7-12 months NA NA,NANA >= 18 yo,Homogeneous,Dialectical Behavioral Therapy (DBT)_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At follow-up (closest to 26 weeks)_>= 18 yo Ostinelli (2025) - Dialectical Behavioral Therapy (DBT)_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At follow-up (closest to 26 weeks)_>= 18 yo Dialectical Behavioral Therapy (DBT)_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At follow-up (closest to 26 weeks)_>= 18 yo - [Homogeneous] 2025,Dialectical Behavioral Therapy (DBT)_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At follow-up (closest to 26 weeks) 161,TRUE Ostinelli (2025)_Dialectical Behavioral Therapy (DBT)_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At follow-up (closest to 26 weeks) Ostinelli (2025)_Dialectical Behavioral Therapy (DBT)_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At follow-up (closest to 26 weeks),100.00000
Ostinelli (2025),Dialectical Behavioral Therapy (DBT) Combined ADHD symptoms (inattentive + hyperactive/impulsive),Clinician-rated At follow-up (closest to 52 weeks), 104,35.297115 35.297115,35.297115,35.297115,35.297115,35.297115,35.297115 35.297115, 999 100.000000,104.00000  49.491346,35.297115,NA 11.96777906 NA,100.00000   0.00000,100.00000,100,100.000000,100.000000,100.00000,100.00000 100.000000 100.00000 100.000000   3  5  1,104.00000 1.000000  1,1 Philipsen,2015,Ostinelli 10.1016/S2215-0366(24)00360-2 Dialectical Behavioral Therapy (DBT) placebo,NA,CAARS-O:L,NA,RCT NA Placebo,NA High 35.2971153846154,35.2971153846154 NA NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Quality of life (patients) | Emotional dysregulation | Tolerability (discontinuation due to adverse events),Ostinelli (2025) 35.2532407407407,37.004132231405 NA NA,NA,NA NA NA 7-12 months NA NA,NANA >= 18 yo,Homogeneous Dialectical Behavioral Therapy (DBT)_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At follow-up (closest to 52 weeks)_>= 18 yo,Ostinelli (2025) - Dialectical Behavioral Therapy (DBT)_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At follow-up (closest to 52 weeks)_>= 18 yo,Dialectical Behavioral Therapy (DBT)_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At follow-up (closest to 52 weeks)_>= 18 yo - [Homogeneous] 2025,Dialectical Behavioral Therapy (DBT)_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At follow-up (closest to 52 weeks) 162,TRUE,Ostinelli (2025)_Dialectical Behavioral Therapy (DBT)_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At follow-up (closest to 52 weeks),Ostinelli (2025)_Dialectical Behavioral Therapy (DBT)_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At follow-up (closest to 52 weeks) 100.00000
Ostinelli (2025) Dialectical Behavioral Therapy (DBT) Combined ADHD symptoms (inattentive + hyperactive/impulsive),Clinician-rated At study endpoint (closest to 12 weeks), 166 35.262651,35.262651 35.262651 35.262651,35.262651,35.262651,35.262651,35.262651  999,100.000000 166.00000  49.900000 35.262651,NA,11.96777906 NA,100.00000,  0.00000,100.00000,100,100.000000,100.000000 100.00000,100.00000,100.000000,100.00000,100.000000   3  5, 1,166.00000,1.000000  1,1 Philipsen,2015 Ostinelli,10.1016/S2215-0366(24)00360-2 Dialectical Behavioral Therapy (DBT) placebo,NA CAARS-O:L,NA,RCT,NA Placebo NA,High 35.2626506024096 35.2626506024096 NA,NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Quality of life (patients) | Emotional dysregulation | Tolerability (discontinuation due to adverse events) Ostinelli (2025) 35.2532407407407 37.004132231405 NA NA,NA NA NA,NA 7-12 months NA NA,NANA >= 18 yo Homogeneous,Dialectical Behavioral Therapy (DBT)_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks)_>= 18 yo Ostinelli (2025) - Dialectical Behavioral Therapy (DBT)_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks)_>= 18 yo Dialectical Behavioral Therapy (DBT)_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks)_>= 18 yo - [Homogeneous],2025 Dialectical Behavioral Therapy (DBT)_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks),163,TRUE,Ostinelli (2025)_Dialectical Behavioral Therapy (DBT)_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks) Ostinelli (2025)_Dialectical Behavioral Therapy (DBT)_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks) 100.00000
Ostinelli (2025) Dialectical Behavioral Therapy (DBT),Combined ADHD symptoms (inattentive + hyperactive/impulsive) Self-rated At follow-up (closest to 26 weeks)  127,35.280315,35.280315 35.280315 35.280315,35.280315 35.280315,35.280315,35.280315, 999,100.000000,127.00000  49.690551,35.280315 NA 11.96777906 NA 100.00000,  0.00000 100.00000 100 100.000000,100.000000 100.00000 100.00000,100.000000,100.00000,100.000000,  3, 5  1 127.00000,1.000000, 1 1 Philipsen,2015,Ostinelli,10.1016/S2215-0366(24)00360-2 Dialectical Behavioral Therapy (DBT),placebo NA,CAARS-S:L NA RCT NA,Placebo,NA High 35.2803149606299,35.2803149606299,NA,NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Quality of life (patients) | Emotional dysregulation | Tolerability (discontinuation due to adverse events) Ostinelli (2025),35.2532407407407 37.004132231405 NA,NA NA,NA,NA,NA 7-12 months,NA,NA,NANA,>= 18 yo,Homogeneous,Dialectical Behavioral Therapy (DBT)_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Self-rated_At follow-up (closest to 26 weeks)_>= 18 yo,Ostinelli (2025) - Dialectical Behavioral Therapy (DBT)_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Self-rated_At follow-up (closest to 26 weeks)_>= 18 yo Dialectical Behavioral Therapy (DBT)_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Self-rated_At follow-up (closest to 26 weeks)_>= 18 yo - [Homogeneous],2025 Dialectical Behavioral Therapy (DBT)_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Self-rated_At follow-up (closest to 26 weeks) 164,TRUE Ostinelli (2025)_Dialectical Behavioral Therapy (DBT)_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Self-rated_At follow-up (closest to 26 weeks),Ostinelli (2025)_Dialectical Behavioral Therapy (DBT)_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Self-rated_At follow-up (closest to 26 weeks) 100.00000
Ostinelli (2025),Dialectical Behavioral Therapy (DBT) Combined ADHD symptoms (inattentive + hyperactive/impulsive),Self-rated,At follow-up (closest to 52 weeks)   99 35.295960,35.295960 35.295960 35.295960 35.295960 35.295960,35.295960 35.295960, 999 100.000000  99.00000, 49.505051 35.295960 NA 11.96777906 NA,100.00000,  0.00000,100.00000 100 100.000000,100.000000 100.00000,100.00000 100.000000 100.00000 100.000000,  3  5  1  99.00000 1.000000  1,1,Philipsen 2015,Ostinelli,10.1016/S2215-0366(24)00360-2 Dialectical Behavioral Therapy (DBT) placebo,NA,CAARS-S:L,NA RCT,NA,Placebo NA,High,35.2959595959596 35.2959595959596,NA,NA Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Quality of life (patients) | Emotional dysregulation | Tolerability (discontinuation due to adverse events) Ostinelli (2025),35.2532407407407,37.004132231405,NA NA NA,NA,NA NA 7-12 months,NA NA NANA,>= 18 yo,Homogeneous,Dialectical Behavioral Therapy (DBT)_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Self-rated_At follow-up (closest to 52 weeks)_>= 18 yo Ostinelli (2025) - Dialectical Behavioral Therapy (DBT)_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Self-rated_At follow-up (closest to 52 weeks)_>= 18 yo Dialectical Behavioral Therapy (DBT)_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Self-rated_At follow-up (closest to 52 weeks)_>= 18 yo - [Homogeneous] 2025,Dialectical Behavioral Therapy (DBT)_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Self-rated_At follow-up (closest to 52 weeks),165 TRUE,Ostinelli (2025)_Dialectical Behavioral Therapy (DBT)_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Self-rated_At follow-up (closest to 52 weeks) Ostinelli (2025)_Dialectical Behavioral Therapy (DBT)_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Self-rated_At follow-up (closest to 52 weeks),100.00000
Ostinelli (2025),Dialectical Behavioral Therapy (DBT) Combined ADHD symptoms (inattentive + hyperactive/impulsive),Self-rated At study endpoint (closest to 12 weeks), 286 35.260736 35.260736 35.260736,35.260736,35.260736,36.989583 36.989583 36.989583  999, 66.433566,127.67133, 52.208880 35.901544 NA, 8.16306823,NA  90.55944   0.00000 100.00000 100 100.000000 100.000000,100.00000 100.00000 100.000000 100.00000 100.000000,  3  5  1 127.67133 1.000000  3 1 Halmoy | Moritz | Philipsen 2022 | 2020 | 2015 Ostinelli 10.1016/S2215-0366(24)00360-2 Dialectical Behavioral Therapy (DBT) tau | placebo NA,ASRS | CAARS-S:L,NA,RCT NA WLC | TAU | Placebo,NA High 35.260736196319,36.9895833333333 NA,NA Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Quality of life (patients) | Emotional dysregulation | Tolerability (discontinuation due to adverse events),Ostinelli (2025) 35.2532407407407 37.004132231405,NA,NA NA,NA NA NA 7-12 months,NA,NA,NANA >= 18 yo,Homogeneous,Dialectical Behavioral Therapy (DBT)_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Self-rated_At study endpoint (closest to 12 weeks)_>= 18 yo Ostinelli (2025) - Dialectical Behavioral Therapy (DBT)_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Self-rated_At study endpoint (closest to 12 weeks)_>= 18 yo,Dialectical Behavioral Therapy (DBT)_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Self-rated_At study endpoint (closest to 12 weeks)_>= 18 yo - [Homogeneous],2025,Dialectical Behavioral Therapy (DBT)_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Self-rated_At study endpoint (closest to 12 weeks) 166,TRUE,Ostinelli (2025)_Dialectical Behavioral Therapy (DBT)_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Self-rated_At study endpoint (closest to 12 weeks),Ostinelli (2025)_Dialectical Behavioral Therapy (DBT)_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Self-rated_At study endpoint (closest to 12 weeks) 100.00000
Ostinelli (2025) Dialectical Behavioral Therapy (DBT),Emotional dysregulation Mixed,At follow-up (closest to 26 weeks)  127 35.280315,35.280315 35.280315 35.280315 35.280315 35.280315 35.280315 35.280315, 999 100.000000 127.00000, 49.690551,35.280315,NA,11.96777906 NA 100.00000,  0.00000,100.00000 100 100.000000 100.000000,100.00000,100.00000 100.000000,100.00000 100.000000   3, 5  1,127.00000 1.000000  1 1,Philipsen 2015,Ostinelli 10.1016/S2215-0366(24)00360-2 Dialectical Behavioral Therapy (DBT) placebo NA CAARS impulsivity/emotional lability,NA,RCT,NA Placebo NA High,35.2803149606299,35.2803149606299,NA NA Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Quality of life (patients) | Emotional dysregulation | Tolerability (discontinuation due to adverse events) Ostinelli (2025) 35.2532407407407,37.004132231405,NA NA NA,NA,NA NA,7-12 months NA,NA NANA,>= 18 yo Homogeneous Dialectical Behavioral Therapy (DBT)_Emotional dysregulation_Mixed_At follow-up (closest to 26 weeks)_>= 18 yo,Ostinelli (2025) - Dialectical Behavioral Therapy (DBT)_Emotional dysregulation_Mixed_At follow-up (closest to 26 weeks)_>= 18 yo,Dialectical Behavioral Therapy (DBT)_Emotional dysregulation_Mixed_At follow-up (closest to 26 weeks)_>= 18 yo - [Homogeneous] 2025,Dialectical Behavioral Therapy (DBT)_Emotional dysregulation_Mixed_At follow-up (closest to 26 weeks),167,TRUE Ostinelli (2025)_Dialectical Behavioral Therapy (DBT)_Emotional dysregulation_Mixed_At follow-up (closest to 26 weeks),Ostinelli (2025)_Dialectical Behavioral Therapy (DBT)_Emotional dysregulation_Mixed_At follow-up (closest to 26 weeks),100.00000
Ostinelli (2025),Dialectical Behavioral Therapy (DBT) Emotional dysregulation Mixed At follow-up (closest to 52 weeks)   99,35.295960 35.295960,35.295960 35.295960 35.295960 35.295960,35.295960,35.295960, 999 100.000000  99.00000, 49.505051 35.295960 NA,11.96777906,NA 100.00000,  0.00000,100.00000,100,100.000000,100.000000 100.00000 100.00000,100.000000 100.00000 100.000000   3, 5  1, 99.00000 1.000000, 1 1 Philipsen 2015,Ostinelli,10.1016/S2215-0366(24)00360-2 Dialectical Behavioral Therapy (DBT),placebo,NA,CAARS impulsivity/emotional lability NA RCT NA Placebo,NA High,35.2959595959596 35.2959595959596,NA,NA Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Quality of life (patients) | Emotional dysregulation | Tolerability (discontinuation due to adverse events) Ostinelli (2025),35.2532407407407 37.004132231405 NA NA,NA NA NA,NA 7-12 months NA NA NANA,>= 18 yo Homogeneous,Dialectical Behavioral Therapy (DBT)_Emotional dysregulation_Mixed_At follow-up (closest to 52 weeks)_>= 18 yo Ostinelli (2025) - Dialectical Behavioral Therapy (DBT)_Emotional dysregulation_Mixed_At follow-up (closest to 52 weeks)_>= 18 yo,Dialectical Behavioral Therapy (DBT)_Emotional dysregulation_Mixed_At follow-up (closest to 52 weeks)_>= 18 yo - [Homogeneous] 2025 Dialectical Behavioral Therapy (DBT)_Emotional dysregulation_Mixed_At follow-up (closest to 52 weeks) 168,TRUE,Ostinelli (2025)_Dialectical Behavioral Therapy (DBT)_Emotional dysregulation_Mixed_At follow-up (closest to 52 weeks) Ostinelli (2025)_Dialectical Behavioral Therapy (DBT)_Emotional dysregulation_Mixed_At follow-up (closest to 52 weeks) 100.00000
Ostinelli (2025),Dialectical Behavioral Therapy (DBT),Emotional dysregulation Mixed,At study endpoint (closest to 12 weeks)  163 35.260736,35.260736,35.260736 35.260736 35.260736,35.260736 35.260736,35.260736  999,100.000000 163.00000  49.922699,35.260736,NA,11.96777906,NA,100.00000,  0.00000 100.00000 100 100.000000 100.000000 100.00000 100.00000,100.000000,100.00000 100.000000   3  5  1,163.00000,1.000000, 1 1,Philipsen,2015 Ostinelli,10.1016/S2215-0366(24)00360-2,Dialectical Behavioral Therapy (DBT) placebo NA,CAARS impulsivity/emotional lability NA,RCT,NA,Placebo NA High 35.260736196319 35.260736196319 NA,NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Quality of life (patients) | Emotional dysregulation | Tolerability (discontinuation due to adverse events) Ostinelli (2025),35.2532407407407,37.004132231405,NA,NA,NA,NA,NA NA,7-12 months,NA NA,NANA >= 18 yo,Homogeneous,Dialectical Behavioral Therapy (DBT)_Emotional dysregulation_Mixed_At study endpoint (closest to 12 weeks)_>= 18 yo Ostinelli (2025) - Dialectical Behavioral Therapy (DBT)_Emotional dysregulation_Mixed_At study endpoint (closest to 12 weeks)_>= 18 yo Dialectical Behavioral Therapy (DBT)_Emotional dysregulation_Mixed_At study endpoint (closest to 12 weeks)_>= 18 yo - [Homogeneous],2025 Dialectical Behavioral Therapy (DBT)_Emotional dysregulation_Mixed_At study endpoint (closest to 12 weeks) 169,TRUE Ostinelli (2025)_Dialectical Behavioral Therapy (DBT)_Emotional dysregulation_Mixed_At study endpoint (closest to 12 weeks) Ostinelli (2025)_Dialectical Behavioral Therapy (DBT)_Emotional dysregulation_Mixed_At study endpoint (closest to 12 weeks),100.00000
Ostinelli (2025) Dialectical Behavioral Therapy (DBT) Quality of life (patients),Mixed,At study endpoint (closest to 12 weeks),  96 36.989583,36.989583,36.989583,36.989583,36.989583 36.989583,36.989583 36.989583, 999,  0.000000, 96.00000, 56.090625 36.989583 NA, 3.22209436 NA,100.00000,  0.00000,100.00000 100 100.000000 100.000000 100.00000,100.00000 100.000000 100.00000 100.000000,  3, 5  1  96.00000 1.000000  1,1,Halmoy,2022 Ostinelli 10.1016/S2215-0366(24)00360-2 Dialectical Behavioral Therapy (DBT) NA NA,AAQoL,NA RCT,NA WLC NA High,36.9895833333333 36.9895833333333,NA NA Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Quality of life (patients) | Emotional dysregulation | Tolerability (discontinuation due to adverse events),Ostinelli (2025) 35.2532407407407,37.004132231405,NA NA,NA NA NA NA 2-6 months NA NA,NANA >= 18 yo Homogeneous,Dialectical Behavioral Therapy (DBT)_Quality of life (patients)_Mixed_At study endpoint (closest to 12 weeks)_>= 18 yo Ostinelli (2025) - Dialectical Behavioral Therapy (DBT)_Quality of life (patients)_Mixed_At study endpoint (closest to 12 weeks)_>= 18 yo,Dialectical Behavioral Therapy (DBT)_Quality of life (patients)_Mixed_At study endpoint (closest to 12 weeks)_>= 18 yo - [Homogeneous],2025 Dialectical Behavioral Therapy (DBT)_Quality of life (patients)_Mixed_At study endpoint (closest to 12 weeks) 170 TRUE,Ostinelli (2025)_Dialectical Behavioral Therapy (DBT)_Quality of life (patients)_Mixed_At study endpoint (closest to 12 weeks),Ostinelli (2025)_Dialectical Behavioral Therapy (DBT)_Quality of life (patients)_Mixed_At study endpoint (closest to 12 weeks) 100.00000
Ostinelli (2025) Dialectical Behavioral Therapy (DBT) Tolerability (discontinuation due to adverse events),NA,At study endpoint (closest to 12 weeks), 216,35.253241,35.253241 35.253241 35.253241,35.253241,35.253241,35.253241 35.253241  999 100.000000,216.00000  50.011574,35.253241,NA,11.96777906 NA,100.00000,  0.00000,100.00000,100 100.000000 100.000000,100.00000 100.00000 100.000000,100.00000,100.000000   3, 5  1 216.00000 1.000000, 1 1,Philipsen 2015 Ostinelli,10.1016/S2215-0366(24)00360-2,Dialectical Behavioral Therapy (DBT) placebo NA,Tolerability,NA,RCT NA Placebo,NA,High,35.2532407407407,35.2532407407407 NA,NA Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Quality of life (patients) | Emotional dysregulation | Tolerability (discontinuation due to adverse events),Ostinelli (2025) 35.2532407407407,37.004132231405 NA NA NA,NA,NA NA,7-12 months,NA,NA NANA >= 18 yo,Homogeneous,Dialectical Behavioral Therapy (DBT)_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks)_>= 18 yo Ostinelli (2025) - Dialectical Behavioral Therapy (DBT)_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks)_>= 18 yo Dialectical Behavioral Therapy (DBT)_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks)_>= 18 yo - [Homogeneous],2025 Dialectical Behavioral Therapy (DBT)_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks),171 TRUE Ostinelli (2025)_Dialectical Behavioral Therapy (DBT)_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks) Ostinelli (2025)_Dialectical Behavioral Therapy (DBT)_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks),100.00000
Ostinelli (2025) Goal Management Training (GMT) Acceptability: all-cause discontinuation NA At study endpoint (closest to 12 weeks)   81 31.298765 31.298765,31.298765 31.298765 31.298765,31.298765 31.298765,31.298765, 999 100.000000  81.00000  58.034568,31.298765,NA  1.84119678,NA 100.00000,  0.00000,100.00000 100 100.000000,100.000000,100.00000 100.00000 100.000000,100.00000,100.000000   1  1  1, 81.00000 1.000000  1 1 Hanssen 2023,Ostinelli,10.1016/S2215-0366(24)00360-2 Goal Management Training (GMT),tau NA Acceptability,NA,RCT,NA TAU,NA,High 31.2987654320988 31.2987654320988 NA NA Acceptability: all-cause discontinuation Ostinelli (2025) 31.2987654320988,31.2987654320988 NA NA,NA,NA,NA,NA < 2 months NA NA,NANA >= 18 yo Homogeneous Goal Management Training (GMT)_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_>= 18 yo Ostinelli (2025) - Goal Management Training (GMT)_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_>= 18 yo,Goal Management Training (GMT)_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_>= 18 yo - [Homogeneous] 2025 Goal Management Training (GMT)_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks) 172,TRUE Ostinelli (2025)_Goal Management Training (GMT)_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks),Ostinelli (2025)_Goal Management Training (GMT)_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks) 100.00000
Ostinelli (2025),Hypnotherapy Combined ADHD symptoms (inattentive + hyperactive/impulsive),Self-rated,At study endpoint (closest to 12 weeks)   18,34.000000 34.000000 34.000000,34.000000,34.000000,34.000000 34.000000 34.000000  999,  0.000000, 18.00000, 60.000000,34.000000 NA  2.76179517 NA,100.00000   0.00000,100.00000,100,100.000000,100.000000,100.00000,100.00000 100.000000,100.00000 100.000000   1  2  1  18.00000 1.000000, 1 1 Virta,2010,Ostinelli 10.1016/S2215-0366(24)00360-2 Hypnotherapy,NA,NA BADDS-adults,NA,RCT NA No treatment,NA,High 34,34 NA,NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients),Ostinelli (2025) 34 34 NA NA,NA,NA,NA NA 2-6 months NA,NA NANA >= 18 yo,Homogeneous,Hypnotherapy_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Self-rated_At study endpoint (closest to 12 weeks)_>= 18 yo,Ostinelli (2025) - Hypnotherapy_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Self-rated_At study endpoint (closest to 12 weeks)_>= 18 yo Hypnotherapy_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Self-rated_At study endpoint (closest to 12 weeks)_>= 18 yo - [Homogeneous] 2025,Hypnotherapy_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Self-rated_At study endpoint (closest to 12 weeks),173,TRUE,Ostinelli (2025)_Hypnotherapy_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Self-rated_At study endpoint (closest to 12 weeks) Ostinelli (2025)_Hypnotherapy_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Self-rated_At study endpoint (closest to 12 weeks) 100.00000
Ostinelli (2025),Hypnotherapy Quality of life (patients),Mixed At study endpoint (closest to 12 weeks)   18,34.000000 34.000000,34.000000 34.000000 34.000000,34.000000 34.000000 34.000000, 999   0.000000, 18.00000  60.000000,34.000000,NA  2.76179517 NA 100.00000,  0.00000 100.00000 100,100.000000 100.000000 100.00000 100.00000,100.000000,100.00000 100.000000   1, 2  1, 18.00000,1.000000  1,1,Virta,2010,Ostinelli 10.1016/S2215-0366(24)00360-2 Hypnotherapy NA NA,Q-LES-Q,NA,RCT NA,No treatment,NA,High 34 34 NA NA Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients),Ostinelli (2025),34 34,NA NA NA,NA,NA,NA,2-6 months NA NA NANA >= 18 yo Homogeneous Hypnotherapy_Quality of life (patients)_Mixed_At study endpoint (closest to 12 weeks)_>= 18 yo,Ostinelli (2025) - Hypnotherapy_Quality of life (patients)_Mixed_At study endpoint (closest to 12 weeks)_>= 18 yo,Hypnotherapy_Quality of life (patients)_Mixed_At study endpoint (closest to 12 weeks)_>= 18 yo - [Homogeneous] 2025 Hypnotherapy_Quality of life (patients)_Mixed_At study endpoint (closest to 12 weeks) 174,TRUE,Ostinelli (2025)_Hypnotherapy_Quality of life (patients)_Mixed_At study endpoint (closest to 12 weeks) Ostinelli (2025)_Hypnotherapy_Quality of life (patients)_Mixed_At study endpoint (closest to 12 weeks),100.00000
Ostinelli (2025),Methylphenidate,Acceptability: all-cause discontinuation,NA,At study endpoint (closest to 12 weeks) 3925,33.747535 34.739833 34.739833,35.254839 35.695699,36.900000,37.798824,38.100000  999,  0.000000,343.86879  44.984270 35.848841 NA  2.68662274   51.903412 100.00000   0.00000,100.00000 100 100.000000,100.000000 100.00000,100.00000 100.000000,100.00000 100.000000 141 14 11 343.86879,1.000000 20 1,Adler | Biehl | Bron | Casas | Ginsberg | Goodman | Huss | Konstenius | Kooij | Levin | Philipsen | Rosler | Schrantee | Spencer | Takahashi | Weisler | Weiss | Wender | Winhusen,2009 | 2016 | 2014 | 2013 | 2012 | 2010 | 2004 | 2007 | 2015 | 1995 | 2020 | 2011 Ostinelli 10.1016/S2215-0366(24)00360-2,Methylphenidate NA,NA Acceptability NA RCT NA,Placebo | Active [Placebo + skill training] | Active [Placebo + cbt] mg/d High 28.7959183673469,40 NA NA,Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events),Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018),4.42,50.1 60,109.9 NA, 99.5875,97.45,105.60 2-6 months,NA NA,51.9mg/d >= 18 yo Homogeneous Methylphenidate_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_>= 18 yo Ostinelli (2025) - Methylphenidate_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_>= 18 yo,Methylphenidate_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_>= 18 yo - [Homogeneous] 2025,Methylphenidate_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks) 175,TRUE Ostinelli (2025)_Methylphenidate_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks) Ostinelli (2025)_Methylphenidate_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks),100.00000
Ostinelli (2025) Methylphenidate,Combined ADHD symptoms (inattentive + hyperactive/impulsive),Clinician-rated At follow-up (closest to 26 weeks)  506,34.739833,34.739833 34.739833,34.739833,34.739833,35.304762 35.304762,35.304762, 999   0.000000,297.41107, 50.665810 34.903953,NA  7.39571631,  41.200000,100.00000,  0.00000,100.00000,100,100.000000 100.000000,100.00000,100.00000, 29.051383 100.00000 100.000000 141,14 11,297.41107,1.000000, 2 1 Philipsen | Rosler,2015 | 2009 Ostinelli 10.1016/S2215-0366(24)00360-2 Methylphenidate NA NA,CAARS-O:L | Other,NA,RCT,NA Placebo,mg/d High 34.7398328690808 35.3047619047619,NA,NA Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events),Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018),4.42 50.1 60,109.9 NA, 99.5875 97.45 105.60,7-12 months,NA NA,41.2mg/d >= 18 yo,Homogeneous Methylphenidate_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At follow-up (closest to 26 weeks)_>= 18 yo,Ostinelli (2025) - Methylphenidate_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At follow-up (closest to 26 weeks)_>= 18 yo Methylphenidate_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At follow-up (closest to 26 weeks)_>= 18 yo - [Homogeneous],2025,Methylphenidate_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At follow-up (closest to 26 weeks),176 TRUE Ostinelli (2025)_Methylphenidate_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At follow-up (closest to 26 weeks) Ostinelli (2025)_Methylphenidate_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At follow-up (closest to 26 weeks) 100.00000
Ostinelli (2025) Methylphenidate Combined ADHD symptoms (inattentive + hyperactive/impulsive),Clinician-rated,At follow-up (closest to 52 weeks), 115 35.326087 35.326087 35.326087 35.326087 35.326087,35.326087,35.326087 35.326087, 999   0.000000 115.00000, 52.191304 35.326087 NA,11.96777906 NA,100.00000,  0.00000,100.00000 100,100.000000 100.000000 100.00000 100.00000,100.000000,100.00000 100.000000,141,14,11 115.00000,1.000000, 1,1 Philipsen,2015,Ostinelli 10.1016/S2215-0366(24)00360-2,Methylphenidate NA,NA CAARS-O:L,NA RCT NA,Placebo NA High 35.3260869565217 35.3260869565217,NA,NA Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events),Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018) 4.42,50.1,60,109.9 NA  99.5875 97.45,105.60 7-12 months NA NA NANA >= 18 yo,Homogeneous,Methylphenidate_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At follow-up (closest to 52 weeks)_>= 18 yo,Ostinelli (2025) - Methylphenidate_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At follow-up (closest to 52 weeks)_>= 18 yo Methylphenidate_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At follow-up (closest to 52 weeks)_>= 18 yo - [Homogeneous],2025,Methylphenidate_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At follow-up (closest to 52 weeks) 177,TRUE,Ostinelli (2025)_Methylphenidate_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At follow-up (closest to 52 weeks),Ostinelli (2025)_Methylphenidate_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At follow-up (closest to 52 weeks) 100.00000
Ostinelli (2025),Methylphenidate Combined ADHD symptoms (inattentive + hyperactive/impulsive) Clinician-rated At study endpoint (closest to 12 weeks) 3680,33.746290,34.044670 34.044670,34.400000,35.695699 36.053600 37.798605 38.434483  999   0.000000 319.48315  45.447011,35.665555,NA, 2.11856457,  40.776708  96.16848,  0.00000 100.00000 100 100.000000,100.000000 100.00000 100.00000, 89.429348,100.00000 100.000000,141,14 11 319.48315,1.000000,18 1 Adler | Biederman | Casas | Ginsberg | Goodman | Herring | Huss | Konstenius | Medori | Philipsen | Reimherr | Spencer | Takahashi | Weisler | Weiss | Wender | Winhusen 2009 | 2006 | 2013 | 2012 | 2016 | 2014 | 2010 | 2008 | 2015 | 2007 | 1995 | 2005 | 2020 | 2011,Ostinelli,10.1016/S2215-0366(24)00360-2 Methylphenidate,NA,NA,Other | CAARS-O:S | ADHD-SRS total | CAARS-O:L | ADHD-RS total,NA,RCT,NA Placebo | Active [Placebo + skill training] mg/d | mg/kg/d,High 30.6 40,NA NA,Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events) Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018),4.42 50.1,60 109.9 NA, 99.5875 97.45,105.60,2-6 months NA,NA,40.78mg/d | mg/kg/d >= 18 yo Homogeneous,Methylphenidate_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks)_>= 18 yo Ostinelli (2025) - Methylphenidate_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks)_>= 18 yo Methylphenidate_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks)_>= 18 yo - [Homogeneous] 2025,Methylphenidate_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks) 178 TRUE Ostinelli (2025)_Methylphenidate_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks) Ostinelli (2025)_Methylphenidate_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks),100.00000
Ostinelli (2025),Methylphenidate,Combined ADHD symptoms (inattentive + hyperactive/impulsive),Self-rated,At follow-up (closest to 26 weeks), 498 34.737255 34.737255 34.737255 34.737255,34.737255,35.312057 35.312057 35.312057  999,  0.000000,295.84337  50.639157 34.900000 NA  7.34814979   41.200000 100.00000   0.00000,100.00000 100 100.000000 100.000000,100.00000 100.00000, 28.313253 100.00000,100.000000 141,14 11 295.84337,1.000000, 2 1 Philipsen | Rosler,2015 | 2009,Ostinelli 10.1016/S2215-0366(24)00360-2,Methylphenidate,NA,NA CAARS-S:L NA,RCT NA,Placebo,mg/d,High 34.7372549019608,35.3120567375887,NA NA,Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events) Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018) 4.42 50.1 60 109.9 NA, 99.5875,97.45 105.60,7-12 months,NA NA,41.2mg/d >= 18 yo,Homogeneous Methylphenidate_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Self-rated_At follow-up (closest to 26 weeks)_>= 18 yo,Ostinelli (2025) - Methylphenidate_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Self-rated_At follow-up (closest to 26 weeks)_>= 18 yo Methylphenidate_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Self-rated_At follow-up (closest to 26 weeks)_>= 18 yo - [Homogeneous],2025 Methylphenidate_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Self-rated_At follow-up (closest to 26 weeks),179,TRUE Ostinelli (2025)_Methylphenidate_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Self-rated_At follow-up (closest to 26 weeks),Ostinelli (2025)_Methylphenidate_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Self-rated_At follow-up (closest to 26 weeks),100.00000
Ostinelli (2025) Methylphenidate Combined ADHD symptoms (inattentive + hyperactive/impulsive) Self-rated,At follow-up (closest to 52 weeks)  108,35.321296,35.321296 35.321296,35.321296 35.321296 35.321296,35.321296,35.321296  999   0.000000,108.00000, 52.213889,35.321296,NA 11.96777906,NA 100.00000,  0.00000,100.00000,100 100.000000 100.000000,100.00000,100.00000,100.000000,100.00000,100.000000 141,14 11 108.00000 1.000000, 1 1 Philipsen,2015,Ostinelli 10.1016/S2215-0366(24)00360-2,Methylphenidate,NA NA,CAARS-S:L,NA,RCT NA,Placebo NA High,35.3212962962963 35.3212962962963 NA,NA,Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events),Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018) 4.42 50.1 60,109.9,NA, 99.5875 97.45,105.60 7-12 months NA,NA NANA >= 18 yo Homogeneous Methylphenidate_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Self-rated_At follow-up (closest to 52 weeks)_>= 18 yo Ostinelli (2025) - Methylphenidate_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Self-rated_At follow-up (closest to 52 weeks)_>= 18 yo Methylphenidate_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Self-rated_At follow-up (closest to 52 weeks)_>= 18 yo - [Homogeneous],2025 Methylphenidate_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Self-rated_At follow-up (closest to 52 weeks) 180,TRUE Ostinelli (2025)_Methylphenidate_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Self-rated_At follow-up (closest to 52 weeks) Ostinelli (2025)_Methylphenidate_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Self-rated_At follow-up (closest to 52 weeks),100.00000
Ostinelli (2025) Methylphenidate Combined ADHD symptoms (inattentive + hyperactive/impulsive),Self-rated At study endpoint (closest to 12 weeks) 2944,34.047170 34.047170,34.047170 34.737255 35.363953 35.746847 36.053600,36.053600  999   0.000000,364.25679, 47.755707,35.300951 NA  2.73216653   35.733559,100.00000,  0.00000 100.00000,100 100.000000,100.000000,100.00000  98.36957, 78.396739 100.00000 100.000000,141 14,11 364.25679,1.000000,13 1 Biehl | Casas | Ginsberg | Goodman | Huss | Konstenius | Kooij | Medori | Philipsen | Rosler | Takahashi | Tenenbaum | Weiss 2016 | 2013 | 2012 | 2014 | 2010 | 2004 | 2008 | 2015 | 2009 | 2002 | 2020,Ostinelli,10.1016/S2215-0366(24)00360-2,Methylphenidate,NA,NA,CAARS-S:L | CAARS-S:S | ASRS | Other | BADDS-adults | CAARS-S,NA,RCT NA Placebo | Active [Placebo + skill training] mg/d,High,33.7462897526502 42,NA,NA,Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events) Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018) 4.42 50.1 60 109.9,NA  99.5875,97.45 105.60,2-6 months,NA,NA,35.73mg/d,>= 18 yo Homogeneous,Methylphenidate_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Self-rated_At study endpoint (closest to 12 weeks)_>= 18 yo Ostinelli (2025) - Methylphenidate_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Self-rated_At study endpoint (closest to 12 weeks)_>= 18 yo,Methylphenidate_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Self-rated_At study endpoint (closest to 12 weeks)_>= 18 yo - [Homogeneous],2025 Methylphenidate_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Self-rated_At study endpoint (closest to 12 weeks) 181,TRUE,Ostinelli (2025)_Methylphenidate_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Self-rated_At study endpoint (closest to 12 weeks) Ostinelli (2025)_Methylphenidate_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Self-rated_At study endpoint (closest to 12 weeks),100.00000
Ostinelli (2025) Methylphenidate Emotional dysregulation,Mixed At follow-up (closest to 26 weeks), 141,35.312057 35.312057,35.312057,35.312057,35.312057,35.312057,35.312057,35.312057, 999,  0.000000 141.00000, 52.257447 35.312057 NA 11.96777906 NA,100.00000   0.00000 100.00000,100,100.000000 100.000000,100.00000 100.00000,100.000000,100.00000,100.000000 141 14 11 141.00000 1.000000  1,1 Philipsen 2015 Ostinelli,10.1016/S2215-0366(24)00360-2,Methylphenidate NA NA CAARS impulsivity/emotional lability,NA RCT,NA Placebo,NA,High 35.3120567375887,35.3120567375887,NA NA Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events) Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018),4.42 50.1 60 109.9 NA, 99.5875 97.45 105.60 7-12 months NA,NA,NANA >= 18 yo,Homogeneous Methylphenidate_Emotional dysregulation_Mixed_At follow-up (closest to 26 weeks)_>= 18 yo Ostinelli (2025) - Methylphenidate_Emotional dysregulation_Mixed_At follow-up (closest to 26 weeks)_>= 18 yo,Methylphenidate_Emotional dysregulation_Mixed_At follow-up (closest to 26 weeks)_>= 18 yo - [Homogeneous] 2025 Methylphenidate_Emotional dysregulation_Mixed_At follow-up (closest to 26 weeks) 182 TRUE,Ostinelli (2025)_Methylphenidate_Emotional dysregulation_Mixed_At follow-up (closest to 26 weeks),Ostinelli (2025)_Methylphenidate_Emotional dysregulation_Mixed_At follow-up (closest to 26 weeks) 100.00000
Ostinelli (2025),Methylphenidate Emotional dysregulation Mixed,At follow-up (closest to 52 weeks)  108,35.321296,35.321296 35.321296 35.321296 35.321296 35.321296 35.321296,35.321296, 999   0.000000 108.00000, 52.213889 35.321296 NA 11.96777906,NA 100.00000,  0.00000 100.00000 100,100.000000 100.000000 100.00000 100.00000,100.000000 100.00000 100.000000 141,14 11 108.00000,1.000000, 1,1 Philipsen,2015 Ostinelli,10.1016/S2215-0366(24)00360-2 Methylphenidate,NA NA CAARS impulsivity/emotional lability NA,RCT,NA,Placebo,NA High,35.3212962962963 35.3212962962963 NA NA,Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events) Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018) 4.42,50.1 60,109.9 NA  99.5875 97.45 105.60 7-12 months,NA,NA NANA >= 18 yo Homogeneous,Methylphenidate_Emotional dysregulation_Mixed_At follow-up (closest to 52 weeks)_>= 18 yo,Ostinelli (2025) - Methylphenidate_Emotional dysregulation_Mixed_At follow-up (closest to 52 weeks)_>= 18 yo Methylphenidate_Emotional dysregulation_Mixed_At follow-up (closest to 52 weeks)_>= 18 yo - [Homogeneous],2025 Methylphenidate_Emotional dysregulation_Mixed_At follow-up (closest to 52 weeks) 183,TRUE,Ostinelli (2025)_Methylphenidate_Emotional dysregulation_Mixed_At follow-up (closest to 52 weeks),Ostinelli (2025)_Methylphenidate_Emotional dysregulation_Mixed_At follow-up (closest to 52 weeks),100.00000
Ostinelli (2025) Methylphenidate Emotional dysregulation,Mixed At study endpoint (closest to 12 weeks), 655 34.047170 34.047170 34.047170,34.047170,34.047170,35.274706 36.900000 36.900000, 999,  0.000000,274.10229, 44.307176,34.862290 NA, 3.83805199   10.559732 100.00000   0.00000,100.00000,100,100.000000 100.000000 100.00000,100.00000,100.000000,100.00000,100.000000,141,14 11,274.10229 1.000000  3 1,Medori | Philipsen | Wender 2008 | 2015 | 2011,Ostinelli,10.1016/S2215-0366(24)00360-2,Methylphenidate,NA,NA CAARS impulsivity/emotional lability | WRAADDS NA,RCT NA,Placebo mg/d,High 34.0471698113208 36.9,NA NA Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events),Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018),4.42 50.1 60 109.9,NA  99.5875 97.45 105.60,2-6 months NA,NA,10.56mg/d >= 18 yo Homogeneous Methylphenidate_Emotional dysregulation_Mixed_At study endpoint (closest to 12 weeks)_>= 18 yo Ostinelli (2025) - Methylphenidate_Emotional dysregulation_Mixed_At study endpoint (closest to 12 weeks)_>= 18 yo Methylphenidate_Emotional dysregulation_Mixed_At study endpoint (closest to 12 weeks)_>= 18 yo - [Homogeneous],2025 Methylphenidate_Emotional dysregulation_Mixed_At study endpoint (closest to 12 weeks) 184,TRUE Ostinelli (2025)_Methylphenidate_Emotional dysregulation_Mixed_At study endpoint (closest to 12 weeks),Ostinelli (2025)_Methylphenidate_Emotional dysregulation_Mixed_At study endpoint (closest to 12 weeks),100.00000
Ostinelli (2025),Methylphenidate Executive functioning (tests),Mixed At study endpoint (closest to 12 weeks),  71,30.500000,30.500000,30.500000,30.500000,38.440816,38.440816 38.440816,38.440816  999   0.000000, 40.63380  31.715493,35.980282,NA  0.77797047,  72.000000 100.00000,  0.00000 100.00000 100 100.000000,100.000000,100.00000 100.00000 100.000000,100.00000 100.000000,141 14 11, 40.63380,1.000000, 2,1,Bron | Herring 2014 | 2012 Ostinelli 10.1016/S2215-0366(24)00360-2,Methylphenidate NA NA CPT omission | CPT commission,NA RCT,NA,Placebo,mg/d,High,30.5,38.4408163265306 NA,NA Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events) Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018),4.42 50.1,60 109.9,NA, 99.5875 97.45,105.60 < 2 months,NA NA,72mg/d,>= 18 yo,Homogeneous,Methylphenidate_Executive functioning (tests)_Mixed_At study endpoint (closest to 12 weeks)_>= 18 yo Ostinelli (2025) - Methylphenidate_Executive functioning (tests)_Mixed_At study endpoint (closest to 12 weeks)_>= 18 yo,Methylphenidate_Executive functioning (tests)_Mixed_At study endpoint (closest to 12 weeks)_>= 18 yo - [Homogeneous],2025,Methylphenidate_Executive functioning (tests)_Mixed_At study endpoint (closest to 12 weeks) 185 TRUE,Ostinelli (2025)_Methylphenidate_Executive functioning (tests)_Mixed_At study endpoint (closest to 12 weeks),Ostinelli (2025)_Methylphenidate_Executive functioning (tests)_Mixed_At study endpoint (closest to 12 weeks) 100.00000
Ostinelli (2025),Methylphenidate,Quality of life (patients) Mixed,At study endpoint (closest to 12 weeks), 490,33.747518 33.747518,33.747518,33.747518,33.747518 38.100000,38.100000 38.100000  999   0.000000,250.58776  50.202204 35.595102 NA  1.54810831   51.500000,100.00000   0.00000,100.00000 100 100.000000 100.000000,100.00000,100.00000 100.000000,100.00000 100.000000 141,14 11 250.58776 1.000000, 2,1 Spencer | Takahashi,2007 | 2014 Ostinelli 10.1016/S2215-0366(24)00360-2 Methylphenidate NA,NA,Q-LES-Q NA RCT,NA,Placebo mg/d,High 33.7475177304965 38.1 NA,NA,Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events) Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018),4.42 50.1,60,109.9 NA, 99.5875 97.45 105.60,< 2 months NA,NA,51.5mg/d,>= 18 yo,Homogeneous Methylphenidate_Quality of life (patients)_Mixed_At study endpoint (closest to 12 weeks)_>= 18 yo,Ostinelli (2025) - Methylphenidate_Quality of life (patients)_Mixed_At study endpoint (closest to 12 weeks)_>= 18 yo Methylphenidate_Quality of life (patients)_Mixed_At study endpoint (closest to 12 weeks)_>= 18 yo - [Homogeneous] 2025 Methylphenidate_Quality of life (patients)_Mixed_At study endpoint (closest to 12 weeks) 186 TRUE Ostinelli (2025)_Methylphenidate_Quality of life (patients)_Mixed_At study endpoint (closest to 12 weeks) Ostinelli (2025)_Methylphenidate_Quality of life (patients)_Mixed_At study endpoint (closest to 12 weeks),100.00000
Ostinelli (2025) Methylphenidate Tolerability (discontinuation due to adverse events) NA At study endpoint (closest to 12 weeks) 4389 33.747535 34.043641,34.043641,34.739833 35.374345 36.900000,37.798824,38.100000  999   0.000000 345.74596, 44.992928,35.728047,NA  2.51088019,  40.518070,100.00000,  0.00000,100.00000 100  88.881294, 88.881294, 88.88129, 88.88129, 88.881294  88.88129, 88.881294,141 14,11,345.74596,1.000000 21,1,Adler | Biehl | Bron | Casas | Ginsberg | Goodman | Herring | Huss | Kooij | Levin | Medori | Philipsen | Rosler | Schrantee | Spencer | Takahashi | Weisler | Weiss | Wender | Winhusen,2009 | 2016 | 2014 | 2013 | 2012 | 2004 | 2007 | 2008 | 2015 | 1995 | 2020 | 2011 | 2010 Ostinelli,10.1016/S2215-0366(24)00360-2,Methylphenidate NA NA,Tolerability,NA,RCT NA,Placebo | Active [Placebo + cbt],mg/d High,28.7959183673469 40,NA NA,Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events),Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018),4.42,50.1,60 109.9,NA  99.5875 97.45,105.60 2-6 months NA NA 40.52mg/d,>= 18 yo Homogeneous,Methylphenidate_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks)_>= 18 yo,Ostinelli (2025) - Methylphenidate_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks)_>= 18 yo Methylphenidate_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks)_>= 18 yo - [Homogeneous],2025 Methylphenidate_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks) 187,TRUE Ostinelli (2025)_Methylphenidate_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks),Ostinelli (2025)_Methylphenidate_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks) 100.00000
Ostinelli (2025) Mindfulness Acceptability: all-cause discontinuation,NA,At study endpoint (closest to 12 weeks), 301,20.288929,20.288929 35.894175 35.894175 35.894175 39.350000 39.350000,39.350000, 999  39.867110  95.11296, 52.489701,34.550664,NA, 2.07058176 NA 100.00000,  0.00000,100.00000,100,100.000000,100.000000 100.00000,100.00000 100.000000 100.00000 100.000000, 13  8, 4  95.11296 1.000000  4,1,Gu | Hepark | Janssen | Mitchell,2017 | 2015 | 2018 Ostinelli 10.1016/S2215-0366(24)00360-2,Mindfulness tau,NA Acceptability,NA RCT NA WLC | TAU,NA High,20.2889285714286 39.35 NA NA,Generalized anxiety | Depressive disorder symptoms | Quality of life (patients) | Executive functioning (mixed) | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (tests) | Acceptability: all-cause discontinuation | Emotional dysregulation,Lopez-Pinar (2019) | Liu (2023) | Zhang (2023) | Ostinelli (2025),6.08,39.35 NA,NA NA NA,NA,NA 2-6 months NA NA,NANA >= 18 yo Homogeneous,Mindfulness_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_>= 18 yo Ostinelli (2025) - Mindfulness_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_>= 18 yo,Mindfulness_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_>= 18 yo - [Homogeneous],2025 Mindfulness_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks) 188,TRUE,Ostinelli (2025)_Mindfulness_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks) Ostinelli (2025)_Mindfulness_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks),100.00000
Ostinelli (2025) Mindfulness,Combined ADHD symptoms (inattentive + hyperactive/impulsive) Clinician-rated,At follow-up (closest to 26 weeks)  108 39.337037 39.337037 39.337037,39.337037,39.337037,39.337037,39.337037,39.337037, 999,100.000000,108.00000, 53.000000 39.337037 NA  1.84119678,NA 100.00000,  0.00000 100.00000 100,100.000000 100.000000 100.00000,100.00000,100.000000 100.00000 100.000000, 13  8  4 108.00000 1.000000, 1,1 Janssen 2018 Ostinelli,10.1016/S2215-0366(24)00360-2 Mindfulness tau NA CAARS-INV:SV,NA RCT,NA TAU,NA,High 39.337037037037,39.337037037037,NA,NA,Generalized anxiety | Depressive disorder symptoms | Quality of life (patients) | Executive functioning (mixed) | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (tests) | Acceptability: all-cause discontinuation | Emotional dysregulation Lopez-Pinar (2019) | Liu (2023) | Zhang (2023) | Ostinelli (2025) 6.08,39.35,NA NA NA NA,NA,NA,< 2 months NA,NA,NANA,>= 18 yo Homogeneous Mindfulness_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At follow-up (closest to 26 weeks)_>= 18 yo,Ostinelli (2025) - Mindfulness_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At follow-up (closest to 26 weeks)_>= 18 yo Mindfulness_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At follow-up (closest to 26 weeks)_>= 18 yo - [Homogeneous],2025 Mindfulness_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At follow-up (closest to 26 weeks),189 TRUE Ostinelli (2025)_Mindfulness_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At follow-up (closest to 26 weeks) Ostinelli (2025)_Mindfulness_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At follow-up (closest to 26 weeks) 100.00000
Ostinelli (2025),Mindfulness Combined ADHD symptoms (inattentive + hyperactive/impulsive) Clinician-rated At study endpoint (closest to 12 weeks)  210,35.842169 35.842169 35.842169,35.842169 39.340187,39.340187,39.340187 39.340187, 999, 50.952381  89.22857  54.022857,37.887286,NA, 2.20505233,NA,100.00000,  0.00000,100.00000 100 100.000000,100.000000 100.00000 100.00000,100.000000 100.00000,100.000000, 13, 8  4  89.22857 1.000000  3 1 Hepark | Janssen | Mitchell 2015 | 2018 | 2017 Ostinelli,10.1016/S2215-0366(24)00360-2,Mindfulness tau NA CAARS-O:L | CAARS-INV:SV | Current ADHD Symptom Scale,NA RCT,NA,WLC | TAU NA High 35.8421686746988 39.3401869158878,NA NA,Generalized anxiety | Depressive disorder symptoms | Quality of life (patients) | Executive functioning (mixed) | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (tests) | Acceptability: all-cause discontinuation | Emotional dysregulation Lopez-Pinar (2019) | Liu (2023) | Zhang (2023) | Ostinelli (2025) 6.08,39.35,NA,NA NA NA NA,NA,2-6 months,NA,NA NANA,>= 18 yo,Homogeneous Mindfulness_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks)_>= 18 yo,Ostinelli (2025) - Mindfulness_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks)_>= 18 yo,Mindfulness_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks)_>= 18 yo - [Homogeneous],2025,Mindfulness_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks) 190 TRUE,Ostinelli (2025)_Mindfulness_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks),Ostinelli (2025)_Mindfulness_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks) 100.00000
Ostinelli (2025),Mindfulness Combined ADHD symptoms (inattentive + hyperactive/impulsive) Self-rated At follow-up (closest to 26 weeks)  162 20.291852 20.291852 20.291852 20.291852,39.337037,39.337037 39.337037,39.337037, 999, 66.666667, 90.00000, 50.162963,32.988642,NA, 1.68776371,NA 100.00000,  0.00000 100.00000,100 100.000000 100.000000 100.00000 100.00000,100.000000 100.00000,100.000000, 13, 8  4, 90.00000,1.000000  2 1,Gu | Janssen,2017 | 2018,Ostinelli 10.1016/S2215-0366(24)00360-2,Mindfulness,tau NA,CAARS-S:S,NA,RCT NA,WLC | TAU,NA,High,20.2918518518519 39.337037037037 NA,NA,Generalized anxiety | Depressive disorder symptoms | Quality of life (patients) | Executive functioning (mixed) | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (tests) | Acceptability: all-cause discontinuation | Emotional dysregulation Lopez-Pinar (2019) | Liu (2023) | Zhang (2023) | Ostinelli (2025) 6.08,39.35 NA NA NA,NA,NA NA,< 2 months NA,NA NANA >= 18 yo Homogeneous,Mindfulness_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Self-rated_At follow-up (closest to 26 weeks)_>= 18 yo Ostinelli (2025) - Mindfulness_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Self-rated_At follow-up (closest to 26 weeks)_>= 18 yo Mindfulness_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Self-rated_At follow-up (closest to 26 weeks)_>= 18 yo - [Homogeneous],2025,Mindfulness_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Self-rated_At follow-up (closest to 26 weeks),191,TRUE,Ostinelli (2025)_Mindfulness_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Self-rated_At follow-up (closest to 26 weeks) Ostinelli (2025)_Mindfulness_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Self-rated_At follow-up (closest to 26 weeks),100.00000
Ostinelli (2025),Mindfulness Combined ADHD symptoms (inattentive + hyperactive/impulsive) Self-rated At study endpoint (closest to 12 weeks), 264 20.291852 20.291852,20.291852,35.842169 35.842169 39.340187,39.340187,39.340187  999, 40.530303  82.02273, 52.072727,34.288220 NA  2.03647522,NA 100.00000,  0.00000,100.00000,100 100.000000,100.000000,100.00000,100.00000,100.000000,100.00000,100.000000  13, 8  4  82.02273,1.000000, 4 1 Gu | Hepark | Janssen | Mitchell 2017 | 2015 | 2018 Ostinelli,10.1016/S2215-0366(24)00360-2,Mindfulness tau NA,CAARS-S:L | CAARS-S:S | CASS-L,NA RCT NA WLC | TAU NA High 20.2918518518519 39.3401869158878,NA,NA Generalized anxiety | Depressive disorder symptoms | Quality of life (patients) | Executive functioning (mixed) | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (tests) | Acceptability: all-cause discontinuation | Emotional dysregulation Lopez-Pinar (2019) | Liu (2023) | Zhang (2023) | Ostinelli (2025),6.08 39.35,NA NA NA,NA,NA NA,2-6 months,NA,NA,NANA >= 18 yo Homogeneous Mindfulness_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Self-rated_At study endpoint (closest to 12 weeks)_>= 18 yo,Ostinelli (2025) - Mindfulness_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Self-rated_At study endpoint (closest to 12 weeks)_>= 18 yo,Mindfulness_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Self-rated_At study endpoint (closest to 12 weeks)_>= 18 yo - [Homogeneous],2025,Mindfulness_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Self-rated_At study endpoint (closest to 12 weeks) 192,TRUE,Ostinelli (2025)_Mindfulness_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Self-rated_At study endpoint (closest to 12 weeks) Ostinelli (2025)_Mindfulness_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Self-rated_At study endpoint (closest to 12 weeks),100.00000
Ostinelli (2025),Mindfulness,Emotional dysregulation,Mixed,At study endpoint (closest to 12 weeks)  103,35.842169 35.842169,35.842169,35.842169 35.842169,35.842169 38.601500 38.601500  999   0.000000  70.76699, 55.085437 36.377961 NA, 2.58303820,NA,100.00000,  0.00000 100.00000 100 100.000000 100.000000 100.00000 100.00000 100.000000,100.00000 100.000000, 13, 8  4  70.76699,1.000000, 2 1 Hepark | Mitchell,2015 | 2017,Ostinelli 10.1016/S2215-0366(24)00360-2,Mindfulness,NA NA BRIEF-ASR Emotional control,NA,RCT,NA,WLC NA High,35.8421686746988 38.6015 NA,NA Generalized anxiety | Depressive disorder symptoms | Quality of life (patients) | Executive functioning (mixed) | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (tests) | Acceptability: all-cause discontinuation | Emotional dysregulation Lopez-Pinar (2019) | Liu (2023) | Zhang (2023) | Ostinelli (2025),6.08,39.35,NA,NA,NA,NA NA,NA,2-6 months NA NA NANA >= 18 yo,Homogeneous Mindfulness_Emotional dysregulation_Mixed_At study endpoint (closest to 12 weeks)_>= 18 yo,Ostinelli (2025) - Mindfulness_Emotional dysregulation_Mixed_At study endpoint (closest to 12 weeks)_>= 18 yo Mindfulness_Emotional dysregulation_Mixed_At study endpoint (closest to 12 weeks)_>= 18 yo - [Homogeneous],2025,Mindfulness_Emotional dysregulation_Mixed_At study endpoint (closest to 12 weeks),193,TRUE Ostinelli (2025)_Mindfulness_Emotional dysregulation_Mixed_At study endpoint (closest to 12 weeks) Ostinelli (2025)_Mindfulness_Emotional dysregulation_Mixed_At study endpoint (closest to 12 weeks),100.00000
Ostinelli (2025),Mindfulness Executive functioning (tests) Mixed,At follow-up (closest to 26 weeks), 162,20.291852,20.291852,20.291852,20.291852,39.337037,39.337037,39.337037 39.337037, 999  66.666667, 90.00000, 50.162963,32.988642 NA, 1.68776371,NA 100.00000   0.00000 100.00000,100,100.000000 100.000000 100.00000 100.00000,100.000000,100.00000,100.000000  13  8, 4, 90.00000 1.000000  2,1 Gu | Janssen,2017 | 2018 Ostinelli 10.1016/S2215-0366(24)00360-2 Mindfulness tau NA ANT alerting error score | BRIEF-A Executive function NA,RCT NA,WLC | TAU NA High,20.2918518518519 39.337037037037,NA,NA,Generalized anxiety | Depressive disorder symptoms | Quality of life (patients) | Executive functioning (mixed) | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (tests) | Acceptability: all-cause discontinuation | Emotional dysregulation,Lopez-Pinar (2019) | Liu (2023) | Zhang (2023) | Ostinelli (2025) 6.08,39.35 NA NA NA NA NA,NA,< 2 months,NA NA,NANA >= 18 yo,Homogeneous,Mindfulness_Executive functioning (tests)_Mixed_At follow-up (closest to 26 weeks)_>= 18 yo Ostinelli (2025) - Mindfulness_Executive functioning (tests)_Mixed_At follow-up (closest to 26 weeks)_>= 18 yo,Mindfulness_Executive functioning (tests)_Mixed_At follow-up (closest to 26 weeks)_>= 18 yo - [Homogeneous],2025 Mindfulness_Executive functioning (tests)_Mixed_At follow-up (closest to 26 weeks),194 TRUE,Ostinelli (2025)_Mindfulness_Executive functioning (tests)_Mixed_At follow-up (closest to 26 weeks),Ostinelli (2025)_Mindfulness_Executive functioning (tests)_Mixed_At follow-up (closest to 26 weeks),100.00000
Ostinelli (2025) Mindfulness Executive functioning (tests),Mixed At study endpoint (closest to 12 weeks)   74,20.291852,20.291852 20.291852 20.291852 20.291852,38.601500 38.601500,38.601500, 999,  0.000000, 44.81081, 48.678378,25.240405 NA, 1.50530277,NA,100.00000,  0.00000 100.00000 100,100.000000 100.000000 100.00000,100.00000 100.000000,100.00000,100.000000  13  8  4  44.81081 1.000000, 2,1 Gu | Mitchell 2017 Ostinelli 10.1016/S2215-0366(24)00360-2,Mindfulness,NA,NA,ANT alerting error score | CPT omission,NA,RCT NA WLC NA High 20.2918518518519 38.6015 NA,NA Generalized anxiety | Depressive disorder symptoms | Quality of life (patients) | Executive functioning (mixed) | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (tests) | Acceptability: all-cause discontinuation | Emotional dysregulation,Lopez-Pinar (2019) | Liu (2023) | Zhang (2023) | Ostinelli (2025),6.08 39.35 NA NA NA NA NA,NA < 2 months NA,NA,NANA,>= 18 yo Homogeneous Mindfulness_Executive functioning (tests)_Mixed_At study endpoint (closest to 12 weeks)_>= 18 yo Ostinelli (2025) - Mindfulness_Executive functioning (tests)_Mixed_At study endpoint (closest to 12 weeks)_>= 18 yo Mindfulness_Executive functioning (tests)_Mixed_At study endpoint (closest to 12 weeks)_>= 18 yo - [Homogeneous],2025 Mindfulness_Executive functioning (tests)_Mixed_At study endpoint (closest to 12 weeks),195,TRUE,Ostinelli (2025)_Mindfulness_Executive functioning (tests)_Mixed_At study endpoint (closest to 12 weeks),Ostinelli (2025)_Mindfulness_Executive functioning (tests)_Mixed_At study endpoint (closest to 12 weeks) 100.00000
Ostinelli (2025) Modafinil Combined ADHD symptoms (inattentive + hyperactive/impulsive) Self-rated At study endpoint (closest to 12 weeks)  257 39.129577,39.129577,39.129577,39.129577 39.129577,39.129577 40.800000,40.800000, 999,  0.000000,184.06615, 39.937743 39.415564,NA, 1.79552507, 282.385992,100.00000,  0.00000,100.00000,100 100.000000,100.000000,100.00000 100.00000,100.000000,100.00000 100.000000   8  4, 3,184.06615 1.000000  2,1,Arnold | Taylor 2014 | 2000,Ostinelli,10.1016/S2215-0366(24)00360-2,Modafinil,NA,NA,ASRS | Other,NA RCT NA Placebo,mg/d,High,39.1295774647887 40.8 NA,NA Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) Ostinelli (2025) | Cortese - Adults (2018) | Cortese - Children (2018),7.875,40.8,NA,NA NA NA,NA,NA,< 2 months,NA,NA,282.39mg/d >= 18 yo Homogeneous,Modafinil_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Self-rated_At study endpoint (closest to 12 weeks)_>= 18 yo,Ostinelli (2025) - Modafinil_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Self-rated_At study endpoint (closest to 12 weeks)_>= 18 yo,Modafinil_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Self-rated_At study endpoint (closest to 12 weeks)_>= 18 yo - [Homogeneous],2025,Modafinil_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Self-rated_At study endpoint (closest to 12 weeks),196,TRUE Ostinelli (2025)_Modafinil_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Self-rated_At study endpoint (closest to 12 weeks) Ostinelli (2025)_Modafinil_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Self-rated_At study endpoint (closest to 12 weeks) 100.00000
Ostinelli (2025),Modafinil Quality of life (patients) Mixed At study endpoint (closest to 12 weeks)  131,39.088550 39.088550 39.088550 39.088550,39.088550 39.088550 39.088550,39.088550, 999   0.000000 131.00000  40.282443,39.088550,NA, 2.07134638  298.000000 100.00000,  0.00000 100.00000,100,100.000000,100.000000 100.00000 100.00000 100.000000,100.00000,100.000000   8, 4  3,131.00000 1.000000, 1 1,Arnold 2014 Ostinelli,10.1016/S2215-0366(24)00360-2 Modafinil,NA,NA Q-LES-Q NA,RCT,NA Placebo,mg/d,High,39.0885496183206,39.0885496183206 NA NA Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) Ostinelli (2025) | Cortese - Adults (2018) | Cortese - Children (2018),7.875 40.8,NA,NA NA NA,NA NA,2-6 months,NA,NA 298mg/d,>= 18 yo,Homogeneous,Modafinil_Quality of life (patients)_Mixed_At study endpoint (closest to 12 weeks)_>= 18 yo Ostinelli (2025) - Modafinil_Quality of life (patients)_Mixed_At study endpoint (closest to 12 weeks)_>= 18 yo,Modafinil_Quality of life (patients)_Mixed_At study endpoint (closest to 12 weeks)_>= 18 yo - [Homogeneous] 2025,Modafinil_Quality of life (patients)_Mixed_At study endpoint (closest to 12 weeks),197 TRUE,Ostinelli (2025)_Modafinil_Quality of life (patients)_Mixed_At study endpoint (closest to 12 weeks) Ostinelli (2025)_Modafinil_Quality of life (patients)_Mixed_At study endpoint (closest to 12 weeks),100.00000
Ostinelli (2025),Physical training,Acceptability: all-cause discontinuation NA,At study endpoint (closest to 12 weeks)   60,35.320000 35.320000,35.320000,35.320000,35.320000,35.320000 35.320000 35.320000  999,  0.000000, 60.00000 100.000000 35.320000,NA, 5.52359033 NA,100.00000,  0.00000,100.00000,100,100.000000,100.000000 100.00000,100.00000,100.000000,100.00000,100.000000  22, 4  3  60.00000,1.000000, 1 1,Kouhbanani 2023,Ostinelli 10.1016/S2215-0366(24)00360-2 Physical training,NA NA Acceptability,NA,RCT,NA,WLC,NA High 35.32 35.32 NA NA,Executive functioning (tests) | Acceptability: all-cause discontinuation | Social-communication skills | Combined ADHD symptoms (inattentive + hyperactive/impulsive),Huang (2022) | Seiffer (2022) | Ostinelli (2025),7.7 35.3230769230769 NA NA NA,NA NA NA 2-6 months,NA,NA,NANA,>= 18 yo Homogeneous Physical training_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_>= 18 yo,Ostinelli (2025) - Physical training_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_>= 18 yo Physical training_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_>= 18 yo - [Homogeneous] 2025,Physical training_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks) 198,TRUE,Ostinelli (2025)_Physical training_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks),Ostinelli (2025)_Physical training_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks),100.00000
Ostinelli (2025) Physical training Executive functioning (tests),Mixed At follow-up (closest to 26 weeks)   52,35.323077 35.323077,35.323077 35.323077 35.323077,35.323077 35.323077 35.323077, 999,  0.000000  52.00000 100.000000 35.323077 NA, 5.52359033 NA 100.00000   0.00000,100.00000,100,  0.000000   0.000000   0.00000,  0.00000,  0.000000   0.00000,  0.000000  22, 4, 3, 52.00000 1.000000  1,1 Kouhbanani 2023,Ostinelli 10.1016/S2215-0366(24)00360-2 Physical training,NA NA CPT NA,RCT NA WLC NA,High 35.3230769230769,35.3230769230769 NA,NA Executive functioning (tests) | Acceptability: all-cause discontinuation | Social-communication skills | Combined ADHD symptoms (inattentive + hyperactive/impulsive),Huang (2022) | Seiffer (2022) | Ostinelli (2025),7.7 35.3230769230769 NA,NA,NA NA,NA NA,2-6 months,NA NA,NANA,>= 18 yo Homogeneous Physical training_Executive functioning (tests)_Mixed_At follow-up (closest to 26 weeks)_>= 18 yo Ostinelli (2025) - Physical training_Executive functioning (tests)_Mixed_At follow-up (closest to 26 weeks)_>= 18 yo,Physical training_Executive functioning (tests)_Mixed_At follow-up (closest to 26 weeks)_>= 18 yo - [Homogeneous],2025,Physical training_Executive functioning (tests)_Mixed_At follow-up (closest to 26 weeks) 199,TRUE,Ostinelli (2025)_Physical training_Executive functioning (tests)_Mixed_At follow-up (closest to 26 weeks) Ostinelli (2025)_Physical training_Executive functioning (tests)_Mixed_At follow-up (closest to 26 weeks) 100.00000
Ostinelli (2025),Physical training,Executive functioning (tests),Mixed At follow-up (closest to 52 weeks),  52 35.323077,35.323077 35.323077,35.323077 35.323077,35.323077 35.323077 35.323077  999   0.000000  52.00000,100.000000 35.323077,NA, 5.52359033,NA 100.00000,  0.00000 100.00000 100,  0.000000   0.000000   0.00000   0.00000   0.000000,  0.00000,  0.000000  22  4, 3  52.00000,1.000000  1 1,Kouhbanani 2023,Ostinelli 10.1016/S2215-0366(24)00360-2,Physical training NA,NA,CPT NA,RCT,NA,WLC,NA,High 35.3230769230769,35.3230769230769 NA,NA Executive functioning (tests) | Acceptability: all-cause discontinuation | Social-communication skills | Combined ADHD symptoms (inattentive + hyperactive/impulsive) Huang (2022) | Seiffer (2022) | Ostinelli (2025) 7.7 35.3230769230769 NA NA,NA NA NA,NA 2-6 months,NA,NA,NANA,>= 18 yo Homogeneous Physical training_Executive functioning (tests)_Mixed_At follow-up (closest to 52 weeks)_>= 18 yo,Ostinelli (2025) - Physical training_Executive functioning (tests)_Mixed_At follow-up (closest to 52 weeks)_>= 18 yo,Physical training_Executive functioning (tests)_Mixed_At follow-up (closest to 52 weeks)_>= 18 yo - [Homogeneous],2025 Physical training_Executive functioning (tests)_Mixed_At follow-up (closest to 52 weeks),200,TRUE Ostinelli (2025)_Physical training_Executive functioning (tests)_Mixed_At follow-up (closest to 52 weeks) Ostinelli (2025)_Physical training_Executive functioning (tests)_Mixed_At follow-up (closest to 52 weeks),100.00000
Ostinelli (2025),TMS ([repetitive] transcranial magnetic stimulation),Acceptability: all-cause discontinuation NA,At study endpoint (closest to 12 weeks), 141 27.073333 27.073333 27.073333,27.073333 34.256250,35.079149 35.079149,35.079149  999   0.000000, 36.51429, 48.434161 32.154149,NA, 1.16389939,NA,100.00000,  0.00000 100.00000 100  77.142857, 77.142857  77.14286, 77.14286, 77.142857, 77.14286  77.142857,  4, 5  1, 36.84286 1.328571, 4 1,Alyagon | Bleich-Cohen | NCT03663179 | Paz 2020 | 2021 | 2017 Ostinelli,10.1016/S2215-0366(24)00360-2 TMS ([repetitive] transcranial magnetic stimulation),NA NA Acceptability NA RCT NA,Sham,NA High 27.0733333333333,35.22,NA,NA Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Quality of life (patients) | Executive functioning (tests) Ostinelli (2025) 27.0733333333333,35.24,NA NA,NA NA NA NA < 2 months,NA,NA,NANA,>= 18 yo Homogeneous TMS ([repetitive] transcranial magnetic stimulation)_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_>= 18 yo Ostinelli (2025) - TMS ([repetitive] transcranial magnetic stimulation)_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_>= 18 yo TMS ([repetitive] transcranial magnetic stimulation)_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_>= 18 yo - [Homogeneous] 2025 TMS ([repetitive] transcranial magnetic stimulation)_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks),201,TRUE Ostinelli (2025)_TMS ([repetitive] transcranial magnetic stimulation)_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks),Ostinelli (2025)_TMS ([repetitive] transcranial magnetic stimulation)_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks),100.00000
Ostinelli (2025) TMS ([repetitive] transcranial magnetic stimulation) Combined ADHD symptoms (inattentive + hyperactive/impulsive) Self-rated At study endpoint (closest to 12 weeks), 118,27.112414,27.112414 27.112414,31.361364,34.392593 35.085789 35.085789 35.085789, 999   0.000000, 30.55556, 47.901714,32.249195,NA  1.17041889 NA 100.00000,  0.00000,100.00000,100, 76.923077, 76.923077  76.92308  76.92308, 76.923077  76.92308  76.923077   4  5  1, 30.88889 1.333333, 4,1 Alyagon | Bleich-Cohen | NCT03663179 | Paz,2020 | 2021 | 2017,Ostinelli,10.1016/S2215-0366(24)00360-2,TMS ([repetitive] transcranial magnetic stimulation) NA,NA,CAARS-S:L NA RCT NA Sham,NA High 27.1124137931034,35.24,NA,NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Quality of life (patients) | Executive functioning (tests),Ostinelli (2025) 27.0733333333333,35.24 NA NA,NA NA NA,NA,< 2 months,NA NA NANA,>= 18 yo,Homogeneous TMS ([repetitive] transcranial magnetic stimulation)_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Self-rated_At study endpoint (closest to 12 weeks)_>= 18 yo Ostinelli (2025) - TMS ([repetitive] transcranial magnetic stimulation)_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Self-rated_At study endpoint (closest to 12 weeks)_>= 18 yo TMS ([repetitive] transcranial magnetic stimulation)_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Self-rated_At study endpoint (closest to 12 weeks)_>= 18 yo - [Homogeneous],2025,TMS ([repetitive] transcranial magnetic stimulation)_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Self-rated_At study endpoint (closest to 12 weeks),202,TRUE Ostinelli (2025)_TMS ([repetitive] transcranial magnetic stimulation)_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Self-rated_At study endpoint (closest to 12 weeks),Ostinelli (2025)_TMS ([repetitive] transcranial magnetic stimulation)_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Self-rated_At study endpoint (closest to 12 weeks) 100.00000
Ostinelli (2025),TMS ([repetitive] transcranial magnetic stimulation) Executive functioning (tests),Mixed,At study endpoint (closest to 12 weeks),  22 31.361364 31.361364,31.361364,31.361364 31.361364,31.361364,31.361364 31.361364  999   0.000000, 22.00000  36.413636 31.361364,NA  0.92059839 NA,100.00000,  0.00000,100.00000,100,100.000000 100.000000 100.00000,100.00000 100.000000 100.00000 100.000000,  4  5, 1  22.00000 1.000000  1 1 Paz 2017,Ostinelli 10.1016/S2215-0366(24)00360-2 TMS ([repetitive] transcranial magnetic stimulation) NA,NA TOVA NA RCT,NA,Sham NA High 31.3613636363636 31.3613636363636 NA,NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Quality of life (patients) | Executive functioning (tests) Ostinelli (2025) 27.0733333333333,35.24,NA,NA NA NA NA,NA < 2 months NA NA,NANA >= 18 yo Homogeneous,TMS ([repetitive] transcranial magnetic stimulation)_Executive functioning (tests)_Mixed_At study endpoint (closest to 12 weeks)_>= 18 yo Ostinelli (2025) - TMS ([repetitive] transcranial magnetic stimulation)_Executive functioning (tests)_Mixed_At study endpoint (closest to 12 weeks)_>= 18 yo,TMS ([repetitive] transcranial magnetic stimulation)_Executive functioning (tests)_Mixed_At study endpoint (closest to 12 weeks)_>= 18 yo - [Homogeneous] 2025,TMS ([repetitive] transcranial magnetic stimulation)_Executive functioning (tests)_Mixed_At study endpoint (closest to 12 weeks) 203 TRUE Ostinelli (2025)_TMS ([repetitive] transcranial magnetic stimulation)_Executive functioning (tests)_Mixed_At study endpoint (closest to 12 weeks),Ostinelli (2025)_TMS ([repetitive] transcranial magnetic stimulation)_Executive functioning (tests)_Mixed_At study endpoint (closest to 12 weeks),100.00000
Ostinelli (2025),TMS ([repetitive] transcranial magnetic stimulation) Quality of life (patients) Mixed At study endpoint (closest to 12 weeks)   40 35.085789 35.085789 35.085789,35.085789 35.085789 35.085789 35.085789,35.085789  999   0.000000  39.00000, 38.520526 35.085789 NA, 1.84119678,NA,100.00000,  0.00000,100.00000,100,100.000000,100.000000 100.00000,100.00000 100.000000,100.00000 100.000000,  4  5  1  40.00000 2.000000, 1 1,Bleich-Cohen,2021 Ostinelli,10.1016/S2215-0366(24)00360-2 TMS ([repetitive] transcranial magnetic stimulation) NA,NA,AAQoL,NA RCT,NA Sham,NA High 34.9315789473684 35.24 NA NA Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Quality of life (patients) | Executive functioning (tests) Ostinelli (2025),27.0733333333333 35.24 NA NA,NA NA,NA,NA,< 2 months,NA,NA NANA,>= 18 yo,Homogeneous TMS ([repetitive] transcranial magnetic stimulation)_Quality of life (patients)_Mixed_At study endpoint (closest to 12 weeks)_>= 18 yo Ostinelli (2025) - TMS ([repetitive] transcranial magnetic stimulation)_Quality of life (patients)_Mixed_At study endpoint (closest to 12 weeks)_>= 18 yo TMS ([repetitive] transcranial magnetic stimulation)_Quality of life (patients)_Mixed_At study endpoint (closest to 12 weeks)_>= 18 yo - [Homogeneous],2025,TMS ([repetitive] transcranial magnetic stimulation)_Quality of life (patients)_Mixed_At study endpoint (closest to 12 weeks),204 TRUE,Ostinelli (2025)_TMS ([repetitive] transcranial magnetic stimulation)_Quality of life (patients)_Mixed_At study endpoint (closest to 12 weeks) Ostinelli (2025)_TMS ([repetitive] transcranial magnetic stimulation)_Quality of life (patients)_Mixed_At study endpoint (closest to 12 weeks) 100.00000
Ostinelli (2025) TMS ([repetitive] transcranial magnetic stimulation),Tolerability (discontinuation due to adverse events) NA,At study endpoint (closest to 12 weeks)  115 27.073333,27.073333 27.073333 27.073333,34.256250 35.079149,35.079149,35.079149, 999   0.000000  38.91228, 51.236689 32.320007 NA  1.21938909,NA,100.00000,  0.00000,100.00000 100  71.929825, 71.929825, 71.92982  71.92982  71.929825, 71.92982, 71.929825,  4, 5  1, 39.31579,1.403509, 3,1,Alyagon | Bleich-Cohen | NCT03663179 2020 | 2021 Ostinelli,10.1016/S2215-0366(24)00360-2 TMS ([repetitive] transcranial magnetic stimulation),NA NA,Tolerability NA,RCT NA Sham NA High,27.0733333333333,35.22 NA NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Quality of life (patients) | Executive functioning (tests),Ostinelli (2025),27.0733333333333 35.24,NA,NA,NA,NA,NA NA,< 2 months NA,NA NANA >= 18 yo Homogeneous TMS ([repetitive] transcranial magnetic stimulation)_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks)_>= 18 yo Ostinelli (2025) - TMS ([repetitive] transcranial magnetic stimulation)_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks)_>= 18 yo,TMS ([repetitive] transcranial magnetic stimulation)_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks)_>= 18 yo - [Homogeneous] 2025,TMS ([repetitive] transcranial magnetic stimulation)_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks) 205,TRUE,Ostinelli (2025)_TMS ([repetitive] transcranial magnetic stimulation)_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks) Ostinelli (2025)_TMS ([repetitive] transcranial magnetic stimulation)_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks) 100.00000
Ostinelli (2025),Viloxazine Acceptability: all-cause discontinuation NA,At study endpoint (closest to 12 weeks), 374 34.739572 34.739572 34.739572,34.739572 34.739572,34.739572,34.739572 34.739572  999   0.000000,374.00000, 45.180749,34.739572,NA, 1.38089758,NA 100.00000,  0.00000 100.00000 100,100.000000,100.000000 100.00000,100.00000,100.000000 100.00000,100.000000   6  6, 2,374.00000,1.000000, 1 1 Nasser 2022,Ostinelli 10.1016/S2215-0366(24)00360-2 Viloxazine,NA,NA,Acceptability NA,RCT NA,Placebo NA,High 34.7395721925134,34.7395721925134 NA NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Specific adverse events: sleep problems | Specific adverse events: decreased appetite | Tolerability (discontinuation due to adverse events) | Acceptability: all-cause discontinuation | Emotional dysregulation,Yu (2024) | Ostinelli (2025),8.45,34.7573446327684 NA NA NA NA,NA,NA,< 2 months,NA,NA,NANA >= 18 yo,Homogeneous,Viloxazine_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_>= 18 yo Ostinelli (2025) - Viloxazine_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_>= 18 yo,Viloxazine_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_>= 18 yo - [Homogeneous] 2025,Viloxazine_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks) 206 TRUE Ostinelli (2025)_Viloxazine_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks),Ostinelli (2025)_Viloxazine_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks) 100.00000
Ostinelli (2025),Viloxazine Combined ADHD symptoms (inattentive + hyperactive/impulsive),Clinician-rated At study endpoint (closest to 12 weeks), 354,34.757345,34.757345 34.757345 34.757345,34.757345,34.757345 34.757345 34.757345, 999,  0.000000 354.00000  45.213559 34.757345,NA  1.38089758,NA,100.00000,  0.00000,100.00000 100,100.000000,100.000000,100.00000,100.00000   0.000000,100.00000 100.000000   6, 6, 2,354.00000,1.000000, 1,1 Nasser,2022 Ostinelli 10.1016/S2215-0366(24)00360-2 Viloxazine,NA NA AISRS NA RCT NA Placebo,NA High,34.7573446327684 34.7573446327684 NA,NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Specific adverse events: sleep problems | Specific adverse events: decreased appetite | Tolerability (discontinuation due to adverse events) | Acceptability: all-cause discontinuation | Emotional dysregulation Yu (2024) | Ostinelli (2025),8.45 34.7573446327684 NA NA NA,NA NA NA < 2 months,NA NA NANA >= 18 yo Homogeneous,Viloxazine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks)_>= 18 yo,Ostinelli (2025) - Viloxazine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks)_>= 18 yo Viloxazine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks)_>= 18 yo - [Homogeneous] 2025,Viloxazine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks),207,TRUE,Ostinelli (2025)_Viloxazine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks),Ostinelli (2025)_Viloxazine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks),100.00000
Ostinelli (2025) Viloxazine Emotional dysregulation,Mixed,At study endpoint (closest to 12 weeks), 354,34.757345,34.757345,34.757345 34.757345 34.757345,34.757345 34.757345 34.757345  999,  0.000000 354.00000  45.213559,34.757345,NA, 1.38089758,NA 100.00000   0.00000 100.00000 100 100.000000 100.000000 100.00000 100.00000,  0.000000 100.00000 100.000000   6  6, 2,354.00000 1.000000  1,1,Nasser,2022 Ostinelli 10.1016/S2215-0366(24)00360-2,Viloxazine NA,NA BRIEF-ASR Emotional control,NA,RCT NA,Placebo NA High,34.7573446327684,34.7573446327684,NA NA Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Specific adverse events: sleep problems | Specific adverse events: decreased appetite | Tolerability (discontinuation due to adverse events) | Acceptability: all-cause discontinuation | Emotional dysregulation Yu (2024) | Ostinelli (2025) 8.45 34.7573446327684 NA NA NA NA NA,NA,< 2 months,NA NA NANA,>= 18 yo Homogeneous Viloxazine_Emotional dysregulation_Mixed_At study endpoint (closest to 12 weeks)_>= 18 yo,Ostinelli (2025) - Viloxazine_Emotional dysregulation_Mixed_At study endpoint (closest to 12 weeks)_>= 18 yo,Viloxazine_Emotional dysregulation_Mixed_At study endpoint (closest to 12 weeks)_>= 18 yo - [Homogeneous] 2025 Viloxazine_Emotional dysregulation_Mixed_At study endpoint (closest to 12 weeks),208,TRUE Ostinelli (2025)_Viloxazine_Emotional dysregulation_Mixed_At study endpoint (closest to 12 weeks),Ostinelli (2025)_Viloxazine_Emotional dysregulation_Mixed_At study endpoint (closest to 12 weeks),100.00000
Ostinelli (2025),Viloxazine,Tolerability (discontinuation due to adverse events),NA At study endpoint (closest to 12 weeks)  374,34.739572 34.739572,34.739572 34.739572,34.739572 34.739572,34.739572,34.739572, 999,  0.000000 374.00000  45.180749,34.739572 NA, 1.38089758,NA 100.00000,  0.00000,100.00000,100,100.000000 100.000000 100.00000,100.00000 100.000000,100.00000 100.000000   6  6, 2 374.00000,1.000000, 1 1,Nasser,2022 Ostinelli 10.1016/S2215-0366(24)00360-2 Viloxazine,NA,NA,Tolerability,NA RCT,NA,Placebo,NA High,34.7395721925134 34.7395721925134 NA,NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Specific adverse events: sleep problems | Specific adverse events: decreased appetite | Tolerability (discontinuation due to adverse events) | Acceptability: all-cause discontinuation | Emotional dysregulation Yu (2024) | Ostinelli (2025) 8.45 34.7573446327684,NA NA NA NA,NA NA < 2 months NA,NA,NANA,>= 18 yo,Homogeneous,Viloxazine_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks)_>= 18 yo,Ostinelli (2025) - Viloxazine_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks)_>= 18 yo Viloxazine_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks)_>= 18 yo - [Homogeneous],2025,Viloxazine_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks),209 TRUE,Ostinelli (2025)_Viloxazine_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks) Ostinelli (2025)_Viloxazine_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks),100.00000
Ostinelli (2025),tDCS (transcranial direct current stimulation),Acceptability: all-cause discontinuation,NA At study endpoint (closest to 12 weeks), 103,22.085000,22.085000 22.085000 32.294118 38.300000 38.300000 38.300000 38.300000  999   0.000000, 47.27184, 44.686408 33.845340 NA  0.77312389,NA 100.00000   0.00000 100.00000,100,100.000000 100.000000 100.00000,100.00000 100.000000,100.00000 100.000000, 19  5  3  47.27184 1.000000  3,1 Barham | Cachoeira | Leffa,2022 | 2016,Ostinelli,10.1016/S2215-0366(24)00360-2,tDCS (transcranial direct current stimulation),NA,NA,Acceptability NA RCT,NA Sham,NA High,22.085 38.3,NA,NA Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (tests) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Emotional dysregulation Yin - adults (2024) | Yin - children (2024) | Ostinelli (2025),8.86,38.3142857142857 NA,NA NA NA NA NA,< 2 months NA NA,NANA,>= 18 yo Homogeneous tDCS (transcranial direct current stimulation)_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_>= 18 yo,Ostinelli (2025) - tDCS (transcranial direct current stimulation)_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_>= 18 yo tDCS (transcranial direct current stimulation)_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_>= 18 yo - [Homogeneous],2025,tDCS (transcranial direct current stimulation)_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks) 210,TRUE Ostinelli (2025)_tDCS (transcranial direct current stimulation)_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks) Ostinelli (2025)_tDCS (transcranial direct current stimulation)_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks),100.00000
Ostinelli (2025),tDCS (transcranial direct current stimulation) Combined ADHD symptoms (inattentive + hyperactive/impulsive) Clinician-rated,At study endpoint (closest to 12 weeks),  64 38.300000 38.300000 38.300000,38.300000,38.300000,38.300000 38.300000,38.300000  999   0.000000, 64.00000  46.900000,38.300000 NA  0.92059839 NA,100.00000   0.00000,100.00000,100 100.000000 100.000000 100.00000,100.00000,100.000000 100.00000,100.000000, 19, 5, 3, 64.00000 1.000000, 1 1,Leffa 2022,Ostinelli 10.1016/S2215-0366(24)00360-2,tDCS (transcranial direct current stimulation),NA,NA,ADHD-RS total,NA RCT NA Sham NA,High 38.3 38.3 NA,NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (tests) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Emotional dysregulation,Yin - adults (2024) | Yin - children (2024) | Ostinelli (2025),8.86,38.3142857142857,NA,NA,NA NA NA NA,< 2 months,NA NA,NANA,>= 18 yo Homogeneous,tDCS (transcranial direct current stimulation)_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks)_>= 18 yo,Ostinelli (2025) - tDCS (transcranial direct current stimulation)_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks)_>= 18 yo tDCS (transcranial direct current stimulation)_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks)_>= 18 yo - [Homogeneous] 2025 tDCS (transcranial direct current stimulation)_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks),211,TRUE Ostinelli (2025)_tDCS (transcranial direct current stimulation)_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks) Ostinelli (2025)_tDCS (transcranial direct current stimulation)_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks),100.00000
Ostinelli (2025) tDCS (transcranial direct current stimulation),Combined ADHD symptoms (inattentive + hyperactive/impulsive),Self-rated At study endpoint (closest to 12 weeks)   16,32.375000 32.375000 32.375000 32.375000,32.375000,32.375000,32.375000,32.375000  999,  0.000000  16.00000, 52.800000,32.375000 NA, 0.92059839,NA 100.00000,  0.00000,100.00000 100 100.000000 100.000000,100.00000,100.00000 100.000000 100.00000 100.000000, 19  5  3, 16.00000,1.000000, 1,1 Cachoeira 2016 Ostinelli,10.1016/S2215-0366(24)00360-2,tDCS (transcranial direct current stimulation),NA,NA,ASRS,NA,RCT,NA,Sham,NA,High 32.375 32.375 NA,NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (tests) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Emotional dysregulation,Yin - adults (2024) | Yin - children (2024) | Ostinelli (2025) 8.86,38.3142857142857 NA,NA NA NA NA NA < 2 months NA NA,NANA,>= 18 yo Homogeneous,tDCS (transcranial direct current stimulation)_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Self-rated_At study endpoint (closest to 12 weeks)_>= 18 yo Ostinelli (2025) - tDCS (transcranial direct current stimulation)_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Self-rated_At study endpoint (closest to 12 weeks)_>= 18 yo,tDCS (transcranial direct current stimulation)_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Self-rated_At study endpoint (closest to 12 weeks)_>= 18 yo - [Homogeneous],2025,tDCS (transcranial direct current stimulation)_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Self-rated_At study endpoint (closest to 12 weeks) 212,TRUE,Ostinelli (2025)_tDCS (transcranial direct current stimulation)_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Self-rated_At study endpoint (closest to 12 weeks),Ostinelli (2025)_tDCS (transcranial direct current stimulation)_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Self-rated_At study endpoint (closest to 12 weeks) 100.00000
Ostinelli (2025) tDCS (transcranial direct current stimulation),Emotional dysregulation Mixed,At study endpoint (closest to 12 weeks)   49 38.314286 38.314286,38.314286,38.314286 38.314286 38.314286 38.314286,38.314286  999   0.000000  49.00000, 45.114286,38.314286 NA, 0.92059839,NA,100.00000   0.00000 100.00000 100,100.000000 100.000000,100.00000 100.00000,100.000000 100.00000 100.000000  19  5, 3  49.00000,1.000000  1 1 Leffa 2022,Ostinelli,10.1016/S2215-0366(24)00360-2 tDCS (transcranial direct current stimulation),NA NA BRIEF-ASR Emotional control NA RCT NA,Sham NA,High,38.3142857142857 38.3142857142857,NA,NA Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (tests) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Emotional dysregulation,Yin - adults (2024) | Yin - children (2024) | Ostinelli (2025),8.86,38.3142857142857,NA,NA,NA,NA,NA NA < 2 months,NA NA,NANA >= 18 yo Homogeneous tDCS (transcranial direct current stimulation)_Emotional dysregulation_Mixed_At study endpoint (closest to 12 weeks)_>= 18 yo Ostinelli (2025) - tDCS (transcranial direct current stimulation)_Emotional dysregulation_Mixed_At study endpoint (closest to 12 weeks)_>= 18 yo tDCS (transcranial direct current stimulation)_Emotional dysregulation_Mixed_At study endpoint (closest to 12 weeks)_>= 18 yo - [Homogeneous] 2025,tDCS (transcranial direct current stimulation)_Emotional dysregulation_Mixed_At study endpoint (closest to 12 weeks) 213,TRUE,Ostinelli (2025)_tDCS (transcranial direct current stimulation)_Emotional dysregulation_Mixed_At study endpoint (closest to 12 weeks) Ostinelli (2025)_tDCS (transcranial direct current stimulation)_Emotional dysregulation_Mixed_At study endpoint (closest to 12 weeks),100.00000
Ostinelli (2025),tDCS (transcranial direct current stimulation),Tolerability (discontinuation due to adverse events) NA At study endpoint (closest to 12 weeks)   81 32.294118 32.294118 32.294118,38.300000 38.300000,38.300000 38.300000,38.300000, 999   0.000000, 54.13580  48.172840 37.039506,NA  0.92059839,NA 100.00000,  0.00000 100.00000,100,100.000000,100.000000 100.00000 100.00000 100.000000 100.00000,100.000000  19, 5, 3, 54.13580 1.000000, 2 1 Cachoeira | Leffa,2016 | 2022 Ostinelli 10.1016/S2215-0366(24)00360-2 tDCS (transcranial direct current stimulation),NA NA,Tolerability NA RCT,NA,Sham NA High 32.2941176470588 38.3 NA NA Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (tests) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Emotional dysregulation,Yin - adults (2024) | Yin - children (2024) | Ostinelli (2025) 8.86 38.3142857142857 NA NA,NA NA NA NA < 2 months NA,NA,NANA,>= 18 yo,Homogeneous,tDCS (transcranial direct current stimulation)_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks)_>= 18 yo Ostinelli (2025) - tDCS (transcranial direct current stimulation)_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks)_>= 18 yo tDCS (transcranial direct current stimulation)_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks)_>= 18 yo - [Homogeneous] 2025,tDCS (transcranial direct current stimulation)_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks) 214,TRUE,Ostinelli (2025)_tDCS (transcranial direct current stimulation)_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks) Ostinelli (2025)_tDCS (transcranial direct current stimulation)_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks),100.00000
Otasowie (2014),Desipramine Combined ADHD symptoms (inattentive + hyperactive/impulsive),Parent-rated At study endpoint (closest to 12 weeks),  99,11.000000,11.000000,11.000000,11.000000,11.500000 11.500000,11.500000 11.500000,2646,  0.000000  50.95960  10.848182,11.292929 NA  1.38089758,   6.839394 100.00000   0.00000 100.00000,100,100.000000 100.000000,100.00000,100.00000 100.000000 100.00000 100.000000   4  3  2, 50.95960 1.000000  2,1 Biederman | Spencer,1989 | 2002 Otasowie,10.1002/14651858.CD006997.pub2,NA,NA Questionnaire Conners ADHD Rating Scale NA RCT (parallel, crossover, open-label),DSM-III | DSM-IV Placebo mg/kg/d,High 11,11.5 NA,NA Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events),Otasowie (2014) | Catala-Lopez (2017),11 11.5,NA,NA,NA,NA,NA NA < 2 months,NA,NA 6.84mg/kg/d 6-17 yo,Homogeneous Desipramine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks)_6-17 yo,Otasowie (2014) - Desipramine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks)_6-17 yo Desipramine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks)_6-17 yo - [Homogeneous],2014,Desipramine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks) 215 NA,Otasowie (2014)_Desipramine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks) Otasowie (2014)_Desipramine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks),100.00000
Otasowie (2014) Desipramine,Combined ADHD symptoms (inattentive + hyperactive/impulsive) Teacher-rated At study endpoint (closest to 12 weeks)   89,11.500000 11.500000 11.500000 11.500000 11.500000,11.500000,11.500000 11.500000,2646   0.000000  48.59551,  4.203371 11.500000,NA  1.06023972    7.179775  65.16854   0.00000 100.00000 100,100.000000 100.000000,100.00000,100.00000 100.000000,100.00000 100.000000   4, 3, 2  48.59551 1.000000, 2,1,Biederman | Donnelly,1989 | 1986 Otasowie 10.1002/14651858.CD006997.pub2,NA NA Questionnaire,Conners ADHD Rating Scale NA RCT (parallel, crossover, open-label),DSM-III,Placebo,mg/kg/d High,11.5,11.5 NA NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events),Otasowie (2014) | Catala-Lopez (2017) 11 11.5,NA NA NA,NA,NA NA,< 2 months NA NA,7.18mg/kg/d,6-17 yo,Homogeneous Desipramine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Teacher-rated_At study endpoint (closest to 12 weeks)_6-17 yo,Otasowie (2014) - Desipramine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Teacher-rated_At study endpoint (closest to 12 weeks)_6-17 yo Desipramine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Teacher-rated_At study endpoint (closest to 12 weeks)_6-17 yo - [Homogeneous],2014 Desipramine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Teacher-rated_At study endpoint (closest to 12 weeks),216,NA Otasowie (2014)_Desipramine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Teacher-rated_At study endpoint (closest to 12 weeks) Otasowie (2014)_Desipramine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Teacher-rated_At study endpoint (closest to 12 weeks),100.00000
Pievsky (2018) Methylphenidate,Driving Clinician-rated At study endpoint (closest to 12 weeks)  154 31.300000 31.300000 31.300000,31.300000,31.300000,31.300000 38.300000,38.300000 2785   0.000000, 79.92208, 26.675325,32.103636 NA, 0.03278689   14.406780,100.00000,  0.00000 100.00000 100, 67.532468  67.532468, 90.90909,100.00000  90.909091, 76.62338 100.000000 141 14 11  79.92208 6.662338  3,1,Barkley | Cox | Verster,2005 | 2000 | 2008 Pievsky 10.1016/j.neubiorev.2018.05.012 methylphenidate Immediate release,NA Test Speed variability on standard driving course + Number of crashes on standard driving course + Steering variability on standard driving course + # turn signals on standard driving course + Impaired driving score based on driving simulation + # lapses while driving + Total lapse time (s) + SD of lateral position (cm) + Standard deviation of lateral position (weaving of the car; cm) + Lateral position (cm),NA,RCT (parallel, crossover, open-label) NA Placebo mg,Critically low 22.14,38.3,NA,NA Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events) Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018) 4.42 50.1,60 109.9 NA, 99.5875,97.45,105.60 < 2 months,NA NA 14.41mg,>= 18 yo Homogeneous,Methylphenidate_Driving_Clinician-rated_At study endpoint (closest to 12 weeks)_>= 18 yo Pievsky (2018) - Methylphenidate_Driving_Clinician-rated_At study endpoint (closest to 12 weeks)_>= 18 yo Methylphenidate_Driving_Clinician-rated_At study endpoint (closest to 12 weeks)_>= 18 yo - [Homogeneous] 2018,Methylphenidate_Driving_Clinician-rated_At study endpoint (closest to 12 weeks) 217 FALSE,Pievsky (2018)_Methylphenidate_Driving_Clinician-rated_At study endpoint (closest to 12 weeks),Pievsky (2018)_Methylphenidate_Driving_Clinician-rated_At study endpoint (closest to 12 weeks) 100.00000
Pievsky (2018) Methylphenidate Executive functioning (tests) Clinician-rated,At study endpoint (closest to 12 weeks), 973,30.500000,31.300000,31.300000 31.840000 35.740000 35.740000,36.100000,38.900000 2785   0.000000,159.39466, 40.996785 34.862154 NA, 0.78506562,  43.223227  95.88900,  0.00000,100.00000 100  82.939363, 82.939363, 93.83350 100.00000, 91.572456, 89.10586, 98.150051,141 14,11,159.39466 2.273381,15,1,Agay | Barkley | Biederman | Biehl | Boonstra | Bouffard | Bron | Epstein | Goodman | Kollins | Kuperman | Levin | Overtoom | Turner 2010 | 2014 | 2005 | 2011 | 2016 | 2003 | 2007 | 2013 | 2001 | 2009,Pievsky,10.1016/j.neubiorev.2018.05.012 methylphenidate | methylphenidate Immediate release | methylphenidate mixed release | Methylphenidate | methylphenidate Sustained release,NA,Test Digits forward + digits backwards + Forwards digit span + Backwards digit span + CANTAB SWM total + CANTAB SWM strategy score + 0-back % correct, day 1 + 0-back % incorrect, day 1 + 0-back % missed trials, day 1 + 1-back % correct, day 1 + 1-back % incorrect, day 1 + 1-back % missed trials, day 1 + 2-back % correct, day 1+ 2-back % incorrect, day 1 + 2-back % missed trials, day 1 + 0-back % correct, day 42 + 0-back % incorrect, day 42 + 0-back % missed trials, day 42 + 1-back % correct, day 42 + 1-back % incorrect, day 42 + 1-back % missed trials, day 42 + 2-back % correct, day 42 + 2-back % incorrect, day 42 + 2-back % missed trials, day 42 + Digit ordering + CANTAB SWM strategy score + CANTAB SWM between errors score, 6-box stage + CANTAB SWM between errors score, 8-box stage + CANTAB SWM within errors + CANTAB SSP span length + CANTAB SSP total errors | TOVA CE + C-CPT CE + C-CPT CE + SST tracked stop trial delay mean + C-CPT CE + CPT % commission errors + GNG CE + SST choice-error rate + SST % successful stops
MPH
MPH | Digits forward + digits backwards + Forwards digit span + Backwards digit span + CANTAB SWM total + CANTAB SWM strategy score + 0-back % correct, day 1 + 0-back % incorrect, day 1 + 0-back % missed trials, day 1 + 1-back % correct, day 1 + 1-back % incorrect, day 1 + 1-back % missed trials, day 1 + 2-back % correct, day 1+ 2-back % incorrect, day 1 + 2-back % missed trials, day 1 + 0-back % correct, day 42 + 0-back % incorrect, day 42 + 0-back % missed trials, day 42 + 1-back % correct, day 42 + 1-back % incorrect, day 42 + 1-back % missed trials, day 42 + 2-back % correct, day 42 + 2-back % incorrect, day 42 + 2-back % missed trials, day 42 + Digit ordering + CANTAB SWM strategy score + CANTAB SWM between errors score, 6-box stage + CANTAB SWM between errors score, 8-box stage + CANTAB SWM within errors + CANTAB SSP span length + CANTAB SSP total errors | TOVA CE + C-CPT CE + C-CPT CE + SST tracked stop trial delay mean + C-CPT CE + CPT % commission errors + GNG CE + SST choice-error rate + SST % successful stops
MPH
MPH | CNSVS Shifting Attention Test accuracy + Trails B | Digits forward + digits backwards + Forwards digit span + Backwards digit span + CANTAB SWM total + CANTAB SWM strategy score + 0-back % correct, day 1 + 0-back % incorrect, day 1 + 0-back % missed trials, day 1 + 1-back % correct, day 1 + 1-back % incorrect, day 1 + 1-back % missed trials, day 1 + 2-back % correct, day 1+ 2-back % incorrect, day 1 + 2-back % missed trials, day 1 + 0-back % correct, day 42 + 0-back % incorrect, day 42 + 0-back % missed trials, day 42 + 1-back % correct, day 42 + 1-back % incorrect, day 42 + 1-back % missed trials, day 42 + 2-back % correct, day 42 + 2-back % incorrect, day 42 + 2-back % missed trials, day 42 + Digit ordering + CANTAB SWM strategy score + CANTAB SWM between errors score, 6-box stage + CANTAB SWM between errors score, 8-box stage + CANTAB SWM within errors + CANTAB SSP span length + CANTAB SSP total errors | CNSVS Shifting Attention Test accuracy + Trails B NA,RCT (parallel, crossover, open-label),NA,Placebo mg | mg/kg,Critically low,28.44 50.1,NA NA Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events),Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018) 4.42,50.1 60,109.9 NA, 99.5875 97.45,105.60,< 2 months NA NA,43.22mg | mg/kg >= 18 yo,Homogeneous Methylphenidate_Executive functioning (tests)_Clinician-rated_At study endpoint (closest to 12 weeks)_>= 18 yo,Pievsky (2018) - Methylphenidate_Executive functioning (tests)_Clinician-rated_At study endpoint (closest to 12 weeks)_>= 18 yo Methylphenidate_Executive functioning (tests)_Clinician-rated_At study endpoint (closest to 12 weeks)_>= 18 yo - [Homogeneous],2018,Methylphenidate_Executive functioning (tests)_Clinician-rated_At study endpoint (closest to 12 weeks),218,FALSE Pievsky (2018)_Methylphenidate_Executive functioning (tests)_Clinician-rated_At study endpoint (closest to 12 weeks) Pievsky (2018)_Methylphenidate_Executive functioning (tests)_Clinician-rated_At study endpoint (closest to 12 weeks) 100.00000
Punja (2016),Amphetamine Academic/job performance,NA,At study endpoint (closest to 12 weeks), 826  9.100000, 9.100000  9.100000  9.100000  9.600000 10.580000 10.580000,10.580000 2877,  0.000000,145.63196  25.894431, 9.673317,NA  0.83465172   41.276966,100.00000   0.00000,100.00000 100 100.000000 100.000000,100.00000,100.00000  86.682809,100.00000,100.000000  43 14, 9 145.63196 1.000000  8 1,Biederman | Borcherding | Childress | James | McCracken | Nemzer | Shekim | Wigal,2007a | 1990 | 2015 | 2001 | 2003 | 1986 | 2009,Punja,10.1002/14651858.CD009996.pub2,Mixed amphetamine salts (long acting) or Lisdexamphetamine (long acting) | Dextroamphetamine (short acting) | Mixed amphetamine salts (short acting) | Dextroamphetamine (short acting) or Dextroamphetamine spansules (long acting) or Mixed amphetamine salts (long acting)* | Mixed amphetamine salts (short acting and long acting) | Lisdexamphetamine (long acting) NA Test Permanent Product Measure of Performance scale | Barnell LoT, Ltd, Developing Key Concepts in Math test | Permanent Product Measure of Performance | 5-minute timed math task | Wechsler Intelligence Scale for Children - Revised | Wide Range Achievement Test - math subset NA,RCT (parallel, crossover, open-label),DSM-IV-TR | DSM-III | DSM-IV Placebo mg/d High,8.6,10.58,NA NA,Disruptive behaviors | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Academic/job performance | Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Depressive disorder symptoms | Generalized anxiety | Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Executive functioning (tests),Faraone (2002) | Punja (2016) | Castells (2018) | Elliott (2020) | Bellato - adults (2024) | Bellatto - children (2024) | Lenzi (2018) | Ostinelli (2025) | Cortese - Children (2018) 8 41.2,NA,NA NA,NA,NA NA,< 2 months,NA NA,41.28mg/d 6-17 yo Homogeneous,Amphetamine_Academic/job performance_NA_At study endpoint (closest to 12 weeks)_6-17 yo Punja (2016) - Amphetamine_Academic/job performance_NA_At study endpoint (closest to 12 weeks)_6-17 yo Amphetamine_Academic/job performance_NA_At study endpoint (closest to 12 weeks)_6-17 yo - [Homogeneous] 2016,Amphetamine_Academic/job performance_NA_At study endpoint (closest to 12 weeks),219 FALSE,Punja (2016)_Amphetamine_Academic/job performance_NA_At study endpoint (closest to 12 weeks) Punja (2016)_Amphetamine_Academic/job performance_NA_At study endpoint (closest to 12 weeks) 100.00000
Punja (2016) Amphetamine CGI Mixed At study endpoint (closest to 12 weeks),  86  8.200000, 8.200000, 8.200000, 8.200000, 8.600000  8.600000, 8.600000  8.600000 2877,  0.000000, 51.39535,  0.000000  8.488372,NA  1.63454385,  45.930233,100.00000   0.00000 100.00000 100,100.000000,100.000000,100.00000,100.00000  27.906977,100.00000 100.000000  43,14  9  51.39535,1.000000  2 1,Borcherding | Pliszka,1990 | 2000 Punja,10.1002/14651858.CD009996.pub2 Dextroamphetamine (short acting) | Mixed amphetamine salts (short acting) NA,Observational tool CGI NA,RCT (parallel, crossover, open-label) DSM-III | Diagnostic Interview Schedule for Children Placebo mg/d | mg High,8.2,8.6 NA NA,Disruptive behaviors | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Academic/job performance | Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Depressive disorder symptoms | Generalized anxiety | Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Executive functioning (tests),Faraone (2002) | Punja (2016) | Castells (2018) | Elliott (2020) | Bellato - adults (2024) | Bellatto - children (2024) | Lenzi (2018) | Ostinelli (2025) | Cortese - Children (2018) 8,41.2,NA,NA NA,NA NA,NA < 2 months,NA NA,45.93mg/d | mg,6-17 yo Homogeneous Amphetamine_CGI_Mixed_At study endpoint (closest to 12 weeks)_6-17 yo Punja (2016) - Amphetamine_CGI_Mixed_At study endpoint (closest to 12 weeks)_6-17 yo Amphetamine_CGI_Mixed_At study endpoint (closest to 12 weeks)_6-17 yo - [Homogeneous],2016,Amphetamine_CGI_Mixed_At study endpoint (closest to 12 weeks),220 FALSE,Punja (2016)_Amphetamine_CGI_Mixed_At study endpoint (closest to 12 weeks),Punja (2016)_Amphetamine_CGI_Mixed_At study endpoint (closest to 12 weeks),100.00000
Punja (2016),Amphetamine,Combined ADHD symptoms (inattentive + hyperactive/impulsive) Parent-rated,At study endpoint (closest to 12 weeks),1247  8.600000, 8.600000, 8.600000, 8.600000  9.000000 10.100000 10.900000 10.900000,2877,  0.000000,361.55172  23.567457  9.441043,NA, 0.93531080   30.705694 100.00000,  0.00000,100.00000 100, 83.881315, 83.881315 100.00000,100.00000  78.909383, 83.88132,100.000000, 43 14  9 361.55172 1.000000, 7 1 Barkley | Biederman | Coghill | Manos | Nemzer | Pliszka 2000 | 2002 | 2007b | 2013 | 1999 | 1986 Punja 10.1002/14651858.CD009996.pub2,Mixed amphetamine salts (short acting) | Mixed amphetamine salts (long acting) | Lisdexamphetamine (long acting) | Lisdexampehtamine (long acting) | Dextroamphetamine (short acting),NA Questionnaire,ADHD Rating Scale, Fourth Version | Conners Global Index | ADHD Rating Scale, Fourth Version, and the Conners' Parent Rating Scale-Revised: Short Form | Conners' Parent Rating Scale - Revised | Conners' Abbreviated Symptoms Questionnaire | Conners' Parent Rating Scale | Conners' Parent Global Index,NA,RCT (parallel, crossover, open-label) DSM-IV | DSM-IV-TR | DSM-III | Diagnostic Interview Schedule for Children,Placebo,mg/d | mg High 8.2,14 NA,NA Disruptive behaviors | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Academic/job performance | Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Depressive disorder symptoms | Generalized anxiety | Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Executive functioning (tests),Faraone (2002) | Punja (2016) | Castells (2018) | Elliott (2020) | Bellato - adults (2024) | Bellatto - children (2024) | Lenzi (2018) | Ostinelli (2025) | Cortese - Children (2018),8,41.2 NA NA NA,NA NA NA < 2 months,NA NA,30.71mg/d | mg,6-17 yo Homogeneous Amphetamine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks)_6-17 yo,Punja (2016) - Amphetamine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks)_6-17 yo Amphetamine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks)_6-17 yo - [Homogeneous],2016,Amphetamine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks) 221 FALSE Punja (2016)_Amphetamine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks),Punja (2016)_Amphetamine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks) 100.00000
Punja (2016),Amphetamine,Combined ADHD symptoms (inattentive + hyperactive/impulsive) Teacher-rated,At study endpoint (closest to 12 weeks)  745, 8.600000  8.600000, 8.600000  8.600000  8.600000  8.600000 10.100000 10.100000 2877   0.000000 439.34094  21.102013  8.982926,NA  0.79052525   18.397163 100.00000   0.00000,100.00000 100,100.000000,100.000000,100.00000,100.00000  95.973154,100.00000 100.000000, 43,14  9 439.34094 1.000000, 5,1,Barkley | Biederman | Donnelly | Manos | Nemzer,2000 | 2002 | 1989 | 1999 | 1986,Punja,10.1002/14651858.CD009996.pub2,Mixed amphetamine salts (short acting) | Mixed amphetamine salts (long acting) | Dextroamphetamine (short acting) NA Questionnaire ADHD Rating Scale, Fourth Version | Conners Global Index | Conners' Teacher Rating Scale | Conners' Abbreviated Symptoms Questionnaire - Teacher Version,NA RCT (parallel, crossover, open-label) DSM-IV | DSM-III,Placebo,mg/d High,8 14 NA,NA Disruptive behaviors | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Academic/job performance | Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Depressive disorder symptoms | Generalized anxiety | Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Executive functioning (tests) Faraone (2002) | Punja (2016) | Castells (2018) | Elliott (2020) | Bellato - adults (2024) | Bellatto - children (2024) | Lenzi (2018) | Ostinelli (2025) | Cortese - Children (2018),8,41.2,NA,NA NA,NA,NA,NA,< 2 months,NA,NA,18.4mg/d 6-17 yo Homogeneous Amphetamine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Teacher-rated_At study endpoint (closest to 12 weeks)_6-17 yo Punja (2016) - Amphetamine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Teacher-rated_At study endpoint (closest to 12 weeks)_6-17 yo,Amphetamine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Teacher-rated_At study endpoint (closest to 12 weeks)_6-17 yo - [Homogeneous],2016 Amphetamine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Teacher-rated_At study endpoint (closest to 12 weeks),222 FALSE Punja (2016)_Amphetamine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Teacher-rated_At study endpoint (closest to 12 weeks),Punja (2016)_Amphetamine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Teacher-rated_At study endpoint (closest to 12 weeks),100.00000
Punja (2016) Amphetamine,Specific adverse events: decreased appetite,NA,At study endpoint (closest to 12 weeks),2467  8.600000, 8.600000, 8.600000  8.600000  9.600000 11.400000,14.200000 14.600000,2877,  0.000000 320.40738, 26.141540 10.698800 NA  0.86826664   36.175193,100.00000   0.00000 100.00000 100, 88.285367  88.285367,100.00000, 97.24362  88.285367, 88.28537,100.000000  43,14  9 320.40738,1.000000,11,1,Biederman | Childress | Coghill | Findling | McCracken | Pliszka | Ramtvedt | Spencer | Wigal 2002 | 2007a | 2007b | 2015 | 2013 | 2011 | 2003 | 2000 | 2006 | 2009 Punja,10.1002/14651858.CD009996.pub2,Mixed amphetamine salts (long acting) | Mixed amphetamine salts (long acting) or Lisdexamphetamine (long acting) | Lisdexamphetamine (long acting) | Mixed amphetamine salts (short acting) | Lisdexampehtamine (long acting) | Mixed amphetamine salts (short acting and long acting) | Dextroamphetamine (short acting) NA,Interview,Adverse events,NA RCT (parallel, crossover, open-label),DSM-IV | DSM-IV-TR | Diagnostic Interview Schedule for Children,Placebo mg/d | mg High 8.2,14.6 NA,NA Disruptive behaviors | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Academic/job performance | Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Depressive disorder symptoms | Generalized anxiety | Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Executive functioning (tests),Faraone (2002) | Punja (2016) | Castells (2018) | Elliott (2020) | Bellato - adults (2024) | Bellatto - children (2024) | Lenzi (2018) | Ostinelli (2025) | Cortese - Children (2018) 8 41.2,NA,NA,NA NA NA,NA,< 2 months,NA NA,36.18mg/d | mg,6-17 yo Homogeneous,Amphetamine_Specific adverse events: decreased appetite_NA_At study endpoint (closest to 12 weeks)_6-17 yo Punja (2016) - Amphetamine_Specific adverse events: decreased appetite_NA_At study endpoint (closest to 12 weeks)_6-17 yo Amphetamine_Specific adverse events: decreased appetite_NA_At study endpoint (closest to 12 weeks)_6-17 yo - [Homogeneous],2016,Amphetamine_Specific adverse events: decreased appetite_NA_At study endpoint (closest to 12 weeks) 223 FALSE Punja (2016)_Amphetamine_Specific adverse events: decreased appetite_NA_At study endpoint (closest to 12 weeks) Punja (2016)_Amphetamine_Specific adverse events: decreased appetite_NA_At study endpoint (closest to 12 weeks),100.00000
Punja (2016) Amphetamine,Specific adverse events: sleep problems NA At study endpoint (closest to 12 weeks) 2429, 8.600000, 8.600000, 8.600000  9.000000, 9.600000,14.200000 14.200000 14.600000 2877,  0.000000,324.82544, 26.141540 10.737892,NA  0.87104848,  36.389131,100.00000   0.00000,100.00000,100  88.102100, 88.102100 100.00000, 97.20049, 88.102100, 88.10210,100.000000  43 14, 9,324.82544,1.000000 10,1,Biederman | Childress | Coghill | Findling | McCracken | Ramtvedt | Spencer | Wigal 2002 | 2007a | 2007b | 2015 | 2013 | 2011 | 2003 | 2006 | 2009,Punja 10.1002/14651858.CD009996.pub2 Mixed amphetamine salts (long acting) | Mixed amphetamine salts (long acting) or Lisdexamphetamine (long acting) | Lisdexamphetamine (long acting) | Mixed amphetamine salts (short acting) | Lisdexampehtamine (long acting) | Mixed amphetamine salts (short acting and long acting) | Dextroamphetamine (short acting) NA Interview,Adverse events,NA RCT (parallel, crossover, open-label),DSM-IV | DSM-IV-TR Placebo mg/d High 8.6 14.6 NA,NA Disruptive behaviors | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | CGI | Academic/job performance | Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Depressive disorder symptoms | Generalized anxiety | Executive functioning (report) | Quality of life (patients) | Emotional dysregulation | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Executive functioning (tests) Faraone (2002) | Punja (2016) | Castells (2018) | Elliott (2020) | Bellato - adults (2024) | Bellatto - children (2024) | Lenzi (2018) | Ostinelli (2025) | Cortese - Children (2018) 8,41.2,NA,NA NA NA NA NA < 2 months,NA NA,36.39mg/d 6-17 yo Homogeneous,Amphetamine_Specific adverse events: sleep problems_NA_At study endpoint (closest to 12 weeks)_6-17 yo Punja (2016) - Amphetamine_Specific adverse events: sleep problems_NA_At study endpoint (closest to 12 weeks)_6-17 yo Amphetamine_Specific adverse events: sleep problems_NA_At study endpoint (closest to 12 weeks)_6-17 yo - [Homogeneous] 2016,Amphetamine_Specific adverse events: sleep problems_NA_At study endpoint (closest to 12 weeks),224,FALSE Punja (2016)_Amphetamine_Specific adverse events: sleep problems_NA_At study endpoint (closest to 12 weeks),Punja (2016)_Amphetamine_Specific adverse events: sleep problems_NA_At study endpoint (closest to 12 weeks),100.00000
Radonjic (2023),Alpha-2 agonists (guanfacine / clonidine) Combined ADHD symptoms (inattentive + hyperactive/impulsive) Mixed,At study endpoint (closest to 12 weeks)  235 33.800000 33.800000,33.800000 33.800000,33.800000,33.800000 33.800000,41.200000 2902   0.000000,176.83830  38.900000 34.870638 NA, 0.46029919,   1.100000,100.00000   0.00000,100.00000,100  14.468085  14.468085, 14.46809 100.00000, 14.468085  14.46809  14.468085, 20  7  5 176.83830 1.000000, 2,1,Iwanami | Taylor 2020 | 2021 Radonjic 10.1007/s40263-023-01005-8,Guanfacine NA NA ADHD-RS Total | ADHD Behavior Checklist for Adults NA,RCT (parallel, crossover, open-label) DSM-V | DSM/ICD Placebo,mg,Critically low,33.8 41.2 NA,NA,Specific adverse events: sleep problems | Tics/Tourette disorder symptoms | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Emotional dysregulation | Quality of life (patients) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) Ruggiero (2014) | Fahrat (2024) | Radonjic (2023) | Ostinelli (2025) | Cortese - Children (2018) 8.23931034482759 41.2 NA NA,NA NA,NA,NA < 2 months,NA,NA 1.1mg >= 18 yo,Homogeneous,Alpha-2 agonists (guanfacine / clonidine)_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Mixed_At study endpoint (closest to 12 weeks)_>= 18 yo,Radonjic (2023) - Alpha-2 agonists (guanfacine / clonidine)_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Mixed_At study endpoint (closest to 12 weeks)_>= 18 yo,Alpha-2 agonists (guanfacine / clonidine)_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Mixed_At study endpoint (closest to 12 weeks)_>= 18 yo - [Homogeneous] 2023,Alpha-2 agonists (guanfacine / clonidine)_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Mixed_At study endpoint (closest to 12 weeks),225 FALSE Radonjic (2023)_Alpha-2 agonists (guanfacine / clonidine)_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Mixed_At study endpoint (closest to 12 weeks),Radonjic (2023)_Alpha-2 agonists (guanfacine / clonidine)_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Mixed_At study endpoint (closest to 12 weeks) 100.00000
Ruggiero (2014),Alpha-2 agonists (guanfacine / clonidine) Specific adverse events: sleep problems,NA At study endpoint (closest to 12 weeks),1704, 9.100000  9.100000, 9.400000, 9.400000,10.500000,12.600000 14.500000,14.500000 3090,  0.000000 298.36972 NA 11.134507,NA  2.07620869    2.938674,100.00000   0.00000 100.00000 100, 81.690141  81.690141  81.69014  81.69014  81.690141, 81.69014, 81.690141, 20, 7  5 298.36972,1.000000, 6,1 Biederman | Connor | Kollins | NCT01081132 | Newcorn | Sallee,2008 | 2010 | 2011 | 2014 | 2013 | 2009,Ruggiero 10.1016/j.euroneuro.2014.08.001,Alpha-2 agonists (guanfacine / clonidine),NA,Mixed (different types of tool are used) NA NA RCT (parallel, crossover, open-label),DSM-IV-TR,Placebo,mg/d Critically low,9.1,14.5,NA NA Specific adverse events: sleep problems | Tics/Tourette disorder symptoms | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Emotional dysregulation | Quality of life (patients) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events),Ruggiero (2014) | Fahrat (2024) | Radonjic (2023) | Ostinelli (2025) | Cortese - Children (2018),8.23931034482759 41.2 NA NA,NA NA NA NA,2-6 months,NA,NA,2.94mg/d 6-17 yo,Homogeneous Alpha-2 agonists (guanfacine / clonidine)_Specific adverse events: sleep problems_NA_At study endpoint (closest to 12 weeks)_6-17 yo Ruggiero (2014) - Alpha-2 agonists (guanfacine / clonidine)_Specific adverse events: sleep problems_NA_At study endpoint (closest to 12 weeks)_6-17 yo Alpha-2 agonists (guanfacine / clonidine)_Specific adverse events: sleep problems_NA_At study endpoint (closest to 12 weeks)_6-17 yo - [Homogeneous],2014 Alpha-2 agonists (guanfacine / clonidine)_Specific adverse events: sleep problems_NA_At study endpoint (closest to 12 weeks),226,TRUE Ruggiero (2014)_Alpha-2 agonists (guanfacine / clonidine)_Specific adverse events: sleep problems_NA_At study endpoint (closest to 12 weeks) Ruggiero (2014)_Alpha-2 agonists (guanfacine / clonidine)_Specific adverse events: sleep problems_NA_At study endpoint (closest to 12 weeks),100.00000
Seiffer (2022) Physical training,Acceptability: all-cause discontinuation NA,At study endpoint (closest to 12 weeks), 232, 8.490000  9.700000  9.700000  9.700000 10.430000,12.530000,13.709500,15.900000 3228   0.000000, 42.71552, 19.310345,11.373319 NA  1.59715884   16.922414 100.00000   0.00000,100.00000 100, 32.327586, 32.327586,100.00000 100.00000  35.775862 100.00000, 32.327586, 22, 4, 3  42.71552,1.000000, 6,1 Benzing | Choi | Felmet | Garcia | Kang | Soori 2019 | 2015 | 1998 | 2016 | 2011 | 2020,Seiffer,10.1177/10870547211017982,Physical training,NA,NA CBCL NA,RCT,DSM-III, DSM-IV, DSM-IV-TR, DSM-5, ICD-9, or ICD-10 | DSM-III, DSM-IV, DSM-IV-TR, DSM-5, ICD-9, or ICD-11 | DSM-III, DSM-IV, DSM-IV-TR, DSM-5, ICD-9, or ICD-12 | DSM-III, DSM-IV, DSM-IV-TR, DSM-5, ICD-9, or ICD-13 | DSM-III, DSM-IV, DSM-IV-TR, DSM-5, ICD-9, or ICD-15 | DSM-III, DSM-IV, DSM-IV-TR, DSM-5, ICD-9, or ICD-17,WLC (wait-list control) | Not a therapeutic intervention | No intervention,sessions High,8.49,15.9 NA,NA Executive functioning (tests) | Acceptability: all-cause discontinuation | Social-communication skills | Combined ADHD symptoms (inattentive + hyperactive/impulsive),Huang (2022) | Seiffer (2022) | Ostinelli (2025) 7.7 35.3230769230769,NA NA,NA NA,NA,NA < 2 months,NA NA,16.92sessions 6-17 yo Homogeneous Physical training_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_6-17 yo,Seiffer (2022) - Physical training_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_6-17 yo Physical training_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_6-17 yo - [Homogeneous],2022 Physical training_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks) 227,TRUE,Seiffer (2022)_Physical training_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks),Seiffer (2022)_Physical training_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks) 100.00000
Seiffer (2022),Physical training Combined ADHD symptoms (inattentive + hyperactive/impulsive) Mixed,At study endpoint (closest to 12 weeks), 302  8.490000, 8.900000, 8.900000, 9.470000 10.430000,12.530000,12.530000 15.900000,3228   0.000000  39.39735, 25.086093 10.892947 NA, 1.81833424,  19.331126 100.00000,  0.00000 100.00000 100  27.483444  27.483444,100.00000,100.00000  50.662252,100.00000, 27.483444, 22  4  3  39.39735,1.000000, 9 1,Bahram | Benzing | Choi | Davis | Felmet | Garcia | Kang | Pan | Soori 2014 | 2019 | 2015 | 2017 | 1998 | 2016 | 2011 | 2020,Seiffer,10.1177/10870547211017982 Physical training NA NA Passive,NA RCT,DSM-III, DSM-IV, DSM-IV-TR, DSM-5, ICD-9, or ICD-10 | DSM-III, DSM-IV, DSM-IV-TR, DSM-5, ICD-9, or ICD-11 | DSM-III, DSM-IV, DSM-IV-TR, DSM-5, ICD-9, or ICD-12 | DSM-III, DSM-IV, DSM-IV-TR, DSM-5, ICD-9, or ICD-13 | DSM-III, DSM-IV, DSM-IV-TR, DSM-5, ICD-9, or ICD-15 | DSM-III, DSM-IV, DSM-IV-TR, DSM-5, ICD-9, or ICD-17,No intervention | WLC (wait-list control) | Not a therapeutic intervention sessions,High 8.49,15.9,NA,NA,Executive functioning (tests) | Acceptability: all-cause discontinuation | Social-communication skills | Combined ADHD symptoms (inattentive + hyperactive/impulsive),Huang (2022) | Seiffer (2022) | Ostinelli (2025),7.7 35.3230769230769 NA,NA NA,NA NA NA,< 2 months NA NA,19.33sessions,6-17 yo Homogeneous,Physical training_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Mixed_At study endpoint (closest to 12 weeks)_6-17 yo,Seiffer (2022) - Physical training_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Mixed_At study endpoint (closest to 12 weeks)_6-17 yo Physical training_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Mixed_At study endpoint (closest to 12 weeks)_6-17 yo - [Homogeneous],2022,Physical training_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Mixed_At study endpoint (closest to 12 weeks),228 TRUE,Seiffer (2022)_Physical training_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Mixed_At study endpoint (closest to 12 weeks) Seiffer (2022)_Physical training_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Mixed_At study endpoint (closest to 12 weeks),100.00000
Seiffer (2022) Physical training Social-communication skills Mixed,At study endpoint (closest to 12 weeks),  90  8.490000  8.490000, 8.490000, 8.490000  8.900000,10.270000,10.490000 10.490000,3228   0.000000  27.06667,  7.666667, 9.194000,NA, 1.92302775,  17.511111 100.00000,  0.00000,100.00000 100   8.888889,  8.888889,100.00000,100.00000, 80.000000 100.00000   8.888889  22  4, 3  27.06667,1.000000  4 1,Davis | Garcia | Kang | Pan 2017 | 2016 | 2011 Seiffer 10.1177/10870547211017982,Physical training,NA Questionnaire | Unclear (not able to identify the tools used to measure the outcome) SDQ | CBCL,NA,RCT,DSM-III, DSM-IV, DSM-IV-TR, DSM-5, ICD-9, or ICD-12 | DSM-III, DSM-IV, DSM-IV-TR, DSM-5, ICD-9, or ICD-13 | DSM-III, DSM-IV, DSM-IV-TR, DSM-5, ICD-9, or ICD-15 | DSM-III, DSM-IV, DSM-IV-TR, DSM-5, ICD-9, or ICD-17 WLC (wait-list control) | Not a therapeutic intervention,sessions,High 8.49 10.49,NA NA Executive functioning (tests) | Acceptability: all-cause discontinuation | Social-communication skills | Combined ADHD symptoms (inattentive + hyperactive/impulsive),Huang (2022) | Seiffer (2022) | Ostinelli (2025),7.7,35.3230769230769,NA,NA NA NA NA,NA < 2 months NA,NA 17.51sessions 6-17 yo Homogeneous Physical training_Social-communication skills_Mixed_At study endpoint (closest to 12 weeks)_6-17 yo Seiffer (2022) - Physical training_Social-communication skills_Mixed_At study endpoint (closest to 12 weeks)_6-17 yo,Physical training_Social-communication skills_Mixed_At study endpoint (closest to 12 weeks)_6-17 yo - [Homogeneous],2022,Physical training_Social-communication skills_Mixed_At study endpoint (closest to 12 weeks) 229 TRUE,Seiffer (2022)_Physical training_Social-communication skills_Mixed_At study endpoint (closest to 12 weeks) Seiffer (2022)_Physical training_Social-communication skills_Mixed_At study endpoint (closest to 12 weeks) 100.00000
Sonuga-Barke (2014) Diet (restricted/elimination) Combined ADHD symptoms (inattentive + hyperactive/impulsive) Mixed,At study endpoint (closest to 12 weeks), 218, 4.500000, 4.500000  4.500000, 7.500000  7.500000  9.500000, 9.500000, 9.500000 3367,  0.000000  66.84404  10.880734  7.711009,NA, 0.36211611 NA,100.00000   0.00000,100.00000,100,  0.000000   0.000000  77.06422   0.00000 100.000000,  0.00000,100.000000,  8, 3, 2  66.84404 2.000000  4 1,Boris | Carter | Kaplan | Schmidt,1994 | 1993 | 1989 | 1997,Sonuga-Barke 10.1176/appi.ajp.2012.12070991,known antigenic food | specific provoking food | oligoantigenic diet NA Questionnaire | Questionnaire | Observational tool,CPRS | CPRS | Test session observation | CPRS | CTRS | CTRS NA RCT (parallel, crossover, open-label),DSM-III-R | DSM-III,Placebo | Not a therapeutic intervention NA,Moderate,4.5 9.5 NA,NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) Sonuga-Barke (2014) | Catala-Lopez (2017) 4.5,9.5,NA NA NA NA,NA,NA,< 2 months,NA,NA,NANA,6-17 yo Mixed Diet (restricted/elimination)_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Mixed_At study endpoint (closest to 12 weeks)_6-17 yo,Sonuga-Barke (2014) - Diet (restricted/elimination)_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Mixed_At study endpoint (closest to 12 weeks)_6-17 yo Diet (restricted/elimination)_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Mixed_At study endpoint (closest to 12 weeks)_6-17 yo - [Mixed] 2014,Diet (restricted/elimination)_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Mixed_At study endpoint (closest to 12 weeks) 230 FALSE Sonuga-Barke (2014)_Diet (restricted/elimination)_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Mixed_At study endpoint (closest to 12 weeks) Sonuga-Barke (2014)_Diet (restricted/elimination)_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Mixed_At study endpoint (closest to 12 weeks) 100.00000
Storebo (2019) Social skill training Academic/job performance Teacher-rated,At follow-up (closest to 26 weeks)   53 10.396226 10.396226 10.396226 10.396226,10.396226 10.396226,10.396226,10.396226,3419   0.000000  53.00000, 29.000000,10.396226  94.35849, 1.84119678 NA,100.00000 100.00000,100.00000 100 100.000000 100.000000 100.00000   0.00000 100.000000 100.00000,100.000000   5, 3, 1, 53.00000 1.000000  1 1,Storebo,2012,Storebo 10.1002/14651858.CD008223.pub3,Social skill training NA Mixed (different types of tool are used),Classroom Performance Survey (CPS) + Conners Behavior Rating Scale (CBRS): Academic Performance Index + Social Skills Improvement System (SSIS): Academic Competence Scale + Academic Performance Rating Scale (APRS) + Wechsler Individual Achievement Test (WIAT) + German teacher-rated questionnaire for learning and working behavior (Arbeitsverhalten Lehrer),NA RCT,DSM-IV,TAU,NA High 10.3962264150943 10.3962264150943,94.3584905660377 94.3584905660377 Social-communication skills | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Academic/job performance,Storebo (2019),9 11.2 94.3418181818182,100,NA  96.9191 94.35 100.00,< 2 months,Average (80-119),NA,NANA,6-17 yo,Homogeneous Social skill training_Academic/job performance_Teacher-rated_At follow-up (closest to 26 weeks)_6-17 yo,Storebo (2019) - Social skill training_Academic/job performance_Teacher-rated_At follow-up (closest to 26 weeks)_6-17 yo,Social skill training_Academic/job performance_Teacher-rated_At follow-up (closest to 26 weeks)_6-17 yo - [Homogeneous] 2019 Social skill training_Academic/job performance_Teacher-rated_At follow-up (closest to 26 weeks),231,TRUE Storebo (2019)_Social skill training_Academic/job performance_Teacher-rated_At follow-up (closest to 26 weeks),Storebo (2019)_Social skill training_Academic/job performance_Teacher-rated_At follow-up (closest to 26 weeks) 100.00000
Storebo (2019) Social skill training,Academic/job performance,Teacher-rated,At study endpoint (closest to 12 weeks),  50 10.392000,10.392000 10.392000 10.392000,10.392000,10.392000,10.392000 10.392000 3419   0.000000  50.00000  29.000000,10.392000  94.36800  1.84119678,NA 100.00000 100.00000,100.00000,100,100.000000,100.000000,100.00000   0.00000 100.000000,100.00000 100.000000,  5  3, 1  50.00000 1.000000  1,1,Storebo 2012 Storebo,10.1002/14651858.CD008223.pub3,Social skill training NA,Mixed (different types of tool are used),Classroom Performance Survey (CPS) + Conners Behavior Rating Scale (CBRS): Academic Performance Index + Social Skills Improvement System (SSIS): Academic Competence Scale + Academic Performance Rating Scale (APRS) + Wechsler Individual Achievement Test (WIAT) + German teacher-rated questionnaire for learning and working behavior (Arbeitsverhalten Lehrer),NA RCT DSM-IV TAU NA High 10.392 10.392 94.368 94.368,Social-communication skills | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Academic/job performance,Storebo (2019) 9,11.2 94.3418181818182 100 NA  96.9191,94.35,100.00,< 2 months Average (80-119),NA NANA 6-17 yo Homogeneous Social skill training_Academic/job performance_Teacher-rated_At study endpoint (closest to 12 weeks)_6-17 yo,Storebo (2019) - Social skill training_Academic/job performance_Teacher-rated_At study endpoint (closest to 12 weeks)_6-17 yo Social skill training_Academic/job performance_Teacher-rated_At study endpoint (closest to 12 weeks)_6-17 yo - [Homogeneous] 2019,Social skill training_Academic/job performance_Teacher-rated_At study endpoint (closest to 12 weeks),232 TRUE Storebo (2019)_Social skill training_Academic/job performance_Teacher-rated_At study endpoint (closest to 12 weeks),Storebo (2019)_Social skill training_Academic/job performance_Teacher-rated_At study endpoint (closest to 12 weeks) 100.00000
Storebo (2019),Social skill training Combined ADHD symptoms (inattentive + hyperactive/impulsive) Teacher-rated At follow-up (closest to 26 weeks)   55 10.403636,10.403636,10.403636 10.403636,10.403636 10.403636 10.403636,10.403636 3419,  0.000000, 55.00000  29.000000,10.403636, 94.34182, 1.84119678 NA,100.00000,100.00000,100.00000 100,100.000000 100.000000 100.00000,  0.00000,100.000000,100.00000 100.000000   5  3  1  55.00000 1.000000, 1 1,Storebo 2012 Storebo 10.1002/14651858.CD008223.pub3 Social skill training,NA Mixed (different types of tool are used),Disruptive Behavior Disorders Rating Scale + ADHD Rating Scales: Hyperactivity and Impulsivity Subscales (total scores) + Conner Teacher Rating Scale: Hyperactivity Index + Strengths and Weaknesses of ADHD Symptoms and Normal Behaviors + ADHD Symptom Checklist + Child Symptom Inventory (ADHD (inattention) scale score) + SNAP-IV (teacher rating scale) NA RCT,DSM-IV,TAU NA High,10.4036363636364,10.4036363636364 94.3418181818182 94.3418181818182,Social-communication skills | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Academic/job performance,Storebo (2019) 9,11.2,94.3418181818182,100,NA, 96.9191,94.35,100.00,< 2 months,Average (80-119) NA,NANA 6-17 yo Homogeneous,Social skill training_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Teacher-rated_At follow-up (closest to 26 weeks)_6-17 yo,Storebo (2019) - Social skill training_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Teacher-rated_At follow-up (closest to 26 weeks)_6-17 yo,Social skill training_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Teacher-rated_At follow-up (closest to 26 weeks)_6-17 yo - [Homogeneous],2019 Social skill training_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Teacher-rated_At follow-up (closest to 26 weeks),233 TRUE,Storebo (2019)_Social skill training_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Teacher-rated_At follow-up (closest to 26 weeks),Storebo (2019)_Social skill training_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Teacher-rated_At follow-up (closest to 26 weeks),100.00000
Storebo (2019),Social skill training Combined ADHD symptoms (inattentive + hyperactive/impulsive) Teacher-rated,At study endpoint (closest to 12 weeks),  83  9.200000, 9.200000, 9.200000, 9.200000,10.400000 10.400000,10.400000,10.400000 3419,  0.000000, 45.26506  29.000000, 9.980723, 96.32410  1.59995563 NA 100.00000,100.00000,100.00000 100  65.060241, 65.060241 100.00000   0.00000 100.000000 100.00000  65.060241,  5  3, 1  45.26506 1.000000, 2,1 Hannesdottir | Storebo,2017 | 2012 Storebo 10.1002/14651858.CD008223.pub3,Social skill training NA Mixed (different types of tool are used) Disruptive Behavior Disorders Rating Scale + ADHD Rating Scales: Hyperactivity and Impulsivity Subscales (total scores) + Conner Teacher Rating Scale: Hyperactivity Index + Strengths and Weaknesses of ADHD Symptoms and Normal Behaviors + ADHD Symptom Checklist + Child Symptom Inventory (ADHD (inattention) scale score) + SNAP-IV (teacher rating scale) NA,RCT,diagnosed by a licensed clinical psychologist or medical doctor | DSM-IV,WLC (wait-list control) | TAU NA,High,9.2,10.4 94.35 100,Social-communication skills | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Academic/job performance Storebo (2019),9 11.2,94.3418181818182,100 NA  96.9191 94.35,100.00 < 2 months Average (80-119),NA,NANA,6-17 yo,Homogeneous Social skill training_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Teacher-rated_At study endpoint (closest to 12 weeks)_6-17 yo,Storebo (2019) - Social skill training_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Teacher-rated_At study endpoint (closest to 12 weeks)_6-17 yo Social skill training_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Teacher-rated_At study endpoint (closest to 12 weeks)_6-17 yo - [Homogeneous],2019 Social skill training_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Teacher-rated_At study endpoint (closest to 12 weeks) 234,TRUE,Storebo (2019)_Social skill training_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Teacher-rated_At study endpoint (closest to 12 weeks),Storebo (2019)_Social skill training_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Teacher-rated_At study endpoint (closest to 12 weeks),100.00000
Storebo (2019),Social skill training,Social-communication skills Mixed,At follow-up (closest to 26 weeks)   73, 9.000000, 9.000000, 9.000000,10.403636 10.403636 10.403636 10.403636,10.403636,3419,  0.000000  45.87671, 29.246575,10.057534, 94.34182  1.84119678 NA,100.00000, 75.34247,100.00000 100  75.342466, 75.342466 100.00000   0.00000,100.000000  75.34247  75.342466   5, 3  1, 45.87671 1.000000  2,1 Pfiffner | Storebo,1997 | 2012 Storebo 10.1002/14651858.CD008223.pub3,Social skill training NA Mixed (different types of tool are used) Conners Behavior Rating Scale: Social Problems Index + Strength and Difficulties Questionnaire: Prosocial Behaviour Subscale (teacher-rated) + Social Skills Improvement System + Social Skills Rating Scale: Coorperation Subscale,NA RCT DSM-III-R | DSM-IV,WLC (wait-list control) | TAU NA High,9 10.4036363636364 94.3418181818182,94.3418181818182 Social-communication skills | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Academic/job performance Storebo (2019),9 11.2 94.3418181818182 100,NA  96.9191,94.35 100.00,< 2 months Average (80-119) NA,NANA 6-17 yo,Homogeneous Social skill training_Social-communication skills_Mixed_At follow-up (closest to 26 weeks)_6-17 yo,Storebo (2019) - Social skill training_Social-communication skills_Mixed_At follow-up (closest to 26 weeks)_6-17 yo,Social skill training_Social-communication skills_Mixed_At follow-up (closest to 26 weeks)_6-17 yo - [Homogeneous],2019,Social skill training_Social-communication skills_Mixed_At follow-up (closest to 26 weeks) 235,TRUE,Storebo (2019)_Social skill training_Social-communication skills_Mixed_At follow-up (closest to 26 weeks),Storebo (2019)_Social skill training_Social-communication skills_Mixed_At follow-up (closest to 26 weeks),100.00000
Storebo (2019),Social skill training,Social-communication skills,Mixed At study endpoint (closest to 12 weeks), 270  9.200000, 9.200000 10.000000,10.000000 10.000000,10.400000 11.200000 11.200000 3419,  0.000000, 77.34074, 32.188889,10.145185, 98.78929, 2.11975085 NA,100.00000, 93.33333 100.00000,100  20.000000, 20.000000,100.00000   0.00000 100.000000, 93.33333, 20.000000,  5  3, 1  77.34074 1.511111  5 1,Antshel | Choib | Hannesdottir | Pfiffner | Storebo 2003 | 2015 | 2017 | 1997 | 2012 Storebo 10.1002/14651858.CD008223.pub3 Social skill training,NA,Mixed (different types of tool are used) | Questionnaire | Questionnaire | Mixed (different types of tool are used),Social Skills Rating Scale + Weiss Functional Impairment Scale: Social Acitivities Domain (parent-rated) + Strength and Difficulties Questionnaire: Prosocial Behavior Subscale + Social Skills Improvement System | Social Skills Rating Scale (SSRS) + Strengths and Difficulties Questionnaire (SDQ): Prosocial Behavior Subscale | Social Skills Rating Scale (SSRS) + Strengths and Difficulties Questionnaire (SDQ): Prosocial Behavior Subscale | Social Skills Rating Scale + Weiss Functional Impairment Scale: Social Acitivities Domain (parent-rated) + Strength and Difficulties Questionnaire: Prosocial Behavior Subscale + Social Skills Improvement System | Conners Behavior Rating Scale: Social Problems Index + Strength and Difficulties Questionnaire: Prosocial Behaviour Subscale (teacher-rated) + Social Skills Improvement System + Social Skills Rating Scale: Coorperation Subscale | Social Skills Rating Scale + Weiss Functional Impairment Scale: Social Acitivities Domain (parent-rated) + Strength and Difficulties Questionnaire: Prosocial Behavior Subscale + Social Skills Improvement System | Conners Behavior Rating Scale: Social Problems Index + Strength and Difficulties Questionnaire: Prosocial Behaviour Subscale (teacher-rated) + Social Skills Improvement System + Social Skills Rating Scale: Coorperation Subscale NA RCT DSM-IV (DICA-R-P) | DSM-IV | diagnosed by a licensed clinical psychologist or medical doctor | DSM-III-R,WLC (wait-list control) | TAU,NA,High,9 11.2 94.35,100 Social-communication skills | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Academic/job performance Storebo (2019),9,11.2 94.3418181818182 100,NA  96.9191 94.35,100.00 2-6 months Average (80-119) NA NANA,6-17 yo Homogeneous Social skill training_Social-communication skills_Mixed_At study endpoint (closest to 12 weeks)_6-17 yo Storebo (2019) - Social skill training_Social-communication skills_Mixed_At study endpoint (closest to 12 weeks)_6-17 yo Social skill training_Social-communication skills_Mixed_At study endpoint (closest to 12 weeks)_6-17 yo - [Homogeneous],2019,Social skill training_Social-communication skills_Mixed_At study endpoint (closest to 12 weeks),236,TRUE,Storebo (2019)_Social skill training_Social-communication skills_Mixed_At study endpoint (closest to 12 weeks) Storebo (2019)_Social skill training_Social-communication skills_Mixed_At study endpoint (closest to 12 weeks) 100.00000
Storebo (2023),Methylphenidate,Combined ADHD symptoms (inattentive + hyperactive/impulsive) Parent-rated,At follow-up (closest to 26 weeks)  322, 8.270000  8.270000, 8.400000, 8.400000, 8.400000  8.400000  8.400000, 8.400000 3425  18.633540 224.36025  22.478261  8.375776,100.40000 13.46589569   30.877640 100.00000, 81.36646,100.00000 100,  0.000000,  0.000000  81.36646   0.00000,  0.000000 100.00000,  0.000000,141 14,11,224.36025,1.000000  2 1,Barragan | Jensen,2017 | 1999 Storebo,10.1002/14651858.CD009885.pub3,LA-MPH | MPH Omega3/6 Questionnaire ADHD-RS | SNAP Inattention and Hyperactivity-Impulsivity subscale NA,RCT (parallel, crossover, open-label) DSM-IV-TR | DSM-IV Active (any credible active intervention) | TAU mg/kg/d | mg/d High 8.27,8.4,100.4,100.4 Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events),Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018),4.42,50.1 60,109.9 NA  99.5875,97.45,105.60,> 12 months Average (80-119) NA,30.88mg/kg/d | mg/d,6-17 yo Homogeneous,Methylphenidate_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At follow-up (closest to 26 weeks)_6-17 yo,Storebo (2023) - Methylphenidate_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At follow-up (closest to 26 weeks)_6-17 yo Methylphenidate_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At follow-up (closest to 26 weeks)_6-17 yo - [Homogeneous],2023,Methylphenidate_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At follow-up (closest to 26 weeks),237,FALSE,Storebo (2023)_Methylphenidate_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At follow-up (closest to 26 weeks) Storebo (2023)_Methylphenidate_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At follow-up (closest to 26 weeks),100.00000
Storebo (2023),Methylphenidate,Quality of life (patients),Mixed At study endpoint (closest to 12 weeks)  514 10.175097 10.175097 10.175097,10.175097 10.537549,10.900000,10.900000,10.900000,3425,  0.000000,226.04280, 21.839300,10.586576  99.25759, 2.01934605   39.520661,100.00000, 50.00000 100.00000 100 100.000000 100.000000 100.00000,100.00000 100.000000,100.00000,100.000000 141,14 11,226.04280,1.000000, 3,1,Coghill | Newcorn | Szobot 2013 | 2008 | 2004 Storebo,10.1002/14651858.CD009885.pub3 ER-MPH | SODAS-MPH NA,Questionnaire Child Health and Illness Profile | Child Health Questionnaire (CHQ) | Children´s Global Assessment Scale (CGAS) NA RCT (parallel, crossover, open-label),DSM-IV-TR | DSM-IV,Placebo,mg/d | mg/kg/d,High,10.1750972762646,11.6 94.7,100 Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events) Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018) 4.42 50.1,60,109.9 NA, 99.5875 97.45 105.60,2-6 months Average (80-119) NA 39.52mg/d | mg/kg/d,6-17 yo Homogeneous Methylphenidate_Quality of life (patients)_Mixed_At study endpoint (closest to 12 weeks)_6-17 yo Storebo (2023) - Methylphenidate_Quality of life (patients)_Mixed_At study endpoint (closest to 12 weeks)_6-17 yo Methylphenidate_Quality of life (patients)_Mixed_At study endpoint (closest to 12 weeks)_6-17 yo - [Homogeneous],2023,Methylphenidate_Quality of life (patients)_Mixed_At study endpoint (closest to 12 weeks) 238 FALSE Storebo (2023)_Methylphenidate_Quality of life (patients)_Mixed_At study endpoint (closest to 12 weeks),Storebo (2023)_Methylphenidate_Quality of life (patients)_Mixed_At study endpoint (closest to 12 weeks),100.00000
Storebo (2023) Methylphenidate,Specific adverse events: decreased appetite NA,At study endpoint (closest to 12 weeks) 6091, 8.200000  8.400000, 8.800000  9.000000, 9.100000, 9.600000,10.200000,10.710000 3425,  1.149237 354.38434  25.817679  9.290760 102.19636  0.80748369,  17.876617,100.00000, 28.15630,100.00000 100  73.600394  73.600394, 91.98818, 90.74044  91.643408  81.61221  94.188146 141,14,11,354.38434 1.000000 41 1 Barkley | Bhat | Brams | Buitelaar | Bukstein | CRIT124US02 | Castellanos | Chacko | Chronis | DuPaul | Findling | Fine | Fitzpatrick | Froehlich | Huang | Klorman | Kollins | Manos | McBride | McGough | Muniz | Musten | NCT02039908 | NCT02536105 | Pearson | Pelham | Ramtvedt | Rapport | Schulz | Sharp | Silva | Stein | Swanson | Wilens | Zeni,1989 | 2020 | 2012 | 1995 | 1998 | 1997 | 2005 | 2003 | 1996 | 2007 | 1993 | 1992 | 2018 | 2021 | 1990 | 2006 | 1999 | 1988 | 2008 | 2013 | 2001 | 2011 | 2010 | 2004 | 2009 Storebo,10.1002/14651858.CD009885.pub3,MPH | ER-d-MPH | LA-MPH | IR-MPH | ER-MPH | MPH transdermal | IR-MPH or ER-MPH | IR-MPH or transdermal-MPH ER-MPH, Standard-MPH or combination | MPH and aripiprazol Questionnaire | Interview | Unclear (not able to identify the tools used to measure the outcome) | Mixed (different types of tool are used) Barkley Side Effects Rating Scale: | Barkley Side Effects Rating Scale | Spontaneously reported Aes | Adverse effects checklist | Side Effects Rating Scale | Monitoring and reporting of Aes | AEs | daily ratings of the presence and severity
of common stimulant side effects | Pittsburgh Side Effects Rating Scale | Side Effects/Behavior Monitoring Scale | Side effects questionnaire: | Interviewed: 12 side effect symptoms: drawn from Subject’s Treatment Emergent Symptom Scale | Pittsburgh Side Effect Rating Scale | A structured interview | Side Effects Behavior Monitoring Scale | monitoring and recording all Aes | Side Effects Rating Scale (Barkley 1990) | side effect checklist | parents provided responses to questions on Aes | Barkley Side Effect Rating Scale | Recorded AEs described | Stimulant Side Effects Rating Scale (SSERS) | Side Effect Rating Scale (SERS; Barkley 1990) | Stimulant Side Effects Rating Scale (Barkley 1990) | Serious Adverse Event Rating Scale (SAERS) NA,RCT (parallel, crossover, open-label) DSM-III-R | DSM-IV | DSM/DISC-4 | DSM-III | DSM-5 | DSM-IV-TR Placebo | Placebo + aripiprazol mg/kg/d | mg/d | mg/h/d High,4.76,15,85 109.9 Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events) Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018),4.42,50.1 60,109.9,NA, 99.5875 97.45 105.60,< 2 months Average (80-119),NA 17.88mg/kg/d | mg/d | mg/h/d,6-17 yo,Homogeneous Methylphenidate_Specific adverse events: decreased appetite_NA_At study endpoint (closest to 12 weeks)_6-17 yo,Storebo (2023) - Methylphenidate_Specific adverse events: decreased appetite_NA_At study endpoint (closest to 12 weeks)_6-17 yo,Methylphenidate_Specific adverse events: decreased appetite_NA_At study endpoint (closest to 12 weeks)_6-17 yo - [Homogeneous],2023 Methylphenidate_Specific adverse events: decreased appetite_NA_At study endpoint (closest to 12 weeks) 239,FALSE Storebo (2023)_Methylphenidate_Specific adverse events: decreased appetite_NA_At study endpoint (closest to 12 weeks) Storebo (2023)_Methylphenidate_Specific adverse events: decreased appetite_NA_At study endpoint (closest to 12 weeks) 100.00000
Storebo (2023),Methylphenidate,Specific adverse events: sleep problems,NA,At study endpoint (closest to 12 weeks),5499, 8.200000  8.400000, 8.700000  9.000000  9.100000  9.600000 10.100000,10.430000 3425   1.272959 369.99873  26.626909  9.245637 102.27773  0.81499537,  18.566119 100.00000  30.82379,100.00000,100, 73.031460  73.031460  92.08947  89.74359  90.743772  80.94199  93.562466 141 14 11 369.99873,1.000000,37 1,Barkley | Bhat | Brams | Buitelaar | CRIT124US02 | Castellanos | Chronis | Corkum | DuPaul | Findling | Fine | Fitzpatrick | Froehlich | Huang | Klorman | Kollins | Manos | Muniz | Musten | NCT02039908 | NCT02536105 | Pearson | Pelham | Ramtvedt | Rapport | Sharp | Silva | Stein | Swanson | Wigal | Wilens | Zeni,1989 | 2020 | 2012 | 1995 | 1997 | 2003 | 2008 | 1996 | 2007 | 1993 | 1992 | 2018 | 2021 | 1990 | 2006 | 1999 | 2013 | 2001 | 2005 | 2011 | 2004 | 2014 | 2010 | 2009 Storebo 10.1002/14651858.CD009885.pub3,MPH | ER-d-MPH | LA-MPH | IR-MPH | ER-MPH | IR-MPH or ER-MPH | MPH transdermal | MPH-MLR,ER-MPH, Standard-MPH or combination | MPH and aripiprazol,Questionnaire | Interview | Unclear (not able to identify the tools used to measure the outcome) | Mixed (different types of tool are used) | Observational tool Barkley Side Effects Rating Scale: | Barkley Side Effects Rating Scale | Spontaneously reported Aes | Adverse effects checklist | Monitoring and reporting of Aes | AEs | Pittsburgh Side Effects Rating Scale | Sleep Disturbances Scale for Children; Actigraphy; Sleep diary | Side Effects/Behavior Monitoring Scale | Side effects questionnaire: | Interviewed: 12 side effect symptoms: drawn from Subject’s Treatment Emergent Symptom Scale | Pittsburgh Side Effect Rating Scale | A structured interview | Parent Adverse Events Checklist | Side Effects Behavior Monitoring Scale | monitoring and recording all Aes | Side Effects Rating Scale (Barkley 1990) | side effect checklist | parents provided responses to questions on Aes | Barkley Side Effect Rating Scale | Recorded AEs described | Sleep log | Side Effect Rating Scale (SERS; Barkley 1990) | Sleep measured by actigraphy and questionnaires | Serious Adverse Event Rating Scale (SAERS) NA RCT (parallel, crossover, open-label) DSM-III-R | DSM-IV | DSM/DISC-4 | DSM-III | DSM-5 | DSM-IV-TR | DSM-IV-TR/KSADS,Placebo | Placebo + aripiprazol mg/kg/d | mg/d | mg/h/d,High 4.76 15,85,109.9 Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events) Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018) 4.42 50.1 60 109.9 NA, 99.5875,97.45 105.60,< 2 months Average (80-119),NA,18.57mg/kg/d | mg/d | mg/h/d 6-17 yo Homogeneous,Methylphenidate_Specific adverse events: sleep problems_NA_At study endpoint (closest to 12 weeks)_6-17 yo Storebo (2023) - Methylphenidate_Specific adverse events: sleep problems_NA_At study endpoint (closest to 12 weeks)_6-17 yo,Methylphenidate_Specific adverse events: sleep problems_NA_At study endpoint (closest to 12 weeks)_6-17 yo - [Homogeneous] 2023 Methylphenidate_Specific adverse events: sleep problems_NA_At study endpoint (closest to 12 weeks) 240 FALSE,Storebo (2023)_Methylphenidate_Specific adverse events: sleep problems_NA_At study endpoint (closest to 12 weeks) Storebo (2023)_Methylphenidate_Specific adverse events: sleep problems_NA_At study endpoint (closest to 12 weeks),100.00000
Storebo (2023) Methylphenidate,Suicidal ideation/behavior,Mixed,At study endpoint (closest to 12 weeks),1032, 9.000000  9.200000, 9.400000, 9.400000,14.700000,14.700000,14.700000 14.700000 3425,  0.000000 224.99612  34.287112,12.459496 NA  1.09990098,  41.858189,100.00000,  0.00000 100.00000,100  89.341085  89.341085 100.00000 100.00000, 41.472868  89.34109,100.000000 141 14,11,224.99612 1.225775, 6,1,Childress | NCT02293655 | Newcorn | Wigal,2017 | 2020 | 2017a | 2017b Storebo 10.1002/14651858.CD009885.pub3 ER-MPH | MPH,NA Questionnaire C-SSRS NA,RCT (parallel, crossover, open-label),DSM-IV-TR | DSM-5 | DSM-IV-TR/KSADS,Placebo mg/d High,9 14.7,NA,NA Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events),Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018),4.42,50.1 60,109.9,NA  99.5875,97.45,105.60,< 2 months,NA,NA 41.86mg/d 6-17 yo,Homogeneous Methylphenidate_Suicidal ideation/behavior_Mixed_At study endpoint (closest to 12 weeks)_6-17 yo Storebo (2023) - Methylphenidate_Suicidal ideation/behavior_Mixed_At study endpoint (closest to 12 weeks)_6-17 yo,Methylphenidate_Suicidal ideation/behavior_Mixed_At study endpoint (closest to 12 weeks)_6-17 yo - [Homogeneous] 2023,Methylphenidate_Suicidal ideation/behavior_Mixed_At study endpoint (closest to 12 weeks) 241 FALSE,Storebo (2023)_Methylphenidate_Suicidal ideation/behavior_Mixed_At study endpoint (closest to 12 weeks),Storebo (2023)_Methylphenidate_Suicidal ideation/behavior_Mixed_At study endpoint (closest to 12 weeks) 100.00000
Stuhec (2015) Bupropion,Combined ADHD symptoms (inattentive + hyperactive/impulsive) Mixed,At study endpoint (closest to 12 weeks)  124, 8.500000  8.500000  8.500000, 8.500000, 8.500000, 8.500000  8.500000  8.500000 3442,  0.000000, 80.64516   8.554839  8.500000,NA  0.92059839    5.300000, 77.41935,  0.00000,100.00000,100  77.419355  77.419355 100.00000 100.00000  77.419355, 77.41935 100.000000, 10  7, 6, 80.64516,1.000000, 2 1,Clay | Conners,1998 | 1996 Stuhec,10.1016/j.jad.2015.03.006,Bupropion,NA,Questionnaire Conners' Parent Rating Scale NA RCT (parallel, crossover, open-label) DSM-III,Placebo,mg/d Critically low 8.5,8.5,NA NA Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Depressive disorder symptoms | Generalized anxiety | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Executive functioning (tests) | Emotional dysregulation Stuhec (2015) | Verbeeck (2017) | Ostinelli (2025) | Cortese - Children (2018) | Cortese - Adults (2018) | Catala-Lopez (2017) 8.5,40.25 NA NA,NA NA,NA NA,< 2 months,NA,NA,5.3mg/d 6-17 yo,Homogeneous Bupropion_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Mixed_At study endpoint (closest to 12 weeks)_6-17 yo Stuhec (2015) - Bupropion_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Mixed_At study endpoint (closest to 12 weeks)_6-17 yo,Bupropion_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Mixed_At study endpoint (closest to 12 weeks)_6-17 yo - [Homogeneous] 2015 Bupropion_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Mixed_At study endpoint (closest to 12 weeks),242,TRUE Stuhec (2015)_Bupropion_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Mixed_At study endpoint (closest to 12 weeks) Stuhec (2015)_Bupropion_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Mixed_At study endpoint (closest to 12 weeks),100.00000
Sugaya (2023),Methylphenidate Acceptability: all-cause discontinuation NA,At study endpoint (closest to 12 weeks)  216, 4.760000, 4.760000  4.760000  4.760000, 4.760000, 5.020000, 5.020000  5.020000 3448,  0.000000 108.33333  21.222222  4.882778 NA  1.35532541   20.239722,100.00000,  0.00000 100.00000 100,100.000000 100.000000,100.00000 100.00000, 47.222222,100.00000 100.000000,141,14,11,108.33333 1.000000, 2 1 Greenhill | Sugaya,2006 | 2022 Sugaya 10.1002/jcv2.12146 MPH-IR NA NA NA NA RCT (parallel, crossover, open-label),NA,Placebo,mg/d Low,4.76 5.02 NA NA,Specific adverse events: decreased appetite | Specific adverse events: sleep problems | Executive functioning (report) | Executive functioning (tests) | Driving | CGI | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Quality of life (patients) | Suicidal ideation/behavior | Tics/Tourette disorder symptoms | Acceptability: all-cause discontinuation | Generalized anxiety | Emotional dysregulation | Tolerability (discontinuation due to adverse events),Boesen (2022) | Elliott (2020) | Pievsky (2018) | Candido (2021) | Storebo (2023) | Farhat (2024) | Sugaya (2023) | Bryant (2021) | Chiu (2022) | Ostinelli (2025) | Cortese - Children (2018) 4.42 50.1,60 109.9 NA  99.5875 97.45,105.60,< 2 months,NA,NA,20.24mg/d < 6 yo Homogeneous,Methylphenidate_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_< 6 yo,Sugaya (2023) - Methylphenidate_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_< 6 yo Methylphenidate_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_< 6 yo - [Homogeneous] 2023,Methylphenidate_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks) 243 FALSE,Sugaya (2023)_Methylphenidate_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks) Sugaya (2023)_Methylphenidate_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks),100.00000
Talebi (2021) Zinc Combined ADHD symptoms (inattentive + hyperactive/impulsive) Mixed,At study endpoint (closest to 12 weeks), 489  7.880000  7.880000  9.310000, 9.310000  9.550000, 9.550000, 9.550000  9.920000,3490, 49.897751 116.74642 NA  9.186728 NA  2.06899311,  25.276074,100.00000,  0.00000,100.00000,100, 51.738241  51.738241, 89.36605 100.00000  60.531697, 62.37219, 89.366053   6, 3, 2,116.74642,1.000000, 6,1 Akhondzadeh | Arnold | Bilici | Noorazar | Salehi | Zamora,2004 | 2011 | 2019 | 2016 Talebi,10.1080/10408398.2021.1940833 NA,Methylphenidate Mixed (different types of tool are used) PTR-ADHDS | CPTRS & SNAP | ADHDS | CPQ | CPTRS | CGI NA RCT (parallel, crossover, open-label),DSM-IV | Psychiatrist & K-SADS Active (any credible active intervention) | Placebo mg/d Low 7.14 9.92 NA NA Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) Talebi (2021) | Catala-Lopez (2017),7.14,9.92 NA NA NA,NA NA,NA 2-6 months NA,NA 25.28mg/d,6-17 yo,Homogeneous,Zinc_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Mixed_At study endpoint (closest to 12 weeks)_6-17 yo,Talebi (2021) - Zinc_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Mixed_At study endpoint (closest to 12 weeks)_6-17 yo Zinc_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Mixed_At study endpoint (closest to 12 weeks)_6-17 yo - [Homogeneous] 2021 Zinc_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Mixed_At study endpoint (closest to 12 weeks) 244,NA,Talebi (2021)_Zinc_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Mixed_At study endpoint (closest to 12 weeks) Talebi (2021)_Zinc_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Mixed_At study endpoint (closest to 12 weeks) 100.00000
Verbeeck (2017) Bupropion Depressive disorder symptoms,Mixed At study endpoint (closest to 12 weeks)  184,32.700000 40.250000 40.250000 40.250000,40.250000,40.250000,40.250000 40.250000,3681   0.000000 145.26087  38.804348,39.347283 NA  1.81367889  432.065217,100.00000,  0.00000 100.00000,100,100.000000 100.000000,100.00000 100.00000   0.000000,100.00000,100.000000  10  7, 6 145.26087,1.000000  2,1,Kuperman | Wilens 2001 | 2005 Verbeeck,10.1002/14651858.CD009504.pub2 Bupropion,NA Questionnaire HAM-D,NA RCT (parallel, crossover, open-label),DSM-IV Placebo mg/d,High,32.7,40.25,NA,NA Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Depressive disorder symptoms | Generalized anxiety | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Executive functioning (tests) | Emotional dysregulation,Stuhec (2015) | Verbeeck (2017) | Ostinelli (2025) | Cortese - Children (2018) | Cortese - Adults (2018) | Catala-Lopez (2017) 8.5,40.25,NA,NA NA NA NA,NA < 2 months,NA,NA 432.07mg/d,>= 18 yo,Homogeneous,Bupropion_Depressive disorder symptoms_Mixed_At study endpoint (closest to 12 weeks)_>= 18 yo,Verbeeck (2017) - Bupropion_Depressive disorder symptoms_Mixed_At study endpoint (closest to 12 weeks)_>= 18 yo,Bupropion_Depressive disorder symptoms_Mixed_At study endpoint (closest to 12 weeks)_>= 18 yo - [Homogeneous],2017,Bupropion_Depressive disorder symptoms_Mixed_At study endpoint (closest to 12 weeks),245 TRUE,Verbeeck (2017)_Bupropion_Depressive disorder symptoms_Mixed_At study endpoint (closest to 12 weeks),Verbeeck (2017)_Bupropion_Depressive disorder symptoms_Mixed_At study endpoint (closest to 12 weeks),100.00000
Verbeeck (2017),Bupropion,Generalized anxiety,Mixed At study endpoint (closest to 12 weeks), 184,32.700000,40.250000 40.250000,40.250000,40.250000 40.250000 40.250000,40.250000 3681,  0.000000 145.26087  38.804348,39.347283,NA  1.81367889  432.065217,100.00000   0.00000 100.00000 100,100.000000,100.000000,100.00000 100.00000   0.000000 100.00000 100.000000, 10, 7  6 145.26087 1.000000  2 1 Kuperman | Wilens,2001 | 2005 Verbeeck,10.1002/14651858.CD009504.pub2,Bupropion NA Questionnaire,HAM-A NA,RCT (parallel, crossover, open-label),DSM-IV Placebo mg/d,High 32.7 40.25,NA,NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Depressive disorder symptoms | Generalized anxiety | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Executive functioning (tests) | Emotional dysregulation Stuhec (2015) | Verbeeck (2017) | Ostinelli (2025) | Cortese - Children (2018) | Cortese - Adults (2018) | Catala-Lopez (2017),8.5 40.25 NA,NA,NA,NA,NA NA < 2 months NA,NA,432.07mg/d >= 18 yo,Homogeneous,Bupropion_Generalized anxiety_Mixed_At study endpoint (closest to 12 weeks)_>= 18 yo,Verbeeck (2017) - Bupropion_Generalized anxiety_Mixed_At study endpoint (closest to 12 weeks)_>= 18 yo Bupropion_Generalized anxiety_Mixed_At study endpoint (closest to 12 weeks)_>= 18 yo - [Homogeneous],2017 Bupropion_Generalized anxiety_Mixed_At study endpoint (closest to 12 weeks),246 TRUE Verbeeck (2017)_Bupropion_Generalized anxiety_Mixed_At study endpoint (closest to 12 weeks) Verbeeck (2017)_Bupropion_Generalized anxiety_Mixed_At study endpoint (closest to 12 weeks),100.00000
Westwood - Adults (2024),Cognitive training,Combined ADHD symptoms (inattentive + hyperactive/impulsive),Parent-rated,At study endpoint (closest to 12 weeks)   44,38.910000,38.910000,38.910000 38.910000 38.910000,38.910000 38.910000,38.910000 3836   0.000000, 44.00000,NA,38.910000 NA  1.15074799    3.125000,100.00000   0.00000,100.00000,100 100.000000 100.000000 100.00000 100.00000,  0.000000 100.00000 100.000000  28  6  4  44.00000 1.000000  1 1 Dentz 2020b,Westwood - Adults,10.1038/s41380-023-02000-7,NA,NA,NA Conners-3AI NA,RCT,DSM-IV Cognitive placebo,h/week,High 38.91,38.91,NA NA,Academic/job performance | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (report) | Executive functioning (tests) | Acceptability: all-cause discontinuation | Quality of life (patients),Westwood - Children (2024) | Westwood - Adults (2024) | Ostinelli (2025) | Catala-Lopez (2017),6.55 41.5895454545455 NA NA NA NA NA NA < 2 months NA,NA 3.12h/week >= 18 yo,Homogeneous Cognitive training_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks)_>= 18 yo,Westwood - Adults (2024) - Cognitive training_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks)_>= 18 yo,Cognitive training_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks)_>= 18 yo - [Homogeneous],2024,Cognitive training_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks) 247,NA,Westwood - Adults (2024)_Cognitive training_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks),Westwood - Adults (2024)_Cognitive training_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks) 100.00000
Westwood - Adults (2024) Cognitive training,Executive functioning (report),Self-rated,At study endpoint (closest to 12 weeks),  39 37.200000 37.200000,37.200000,37.200000 37.200000,37.200000,37.200000,37.200000 3836,  0.000000, 39.00000 NA 37.200000 NA NA,NA,100.00000,  0.00000,100.00000,100   0.000000   0.000000,100.00000,  0.00000,  0.000000,100.00000   0.000000, 28, 6, 4, 39.00000 1.000000, 1,1 Stern,2016,Westwood - Adults 10.1038/s41380-023-02000-7 NA,NA NA BRIEF NA RCT,DSM-IV-TR Non-adaptive,h/week High 37.2 37.2 NA,NA,Academic/job performance | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (report) | Executive functioning (tests) | Acceptability: all-cause discontinuation | Quality of life (patients),Westwood - Children (2024) | Westwood - Adults (2024) | Ostinelli (2025) | Catala-Lopez (2017),6.55 41.5895454545455,NA NA NA,NA,NA,NA NA,NA,NA NAh/week,>= 18 yo,Homogeneous Cognitive training_Executive functioning (report)_Self-rated_At study endpoint (closest to 12 weeks)_>= 18 yo Westwood - Adults (2024) - Cognitive training_Executive functioning (report)_Self-rated_At study endpoint (closest to 12 weeks)_>= 18 yo,Cognitive training_Executive functioning (report)_Self-rated_At study endpoint (closest to 12 weeks)_>= 18 yo - [Homogeneous],2024 Cognitive training_Executive functioning (report)_Self-rated_At study endpoint (closest to 12 weeks),248 NA Westwood - Adults (2024)_Cognitive training_Executive functioning (report)_Self-rated_At study endpoint (closest to 12 weeks) Westwood - Adults (2024)_Cognitive training_Executive functioning (report)_Self-rated_At study endpoint (closest to 12 weeks),100.00000
Westwood - Adults (2024) Cognitive training Executive functioning (tests) NA,At study endpoint (closest to 12 weeks)  141,22.200000,22.200000 24.500000 24.500000 37.200000,38.910000 38.910000,38.910000,3836,  0.000000, 36.11474,NA 32.008584 NA, 1.15074799,   3.125000,100.00000,  0.00000 100.00000 100  31.473534, 31.473534, 58.51216  72.96137  41.487840,100.00000, 72.961373  28, 6  4, 36.43920 2.711016  4 1,Dentz | Dotare | Jaquerod | Stern,2020b | 2020 | 2016,Westwood - Adults,10.1038/s41380-023-02000-7 NA NA,NA,WAIS-III Matrix Reasoning subtest | Corsi Block Tapping Task (Combined Forward/Backward) | WAIS-III Digit Span (Combined Forward/Backward) | Attentional Network Task (aka Flanker Task), Flanker RT Effect (No-cue Incongruent-Congruent) | WAIS-IV Digit Span (Combined Forward/Backward) | GNG - Coms | IntegNeuro - Digit Span (Combined
Forward/Backward) | GNG - Oms | IntegNeuro - Choice RT, MRT | IntegNeuro - Switching of Attention,NA,RCT,DSM-IV | DSM-IV-TR Cognitive placebo | Non-adaptive,h/week High,22.2,38.91,NA NA,Academic/job performance | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (report) | Executive functioning (tests) | Acceptability: all-cause discontinuation | Quality of life (patients),Westwood - Children (2024) | Westwood - Adults (2024) | Ostinelli (2025) | Catala-Lopez (2017),6.55,41.5895454545455 NA,NA NA,NA NA NA,< 2 months,NA,NA 3.12h/week,>= 18 yo Homogeneous Cognitive training_Executive functioning (tests)_NA_At study endpoint (closest to 12 weeks)_>= 18 yo Westwood - Adults (2024) - Cognitive training_Executive functioning (tests)_NA_At study endpoint (closest to 12 weeks)_>= 18 yo,Cognitive training_Executive functioning (tests)_NA_At study endpoint (closest to 12 weeks)_>= 18 yo - [Homogeneous] 2024 Cognitive training_Executive functioning (tests)_NA_At study endpoint (closest to 12 weeks),249,NA Westwood - Adults (2024)_Cognitive training_Executive functioning (tests)_NA_At study endpoint (closest to 12 weeks),Westwood - Adults (2024)_Cognitive training_Executive functioning (tests)_NA_At study endpoint (closest to 12 weeks),100.00000
Westwood - Adults (2025),Neurofeedback Combined ADHD symptoms (inattentive + hyperactive/impulsive) Self-rated,At follow-up (closest to 26 weeks)   46,33.640000 33.640000 33.640000 33.640000,33.640000 33.640000 33.640000,33.640000, 998   0.000000  43.66667 NA 33.640000,NA  4.14269275,   1.600000,100.00000,  0.00000 100.00000 100   0.000000,  0.000000,100.00000 100.00000,100.000000,100.00000,  0.000000  36, 4  3, 46.00000,3.000000, 1 1 Barth 2021 Westwood - Adults 10.1001/jamapsychiatry.2024.3702,NA NA,4_mprox | 1_mprox ADHD-SB Global,NA,NA,DSM-IV Sham_semi_active h/week Moderate,33.64,33.64,NA,NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (tests) | Executive functioning (report) | Acceptability: all-cause discontinuation Westwood - Children (2025) | Westwood - Adults (2025) | Catala-Lopez (2017),8.57 36.9,NA NA NA NA NA,NA,2-6 months,NA,NA,1.6h/week >= 18 yo Homogeneous Neurofeedback_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Self-rated_At follow-up (closest to 26 weeks)_>= 18 yo Westwood - Adults (2025) - Neurofeedback_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Self-rated_At follow-up (closest to 26 weeks)_>= 18 yo,Neurofeedback_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Self-rated_At follow-up (closest to 26 weeks)_>= 18 yo - [Homogeneous] 2025,Neurofeedback_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Self-rated_At follow-up (closest to 26 weeks) 250 NA Westwood - Adults (2025)_Neurofeedback_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Self-rated_At follow-up (closest to 26 weeks) Westwood - Adults (2025)_Neurofeedback_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Self-rated_At follow-up (closest to 26 weeks) 100.00000
Westwood - Adults (2025) Neurofeedback Combined ADHD symptoms (inattentive + hyperactive/impulsive) Self-rated,At study endpoint (closest to 12 weeks),  54,33.640000 33.640000,33.640000 33.640000 33.640000,33.640000 36.900000 36.900000  998   0.000000, 34.25926 NA 34.424815 NA, 3.36700337,   1.600000,100.00000,  0.00000 100.00000 100  24.074074, 24.074074 100.00000,100.00000 100.000000,100.00000, 24.074074  36, 4, 3  34.25926 1.000000, 2,1,Barth | Zilverstand,2021 | 2017 Westwood - Adults,10.1001/jamapsychiatry.2024.3702 NA,NA,1_mprox ADHD-SB Global | ADHD DSM-IV rating scale - Combined NA RCT DSM-IV Sham_semi_active,h/week,Moderate,33.64,36.9 NA NA Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (tests) | Executive functioning (report) | Acceptability: all-cause discontinuation Westwood - Children (2025) | Westwood - Adults (2025) | Catala-Lopez (2017),8.57 36.9,NA NA,NA NA,NA,NA 2-6 months NA,NA,1.6h/week >= 18 yo,Homogeneous Neurofeedback_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Self-rated_At study endpoint (closest to 12 weeks)_>= 18 yo,Westwood - Adults (2025) - Neurofeedback_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Self-rated_At study endpoint (closest to 12 weeks)_>= 18 yo Neurofeedback_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Self-rated_At study endpoint (closest to 12 weeks)_>= 18 yo - [Homogeneous],2025,Neurofeedback_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Self-rated_At study endpoint (closest to 12 weeks) 251,NA,Westwood - Adults (2025)_Neurofeedback_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Self-rated_At study endpoint (closest to 12 weeks) Westwood - Adults (2025)_Neurofeedback_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Self-rated_At study endpoint (closest to 12 weeks) 100.00000
Westwood - Adults (2025) Neurofeedback,Executive functioning (tests) Self-rated At follow-up (closest to 26 weeks)   52,33.640000 33.640000,33.640000 33.640000 33.640000 33.640000,33.640000,33.640000, 998   0.000000  44.66667 NA 33.640000,NA  4.14269275,   1.600000 100.00000   0.00000 100.00000 100,  0.000000,  0.000000,100.00000,100.00000 100.000000,100.00000,  0.000000  36, 4, 3  52.00000,6.000000, 1,1 Barth,2021 Westwood - Adults 10.1001/jamapsychiatry.2024.3702 NA NA NA,d2-R Accuracy | GNG - False alarms | nback Reaction time 0b,NA,NA,DSM-IV,Sham_semi_active,h/week,Moderate 33.64 33.64 NA NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (tests) | Executive functioning (report) | Acceptability: all-cause discontinuation Westwood - Children (2025) | Westwood - Adults (2025) | Catala-Lopez (2017),8.57,36.9,NA,NA,NA,NA,NA,NA 2-6 months NA NA 1.6h/week,>= 18 yo Homogeneous Neurofeedback_Executive functioning (tests)_Self-rated_At follow-up (closest to 26 weeks)_>= 18 yo,Westwood - Adults (2025) - Neurofeedback_Executive functioning (tests)_Self-rated_At follow-up (closest to 26 weeks)_>= 18 yo,Neurofeedback_Executive functioning (tests)_Self-rated_At follow-up (closest to 26 weeks)_>= 18 yo - [Homogeneous],2025,Neurofeedback_Executive functioning (tests)_Self-rated_At follow-up (closest to 26 weeks) 252 NA Westwood - Adults (2025)_Neurofeedback_Executive functioning (tests)_Self-rated_At follow-up (closest to 26 weeks),Westwood - Adults (2025)_Neurofeedback_Executive functioning (tests)_Self-rated_At follow-up (closest to 26 weeks),100.00000
Westwood - Adults (2025) Neurofeedback Executive functioning (tests),Self-rated At study endpoint (closest to 12 weeks),  59,33.640000 33.640000,33.640000,33.640000,33.640000,33.640000 36.900000,36.900000  998,  0.000000, 36.48230 NA,34.390088,NA  3.40132591,   1.600000,100.00000,  0.00000,100.00000,100  23.008850, 23.008850,100.00000 100.00000,100.000000 100.00000, 23.008850, 36, 4, 3  38.40708 7.079646, 2,1,Barth | Zilverstand 2021 | 2017 Westwood - Adults 10.1001/jamapsychiatry.2024.3702,NA,NA,NA d2-R Accuracy | GNG - False alarms | n-back Composite Combined 1-back & 2-back | nback Reaction time 0b | 2-back visuospatial task % correct | Digit Span IQ | SA-DOTS - False Alarms | SART (equivalent to GNG) - Coms,NA,RCT DSM-IV,Sham_semi_active h/week Moderate 33.64 36.9,NA,NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (tests) | Executive functioning (report) | Acceptability: all-cause discontinuation,Westwood - Children (2025) | Westwood - Adults (2025) | Catala-Lopez (2017),8.57 36.9,NA,NA NA,NA,NA NA,2-6 months NA NA,1.6h/week,>= 18 yo,Homogeneous Neurofeedback_Executive functioning (tests)_Self-rated_At study endpoint (closest to 12 weeks)_>= 18 yo Westwood - Adults (2025) - Neurofeedback_Executive functioning (tests)_Self-rated_At study endpoint (closest to 12 weeks)_>= 18 yo Neurofeedback_Executive functioning (tests)_Self-rated_At study endpoint (closest to 12 weeks)_>= 18 yo - [Homogeneous] 2025,Neurofeedback_Executive functioning (tests)_Self-rated_At study endpoint (closest to 12 weeks) 253 NA,Westwood - Adults (2025)_Neurofeedback_Executive functioning (tests)_Self-rated_At study endpoint (closest to 12 weeks),Westwood - Adults (2025)_Neurofeedback_Executive functioning (tests)_Self-rated_At study endpoint (closest to 12 weeks) 100.00000
Westwood - Children (2024) Cognitive training,Academic/job performance NA At follow-up (closest to 26 weeks)  180, 8.980000, 8.980000, 8.980000,10.000000 10.500000 10.500000 11.590000 11.590000 3836   0.000000  48.96667,NA,10.301444,NA, 1.55809241    2.443142,100.00000   0.00000 100.00000 100  17.222222  17.222222,100.00000,100.00000, 82.777778, 76.66667, 40.555556, 28  6, 4, 48.96667 1.000000, 4 1 Bigorra | Egeland | Rivard (Dentz 2020a) | Sandberg 2016 | 2013 | 2020 | 2021 Westwood - Children,10.1038/s41380-023-02000-7,NA,NA NA Reading Comprehension Test | LOGOS Word Decoding Quality | WIAT-II Reading Comprehension | WIAT - Reading Comprehension NA RCT,DSM-IV | F-90 ICD-10 | DSM-V Non-adaptive | TAU | WLC,h/week,High,8.98,11.59 NA NA Academic/job performance | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (report) | Executive functioning (tests) | Acceptability: all-cause discontinuation | Quality of life (patients) Westwood - Children (2024) | Westwood - Adults (2024) | Ostinelli (2025) | Catala-Lopez (2017) 6.55 41.5895454545455,NA NA NA NA NA NA,< 2 months NA NA 2.44h/week 6-17 yo,Homogeneous Cognitive training_Academic/job performance_NA_At follow-up (closest to 26 weeks)_6-17 yo Westwood - Children (2024) - Cognitive training_Academic/job performance_NA_At follow-up (closest to 26 weeks)_6-17 yo Cognitive training_Academic/job performance_NA_At follow-up (closest to 26 weeks)_6-17 yo - [Homogeneous],2024 Cognitive training_Academic/job performance_NA_At follow-up (closest to 26 weeks),254,NA Westwood - Children (2024)_Cognitive training_Academic/job performance_NA_At follow-up (closest to 26 weeks),Westwood - Children (2024)_Cognitive training_Academic/job performance_NA_At follow-up (closest to 26 weeks) 100.00000
Westwood - Children (2024) Cognitive training Academic/job performance,NA,At study endpoint (closest to 12 weeks)  237, 8.400000  8.400000  8.400000, 8.400000 10.020000 10.500000 11.590000 11.590000,3836,  0.000000, 64.32754 NA  9.857164,NA  1.45604847    2.760204,100.00000   0.00000,100.00000,100, 52.098408  52.098408,100.00000 100.00000, 47.901592,100.00000, 52.098408, 28  6  4  65.58177,2.848046  4 1 Chacko | Dentz | Egeland | Sandberg 2014 | 2020a | 2013 | 2021 Westwood - Children,10.1038/s41380-023-02000-7 NA,NA NA WRAT - Word Reading | WRAT-Math Computation | WRAT Sentence Comprehension | WIAT-II Mathematical Reasoning | WIAT-II Reading Comprehension | Key Math | LOGOS Reading Fluency | LOGOS Word Decoding Quality | WIAT-III Math | WIAT - Reading Comprehension | WIAT - Reading Fluency NA RCT,DSM-IV --> "a diagnosis of ADHD through consensus diagnosis based on parent and teacher ratings on the Disruptive Behavior Disorder Rating Scales (DBD; Pelham, Gnagy, Greenslade, & Milich, 1992) and impairment using the Impairment Rating Scale (Fabiano et al., 2006); and a semistructured interview with the parent using the Kiddie-SADS (Kaufman, Birmaher, Brent, Rao, & Ryan, 1996)" | DSM-IV | F-90 ICD-10 | DSM-V,Non-adaptive | TAU | WLC h/week,High,8.4,11.59 NA,NA,Academic/job performance | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (report) | Executive functioning (tests) | Acceptability: all-cause discontinuation | Quality of life (patients) Westwood - Children (2024) | Westwood - Adults (2024) | Ostinelli (2025) | Catala-Lopez (2017),6.55,41.5895454545455,NA,NA,NA,NA,NA,NA < 2 months NA NA,2.76h/week 6-17 yo,Homogeneous,Cognitive training_Academic/job performance_NA_At study endpoint (closest to 12 weeks)_6-17 yo,Westwood - Children (2024) - Cognitive training_Academic/job performance_NA_At study endpoint (closest to 12 weeks)_6-17 yo Cognitive training_Academic/job performance_NA_At study endpoint (closest to 12 weeks)_6-17 yo - [Homogeneous],2024 Cognitive training_Academic/job performance_NA_At study endpoint (closest to 12 weeks),255,NA,Westwood - Children (2024)_Cognitive training_Academic/job performance_NA_At study endpoint (closest to 12 weeks) Westwood - Children (2024)_Cognitive training_Academic/job performance_NA_At study endpoint (closest to 12 weeks) 100.00000
Westwood - Children (2024) Cognitive training Combined ADHD symptoms (inattentive + hyperactive/impulsive),Clinician-rated At study endpoint (closest to 12 weeks)  111, 6.550000, 6.550000, 6.550000  6.550000  8.650000, 8.650000  8.650000, 8.650000,3836   0.000000  59.28829,NA, 7.874324,NA  3.32783877    1.407658,100.00000,  0.00000 100.00000,100,100.000000,100.000000,100.00000,100.00000,100.000000,100.00000 100.000000  28, 6  4, 59.28829,1.000000, 2 1,Steiner | van Dongen-Boomsma 2014 Westwood - Children 10.1038/s41380-023-02000-7 NA,NA,NA,BOSS | ADHD-RS NA,RCT DSM-IV | DSM-IV-TR,WLC | Non-adaptive,h/week High,6.55 8.65,NA NA Academic/job performance | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (report) | Executive functioning (tests) | Acceptability: all-cause discontinuation | Quality of life (patients) Westwood - Children (2024) | Westwood - Adults (2024) | Ostinelli (2025) | Catala-Lopez (2017),6.55,41.5895454545455 NA NA NA NA NA,NA 2-6 months,NA NA 1.41h/week 6-17 yo Homogeneous,Cognitive training_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks)_6-17 yo Westwood - Children (2024) - Cognitive training_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks)_6-17 yo Cognitive training_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks)_6-17 yo - [Homogeneous],2024 Cognitive training_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks) 256 NA,Westwood - Children (2024)_Cognitive training_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks) Westwood - Children (2024)_Cognitive training_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks) 100.00000
Westwood - Children (2024) Cognitive training,Combined ADHD symptoms (inattentive + hyperactive/impulsive),Parent-rated,At follow-up (closest to 26 weeks), 273  8.980000, 8.980000 10.020000 10.020000 11.590000,12.410000 12.410000 12.410000,3836   0.000000, 65.37363,NA 11.086337,NA  1.31935575    2.929762 100.00000,  0.00000,100.00000,100  33.699634, 33.699634 100.00000,100.00000, 66.300366  84.61538  49.084249  28, 6  4, 65.37363,1.000000  5,1,Bigorra | Dentz | Dovis | Hasslinger | Sandberg,2016 | 2020a | 2015 | 2021 Westwood - Children 10.1038/s41380-023-02000-7 NA,NA,NA CRS-R | Conners-3AI | DBDRS | Conners Rating Scale | CBCL - ADHD Total,NA,RCT,DSM-IV | DSM-IV-TR | ICD-10 | DSM-V Non-adaptive | TAU | WLC h/week High 8.98 12.41,NA NA,Academic/job performance | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (report) | Executive functioning (tests) | Acceptability: all-cause discontinuation | Quality of life (patients),Westwood - Children (2024) | Westwood - Adults (2024) | Ostinelli (2025) | Catala-Lopez (2017),6.55,41.5895454545455,NA NA NA NA NA NA < 2 months,NA,NA,2.93h/week 6-17 yo,Homogeneous,Cognitive training_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At follow-up (closest to 26 weeks)_6-17 yo Westwood - Children (2024) - Cognitive training_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At follow-up (closest to 26 weeks)_6-17 yo,Cognitive training_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At follow-up (closest to 26 weeks)_6-17 yo - [Homogeneous],2024,Cognitive training_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At follow-up (closest to 26 weeks) 257,NA,Westwood - Children (2024)_Cognitive training_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At follow-up (closest to 26 weeks),Westwood - Children (2024)_Cognitive training_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At follow-up (closest to 26 weeks) 100.00000
Westwood - Children (2024) Cognitive training,Combined ADHD symptoms (inattentive + hyperactive/impulsive) Parent-rated,At study endpoint (closest to 12 weeks), 533, 8.400000  8.400000  8.980000, 8.980000 10.020000 11.590000,12.410000,12.410000,3836,  0.000000, 62.48593 NA,10.259456 NA, 1.23969469    2.659857,100.00000   0.00000,100.00000,100  48.217636, 48.217636, 92.49531,100.00000  56.660413, 89.30582, 66.416510  28  6, 4  62.48593 1.048780 10,1,Bigorra | Chacko | Dentz | Dovis | Green | Hasslinger | Klingberg | Meyer | Sandberg | van da oord 2016 | 2014 | 2020a | 2015 | 2012 | 2021 | 2005 | 2020 Westwood - Children,10.1038/s41380-023-02000-7 NA NA NA CRS-R | DBD (Pelham et al., 1992) | Conners-3AI | DBDRS | CPRS | Conners Rating Scale | SNAP-IV | CBCL NA,RCT DSM-IV | DSM-IV --> "a diagnosis of ADHD through consensus diagnosis based on parent and teacher ratings on the Disruptive Behavior Disorder Rating Scales (DBD; Pelham, Gnagy, Greenslade, & Milich, 1992) and impairment using the Impairment Rating Scale (Fabiano et al., 2006); and a semistructured interview with the parent using the Kiddie-SADS (Kaufman, Birmaher, Brent, Rao, & Ryan, 1996)" | DSM-IV-TR | ICD-10 | DSM-IV --> "Confirmation of ADHD diagnosis was performed using the DISC-IV" | DSM-V Non-adaptive | TAU | WLC h/week High,8.4,12.41,NA,NA Academic/job performance | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (report) | Executive functioning (tests) | Acceptability: all-cause discontinuation | Quality of life (patients),Westwood - Children (2024) | Westwood - Adults (2024) | Ostinelli (2025) | Catala-Lopez (2017),6.55 41.5895454545455,NA,NA NA NA,NA NA,< 2 months,NA NA,2.66h/week,6-17 yo,Homogeneous Cognitive training_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks)_6-17 yo,Westwood - Children (2024) - Cognitive training_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks)_6-17 yo,Cognitive training_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks)_6-17 yo - [Homogeneous] 2024,Cognitive training_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks),258,NA,Westwood - Children (2024)_Cognitive training_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks) Westwood - Children (2024)_Cognitive training_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks),100.00000
Westwood - Children (2024),Cognitive training,Combined ADHD symptoms (inattentive + hyperactive/impulsive) Teacher-rated,At follow-up (closest to 26 weeks)   67 10.500000 10.500000,10.500000 10.500000 10.500000 10.500000 10.500000 10.500000,3836   0.000000  67.00000 NA,10.500000,NA NA NA,100.00000,  0.00000 100.00000 100   0.000000   0.000000 100.00000,100.00000 100.000000 100.00000   0.000000, 28, 6  4  67.00000 1.000000, 1,1,Egeland,2013,Westwood - Children 10.1038/s41380-023-02000-7,NA,NA,NA,ADHD-RS NA RCT F-90 ICD-10 TAU NA,High,10.5 10.5 NA NA Academic/job performance | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (report) | Executive functioning (tests) | Acceptability: all-cause discontinuation | Quality of life (patients) Westwood - Children (2024) | Westwood - Adults (2024) | Ostinelli (2025) | Catala-Lopez (2017) 6.55 41.5895454545455,NA NA NA,NA,NA,NA NA NA,NA,NANA 6-17 yo Homogeneous Cognitive training_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Teacher-rated_At follow-up (closest to 26 weeks)_6-17 yo,Westwood - Children (2024) - Cognitive training_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Teacher-rated_At follow-up (closest to 26 weeks)_6-17 yo Cognitive training_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Teacher-rated_At follow-up (closest to 26 weeks)_6-17 yo - [Homogeneous] 2024,Cognitive training_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Teacher-rated_At follow-up (closest to 26 weeks) 259 NA,Westwood - Children (2024)_Cognitive training_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Teacher-rated_At follow-up (closest to 26 weeks) Westwood - Children (2024)_Cognitive training_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Teacher-rated_At follow-up (closest to 26 weeks) 100.00000
Westwood - Children (2024) Cognitive training,Combined ADHD symptoms (inattentive + hyperactive/impulsive) Teacher-rated At study endpoint (closest to 12 weeks), 395  8.400000, 8.400000, 8.400000, 8.400000  9.900000,10.500000 10.600000 10.600000,3836,  0.000000, 61.05570,NA, 9.426481 NA  1.11727168,   2.386636 100.00000,  0.00000 100.00000 100, 58.481013, 58.481013  89.87342,100.00000, 49.620253, 85.56962, 83.037975, 28, 6, 4, 61.05570 1.000000, 7,1 Bigorra | Chacko | Dovis | Egeland | Klingberg | Meyer | van Dongen-Boomsma 2016 | 2014 | 2015 | 2013 | 2005 | 2020,Westwood - Children 10.1038/s41380-023-02000-7 NA,NA,NA CRS-R | DBD | DBDRS | ADHD-RS (DuPaul et al., 1998) | Conners Rating Scale | ADHD-RS,NA,RCT DSM-IV | DSM-IV --> "a diagnosis of ADHD through consensus diagnosis based on parent and teacher ratings on the Disruptive Behavior Disorder Rating Scales (DBD; Pelham, Gnagy, Greenslade, & Milich, 1992) and impairment using the Impairment Rating Scale (Fabiano et al., 2006); and a semistructured interview with the parent using the Kiddie-SADS (Kaufman, Birmaher, Brent, Rao, & Ryan, 1996)" | DSM-IV-TR | F-90 ICD-10 | DSM-IV --> "Confirmation of ADHD diagnosis was performed using the DISC-IV",Non-adaptive | TAU,h/week High 6.55,10.6,NA,NA Academic/job performance | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (report) | Executive functioning (tests) | Acceptability: all-cause discontinuation | Quality of life (patients),Westwood - Children (2024) | Westwood - Adults (2024) | Ostinelli (2025) | Catala-Lopez (2017) 6.55 41.5895454545455 NA,NA,NA,NA,NA NA < 2 months NA,NA 2.39h/week,6-17 yo Homogeneous,Cognitive training_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Teacher-rated_At study endpoint (closest to 12 weeks)_6-17 yo,Westwood - Children (2024) - Cognitive training_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Teacher-rated_At study endpoint (closest to 12 weeks)_6-17 yo Cognitive training_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Teacher-rated_At study endpoint (closest to 12 weeks)_6-17 yo - [Homogeneous],2024 Cognitive training_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Teacher-rated_At study endpoint (closest to 12 weeks) 260,NA Westwood - Children (2024)_Cognitive training_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Teacher-rated_At study endpoint (closest to 12 weeks) Westwood - Children (2024)_Cognitive training_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Teacher-rated_At study endpoint (closest to 12 weeks),100.00000
Westwood - Children (2024),Cognitive training Executive functioning (report),Parent-rated At follow-up (closest to 26 weeks),  82, 8.980000  8.980000  8.980000  8.980000  8.980000 11.590000 11.590000 11.590000 3836   0.000000, 41.02439 NA 10.253171 NA  1.71208847,   2.185366 100.00000,  0.00000 100.00000 100   0.000000,  0.000000 100.00000 100.00000,100.000000  48.78049, 51.219512, 28, 6  4, 41.02439 1.000000, 2,1 Bigorra | Sandberg,2016 | 2021,Westwood - Children 10.1038/s41380-023-02000-7 NA NA NA,BRIEF,NA RCT,DSM-IV | DSM-V Non-adaptive | WLC,h/week High 8.98 11.59 NA NA Academic/job performance | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (report) | Executive functioning (tests) | Acceptability: all-cause discontinuation | Quality of life (patients) Westwood - Children (2024) | Westwood - Adults (2024) | Ostinelli (2025) | Catala-Lopez (2017) 6.55,41.5895454545455 NA,NA NA NA,NA NA,< 2 months,NA NA,2.19h/week,6-17 yo Homogeneous,Cognitive training_Executive functioning (report)_Parent-rated_At follow-up (closest to 26 weeks)_6-17 yo,Westwood - Children (2024) - Cognitive training_Executive functioning (report)_Parent-rated_At follow-up (closest to 26 weeks)_6-17 yo Cognitive training_Executive functioning (report)_Parent-rated_At follow-up (closest to 26 weeks)_6-17 yo - [Homogeneous] 2024 Cognitive training_Executive functioning (report)_Parent-rated_At follow-up (closest to 26 weeks),261 NA,Westwood - Children (2024)_Cognitive training_Executive functioning (report)_Parent-rated_At follow-up (closest to 26 weeks) Westwood - Children (2024)_Cognitive training_Executive functioning (report)_Parent-rated_At follow-up (closest to 26 weeks),100.00000
Westwood - Children (2024),Cognitive training Executive functioning (report),Parent-rated,At study endpoint (closest to 12 weeks), 238, 6.550000  8.650000, 8.650000, 8.650000  8.980000  9.790000,11.590000 11.590000,3836   0.000000  51.72269,NA, 9.141218 NA, 2.60371262    1.730882,100.00000   0.00000 100.00000 100, 42.436975  42.436975 100.00000 100.00000 100.000000  76.05042, 66.386555  28  6  4, 51.72269 1.000000  5,1 Bigorra | Sandberg | Steiner | van Dongen-Boomsma | van da oord,2016 | 2021 | 2014 Westwood - Children,10.1038/s41380-023-02000-7 NA NA NA BRIEF,NA,RCT,DSM-IV | DSM-V | DSM-IV-TR,Non-adaptive | WLC h/week,High,6.55 11.59,NA NA,Academic/job performance | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (report) | Executive functioning (tests) | Acceptability: all-cause discontinuation | Quality of life (patients) Westwood - Children (2024) | Westwood - Adults (2024) | Ostinelli (2025) | Catala-Lopez (2017),6.55 41.5895454545455 NA NA NA NA,NA NA 2-6 months,NA,NA 1.73h/week,6-17 yo Homogeneous Cognitive training_Executive functioning (report)_Parent-rated_At study endpoint (closest to 12 weeks)_6-17 yo,Westwood - Children (2024) - Cognitive training_Executive functioning (report)_Parent-rated_At study endpoint (closest to 12 weeks)_6-17 yo,Cognitive training_Executive functioning (report)_Parent-rated_At study endpoint (closest to 12 weeks)_6-17 yo - [Homogeneous],2024 Cognitive training_Executive functioning (report)_Parent-rated_At study endpoint (closest to 12 weeks) 262,NA Westwood - Children (2024)_Cognitive training_Executive functioning (report)_Parent-rated_At study endpoint (closest to 12 weeks),Westwood - Children (2024)_Cognitive training_Executive functioning (report)_Parent-rated_At study endpoint (closest to 12 weeks) 100.00000
Westwood - Children (2024) Cognitive training Executive functioning (report),NA At follow-up (closest to 26 weeks)  195 10.020000 10.020000 10.500000 10.500000,10.500000,12.410000,12.410000,12.410000,3836,  0.000000, 76.20000,NA,11.373795 NA  1.15074799,   3.598633,100.00000,  0.00000 100.00000 100, 15.897436, 15.897436 100.00000,100.00000, 34.358974,100.00000  15.897436, 28, 6, 4  76.20000,1.000000, 3 1 Dentz | Egeland | Hasslinger,2020a | 2013 | 2022 Westwood - Children 10.1038/s41380-023-02000-7 NA,NA NA BRIEF NA RCT,DSM-IV | F-90 ICD-10 | ICD-10,Non-adaptive | TAU,h/week,High,10.02 12.41,NA,NA Academic/job performance | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (report) | Executive functioning (tests) | Acceptability: all-cause discontinuation | Quality of life (patients),Westwood - Children (2024) | Westwood - Adults (2024) | Ostinelli (2025) | Catala-Lopez (2017),6.55,41.5895454545455 NA,NA NA,NA NA,NA < 2 months NA NA 3.6h/week 6-17 yo Homogeneous Cognitive training_Executive functioning (report)_NA_At follow-up (closest to 26 weeks)_6-17 yo,Westwood - Children (2024) - Cognitive training_Executive functioning (report)_NA_At follow-up (closest to 26 weeks)_6-17 yo Cognitive training_Executive functioning (report)_NA_At follow-up (closest to 26 weeks)_6-17 yo - [Homogeneous] 2024 Cognitive training_Executive functioning (report)_NA_At follow-up (closest to 26 weeks),263,NA,Westwood - Children (2024)_Cognitive training_Executive functioning (report)_NA_At follow-up (closest to 26 weeks) Westwood - Children (2024)_Cognitive training_Executive functioning (report)_NA_At follow-up (closest to 26 weeks) 100.00000
Westwood - Children (2024),Cognitive training,Executive functioning (report) NA At study endpoint (closest to 12 weeks)  195,10.020000 10.020000 10.500000,10.500000 10.500000,12.410000 12.410000 12.410000 3836,  0.000000  75.53333 NA 11.361538 NA  1.15074799,   3.593750,100.00000,  0.00000 100.00000,100, 16.410256  16.410256 100.00000 100.00000, 34.358974 100.00000, 16.410256, 28, 6  4, 75.53333 1.000000, 3,1,Dentz | Egeland | Hasslinger 2020a | 2013 | 2022 Westwood - Children 10.1038/s41380-023-02000-7,NA,NA,NA,BRIEF NA RCT DSM-IV | F-90 ICD-10 | ICD-10,Non-adaptive | TAU h/week,High 10.02,12.41,NA NA,Academic/job performance | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (report) | Executive functioning (tests) | Acceptability: all-cause discontinuation | Quality of life (patients),Westwood - Children (2024) | Westwood - Adults (2024) | Ostinelli (2025) | Catala-Lopez (2017),6.55,41.5895454545455,NA,NA NA NA,NA,NA < 2 months,NA NA,3.59h/week,6-17 yo,Homogeneous Cognitive training_Executive functioning (report)_NA_At study endpoint (closest to 12 weeks)_6-17 yo Westwood - Children (2024) - Cognitive training_Executive functioning (report)_NA_At study endpoint (closest to 12 weeks)_6-17 yo Cognitive training_Executive functioning (report)_NA_At study endpoint (closest to 12 weeks)_6-17 yo - [Homogeneous],2024 Cognitive training_Executive functioning (report)_NA_At study endpoint (closest to 12 weeks) 264,NA,Westwood - Children (2024)_Cognitive training_Executive functioning (report)_NA_At study endpoint (closest to 12 weeks) Westwood - Children (2024)_Cognitive training_Executive functioning (report)_NA_At study endpoint (closest to 12 weeks),100.00000
Westwood - Children (2024),Cognitive training,Executive functioning (tests),NA At follow-up (closest to 26 weeks)  374  8.980000,10.000000,10.000000 10.500000 10.500000,12.410000,12.410000 12.410000 3836,  0.000000, 68.94919,NA 10.815785 NA  1.15074799    3.134010,100.00000   0.00000 100.00000,100, 25.276711  25.276711,100.00000 100.00000, 47.707251  88.61532  36.661396  28  6, 4, 69.63723 2.263384, 6 1,Bigorra | Dovis | Egeland | Hasslinger | Hovik | Rivard (Dentz 2020a) 2016 | 2015 | 2013 | 2022 | 2020,Westwood - Children 10.1038/s41380-023-02000-7,NA NA NA,Conners' CPT-II - oms | Conners' CPT-II - coms | WISC-III Digiti Span Foward & Backward (Digit Recall) | Stop task | Conners' CPT-II | Conners’ CPT-II | Conners' CPT-II | CPT-II | WISC-IV/WAIS-IV Digit Span (Forward) | WISC-IV Digit Span Forward & Backward | CPT | WISC-IV Digit Span Forward & Backward Combined | CPT - Oms | Conners' CPT-II - Coms NA RCT DSM-IV | DSM-IV-TR | F-90 ICD-10 | ICD-10 Non-adaptive | TAU,h/week,High 8.98 12.41 NA NA,Academic/job performance | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (report) | Executive functioning (tests) | Acceptability: all-cause discontinuation | Quality of life (patients) Westwood - Children (2024) | Westwood - Adults (2024) | Ostinelli (2025) | Catala-Lopez (2017) 6.55 41.5895454545455,NA NA,NA,NA NA NA,< 2 months NA,NA 3.13h/week,6-17 yo,Homogeneous Cognitive training_Executive functioning (tests)_NA_At follow-up (closest to 26 weeks)_6-17 yo,Westwood - Children (2024) - Cognitive training_Executive functioning (tests)_NA_At follow-up (closest to 26 weeks)_6-17 yo,Cognitive training_Executive functioning (tests)_NA_At follow-up (closest to 26 weeks)_6-17 yo - [Homogeneous] 2024 Cognitive training_Executive functioning (tests)_NA_At follow-up (closest to 26 weeks) 265 NA Westwood - Children (2024)_Cognitive training_Executive functioning (tests)_NA_At follow-up (closest to 26 weeks),Westwood - Children (2024)_Cognitive training_Executive functioning (tests)_NA_At follow-up (closest to 26 weeks) 100.00000
Westwood - Children (2024),Cognitive training Executive functioning (tests),NA At study endpoint (closest to 12 weeks)  623  8.400000, 8.400000, 8.400000  8.980000,10.500000 10.600000,12.410000,12.410000,3836   0.000000  64.69461,NA 10.014757,NA, 1.15074799,   2.868179 100.00000,  0.00000 100.00000,100  52.591389  52.591389,100.00000 100.00000, 42.485784  90.57677  62.014622, 28  6  4  65.38115 3.868400,11,1 Bigorra | Chacko | Dentz | Dovis | Egeland | Green | Hasslinger | Hovik | Johnstone | Klingberg | van Dongen-Boomsma 2016 | 2014 | 2020a | 2015 | 2013 | 2012 | 2022 | 2010 | 2005,Westwood - Children 10.1038/s41380-023-02000-7 NA,NA NA Conners' CPT-II - oms | Conners' CPT-II - coms | TMT B | A-X CPT Coms | A-X CPT Oms | Raven's porgressive matrices | CPT | Conners' CPT-II - Oms | Wechsler Spatial Span (Combined Forward/Backward) | WISC-IV Digit Span Backward & Forward | Raven coloured progressive matrices | WISC-III Digit Span (Combined Forward/Backward) | Stop task | Corsi Block Tapping Task (Combined Forward/Backward) | Stroop Colour & Word Test, Stroop RT Effect | TMT | Conners' CPT-II | Conners’ CPT-II | LOGOS Word Decoding Quality | D-KEFS Color Word Interference Condition Trials, CW Interference Time | TMT (Task 4) | WISC-IV Digit Span (Combined Forward/Backward) | CPT-II | Conners' CPT-II | WISC-IV/WAIS-IV Digit Span (Combined Forward/Backward) | Block Tapping (Combined Forward/Backward) | CPT Hit MRTs | WISC-IV Digit Span Forward & Backward | GNG | GNG, Go MRTs | Raven's Matrix | Digit Span (Combined Forward/Backward) | Span-Board (Combined Forward/Backward) | Stroop Task Incongruent Trials, Accuracy | Digit Span (Forward & Backward) | Shortened Raven Coloured Progressive Matrices | Knox Cubes LDT (Combined Forward/Backward) | SA-DOTS-02K | Adapted WISC-III Digit Span (Combined Forward/Backward) | Day-Night Stroop Task, Completion Time (Congruent-Incongruent controlling for correct responses) | SA-DOTS-02K, Hit MRT controlling for N NA RCT,DSM-IV | DSM-IV --> "a diagnosis of ADHD through consensus diagnosis based on parent and teacher ratings on the Disruptive Behavior Disorder Rating Scales (DBD; Pelham, Gnagy, Greenslade, & Milich, 1992) and impairment using the Impairment Rating Scale (Fabiano et al., 2006); and a semistructured interview with the parent using the Kiddie-SADS (Kaufman, Birmaher, Brent, Rao, & Ryan, 1996)" | DSM-IV-TR | F-90 ICD-10 | ICD-10,Non-adaptive | TAU h/week,High,6.55 12.41,NA,NA Academic/job performance | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (report) | Executive functioning (tests) | Acceptability: all-cause discontinuation | Quality of life (patients),Westwood - Children (2024) | Westwood - Adults (2024) | Ostinelli (2025) | Catala-Lopez (2017) 6.55 41.5895454545455,NA,NA,NA NA NA NA < 2 months,NA,NA,2.87h/week 6-17 yo Homogeneous Cognitive training_Executive functioning (tests)_NA_At study endpoint (closest to 12 weeks)_6-17 yo,Westwood - Children (2024) - Cognitive training_Executive functioning (tests)_NA_At study endpoint (closest to 12 weeks)_6-17 yo Cognitive training_Executive functioning (tests)_NA_At study endpoint (closest to 12 weeks)_6-17 yo - [Homogeneous],2024 Cognitive training_Executive functioning (tests)_NA_At study endpoint (closest to 12 weeks),266 NA Westwood - Children (2024)_Cognitive training_Executive functioning (tests)_NA_At study endpoint (closest to 12 weeks),Westwood - Children (2024)_Cognitive training_Executive functioning (tests)_NA_At study endpoint (closest to 12 weeks) 100.00000
Westwood - Children (2025),Neurofeedback,Combined ADHD symptoms (inattentive + hyperactive/impulsive),Clinician-rated At study endpoint (closest to 12 weeks)  274, 8.570000  8.570000  8.570000, 8.570000, 8.600000, 8.600000  8.700000 10.600000, 998   0.000000,120.98540 NA, 8.891606,NA, 2.37625259,   2.250000,100.00000   0.00000 100.00000 100, 14.963504, 14.963504 100.00000 100.00000 100.000000,100.00000, 14.963504, 36, 4, 3,120.98540 1.000000  3 1,Lim | Steiner | van Dongen-Boomsma,2019 | 2014 | 2013,Westwood - Children,10.1001/jamapsychiatry.2024.3702 NA,NA NA,ADHD-RS | BOSS Classroom Observation,NA RCT DSM-IV WLC | TAU | Sham_semi_active,h/week Moderate 8.57 10.6,NA,NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (tests) | Executive functioning (report) | Acceptability: all-cause discontinuation Westwood - Children (2025) | Westwood - Adults (2025) | Catala-Lopez (2017),8.57,36.9 NA,NA,NA,NA NA NA 2-6 months,NA,NA,2.25h/week 6-17 yo,Homogeneous,Neurofeedback_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks)_6-17 yo,Westwood - Children (2025) - Neurofeedback_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks)_6-17 yo Neurofeedback_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks)_6-17 yo - [Homogeneous] 2025,Neurofeedback_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks) 267,NA Westwood - Children (2025)_Neurofeedback_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks),Westwood - Children (2025)_Neurofeedback_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Clinician-rated_At study endpoint (closest to 12 weeks),100.00000
Westwood - Children (2025),Neurofeedback Combined ADHD symptoms (inattentive + hyperactive/impulsive),Parent-rated,At follow-up (closest to 26 weeks)  314  8.570000  8.570000, 8.570000, 9.700000 12.400000 13.200000 13.200000 13.200000  998,  0.000000  80.86581,NA,11.229393,NA, 1.77215190,   2.250000,100.00000   0.00000 100.00000 100, 26.517572  26.517572 100.00000 100.00000,100.000000,100.00000  26.517572, 36, 4, 3, 81.18211 1.316294, 4,1 Gevensleben | Hasslinger | Lam | Steiner 2010 | 2021 | 2022 | 2014 Westwood - Children,10.1001/jamapsychiatry.2024.3702,NA,NA NA FBB-HKS | ADHD-C3 parent | ADHD-RS | Conners 3 P NA RCT,DSM-IV | DSM-5 Sham_semi_active | TAU h/week,Moderate,8.57 13.2 NA,NA Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (tests) | Executive functioning (report) | Acceptability: all-cause discontinuation,Westwood - Children (2025) | Westwood - Adults (2025) | Catala-Lopez (2017),8.57,36.9 NA,NA,NA NA,NA,NA < 2 months,NA NA,2.25h/week,6-17 yo,Homogeneous,Neurofeedback_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At follow-up (closest to 26 weeks)_6-17 yo,Westwood - Children (2025) - Neurofeedback_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At follow-up (closest to 26 weeks)_6-17 yo Neurofeedback_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At follow-up (closest to 26 weeks)_6-17 yo - [Homogeneous],2025,Neurofeedback_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At follow-up (closest to 26 weeks),268 NA Westwood - Children (2025)_Neurofeedback_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At follow-up (closest to 26 weeks) Westwood - Children (2025)_Neurofeedback_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At follow-up (closest to 26 weeks),100.00000
Westwood - Children (2025),Neurofeedback,Combined ADHD symptoms (inattentive + hyperactive/impulsive),Parent-rated,At study endpoint (closest to 12 weeks),1195  8.580000  8.580000  8.590000, 8.590000, 9.340000,11.560000 12.400000,12.400000, 998   0.000000  95.94137,NA  9.955268 NA  2.35542688,   1.766217 100.00000,  0.00000,100.00000,100, 22.948074  22.948074 100.00000,100.00000  97.487437 100.00000, 22.948074, 36  4  3  96.02429,1.095477,19 1 Alegria | Arnold | Bakhshayesh | Baumeister | Beauregard | Gelade | Gevensleben | Hasslinger | Heinrich | Holtmann | Lam | Lim | Maurizio | Rahami | Shereena | Steiner | Strehl 2017 | 2013 | 2021 | 2011 | 2018 | 2006 | 2016 | 2009 | 2004 | 2022 | 2019 | 2014,Westwood - Children,10.1001/jamapsychiatry.2024.3702,NA,NA NA,ADHS -RS | SNAP-IV | Conners 3P | FBB-HKS | DISYPS-II | CPRS-R | SWAN | ADHD-C3 parent | FBB-HKS - Total Score | ADHD-RS | CPRS | ADHD RS | CRS-R | Conners 3 P | ADHD FBB-HKS NA RCT,DSM-IV | DSM-5 | ICD-10 Sham_semi_active | WLC | TAU | Active (any credible active intervention),h/week,Moderate,8.57 13.9,NA,NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (tests) | Executive functioning (report) | Acceptability: all-cause discontinuation Westwood - Children (2025) | Westwood - Adults (2025) | Catala-Lopez (2017) 8.57 36.9 NA,NA,NA,NA,NA NA 2-6 months,NA NA,1.77h/week 6-17 yo Homogeneous Neurofeedback_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks)_6-17 yo,Westwood - Children (2025) - Neurofeedback_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks)_6-17 yo,Neurofeedback_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks)_6-17 yo - [Homogeneous],2025 Neurofeedback_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks),269,NA Westwood - Children (2025)_Neurofeedback_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks) Westwood - Children (2025)_Neurofeedback_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_At study endpoint (closest to 12 weeks),100.00000
Westwood - Children (2025) Neurofeedback,Combined ADHD symptoms (inattentive + hyperactive/impulsive) Parent-rated,Closest to 52 weeks, 121, 8.580000  8.580000  8.580000, 8.580000, 8.580000, 8.580000,13.900000 13.900000  998   0.000000, 83.74380 NA, 9.591240,NA  2.51072288,   1.750000 100.00000   0.00000 100.00000 100,100.000000,100.000000 100.00000 100.00000,100.000000,100.00000,100.000000, 36  4  3, 83.74380 1.000000, 2,1,Alegria | Arnold 2017 | 2023 Westwood - Children 10.1001/jamapsychiatry.2024.3702 NA,NA NA ADHS -RS | Conners 3P,NA,RCT DSM-IV | DSM-5 Sham_semi_active,h/week,Moderate,8.58,13.9 NA NA Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (tests) | Executive functioning (report) | Acceptability: all-cause discontinuation,Westwood - Children (2025) | Westwood - Adults (2025) | Catala-Lopez (2017) 8.57,36.9,NA NA NA NA,NA NA,2-6 months NA NA,1.75h/week 6-17 yo,Homogeneous Neurofeedback_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_Closest to 52 weeks_6-17 yo,Westwood - Children (2025) - Neurofeedback_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_Closest to 52 weeks_6-17 yo,Neurofeedback_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_Closest to 52 weeks_6-17 yo - [Homogeneous],2025 Neurofeedback_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_Closest to 52 weeks,270,NA,Westwood - Children (2025)_Neurofeedback_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_Closest to 52 weeks,Westwood - Children (2025)_Neurofeedback_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Parent-rated_Closest to 52 weeks 100.00000
Westwood - Children (2025) Neurofeedback Combined ADHD symptoms (inattentive + hyperactive/impulsive),Teacher-rated At follow-up (closest to 26 weeks)  125, 8.590000  8.590000  8.590000, 8.590000, 8.590000, 8.590000, 8.590000, 8.590000  998,  0.000000 125.00000 NA  8.590000,NA  2.30149597,   1.670000 100.00000   0.00000 100.00000 100,  0.000000   0.000000 100.00000,100.00000,100.000000,100.00000,  0.000000  36, 4  3,125.00000 1.000000  1,1,Aggensteiner,2019,Westwood - Children 10.1001/jamapsychiatry.2024.3702,NA NA NA ADHD FBB-HKS,NA,RCT,DSM-IV,Sham_semi_active,h/week,Moderate 8.59,8.59,NA,NA Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (tests) | Executive functioning (report) | Acceptability: all-cause discontinuation,Westwood - Children (2025) | Westwood - Adults (2025) | Catala-Lopez (2017),8.57 36.9 NA,NA NA,NA NA NA,2-6 months,NA NA 1.67h/week,6-17 yo,Homogeneous Neurofeedback_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Teacher-rated_At follow-up (closest to 26 weeks)_6-17 yo,Westwood - Children (2025) - Neurofeedback_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Teacher-rated_At follow-up (closest to 26 weeks)_6-17 yo,Neurofeedback_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Teacher-rated_At follow-up (closest to 26 weeks)_6-17 yo - [Homogeneous],2025,Neurofeedback_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Teacher-rated_At follow-up (closest to 26 weeks) 271,NA Westwood - Children (2025)_Neurofeedback_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Teacher-rated_At follow-up (closest to 26 weeks),Westwood - Children (2025)_Neurofeedback_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Teacher-rated_At follow-up (closest to 26 weeks) 100.00000
Westwood - Children (2025) Neurofeedback,Combined ADHD symptoms (inattentive + hyperactive/impulsive),Teacher-rated,At study endpoint (closest to 12 weeks)  587  8.580000, 8.580000, 8.580000  8.590000, 8.850000, 9.700000, 9.760000 10.600000  998,  0.000000  95.74276 NA, 9.225230,NA, 2.72751757    1.622921 100.00000   0.00000 100.00000,100  35.093697  35.093697,100.00000 100.00000, 95.741056,100.00000  35.093697, 36  4, 3, 95.74276 1.039182 10,1,Arnold | Bakhshayesh | Blume | Gevensleben | Maurizio | Shereena | Steiner | Strehl | van Dongen-Boomsma 2013 | 2021 | 2011 | 2020 | 2009 | 2014 | 2019 | 2017 Westwood - Children,10.1001/jamapsychiatry.2024.3702 NA NA NA SNAP-IV | Conners 3P | FBB-HKS | Conners3 - DSM-IV | CTRS | ADHD RS | CRS-R | ADHD FBB-HKS | ADHD-RS,NA,RCT,DSM-IV | DSM-5 | ICD-10,Sham_semi_active | TAU | WLC h/week,Moderate,8.58 12.4,NA NA Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (tests) | Executive functioning (report) | Acceptability: all-cause discontinuation Westwood - Children (2025) | Westwood - Adults (2025) | Catala-Lopez (2017),8.57 36.9 NA NA NA,NA,NA NA,2-6 months,NA,NA,1.62h/week,6-17 yo,Homogeneous,Neurofeedback_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Teacher-rated_At study endpoint (closest to 12 weeks)_6-17 yo,Westwood - Children (2025) - Neurofeedback_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Teacher-rated_At study endpoint (closest to 12 weeks)_6-17 yo,Neurofeedback_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Teacher-rated_At study endpoint (closest to 12 weeks)_6-17 yo - [Homogeneous],2025 Neurofeedback_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Teacher-rated_At study endpoint (closest to 12 weeks) 272 NA Westwood - Children (2025)_Neurofeedback_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Teacher-rated_At study endpoint (closest to 12 weeks),Westwood - Children (2025)_Neurofeedback_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Teacher-rated_At study endpoint (closest to 12 weeks) 100.00000
Westwood - Children (2025) Neurofeedback,Combined ADHD symptoms (inattentive + hyperactive/impulsive),Teacher-rated Closest to 52 weeks,  98  8.580000  8.580000, 8.580000, 8.580000  8.580000  8.580000, 8.580000, 8.580000, 998,  0.000000  98.00000,NA, 8.580000,NA  2.99194476,   1.750000,100.00000   0.00000,100.00000,100 100.000000 100.000000,100.00000,100.00000 100.000000 100.00000 100.000000, 36, 4  3, 98.00000,1.000000, 1,1,Arnold,2023,Westwood - Children,10.1001/jamapsychiatry.2024.3702 NA,NA,NA,Conners 3P NA,RCT,DSM-5,Sham_semi_active h/week,Moderate 8.58 8.58 NA NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (tests) | Executive functioning (report) | Acceptability: all-cause discontinuation,Westwood - Children (2025) | Westwood - Adults (2025) | Catala-Lopez (2017),8.57,36.9,NA NA,NA NA,NA,NA 2-6 months NA NA,1.75h/week,6-17 yo Homogeneous,Neurofeedback_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Teacher-rated_Closest to 52 weeks_6-17 yo,Westwood - Children (2025) - Neurofeedback_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Teacher-rated_Closest to 52 weeks_6-17 yo Neurofeedback_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Teacher-rated_Closest to 52 weeks_6-17 yo - [Homogeneous] 2025,Neurofeedback_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Teacher-rated_Closest to 52 weeks 273,NA Westwood - Children (2025)_Neurofeedback_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Teacher-rated_Closest to 52 weeks,Westwood - Children (2025)_Neurofeedback_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Teacher-rated_Closest to 52 weeks 100.00000
Westwood - Children (2025) Neurofeedback Combined ADHD symptoms (inattentive + hyperactive/impulsive),NA,At study endpoint (closest to 12 weeks),  71,16.100000,16.100000 16.100000 16.100000 16.100000,16.100000 16.100000 16.100000, 998   0.000000  65.50000,NA 16.100000 NA  3.79746835,NA,100.00000,  0.00000 100.00000 100,  0.000000   0.000000 100.00000 100.00000 100.000000,100.00000   0.000000  36, 4  3  71.00000 2.000000  1 1,Bink 2016,Westwood - Children,10.1001/jamapsychiatry.2024.3702,NA NA NA ADHS -RS NA RCT DSM-IV,TAU h/week Moderate,16.1,16.1 NA NA Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (tests) | Executive functioning (report) | Acceptability: all-cause discontinuation,Westwood - Children (2025) | Westwood - Adults (2025) | Catala-Lopez (2017) 8.57,36.9 NA NA NA NA NA NA,2-6 months,NA,NA NAh/week 6-17 yo Homogeneous,Neurofeedback_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_NA_At study endpoint (closest to 12 weeks)_6-17 yo Westwood - Children (2025) - Neurofeedback_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_NA_At study endpoint (closest to 12 weeks)_6-17 yo,Neurofeedback_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_NA_At study endpoint (closest to 12 weeks)_6-17 yo - [Homogeneous] 2025,Neurofeedback_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_NA_At study endpoint (closest to 12 weeks) 274 NA,Westwood - Children (2025)_Neurofeedback_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_NA_At study endpoint (closest to 12 weeks),Westwood - Children (2025)_Neurofeedback_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_NA_At study endpoint (closest to 12 weeks),100.00000
Westwood - Children (2025),Neurofeedback,Executive functioning (report),Parent-rated,At study endpoint (closest to 12 weeks), 126, 8.570000  8.570000, 8.570000  8.570000  8.570000, 8.850000 12.400000,12.400000, 998   0.000000, 52.34921,NA, 9.257937 NA, 3.36456792,   1.945873,100.00000   0.00000 100.00000,100   0.000000   0.000000 100.00000 100.00000 100.000000 100.00000   0.000000, 36  4, 3  52.34921,1.000000, 3,1,Arnold | Steiner,2013 | 2011 | 2014,Westwood - Children 10.1001/jamapsychiatry.2024.3702 NA,NA,NA BRIEF NA,RCT,DSM-IV,Sham_semi_active | WLC | TAU h/week Moderate 8.57 12.4,NA NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (tests) | Executive functioning (report) | Acceptability: all-cause discontinuation,Westwood - Children (2025) | Westwood - Adults (2025) | Catala-Lopez (2017),8.57 36.9 NA NA NA NA NA NA,2-6 months,NA,NA 1.95h/week 6-17 yo,Homogeneous Neurofeedback_Executive functioning (report)_Parent-rated_At study endpoint (closest to 12 weeks)_6-17 yo,Westwood - Children (2025) - Neurofeedback_Executive functioning (report)_Parent-rated_At study endpoint (closest to 12 weeks)_6-17 yo,Neurofeedback_Executive functioning (report)_Parent-rated_At study endpoint (closest to 12 weeks)_6-17 yo - [Homogeneous],2025,Neurofeedback_Executive functioning (report)_Parent-rated_At study endpoint (closest to 12 weeks) 275,NA,Westwood - Children (2025)_Neurofeedback_Executive functioning (report)_Parent-rated_At study endpoint (closest to 12 weeks) Westwood - Children (2025)_Neurofeedback_Executive functioning (report)_Parent-rated_At study endpoint (closest to 12 weeks) 100.00000
Westwood - Children (2025),Neurofeedback Executive functioning (report) NA,At study endpoint (closest to 12 weeks), 125 10.300000,10.300000 11.980000,12.400000 12.400000 12.400000,12.400000 12.400000, 998,  0.000000, 84.54016 NA 11.978313,NA  1.61289577 NA,100.00000,  0.00000,100.00000,100,  0.000000   0.000000,100.00000 100.00000,100.000000 100.00000,  0.000000, 36  4, 3  84.93976 1.799197  2,1,Hasslinger | Maurizio 2021 | 2014,Westwood - Children 10.1001/jamapsychiatry.2024.3702 NA NA NA,BRIEF,NA RCT DSM-5 | DSM-IV,TAU | Sham_semi_active h/week,Moderate,10.3 12.4,NA,NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (tests) | Executive functioning (report) | Acceptability: all-cause discontinuation,Westwood - Children (2025) | Westwood - Adults (2025) | Catala-Lopez (2017),8.57,36.9 NA NA,NA NA NA,NA < 2 months NA NA NAh/week,6-17 yo Homogeneous,Neurofeedback_Executive functioning (report)_NA_At study endpoint (closest to 12 weeks)_6-17 yo,Westwood - Children (2025) - Neurofeedback_Executive functioning (report)_NA_At study endpoint (closest to 12 weeks)_6-17 yo,Neurofeedback_Executive functioning (report)_NA_At study endpoint (closest to 12 weeks)_6-17 yo - [Homogeneous] 2025,Neurofeedback_Executive functioning (report)_NA_At study endpoint (closest to 12 weeks),276 NA,Westwood - Children (2025)_Neurofeedback_Executive functioning (report)_NA_At study endpoint (closest to 12 weeks) Westwood - Children (2025)_Neurofeedback_Executive functioning (report)_NA_At study endpoint (closest to 12 weeks),100.00000
Westwood - Children (2025),Neurofeedback Executive functioning (tests),NA,At follow-up (closest to 26 weeks), 279 12.400000,12.400000,12.400000,12.400000 12.400000,13.200000,13.200000,13.200000  998,  0.000000, 93.82914 NA,12.624460 NA, 1.15074799 NA 100.00000   0.00000 100.00000 100  28.057554, 28.057554,100.00000 100.00000 100.000000 100.00000  28.057554, 36  4, 3, 94.18885,2.000000, 3 1 Hasslinger | Lam,2021 | 2022,Westwood - Children,10.1001/jamapsychiatry.2024.3702 NA NA NA,CPT-II - Hit RT | CPT-II Omission | CPT - Oms | CPT -MRT,NA,RCT,DSM-5,TAU | Sham_semi_active h/week,Moderate 12.4,13.2 NA NA Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (tests) | Executive functioning (report) | Acceptability: all-cause discontinuation Westwood - Children (2025) | Westwood - Adults (2025) | Catala-Lopez (2017) 8.57,36.9,NA,NA NA NA NA NA,< 2 months NA,NA NAh/week,6-17 yo,Homogeneous,Neurofeedback_Executive functioning (tests)_NA_At follow-up (closest to 26 weeks)_6-17 yo Westwood - Children (2025) - Neurofeedback_Executive functioning (tests)_NA_At follow-up (closest to 26 weeks)_6-17 yo,Neurofeedback_Executive functioning (tests)_NA_At follow-up (closest to 26 weeks)_6-17 yo - [Homogeneous],2025 Neurofeedback_Executive functioning (tests)_NA_At follow-up (closest to 26 weeks),277 NA Westwood - Children (2025)_Neurofeedback_Executive functioning (tests)_NA_At follow-up (closest to 26 weeks),Westwood - Children (2025)_Neurofeedback_Executive functioning (tests)_NA_At follow-up (closest to 26 weeks),100.00000
Westwood - Children (2025),Neurofeedback Executive functioning (tests) NA,At study endpoint (closest to 12 weeks), 920, 8.730000, 9.030000, 9.200000  9.600000 10.300000,12.400000 13.200000,13.900000, 998   0.000000, 67.00382,NA,11.194048,NA  2.18985310    1.672048 100.00000   0.00000 100.00000,100, 25.384917, 25.384917 100.00000 100.00000  90.817983,100.00000  25.384917  36  4, 3, 68.58731 3.619058,17,1 Aggensteiner | Alegria | Bakhshayesh | Beauregard | Bink | Blume | Dobrakowski | Gelade | Hasslinger | Heinrich | Holtmann | Lam | Maurizio | Shereena | Vollebregt | Wangler 2021 | 2017 | 2011 | 2006 | 2016 | 2020 | 2022 | 2004 | 2009 | 2014 | 2019,Westwood - Children,10.1001/jamapsychiatry.2024.3702,NA,NA NA CPT | Continuous Performance Task | CPT | Digit Span | Go/No-go Task | Integrated Visual and Auditory (IVA) CPT | D2 Test of attention | stroop color word test | Conner's CPT - Coms | Conner's CPT - Oms | n-back | Oddball task | Stop-signal task | VSWM | Block-tapping task - Combined Forward & Backward | CPT-II - Hit RT | CPT-II Commission | Digit Span Composite | CPT-II Commission | CPT-II Omission | Stop signal - Commissions | Stop signal - Omission | CPT | CPT - Oms | WIH WM Sorting | CPT -MRT | D2 - Total Score | Go/No-go test | n-back | Spatial Span Test | Digit span WISC III | Sustained Attention dots task (SA-DOTS) | Visuospatial Sequencing (VSS) | Attention Network Test - Conflict | Attention Network Test - MRT | Attention Network Test - Orienting NA RCT,DSM-IV | ICD-10 | DSM-5,Sham_semi_active | WLC | TAU | Active (any credible active intervention),h/week,Moderate 8.59 16.1 NA NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (tests) | Executive functioning (report) | Acceptability: all-cause discontinuation,Westwood - Children (2025) | Westwood - Adults (2025) | Catala-Lopez (2017) 8.57 36.9,NA NA,NA,NA,NA,NA,2-6 months,NA,NA,1.67h/week 6-17 yo,Homogeneous Neurofeedback_Executive functioning (tests)_NA_At study endpoint (closest to 12 weeks)_6-17 yo,Westwood - Children (2025) - Neurofeedback_Executive functioning (tests)_NA_At study endpoint (closest to 12 weeks)_6-17 yo Neurofeedback_Executive functioning (tests)_NA_At study endpoint (closest to 12 weeks)_6-17 yo - [Homogeneous] 2025 Neurofeedback_Executive functioning (tests)_NA_At study endpoint (closest to 12 weeks),278 NA Westwood - Children (2025)_Neurofeedback_Executive functioning (tests)_NA_At study endpoint (closest to 12 weeks) Westwood - Children (2025)_Neurofeedback_Executive functioning (tests)_NA_At study endpoint (closest to 12 weeks) 100.00000
Yin - adults (2024),tDCS (transcranial direct current stimulation) Combined ADHD symptoms (inattentive + hyperactive/impulsive) Mixed,At study endpoint (closest to 12 weeks)  217,22.000000,22.225000,22.750000 22.750000,32.294118 38.300000,38.300000,38.300000,8996,  0.000000, 55.04608  43.793733,30.728671 NA,NA   22.949309  65.89862,  0.00000,100.00000,100, 65.898618  65.898618,100.00000 100.00000 100.000000,100.00000, 65.898618  19, 5, 3  55.04608 1.557604, 5,1 Allenby | Barham | Cachoeria | Jacoby | Leffa,2018 | 2022 | 2017,Yin - adults 10.3390/brainsci14121237,NA NA Questionnaire ASRS NA,RCT (parallel, crossover, open-label),NA Sham min/session Critically low 22,38.3 NA,NA Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (tests) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Emotional dysregulation Yin - adults (2024) | Yin - children (2024) | Ostinelli (2025) 8.86 38.3142857142857,NA,NA NA NA,NA NA NA,NA NA 22.95min/session,>= 18 yo,Homogeneous tDCS (transcranial direct current stimulation)_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Mixed_At study endpoint (closest to 12 weeks)_>= 18 yo,Yin - adults (2024) - tDCS (transcranial direct current stimulation)_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Mixed_At study endpoint (closest to 12 weeks)_>= 18 yo tDCS (transcranial direct current stimulation)_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Mixed_At study endpoint (closest to 12 weeks)_>= 18 yo - [Homogeneous],2024,tDCS (transcranial direct current stimulation)_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Mixed_At study endpoint (closest to 12 weeks),279,NA,Yin - adults (2024)_tDCS (transcranial direct current stimulation)_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Mixed_At study endpoint (closest to 12 weeks),Yin - adults (2024)_tDCS (transcranial direct current stimulation)_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Mixed_At study endpoint (closest to 12 weeks),100.00000
Yin - adults (2024),tDCS (transcranial direct current stimulation),Executive functioning (tests),Mixed At study endpoint (closest to 12 weeks)  156 22.000000,22.000000,22.000000,22.000000,32.250000,32.250000,32.250000,32.250000 8996,  0.000000, 61.28205, 37.838718 29.500000,NA NA,  20.000000  52.56410,  0.00000,100.00000,100  52.564103, 52.564103 100.00000,100.00000 100.000000 100.00000  52.564103, 19, 5, 3, 61.28205,1.615385  3,1,Allenby | Barham | Cosmo,2018 | 2022 | 2015,Yin - adults,10.3390/brainsci14121237,NA NA Test,stop-signal task | n-bask task | stroop task | digit span task | go/no-go NA RCT (parallel, crossover, open-label),NA Sham,min/session,Critically low,22,32.25,NA NA Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (tests) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Emotional dysregulation,Yin - adults (2024) | Yin - children (2024) | Ostinelli (2025) 8.86 38.3142857142857 NA NA,NA,NA NA,NA NA NA NA 20min/session >= 18 yo,Homogeneous tDCS (transcranial direct current stimulation)_Executive functioning (tests)_Mixed_At study endpoint (closest to 12 weeks)_>= 18 yo Yin - adults (2024) - tDCS (transcranial direct current stimulation)_Executive functioning (tests)_Mixed_At study endpoint (closest to 12 weeks)_>= 18 yo,tDCS (transcranial direct current stimulation)_Executive functioning (tests)_Mixed_At study endpoint (closest to 12 weeks)_>= 18 yo - [Homogeneous],2024 tDCS (transcranial direct current stimulation)_Executive functioning (tests)_Mixed_At study endpoint (closest to 12 weeks),280,NA Yin - adults (2024)_tDCS (transcranial direct current stimulation)_Executive functioning (tests)_Mixed_At study endpoint (closest to 12 weeks),Yin - adults (2024)_tDCS (transcranial direct current stimulation)_Executive functioning (tests)_Mixed_At study endpoint (closest to 12 weeks) 100.00000
Yin - children (2024) tDCS (transcranial direct current stimulation) Combined ADHD symptoms (inattentive + hyperactive/impulsive),Mixed At study endpoint (closest to 12 weeks)   60 11.200000 11.200000 11.200000,11.200000 12.700000,14.200000 14.200000 14.200000 8996,  0.000000  30.00000, 26.665000 12.700000,NA,NA   25.000000,100.00000,  0.00000,100.00000 100,100.000000,100.000000 100.00000 100.00000 100.000000 100.00000 100.000000  19, 5  3, 30.00000,1.500000, 2 1,Guimaraes | Soff,2024 | 2017 Yin - children,10.3390/brainsci14121237 NA,NA Questionnaire FBB-ADHD,NA,RCT (parallel, crossover, open-label),NA,Sham min/session Critically low,11.2 14.2 NA,NA Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (tests) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Emotional dysregulation Yin - adults (2024) | Yin - children (2024) | Ostinelli (2025),8.86,38.3142857142857 NA,NA NA NA NA NA,NA NA,NA 25min/session,6-17 yo,Homogeneous tDCS (transcranial direct current stimulation)_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Mixed_At study endpoint (closest to 12 weeks)_6-17 yo Yin - children (2024) - tDCS (transcranial direct current stimulation)_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Mixed_At study endpoint (closest to 12 weeks)_6-17 yo,tDCS (transcranial direct current stimulation)_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Mixed_At study endpoint (closest to 12 weeks)_6-17 yo - [Homogeneous],2024,tDCS (transcranial direct current stimulation)_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Mixed_At study endpoint (closest to 12 weeks),281,NA,Yin - children (2024)_tDCS (transcranial direct current stimulation)_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Mixed_At study endpoint (closest to 12 weeks) Yin - children (2024)_tDCS (transcranial direct current stimulation)_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Mixed_At study endpoint (closest to 12 weeks) 100.00000
Yin - children (2024),tDCS (transcranial direct current stimulation) Executive functioning (tests),Mixed,At study endpoint (closest to 12 weeks), 370, 8.860000, 9.000000  9.200000  9.250000,10.630000,13.300000,13.409091 16.060000,8996,  0.000000  36.85877  27.927336 11.056068,NA,NA   19.626272 100.00000,  0.00000 100.00000,100  70.767808  70.767808, 92.22942 100.00000,100.000000, 78.53839,100.000000, 19, 5  3, 37.55967 2.397780 11,1 Breitling | Breitling-Ziegler | D'Aiello | Guimaraes | Nejati | Salehinejad | Soltaninejad,2016 | 2020 | 2021 | 2023 | 2024 | 2022 | 2019 Yin - children,10.3390/brainsci14121237,NA,NA Test flanker | n-bask task | go/no-go | n-bask task | stop-signal task | n-bask task | digit span task | go/no-go | n-bask task | wisconsin card sorting | go/no-go NA RCT (parallel, crossover, open-label) NA,Sham min/session,Critically low 8.86 16.06,NA,NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (tests) | Acceptability: all-cause discontinuation | Tolerability (discontinuation due to adverse events) | Emotional dysregulation,Yin - adults (2024) | Yin - children (2024) | Ostinelli (2025) 8.86,38.3142857142857 NA NA,NA NA NA,NA,NA,NA NA,19.63min/session,6-17 yo,Homogeneous tDCS (transcranial direct current stimulation)_Executive functioning (tests)_Mixed_At study endpoint (closest to 12 weeks)_6-17 yo Yin - children (2024) - tDCS (transcranial direct current stimulation)_Executive functioning (tests)_Mixed_At study endpoint (closest to 12 weeks)_6-17 yo tDCS (transcranial direct current stimulation)_Executive functioning (tests)_Mixed_At study endpoint (closest to 12 weeks)_6-17 yo - [Homogeneous],2024 tDCS (transcranial direct current stimulation)_Executive functioning (tests)_Mixed_At study endpoint (closest to 12 weeks) 282 NA,Yin - children (2024)_tDCS (transcranial direct current stimulation)_Executive functioning (tests)_Mixed_At study endpoint (closest to 12 weeks),Yin - children (2024)_tDCS (transcranial direct current stimulation)_Executive functioning (tests)_Mixed_At study endpoint (closest to 12 weeks),100.00000
Yu (2024),Viloxazine Acceptability: all-cause discontinuation NA At study endpoint (closest to 12 weeks), 990  8.475000  8.475000, 8.475000  8.500000  8.500000 13.825640,13.873496 13.873496,8997   0.000000 223.78380  36.504413 10.698678,NA, 1.55389435, 288.894602,100.00000   0.00000,100.00000,100 100.000000,100.000000 100.00000,100.00000,100.000000,100.00000 100.000000   6  6  2,227.78972,2.142931  5 1 Johnson | Nasser,2020 | 2021a | 2021b | 2021c,Yu,10.1001/jamanetworkopen.2024.45885 Viloxazine,NA,NA NA 100 mg | 200 mg | 300 mg | 400 mg | NCT3247530 100 mg | NCT3247530 200 mg | NCT3247556 400 mg | NCT3247556 600 mg | NCT3247517 200 mg | NCT3247517 400 mg | NCT3247543 200 mg | NCT3247543 400 mg RCT (parallel, crossover, open-label) DSM-5,Placebo mg,Low 8.45 13.9015384615385,NA NA Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Specific adverse events: sleep problems | Specific adverse events: decreased appetite | Tolerability (discontinuation due to adverse events) | Acceptability: all-cause discontinuation | Emotional dysregulation,Yu (2024) | Ostinelli (2025) 8.45,34.7573446327684,NA NA NA NA,NA NA < 2 months NA,NA 288.89mg,6-17 yo,Homogeneous Viloxazine_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_6-17 yo,Yu (2024) - Viloxazine_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_6-17 yo,Viloxazine_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks)_6-17 yo - [Homogeneous],2024 Viloxazine_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks),283,TRUE,Yu (2024)_Viloxazine_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks),Yu (2024)_Viloxazine_Acceptability: all-cause discontinuation_NA_At study endpoint (closest to 12 weeks),100.00000
Yu (2024) Viloxazine,Combined ADHD symptoms (inattentive + hyperactive/impulsive),Mixed,At study endpoint (closest to 12 weeks), 990, 8.475000  8.475000, 8.475000  8.500000  8.500000 13.825640,13.873496 13.873496 8997   0.000000,223.78380, 36.504413 10.698678 NA  1.55389435, 288.894602 100.00000,  0.00000,100.00000,100 100.000000,100.000000,100.00000,100.00000 100.000000 100.00000 100.000000,  6  6  2 227.78972,2.142931, 5 1,Johnson | Nasser,2020 | 2021a | 2021b | 2021c Yu 10.1001/jamanetworkopen.2024.45885 Viloxazine NA Questionnaire,ADHD-RS,100 mg | 200 mg | 300 mg | 400 mg | NCT3247530 100 mg | NCT3247530 200 mg | NCT3247556 400 mg | NCT3247556 600 mg | NCT3247517 200 mg | NCT3247517 400 mg | NCT3247543 200 mg | NCT3247543 400 mg,RCT (parallel, crossover, open-label) DSM-5 Placebo mg Low 8.45 13.9015384615385,NA,NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Specific adverse events: sleep problems | Specific adverse events: decreased appetite | Tolerability (discontinuation due to adverse events) | Acceptability: all-cause discontinuation | Emotional dysregulation,Yu (2024) | Ostinelli (2025),8.45 34.7573446327684 NA,NA NA NA NA NA < 2 months,NA,NA,288.89mg 6-17 yo,Homogeneous,Viloxazine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Mixed_At study endpoint (closest to 12 weeks)_6-17 yo,Yu (2024) - Viloxazine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Mixed_At study endpoint (closest to 12 weeks)_6-17 yo Viloxazine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Mixed_At study endpoint (closest to 12 weeks)_6-17 yo - [Homogeneous] 2024 Viloxazine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Mixed_At study endpoint (closest to 12 weeks),284,TRUE,Yu (2024)_Viloxazine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Mixed_At study endpoint (closest to 12 weeks),Yu (2024)_Viloxazine_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Mixed_At study endpoint (closest to 12 weeks),100.00000
Yu (2024) Viloxazine,Specific adverse events: decreased appetite,NA,At study endpoint (closest to 12 weeks)  606  8.475000  8.475000, 8.475000, 8.475000 13.825640,13.873496,13.873496,13.873496 8997,  0.000000,198.56129, 35.942786,12.053874 NA, 1.60969450  365.155332,100.00000,  0.00000 100.00000 100 100.000000 100.000000 100.00000 100.00000,100.000000 100.00000 100.000000   6  6  2 202.08816,2.000000  3 1,Nasser,2021a | 2021b | 2021c Yu 10.1001/jamanetworkopen.2024.45885,Viloxazine,NA Unclear (not able to identify the tools used to measure the outcome) NA NCT3247556 400 mg | NCT3247556 600 mg | NCT3247517 200 mg | NCT3247517 400 mg | NCT3247543 200 mg | NCT3247543 400 mg,RCT (parallel, crossover, open-label),DSM-5,Placebo mg Low 8.45,13.9015384615385 NA NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Specific adverse events: sleep problems | Specific adverse events: decreased appetite | Tolerability (discontinuation due to adverse events) | Acceptability: all-cause discontinuation | Emotional dysregulation Yu (2024) | Ostinelli (2025) 8.45,34.7573446327684 NA NA,NA,NA,NA,NA < 2 months,NA,NA,365.16mg 6-17 yo,Homogeneous,Viloxazine_Specific adverse events: decreased appetite_NA_At study endpoint (closest to 12 weeks)_6-17 yo,Yu (2024) - Viloxazine_Specific adverse events: decreased appetite_NA_At study endpoint (closest to 12 weeks)_6-17 yo Viloxazine_Specific adverse events: decreased appetite_NA_At study endpoint (closest to 12 weeks)_6-17 yo - [Homogeneous] 2024,Viloxazine_Specific adverse events: decreased appetite_NA_At study endpoint (closest to 12 weeks),285 TRUE Yu (2024)_Viloxazine_Specific adverse events: decreased appetite_NA_At study endpoint (closest to 12 weeks) Yu (2024)_Viloxazine_Specific adverse events: decreased appetite_NA_At study endpoint (closest to 12 weeks) 100.00000
Yu (2024),Viloxazine Specific adverse events: sleep problems NA At study endpoint (closest to 12 weeks), 990, 8.475000, 8.475000, 8.475000  8.500000  8.500000,13.825640 13.873496,13.873496,8997,  0.000000,223.78380  36.504413 10.698678 NA, 1.55389435, 288.894602 100.00000,  0.00000,100.00000,100,100.000000,100.000000 100.00000 100.00000 100.000000,100.00000,100.000000,  6, 6  2 227.78972 2.142931  5 1 Johnson | Nasser,2020 | 2021a | 2021b | 2021c,Yu 10.1001/jamanetworkopen.2024.45885,Viloxazine,NA,Unclear (not able to identify the tools used to measure the outcome) NA 100 mg | 200 mg | 300 mg | 400 mg | NCT3247530 100 mg | NCT3247530 200 mg | NCT3247556 400 mg | NCT3247556 600 mg | NCT3247517 200 mg | NCT3247517 400 mg | NCT3247543 200 mg | NCT3247543 400 mg RCT (parallel, crossover, open-label) DSM-5 Placebo,mg,Low,8.45 13.9015384615385,NA,NA,Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Specific adverse events: sleep problems | Specific adverse events: decreased appetite | Tolerability (discontinuation due to adverse events) | Acceptability: all-cause discontinuation | Emotional dysregulation Yu (2024) | Ostinelli (2025),8.45,34.7573446327684,NA,NA NA NA,NA NA < 2 months NA NA,288.89mg,6-17 yo,Homogeneous,Viloxazine_Specific adverse events: sleep problems_NA_At study endpoint (closest to 12 weeks)_6-17 yo,Yu (2024) - Viloxazine_Specific adverse events: sleep problems_NA_At study endpoint (closest to 12 weeks)_6-17 yo,Viloxazine_Specific adverse events: sleep problems_NA_At study endpoint (closest to 12 weeks)_6-17 yo - [Homogeneous],2024 Viloxazine_Specific adverse events: sleep problems_NA_At study endpoint (closest to 12 weeks),286 TRUE,Yu (2024)_Viloxazine_Specific adverse events: sleep problems_NA_At study endpoint (closest to 12 weeks) Yu (2024)_Viloxazine_Specific adverse events: sleep problems_NA_At study endpoint (closest to 12 weeks) 100.00000
Yu (2024) Viloxazine,Tolerability (discontinuation due to adverse events),NA At study endpoint (closest to 12 weeks)  990, 8.475000, 8.475000  8.475000, 8.500000, 8.500000 13.825640,13.873496 13.873496 8997,  0.000000 223.78380, 36.504413 10.698678,NA, 1.55389435  288.894602 100.00000,  0.00000,100.00000 100 100.000000 100.000000,100.00000,100.00000 100.000000 100.00000 100.000000   6  6  2 227.78972 2.142931, 5 1,Johnson | Nasser,2020 | 2021a | 2021b | 2021c,Yu 10.1001/jamanetworkopen.2024.45885 Viloxazine,NA NA NA 100 mg | 200 mg | 300 mg | 400 mg | NCT3247530 100 mg | NCT3247530 200 mg | NCT3247556 400 mg | NCT3247556 600 mg | NCT3247517 200 mg | NCT3247517 400 mg | NCT3247543 200 mg | NCT3247543 400 mg RCT (parallel, crossover, open-label),DSM-5,Placebo mg Low 8.45,13.9015384615385 NA,NA Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Specific adverse events: sleep problems | Specific adverse events: decreased appetite | Tolerability (discontinuation due to adverse events) | Acceptability: all-cause discontinuation | Emotional dysregulation Yu (2024) | Ostinelli (2025),8.45,34.7573446327684 NA NA,NA NA,NA NA < 2 months NA,NA 288.89mg,6-17 yo,Homogeneous Viloxazine_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks)_6-17 yo,Yu (2024) - Viloxazine_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks)_6-17 yo,Viloxazine_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks)_6-17 yo - [Homogeneous] 2024,Viloxazine_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks) 287 TRUE,Yu (2024)_Viloxazine_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks),Yu (2024)_Viloxazine_Tolerability (discontinuation due to adverse events)_NA_At study endpoint (closest to 12 weeks) 100.00000
Zhang (2023),Mindfulness,Combined ADHD symptoms (inattentive + hyperactive/impulsive),Mixed,At study endpoint (closest to 12 weeks), 257  6.080000  6.080000  6.080000, 6.080000,10.965000 11.186408 11.186408 11.186408 4036,  0.000000  85.93385 NA  9.039494 NA  1.66209203,NA 100.00000   0.00000, 90.66148 100, 40.077821, 40.077821  78.98833   0.00000  90.661479  40.07782  40.077821  13  8, 4  85.93385 2.000000, 4,1 Amiri | Lo | Siebelink | Valero 2022 | 2020,Zhang,10.1177/10870547231154897,mindful parent training | family based mindfullness intervention | mindfulness based intervention NA Questionnaire,CTRS | SWAN | CPRS | Conners-3 NA,RCT (parallel, crossover, open-label),DSM-5,WLC (wait-list control) | TAU NA Critically low 6.08,11.1864077669903 NA,NA Generalized anxiety | Depressive disorder symptoms | Quality of life (patients) | Executive functioning (mixed) | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (tests) | Acceptability: all-cause discontinuation | Emotional dysregulation Lopez-Pinar (2019) | Liu (2023) | Zhang (2023) | Ostinelli (2025),6.08,39.35,NA,NA NA NA NA NA,< 2 months NA NA NANA,6-17 yo Homogeneous,Mindfulness_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Mixed_At study endpoint (closest to 12 weeks)_6-17 yo Zhang (2023) - Mindfulness_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Mixed_At study endpoint (closest to 12 weeks)_6-17 yo Mindfulness_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Mixed_At study endpoint (closest to 12 weeks)_6-17 yo - [Homogeneous],2023 Mindfulness_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Mixed_At study endpoint (closest to 12 weeks) 288 FALSE,Zhang (2023)_Mindfulness_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Mixed_At study endpoint (closest to 12 weeks),Zhang (2023)_Mindfulness_Combined ADHD symptoms (inattentive + hyperactive/impulsive)_Mixed_At study endpoint (closest to 12 weeks), 90.66148
Zhang (2023) Mindfulness,Executive functioning (mixed),Mixed At study endpoint (closest to 12 weeks), 187,11.030000,11.030000 11.030000,11.030000 11.186408,11.186408 11.186408,11.186408,4036   0.000000, 83.98396,NA 10.964171 NA  1.78611824,NA 100.00000   0.00000,100.00000 100, 55.080214, 55.080214, 55.08021,  0.00000 100.000000  55.08021, 92.513369  13, 8  4, 83.98396,1.000000  3 1 Rezaei | Robe | Siebelink 2018 | 2022,Zhang 10.1177/10870547231154897,yoga | mindfulness based intervention,NA Mixed (different types of tool are used) NA NA RCT (parallel, crossover, open-label) DSM-5,WLC (wait-list control) | Not a therapeutic intervention | TAU NA Critically low,9,11.1864077669903,NA,NA Generalized anxiety | Depressive disorder symptoms | Quality of life (patients) | Executive functioning (mixed) | Combined ADHD symptoms (inattentive + hyperactive/impulsive) | Executive functioning (tests) | Acceptability: all-cause discontinuation | Emotional dysregulation Lopez-Pinar (2019) | Liu (2023) | Zhang (2023) | Ostinelli (2025) 6.08 39.35 NA NA,NA,NA NA,NA,< 2 months NA,NA NANA,6-17 yo Homogeneous,Mindfulness_Executive functioning (mixed)_Mixed_At study endpoint (closest to 12 weeks)_6-17 yo,Zhang (2023) - Mindfulness_Executive functioning (mixed)_Mixed_At study endpoint (closest to 12 weeks)_6-17 yo,Mindfulness_Executive functioning (mixed)_Mixed_At study endpoint (closest to 12 weeks)_6-17 yo - [Homogeneous] 2023 Mindfulness_Executive functioning (mixed)_Mixed_At study endpoint (closest to 12 weeks) 289,FALSE Zhang (2023)_Mindfulness_Executive functioning (mixed)_Mixed_At study endpoint (closest to 12 weeks) Zhang (2023)_Mindfulness_Executive functioning (mixed)_Mixed_At study endpoint (closest to 12 weeks),100.00000
